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Abstract 
Research conducted in the past has shown the deleterious effects of androgen deprivation 
therapy (ADT) on cognitive impairment in prostate cancer (PC) patients. However, many 
studies have been limited due to small sample sizes and due to unmatched control samples. 
Many previous undertakings have also lacked the comprehensive assessment of patients 
before treatment leading to mixed outcomes of affected cognitive domains during treatment 
which have been found to be in executive function and spatial reasoning. The current study 
therefore aimed to characterise cognitive function in patients compared to age matched 
healthy controls. 
Thirty ageing prostate cancer patients before ADT and twenty-nine ageing older matched 
healthy control participants underwent behavioural cognitive measures and psychosocial 
measures which were analysed to assess differences between groups cross-sectionally. 
Covariates (anxiety, depression and testosterone) were also added to analysis models to 
assess their effects. No significant differences on neuropsychological measures or mood 
scales were found between groups suggesting that executive function and spatial reasoning 
were intact in both groups at baseline. However, a significant difference was found in 
testosterone levels between patients and controls in which patients had higher testosterone 
levels. 
Brain imaging was undertaken of the controls and patients using magnetic resonance imaging 
techniques. Groups underwent fMRI tasks on imaging paradigms (stops signal task and 
mental rotation task) plus task free functional resting state functional connectivity and arterial 
spin labelling. No activation, resting state or arterial spin labelling differences were found 
between groups. However, a significant difference in scanner behavioural performance was 
found in which patients had better accuracy on sub components of the mental rotation task.  
A longitudinal study was subsequently undertaken to assess behavioural cognitive 
performance in healthy ageing participants only and their neural correlates in relation to 
testosterone, anxiety and depression. This was to assess the usefulness of the sample as a 
control sample that was undertaken before. Furthermore, the study was conducted to explore 
the reliability and stability of cognition and neural function over a longitudinal follow-up 
period. Outcomes showed no significant differences were found between baseline and six 
month follow-up. However, testosterone was shown to covary with two subcomponents of 
executive function. Neuroimaging revealed testosterone covaried with one subcomponent of 
spatial reasoning.  
In conclusion, patients and healthy controls were similarly matched for cognitive and neural 
function showing patients had intact executive and spatial reasoning function before they 
began ADT. Patients may have implemented a compensative mechanism that required 
testosterone to gain similar performance to healthy controls 81on tasks of spatial reasoning. 
However, this has implications when patients begin therapy as testosterone will be deprived. 
Therefore, these compensatory mechanisms may not be at play. This informs further research 
and facilitates the development and management of cognition in prostate cancer patients 
before and during therapy to prevent side-effects before therapy so they are not exacerbated 
during therapy. The second study of longitudinal performance in healthy controls showed that 
cognitive and neural; function was reliable and stable across a period of six months. This 
confirmed that the sample was well matched to patients for age and intelligence and provides 
better robustness for the cross-sectional study which assessed patients and controls. 
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CHAPTER 1 
1.0 Introduction 
Androgen deprivation therapy (ADT) is an effective treatment for more locally advanced 
prostate cancer (PC) and acts by moderating hormone levels to prevent cancer metastasis 
thereby prolonging PC survival. However, adverse effects of ADT have been reported, 
particularly in relation to reductions of testosterone. There is also evidence that changing 
hormone levels can moderate cognitive functions, however, existing literature exploring the 
cognitive side effects of ADT is inconsistent and the number and scope of investigations is 
limited. The present study aimed to investigate the nature and basis of cognitive changes that 
occur before ADT using multi-model behavioural and neuroimaging techniques.  
This chapter presents the current literature around prostate cancer and its treatment; the 
effects of androgen deprivation therapy (ADT) among men with prostate cancer and a 
broader picture of how changes in testosterone affect cognition. Finally, the chapter presents 
the current literature around cognitive changes in men with prostate cancer who receive ADT. 
An underexplored area of past literature is the comprehensive assessment of cognition and 
underlying brain changes that occur in PC patients before commencing ADT. Therefore, the 
current investigation was conducted with comprehensive cognitive measures and 
neuroimaging methods before PC patients began ADT. Additionally, past assessments have 
suffered from unmatched control cohorts. Therefore, a further exploration of healthy controls 
was undertaken over a longitudinal period to identify factors that may affect cognition over 
time and to validate that healthy controls were matched in the comparison to patients and 
controls. 
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1.1 Background to PC and its treatment 
The prostate is a gland found in the male reproductive system responsible for secreting an 
alkaline fluid that makes up almost 30 percent of the volume of semen, sperm and seminal 
vesicle fluid (Huggins, Scott, & Heinen, 1942). The alkalinity of semen thereby allows 
neutralization of acidic content of the vaginal tract to prolong the lifespan of sperm (Huggins 
et al., 1942). The prostate has been classified into five zones including the; peripheral zone, 
central zone, transition zone and anterior fibro-muscular zone. Out of these five zones, the 
peripheral zone is located in the posterior portion of the prostate gland that surrounds the 
urethra and has been found to be the most prone to cancer where almost 70-80% of prostate 
cancers are found (Haffner et al., 2009). 
The incidence of PC has been rising. There were 576 males with PC per 100,000 males 
between the ages of 65-69 in the UK in 2013 (Cancer Research UK, 2013). By the ages of 
75-79 years this incidence rate rose to 815.2 per 100,000 (cancer Research UK, 2013). The 
total number of new PC cases diagnosed in 2013 was 47,300 cases (Cancer Research UK, 
2013). This increased from the year 2011 when the number of PC cases diagnosed was 
41,736 (Cancer Research UK, 2011). On average, more than half (54%) of males over 70 are 
diagnosed with PC (Cancer Research UK, 2013). This may be because males over the age of 
50 have been shown to have an increasing number of microscopic focus adenocarcinomas 
compared to younger samples in the prostate gland that eventually become larger glandular 
carcinomas (Scardino, 1989). Increased incidence and prevalence rates may reflect in part, 
improvements in the detection of prostate cancer including  prostate specific antigen tests 
(PSA) and transurethral re-sectioning surgeries that reveal tumour formations (Mayor, 2012). 
Ninety four percent of PC patients have been shown to survive after one year of diagnosis, 
85% after five years and 83.8% after ten years. Therefore, individuals are more likely to 
survive a PC diagnosis due to early discovery (Scardino, 1989). Consequently, due to 
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increased survival rates, current research has now moved focus to the side-effects of 
treatments.  
 
Cancer occurs due to epigenetic and genetic changes to normal cells (Prendergast, Metz, & 
Muller, 2010). This variation in cell structure may lead to abnormal cell formations and then 
to tumorigenesis (Mills, Ferguson, & Alt, 2003). Cell augmentations may be evident in the 
prostate gland which progress to PC through tumorous developments (Butcher & Boland, 
2012). Diagnosis of cancer is accompanied by a Gleason histologic score or grade that has 
been acquired though tissue biopsy of the prostate gland (Draisma, Postma, Schröder, van der 
Kwast, & de Koning, 2006). This grading is a dominant predictor of biologic behaviour and 
has an important role in patient treatment pathways (Draisma et al., 2006). The Gleason 
system is used to evaluate PC prognosis from microscopic tissue samples acquired during a 
biopsy of the gland by appearance of the microscopic prostate tissue. The Gleason score 
ranges from 1 (well segregated small identical circular glands where tumour formation does 
not invade into healthy prostatic tissue) to 5 (poorly segregated glands with loss of 
architecture and tumour incursion into the majority of the gland). The Gleason score (GS) is a 
combination of a primary and secondary score (Freeman & Coard, 2004). The primary 
pattern is assigned to the main trend of the tumour which typically forms more than 50% of 
the total pattern (Pierorazio, Walsh, Partin, & Epstein, 2013). The secondary grade is given to 
the next most prevalent pattern recognised which forms less than 50% of the overall pattern 
seen (Pierorazio et al., 2013). Therefore, the lowest possible score is 2 (non aggressive) and 
highest possible score is 10 (very aggressive) (Freeman et al., 2004; Huang et al., 2014). A 
final grade component may be recognised forming a tertiary part of the pattern which is 
generally more aggressive (Pierorazio et al., 2013). Many studies have showed that patients 
with a GS of more than 7 are at greater risk for extra-prostatic adenocarcinoma growth or 
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biochemical recurrence (Green, Hanlon, Al-Saleem, & Hanks, 1998). The utility of the GS 
has been assessed in the grading of tumours at grade 7. This is because a primary score of 
four plus a secondary score of three may be more likely to increase the chances of mortality 
compared to a primary score of three plus a secondary score of four as the more prominent 
pattern is the primary pattern. A study by Stark et al. (2009) found that 4+3 cancers were 
associated with a three-fold increase in aggressive PC (measured by PC mortality rates) 
compared to 3+4 (95% CI, 1.1 to 8.6). This indicates that primary scores should be given 
more attention in PC diagnosis if the score is high especially in GS 7 diagnosed cancers. 
Inter-observer concordance of Gleason score ratings between pathologists show discrepancy 
between distinguishing prostatic gland abnormalities identified as being either levels six or 
seven (Freeman & Coard, 2004). This may have implications on either over or under-grading 
of tumour severity. This may lead to treatment which may be damaging to healthy tissue if 
under-grading occurs or over administration of treatment if under grading. This may 
inevitably affect mortality and therefore consensus between physicians is required. This 
effect has been attributed due to low biopsy volumes and the Will Rogers phenomenon in 
which there is a systematic upgrading in GS known as a Gleason shift (Freeman & Coard, 
2004; Stark et al., 2009). This has been found to occur because researchers have 
recommended that Gleason scores from 2-4 should not be identified from biopsy of the 
prostate (Epstein, 2000). The assignment of the Gleason score is based on the predominant 
tumour grade and secondary tumour grade. This results in an increase in the Gleason score 
for many patients which may falsely increase the Gleason score due to the lack of biopsy 
availability. This may lead to upgrading of 2 and 3 Gleason scores to higher levels that lead 
to intra-observer discrepancies and incorrect treatment options.  
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1.1.2 Treatments and management 
Treatment choices for PC depend on the grading of cancer at the time of diagnosis. Methods 
to treat PC vary and come with advantages and disadvantages. A common and longstanding 
form of treatment for PC includes radical prostatectomy that involves the complete removal 
of the prostate gland (Anandadas et al., 2011; Petry et al., 2004). This approach has been used 
in forms of localised and metastatic PC in the primary phase and if cancer reoccurs after an 
initial treatment for localised PC (Metcalfe, Smaldone, Lin, Aparicio, & Chapin, 2017). The 
effectiveness of prostatectomy has been demonstrated when PC is locally advanced and 
aggressive requiring a rapid solution to prevent metastatic spread (Graefen & Schlomm, 
2012; van Poppel, 2014). Orchiectomy is another technique that has been used to surgically 
castrate patients to depress the hormonal production of testosterone (Eisenberger et al., 1998). 
Surgical castration lowers the ability of cancer cells to metastasise through testosterone 
binding mechanisms. Prostatectomy on the other hand removes the chances for tumour 
manifestations to be acted upon due to site removal, leading to retardation of prostate cell 
growth (Eisenberger et al., 1998). The effectiveness of surgical ablation has been investigated 
and found to reduce metastasis, and mortality from any cause (Bill-Axelson et al., 2008; 
Holmberg  et al., 2002). A study assigned 166 of 347 males with localised PC for radical 
prostatectomy and 201 patients to a watchful waiting condition with follow-up over 12.8 
years (Bill-Axelson et al., 2008). Researchers found significant differences (p<0.01) in 
mortality rates in which 55 (14.6%) men assigned to surgery died and 81 (20.7%) men 
assigned to watchful waiting died due to PC (Bill-Axelson et al., 2008). Furthermore, patients 
with low grade tumours benefitted more from radical prostatectomy. A shortcoming was that 
the average age of participants was 65, therefore it is not known whether these findings 
extend to older patients.  Bilateral orchiectomy although uncommon was considered the gold 
standard for androgen surgical suppression (Gomella, 2009). The half-life of native 
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testosterone was found to be reduced to 45 minutes (Gomella, 2009) with castrate levels of 
testosterone reached in only 8.6 + 3.2 hours (Lin, Chen, Chen, & Chang, 1994). 
Improvements in patients with metastasis were moreover seen in the first 24 to 48 hours 
(Gomella, 2009). A negative aspect of orchiectomy was of the irreversible nature of the 
procedure and has therefore been associated with a significant psychological impact (Boccon-
Gibod, 2005). Mood disorders such as anxiety and depression have been commonly reported 
in orchiectomy patients and found to stem from a number of factors including impotence and 
the feeling of loss of manhood (Louda et al., 2012). Psychosocial side-effects may be 
partially resolved by the use of testosterone replacement therapy (TRT) but plasma 
testosterone levels may never fully recover to pre surgical levels. Moreover, TRT is not 
viable in PC patients since it has been linked to PC stimulation and may lead to rising PSA or 
cancer recurrence (Rhoden  & Morgentaler 2004). As a result, orchiectomy may induce 
lifelong psychosocial and cognitive impairments that are never fully resolved but can only be 
partially managed (see section 1.3 for the effects of testosterone on cognition). However, 
ADT allows testosterone suppression without surgical intervention to orchiectomy levels with 
a better prospect to resume daily living and quality of life, as testosterone levels return to 
normal after 18-24 weeks of the deprivation period (Murthy et al., 2006; Sun, Choueiri, 
Hamnvik, & et al., 2016).  
Another form of treatment for PC is brachytherapy which is the technique of surgically 
inserting a radiated seed in the cancerous area (Blasko, Grimm, & Ragde, 1993). 
Theoretically, brachytherapy has been found to be advantageous as it can be administered in 
a highly confined area of cancer growth (Blasko et al., 1993). The effectiveness of 
brachytherapy has been demonstrated when administrated in temporary dosages combined 
with external beam therapy or as a permanent implant that loses strength over an extended 
period of time (Blasko et al., 1993; Yu et al., 1999). Moreover, the efficacy of high dose rate 
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brachytherapy (HDR-BT) has been evaluated compared to patients undergoing combined 
HDR-BT and external beam radio therapy (EBRT) in patients with tumours graded between 
Gleason score 2 to 10 (Smolska-Ciszewska et al., 2015). A further treatment option found to 
be effective in the management of PC is cryotherapy which is administered as a primary 
treatment or as an adjuvant therapy (Nguyen, Allen, & Pow-Sang, 2013). Cryotherapy is 
administered at extremely low cryoprobe temperatures to initiate ablation to the prostate 
gland tissue, thereby causing it to lose function (Shinohara, 2003). The above-mentioned 
treatments for PC have been effective in remission and reduced cancer recurrence when 
applied correctly. The recurrence free rates detected through rising PSA levels >20ng/ml 
(suggests major risk of PC) of PC after prostatectomy has been found to be more that 80 
percent over a period of five years (Han et al., 2003; Walsh, 2000). Long term biochemical 
relapse survival has been shown to be 74% after 15 years of bracytherapy treatment in one 
study (Sylvester et al., 2007). Cryotherapy has also been found to prevent biochemical 
relapse by up to 84% after 8.9 months of the therapy (De La Taille et al., 2000). Another 
study showed biochemical free prostate recurrence using cryotherapy as being 64% after 10 
years (Siddiqui et al., 2016). Although the treatments described have low to medium 
recurrence rates, they involve the removal of the prostate or source organs involved in 
supplying androgens to the prostate. Whilst these methods are effective in halting cancer 
progression, they have been known to cause irreversible tissue damage to source organs and 
to healthy surrounding tissue which are not involved in cancer. This can lead to lifelong 
consequences that affect patients psychologically, physiologically and are difficult to 
manage. These side-effects include urinary incontinency, rectum pain, bowel dysfunction, 
erectile dysfunction, impotence and feeling of loss of masculinity (Bill-Axelson et al., 2014; 
Oliffe, 2005; Steineck  et al., 2002). Many of these adverse effects can be treated but may 
require permanent assessment, medication or therapy.  
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A cornerstone treatment of advanced PC is androgen deprivation therapy (ADT). Androgen 
deprivation therapy has been used to down-regulate testosterone production and decrease the 
likelihood of the tumour microenvironment gaining access to testosterone for growth 
(Butcher & Boland, 2012). It was first initiated as a treatment method for PC in 1959 as a 
drug called diethylstilbestrol (DES) and worked by suppressing luteinizing hormone-
releasing hormone (LHRH) (Byar, 1972). This led to reductions in bony metastases (Byar, 
1972). Moreover, researchers showed that orchiectomy combined with DES was not 
cumulatively beneficial compared to standalone DES and that 1mg DES was comparable to 
5mg DES on PC survival (Byar, 1972). However, findings also showed an association of 
DES with cardiovascular toxicity and was therefore not a favoured form of ADT (Malkowicz, 
2001). The LHRH was purified in later years in which chronic exposure to LHRH supressed 
testosterone by desensitising pituitary cells (Schally et al., 1971) with a lower incidence of 
cardiovascular risk (The Leuprolide Study Group, 1984). The above literature demonstrates 
that ADT was a more viable option to treat PC without causing irreversible damage to the 
prostate gland and to surrounding tissue.  
Many forms of testosterone suppression treatment have been documented. The main forms 
recognised in past research are oestrogens, steroidal anti androgens, non-steroidal anti 
androgens, 5α reductase inhibitors and the most commonly administered luteinizing hormone 
releasing hormone (LH-RH) agonists and antagonists (e.g. goserelin acetate) (Miyamoto, 
Messing, & Chang, 2004). Administration techniques include subcutaneous patches, 
intramuscular injection or in oral pill form (Nyman, Andersen, Lodding, Sandin, & 
Varenhorst, 2005; Perlmutter & Lepor, 2008). Additionally, treatment conventionally ranges 
between three to four months continuous or one to twelve months intermittent treatment 
durations (Tunn et al., 1998). Approximately 50 percent of PC patients are reported as 
receiving ADT as an induction therapy before the main treatment or as a standalone therapy 
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(Green et al., 2004). Only one study has compared different LHRH agonists (Heyns, 
Simonin, Grosgurin, Schall, & Porchet, 2003). Findings revealed higher survival rates with 
triptorelin pamoate compared to leuprolide acetate (90% vs. 90.5%) in a nine month 
retrospective randomised controlled study (Heyns et al., 2003). Although this was not 
significant at a pharmaceutical level, there was a trend for triptorelin to maintain superior 
castrate levels over nine months. Whilst these findings point to similarities between LHRH 
subcategories on survival and testosterone suppression, a limitation to the study was that a 
variety of LHRH variants exist that could be compared. 
The effectiveness of ADT has been evaluated in a number of studies. One study compared the 
effects of LHRH to anti-androgen monotherapy in patients with localised PC (Raina, 
Pahalajani, Agarwal, & Zippe, 2007). One group of patients received LHRH agonist 
monotherapy and the other group received anti-androgen monotherapy over the course of 
four years. Findings verified that LHRH was more effective in suppressing PC metastatic 
growth compared to anti-androgen therapy, measured by prostate specific antigen (PSA) 
levels (1.6% vs. 57.1% respectively) (Raina et al., 2007). Furthermore, patients undergoing 
LHRH reached nadir levels of PSA (<0.1 ng/ml) more quickly compared to the antiandrogen 
group. Outcomes indicate that patients undergoing anti-androgen therapy required continuous 
monitoring of PSA levels, and if increases in PSA were present then a switch was required to 
other anti-androgens. Nevertheless, a study assessing the effectiveness of ADT in prolonging 
survival for older men with localised PC, found that ADT was not associated with increased 
survival benefits (Holmes, Chan, Jiang, & Du, 2007). Crude overall mortality was in fact 
higher in the ADT group compared to non-ADT group (hazard ratio =1.54; 95%) (Holmes et 
al., 2007). However, this mortality risk reduced in the non-ADT group after controlling for 
socio-demographic factors (education, percentage living below the poverty line and median 
annual income), tumour features and chemotherapy regimens over the 10 year period. 
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Shortcomings to the study included that patients were older than 65 years of age therefore the 
findings may not be transferable to younger patients. Moreover, medical profiles were not 
provided for patients who had had surgical interventions (orchiectomy, prostatectomy) in 
non-ADT patients or any combined treatments such as additional anti-androgens 
(bicalutamide lead ins etc.), which could be more effective in preventing mortality. Finally, 
males in the age range were more likely to have higher Gleason scores, comorbid conditions 
and be of an older age, which could significantly contribute to age advancing mortality and 
morbidity. For example, ageing when combined with ADT has been associated with a greater 
risk of developing Alzheimer’s disease (Nead et al., 2016). One study assessed 16,888 
subjects with PC with the Kaplan Meiger age stratified analyses to quantify the number of 
patients undergoing ADT that also developed Alzheimer’s disease. Patients who were 70 
years of age and undergoing ADT were found to have a 2.9% probability of developing 
Alzheimer’s disease, over five years compared to younger ADT PC (1.9% probability) and 
age matched non-ADT PC (0.5%) patients calculated with hazards ratio (Nead et al., 2016). 
This suggests that ADT may play a role in the development of Alzheimer’s disease in 
especially ageing participants leading to cognitive impairment (Baudic et al., 2006). The 
development of Alzheimer’s disease may also have a larger role to play in post ADT 
medication regimens, cancer recurrence and mortality rates in geriatric populations.    
 
Although ADT provides a significant clinical response in PC it has been shown that  PC often 
becomes independent of androgens and inevitably leads to metastatic growth regardless of 
androgen deprivation (Miyamoto et al., 2004). LHRH in combination with anti-androgen 
medications appears to be the most effective hormonal treatment method for treating PC in 
the primary treatment stages (Boccardo et al., 1993; Crawford et al., 1989; Janknegt et al., 
1993). However, alterations to medications are recommended when PC becomes independent 
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of androgens. Combined androgen blockade with anti-androgens has been hypothesised to 
lead to a better quality of life as it has been shown to preserve gonadal function compared to 
LHRH monotherapy that has been known to incapacitate gonadal function (Miyamoto et al., 
2004). Despite the reported efficacy of ADT, a myriad of life affecting adverse effects are 
reported in an estimated 80-90 percent of patients (Green et al., 2004). These are presented in 
the next section.  
 
1.2 Side effects and consequences of ADT use in men with prostate cancer 
Physical side-effects of ADT have been described as being the most immediate and 
noticeable of the effects. The initial flare effect reported after LHRH agonist administration 
has been described being the most distressing and serious physiological outcome 
(Thompson, 2001). Past research has shown that approximately 4-11% of patients are 
reported to experience the flare effect and report side effects of the initial flare (Bubley, 
2001; The Leuprolide Study Group, 1984). This effect occurs in the first one to two weeks 
when LHRH agonists attempt to hamper the normal release of LHRH from the 
hypothalamus (Thompson, 2001). Naturally occurring luteinizing hormones (LH) are 
known to peak at three times the baseline level during this period (Waxman et al., 1985) 
resulting in LH stimulation of leydig cells in the testes which exacerbates testosterone 
production (Chen, Hardy, & Zirkin, 2002). Patient have reported that this is uncomfortable 
and is often associated with pain during the first 36 hours of administration (Thompson, 
2001). Nevertheless, researchers have shown that testosterone levels typically return to 
normal levels three weeks after LHRH administration (Thompson, 2001). Complications 
from the initial flare effect include lymphedema (8.7%), urinary obstruction and retention 
(2.7%), spinal compression (4.7%) and death (1.56%) (Kahan, Delrieu, Amor, Chiche, & 
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Steg, 1984; Kreis, Ahmann, Jordan, de Haan, & Scott, 1988; Thompson, Zeidman, & 
Rodriguez, 1990; Waxman et al., 1985). Blockade of flare has been explored through the 
administration of specific additional drugs during the initial lead in period ranging from of 
one week to one month. Agents such as cyproterone acetate (CPA) (Boccon-Gibod, Laudat, 
Dugue, & Steg, 1986), flutamide (Crawford et al., 1989), nilumide (Kuhn et al., 1989) or 
ketoconazole (Allen et al., 1983) have been found to blunt the flare effect.    
 
Other adverse effects of ADT include loss of libido, erectile dysfunction, and hot flashes. 
Amelioration of these side effects requires additional medications such as Venlafaxine, 
gabapentin (Prostate Cancer, 2006; Sountoulides & Rountos, 2013). Non-pharmacological 
interventions have also been found to be effective for hot flashes and erectile dysfunction 
(Stefanopoulou, Yousaf, Grunfeld, & Hunter, 2015). Further treatments such as calcium 
and vitamin D supplements can help reduce side-effects such as osteoporosis (Sountoulides 
& Rountos, 2013). Anaemia is another effect reported in 90% of patients and can occur due 
to a multitude of factors. One important variable to consider is that androgens have been 
known to stimulate erythropoiesis which is a process that allows the formation of red blood 
cells (Crafts, 1946). Therefore deprivation of androgens could reduce this effect leading to 
lower blood counts and anaemia may result. Due to low haemoglobin levels anaemia may 
lead to fatigue - reported in 14 percent of patients undergoing three months of ADT 
(Prostate Cancer, 2006). Insulin resistance is a serious metabolic side effect reported of 
ADT which could progress to diabetes and increased cardiovascular problems 
(Sountoulides & Rountos, 2013). Diabetic medications and statin therapies are commonly 
prescribed to treat these conditions (Prostate Cancer, 2006). A further side effect reported 
in the vast majority (50%) of patients is gynecomastia which can be treated by prophylactic 
radiation (Viani, Bernardes da Silva, & Stefano, 2012).  
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Past literature has shown that participants may experience behavioural changes such as 
problems with cognition in domains of executive functioning, spatial reasoning and 
memory. These changes may occur due to many comorbid factors or treatments used to 
control comorbidities. Comorbid variables in ADT patients may include diabetes, high 
cholesterol levels, fatigue or mood changes. Patients undergoing ADT are 60% more likely 
to develop type 2 diabetes compared to healthy males in the general population (Tsai et al., 
2015). Whilst diabetes in itself has been associated with cognitive impairment (impaired 
executive function and motor speed) even at early stages of discovery (Kodl & Seaquist, 
2008; Ruis et al., 2009; Yeung, Fischer, & Dixon, 2009) treatment of it could intensify this 
effect. One study assessing the usage of metformin among diabetes sufferers found 
participants with diabetes had worse cognitive performance compared to those without 
diabetes. Additionally, diabetics medicated with metformin, had lower general cognitive 
status (mini-mental state exam) scores compared to unmedicated participants. (Moore et al., 
2013). Mechanisms by which metformin may lead to cognitive impairment include through 
its downregulation of vitamin B12 which can lead to cognitive instability (Lachner, Steinle, 
& Regenold, 2012). This is important since metformin is a first line medication, prescribed 
initially due to its efficacy when type 2 diabetes is diagnosed to lower blood glucose levels 
(Rojas & Gomes, 2013). Thus it could lead to cognitive deficits in patients undergoing 
ADT (Rojas & Gomes, 2013). Limitations of the study included that durations of 
metformin use were not reported, severity of diabetes was not reported and only one 
cognitive assessment was implemented to assess cognition. Another study examined the 
effects of metformin on β-amyloid precursor protein (APP) in neurons of mouse models 
(Chen, Zhou, et al., 2009). Outcomes revealed that metformin administered at the levels of 
activating AMP-activated protein kinase (AMPK) increased the generation of Aβ proteins 
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(Chen, Zhou, et al., 2009).  This was found to be due to the upregulation of β-secretase 
(BACE1) resulting in raised protein levels and enzyme activity (Chen, Zhou, et al., 2009). In 
conclusion, metformin did not exert an effect on Aβ degradation which is in contrast to the 
observations made when insulin monotherapy is administered. Thus, metformin monotherapy 
may lead to harmful consequences in geriatric patients with diabetes and could initiate 
cognitive impairments in ADT patients with diabetes. 
Other areas of research show that patients undergoing ADT are susceptible to developing 
high cholesterol levels and are prescribed statin therapies (Mohamedali, Breunis, Timilshina, 
& Alibhai, 2011). Statins have been widely associated with cognitive deficits (Mohamedali et 
al., 2011). The food and drug administration (FDA) have received reports that some widely 
used statins (atorvastin, fluvastin, simvastin etc.) can lead to symptoms of memory loss and 
confusion but which after cessation are reversed and resolved (Administration, 2014). In 
contrast to this warning, some reviews have shown that no cognitive impairments were 
associated with statins (Gauthier & Massicotte, 2015; Gracias, Garrison, & Allan, 2014; 
Richardson et al., 2013).  
 
Finally, mood disorders are commonly diagnosed in patients undergoing ADT. Rates of 
depression in ADT patients are eight times higher than in the general population (Prostate 
Cancer, 2006). Longitudinal studies exploring depression in ADT patients have shown 
differences in depression and anxiety levels across treatment periods. One study reported 
that patients (mean age=68.9, SD=2.5) undergoing ADT experienced adverse effects 
including confusion and depression compared to age matched patients undergoing 
oestrogen therapy and healthy controls at four weeks into ADT (Beer et al., 2006). 
However, a limitation was that mood assessments were not made after longer durations of 
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ADT. Another study also showed that ADT PC patients (mean age=62.05, SD=7.19) had 
greater levels of self-rated irritability, anxiety, moodiness and fatigue at nine months 
compared to age matched healthy controls (Cherrier, Aubin, & Higano, 2009). A further 
experiment by Almeida, Waterreus, Spry, Flicker, and Martins (2004) supports these 
findings showing that ADT patients (mean age=72.4, SD=7.5) had significantly higher 
anxiety and depression levels over a period of nine months compared to baseline. A 
limitation however was that no comparison groups were assessed in the study. As 
illustrated, mood factors are a prevalent side-effect of androgen blockade therapies. 
However, medications used to treat these conditions may be more harmful than beneficial. 
Anti-depressant medications are commonly administered to combat depression however, 
they have side effects of their own (NICE - National Institute for Health and Clinical 
Excellence Pathways, 2015). Researchers tested the effects of anti-depressant regimens 
including diothiepin and fluoxetine with outcomes showing that patients had lower 
performance on tests of sustained attention, concentration and memory with increased 
fatigue (Ramaekers, Muntjewerff, & O'Hanlon, 1995). As a result, anti-depressants may 
inadvertently lower quality of life and affect cognition (Stevanovic, Tadic, & Knez, 2014). 
On the other hand, a recent study by Greer, Sunderajan, Grannemann, Kurian, and Trivedi 
(2014) revealed that the antidepressant Duloxetine significantly improved cognition across 
several domains of psychomotor function, mental processing, and visual and verbal 
learning. The above literature demonstrates that many factors such as comorbities can 
affect cognition in PC patients undergoing ADT. Furthermore, treatments used to 
counteract these simultaneous side-effects have impacts on cognition that may not 
necessarily be beneficial. 
As is illustrated, many physical and behavioural comorbidities that develop as a result of 
ADT that can lead to cognitive impairment. Moreover, medications used to treat 
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comorbidities may have negative impacts on cognition. These impacts may lead to long 
term complications or improvements, depending on whether variables are considered risk 
or resilience factors. Despite reports of extraneous factors having an effect of PC patients, 
the direct effects of ADT on cognition have been reported in a past literature review. One 
meta-analysis and systematic review collated data from 14 studies (McGinty et al., 2014). 
An analysis of effect sizes showed PC patients undergoing ADT had impairments on tasks 
that required spatial reasoning with a reaction time motor component. Further support for  
the review comes from a recent meta-review in which 28 previously conducted reviews 
with 20 primary studies were statistically assessed (Treanor, Li, & Donnelly, 2017). The 
researchers’ analysis of effect sizes showed that the prevalence of cognitive impairment 
ranged from 10% to 69% in domains of executive function, spatial reasoning ability and 
verbal memory. This suggests there is a link between ADT and cognitive impairment. 
However, before exploring studies more specifically, the relationship between testosterone 
and cognition in other and similar contexts will be explored.   
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1.3 The Relationship between Testosterone and Cognition 
1.3.1 Data in Healthy Humans 
Testosterone has been found to modulate cognition in domains of memory, executive 
function, spatial reasoning and processing speed. The relationship between testosterone and 
these domains has been investigated in healthy participants. One study found that neither high 
nor low extremes of testosterone were associated with cognition whilst controlling for age 
(Muller, Aleman, Grobbee, de Haan, & van der Schouw, 2005).  The study aim was to find 
the optimal level of sex hormone that benefitted cognition in healthy participants (Muller et 
al., 2005). Researchers revealed an inverse relationship showing a negative linear relationship 
between decreasing testosterone levels and processing speed and executive function. 
Conversely, a positive relationship was found between increasing testosterone levels and 
cognitive function in the oldest males (70-80 years) (Muller et al., 2005). However, when 
quadratic terms were added to the multivariate model, a curvilinear relationship was found in 
males between the ages of 40 – 70. This relationship showed that processing speed and 
executive function performance increased up to the third quintile z-score distribution but then 
decreased as a function of testosterone level (Muller et al., 2005). Researchers therefore 
showed that higher total and bioavailable testosterone levels were effective to an optimal 
level of between 16.8 to 19.4 nmol/L and 8.4 to 9.9 nmol/L respectively but that levels 
beyond this point did not contribute to better processing speed and executive functions. No 
explanations can clarify the curvilinear relationship. However, the linear relationship 
observed in the oldest cohort may have been due to very low testosterone levels that left 
elderly participants vulnerable to cognitive deficits while cognitive imbalances in younger 
males were due to other factors.  
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Further support for a curvilinear trend between testosterone and cognition comes from two 
studies which found a similar pattern of relationships between spatial scores and androgen 
levels in both healthy males and females (Gouchie & Kimura, 1991; Shute, Pellegrino, 
Hubert, & Reynolds, 1983). Another study found that bioavailable testosterone levels were 
positively correlated with verbal and non-verbal learning (Morley et al., 1997). This suggests 
that mid-range testosterone levels could enhance cognition whereas lower levels that are 
similar to those of ADT patients, lead to cognitive declines. 
 
The relationship between testosterone and cognition in ageing individuals is not well 
understood. However, due to the known decline of testosterone as a function of ageing, it 
may be reasonable to infer that there are age related decreases in cognition that reflect 
declining testosterone levels. Research has shown that domains of executive function and 
spatial reasoning are especially affected as a function of testosterone decline in normal ageing 
males who are transitioning between middle age and elderly. One study assessed 310 older 
men  (mean age 73) and acquired serum and bioavailable testosterone levels (Yaffe, Lui, 
Zmuda, & Cauley, 2002). Outcomes showed higher scores in domains of general cognitive 
function (mini-mental state exam), executive function (trails B test) and working memory 
(digit symbol test) in participants with higher bioavailable testosterone levels compared to 
those with low levels (Yaffe et al., 2002). Serum testosterone and sex hormone binding 
globulin were not associated with any performance differences on any of the tests (Yaffe et 
al., 2002). A shortcoming was that groups were not matched by education as participants 
identified as having cognitive impairment were older and less educated. Another 
investigation in 981 middle aged and older males (40-80 years) initially found significant 
differences between testosterone and at least one task of either working memory, spatial 
reasoning ability, processing speed and attention (Fonda, Bertrand, O'Donnell, Longcope, & 
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McKinlay, 2005). However, after co-varying for age, education level and physical fitness, 
any significant differences found disappeared (Fonda et al., 2005).  The studies show that 
executive function and spatial ability specifically may be impaired as a function of 
testosterone decline in ageing. A confine to the study was that it was cross sectional and 
could not determine causation of cognitive decline through measurement of testosterone 
levels over time. 
Nevertheless, longitudinal studies have been conducted and revealed cognitive impairments 
in areas of memory and spatial abilities in elderly males. One study by Moffat et al. (2002) 
assessed the effects of normal endogenous serum testosterone levels and normal free 
testosterone levels in older males (51-91 yrs) on a battery of cognitive tests over an average 
of 10 years. Outcomes revealed better cognitive performance on tests of visual memory, 
verbal memory, spatial reasoning and visuo motor scanning which were associated with 
higher free testosterone levels. Moreover, greater mean free testosterone levels and upper 
longitudinal free testosterone levels were concomitantly associated with a decreased rate of 
visual memory decline (Moffat et al., 2002). Significantly worse scores on spatial reasoning 
measures were also correlated with visual memory degeneration in hypo-gonadal males 
(Moffat et al., 2002). The study showed a possible beneficial effect of free testosterone on 
cognition in contrast to the findings above (Moffat et al., 2002). A shortcoming was that 
participants classified as hypo-gonadal were on average eight years older than those 
participants with normal testosterone levels. Older participants are known to have cognitive 
difficulties due to older age and age may have been a confounding factor (Lunenfield, 2003). 
The study was followed up with a positron emission tomography (PET) study in 40 older 
males over a period of 14 years to assess regional cerebral blood flow (rCBF) (Moffat & 
Resnick, 2007). Researchers found that free testosterone positively correlated with rCBF in 
the left putamen, bilateral thalamus and left inferior frontal gyrus (Moffat & Resnick, 2007). 
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These findings show one method by which testosterone could exert an effect on cognition 
through cerebral blood flow. Moreover, this provides support for the hypothesis of the 
mediating effects of free testosterone and cerebral blood flow in facilitating certain cognitive 
functions. Additionally, as the nature of the studies were longitudinal, they allowed 
inferences to be made on causation of cognitive decline with age being co-varied into 
regressor models. Cerebral blood flow may be a factor to take into account in androgen 
deprivation patients. This is because testosterone is depleted during ADT leading to reduced 
cerebral blood flow in certain areas of the brain. This could impair cognition due to regional 
hypo-perfusion.  
However, some studies have not found an effect of declining testosterone levels on cognition. 
A study by Emmelot-Vonk et al. (2008) tested the effects of testosterone supplementation on 
hypo-gonadal males (aged 60-80) without cognitive impairment over a six month period. In a 
double-blind placebo-controlled study, participants receiving testosterone showed no 
differences on measures of cognitive functioning (Emmelot-Vonk et al., 2008). However, a 
shortcoming to the study was that participants were assessed over a short period of time. 
Nevertheless, the study was comparable to experiments conducted in the past with shorter 
follow up durations, where significant cognitive changes were reported. A further experiment 
also found no significant differences or correlations in testosterone substituted participants 
compared to a placebo hypo-gonadal group (Sih et al., 1997). 
Many contradictions in testosterone literature have been found regarding its role in cognitive 
modulation. These differences may occur because of variations in participant age, cognitive 
ability, level of hypogonadism, individual differences in testosterone mechanisms, duration 
of treatment and administration techniques (injection, gel, patch). Several studies also had 
small sample sizes. The delineation of hypo-gonadal varies and rejection of participants with 
low psychosocial function, cognitive impairment or depression varies widely among studies. 
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Any of these factors may be influential on the varying effects of testosterone findings, but 
together they suggest the effects of testosterone are subtle and specific to memory and spatial 
cognitive domains. Moreover, causes of cognitive decline in healthy ageing males have been 
attributed to a gradual decline in testosterone as a function of age in healthy ageing 
individuals (Wu, Yu, & Chen, 2000). The studies above show that affected areas are 
analogues to those areas affected in PC patients undergoing ADT. Therefore, these domains 
require careful consideration to separate out affected areas that are a function of normal 
ageing and those that are related to ADT. 
 
1.3.2 Data in Neurodegenerative Conditions Associated with Unhealthy Ageing. 
Studies conducted in cohorts with disorders and disease that are known to lead to cognitive 
impairments were examined to assess the effects of testosterone on these conditions. This 
may assist in clarifying the role of testosterone substitution in cognition independent of 
cancer and allows hypotheses to be formed in patients with PC. One study measured the 
effects of testosterone substitution in hypo-gonadal participants diagnosed with Alzheimer’s 
disease or mild cognitive impairment (Cherrier et al., 2005). Findings revealed that subjects 
substituted with testosterone for six weeks had better spatial memory scores, and 
constructional ability scores compared to a placebo group (Cherrier et al., 2005). Moreover, 
verbal memory scores of the placebo Alzheimer’s group declined compared to those who 
were administered testosterone which stayed the same (Cherrier et al., 2005).  
Indicators of the mechanisms behind testosterone and cognition from past literature of 
neurodegenerative disease suggest that testosterone may increase concentrations of nerve 
growth factor (NGF) (Freeman et al., 2004). This gene is commonly associated with 
maintenance, survival, and growth of neurons in areas such as the hippocampus (Freeman et 
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al., 2004). Testosterone has been demonstrated to especially upregulate NGF receptors in the 
forebrain area (Freeman et al., 2004).  One study explored the effects of testosterone on brain 
derived neutrophic factor (BDNF) which is a protein that is upregulated by NGF (Gold, 
Chalifoux, Giesser, & Voskuhl, 2008). Researchers investigated the protein in patients with 
multiple sclerosis (MS) (Gold et al., 2008) as they are known to have deficits of NGF 
(Acosta, Cortes, MacPhee, & Namaka, 2013). Researchers administered 100mg of 
testosterone in 10 human males with MS, which was applied through gel application once per 
day for six months. This increased T levels to above normal levels (Gold et al., 2008). 
Clinical assessments were undertaken every three months including blood samples and tissue 
samples from the forebrain area. Findings showed a significant increase in BDNF in forebrain 
tissue samples after six months of T administration (Gold et al., 2008). This suggests a 
potential neuroprotective role of testosterone supplementation. A limitation of the study was 
that a specific mechanism could not be identified behind this effect. This is because any 
effect observed may be due to the conversion of testosterone to other hormones such as 
oestrogen through aromatization after passing the blood brain barrier. This conversion is 
debated but is also known to be neuroprotective (Brann, Dhandapani, Wakade, Mahesh, & 
Khan, 2007). The posterior medial amygdala (MePD) is a further region that has been 
associated with testosterone modulating effects that may mediate some aspects of cognition. 
The area is  important for olfactory and pheromonal information and is dependent on 
hormones for function (Zuloaga, Puts, Jordan, & Breedlove, 2008).  
In other literature, androgens have been found to prevent cell death and toxicity. Androgens 
have been shown as being protective against N-methyl-D-aspartate (NMDA) agonist receptor 
excitotoxicity apoptosis in hippocampal neurons. This allows synapse actions to resume as 
cell death from excitotoxicity is prevented by androgens (Morse, DeKosky, & Scheff, 1992). 
Hippocampal synaptic activity has been found to occur when glutamate neurotransmitters 
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bind to NMDA receptors. This leads to synaptic transmission and potentiation in 
hippocampal pyramidal cells. (Pouliot, Handa, & Beck, 1996).  
 
1.4 Findings in PC patients Undergoing ADT 
1.4.1 Cognitive domains affected by testosterone depletion associated with ADT 
The testosterone studies and mechanisms highlighted above show how androgen levels may 
modulate cognition. However, contradictory outcomes have been found in studies evaluating 
the effects of ADT on cognition directly. There is mixed evidence on the specific domains of 
cognition that may be affected. The association between cognition and ADT is largely based 
on cross-sectional studies that have shown cognitive impairments in domains of verbal, 
memory, recognition memory, executive function and spatial reasoning (Bussiere, Beer, 
Neiss, & Janowsky, 2005; Jim, Small, Patterson, Salup, & Jacobsen, 2010) or no impairment 
in one study (Clay et al., 2007). However, due to the cross-sectional nature of the studies, 
they lack the ability to make temporal associations between risk factors and outcomes. 
Therefore, they are not as robust as investigations assessing patients over a period of time. 
Longitudinal studies have been conducted and are advantageous for the purpose of comparing 
treatment effects over time. This is because power is increased due to reductions in 
unsystematic error variance. This allows researchers the ability to detect systematic variance 
(Barrett, 2013). Moreover, it allows temporal associations to be made between risk factors 
and outcomes. Within subjects designs also allow individual change to be measured and 
requires smaller sample sizes to fulfil sample size requirements making studies less 
susceptible to type one and two errors.  
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Longitudinal assessments in PC patients undergoing ADT have found cognitive impairments 
in specific domains such as spatial reasoning. A nine-month prospective pilot study 
conducted by Jenkins, Bloomfield, Shilling, and Edginton (2005) assessed 32 (mean 
age=67.5, SD=4.7) PC patients undergoing LH-RH therapy (ADT) compared to age matched 
healthy controls. Findings initially demonstrated no cognitive group differences, however, 
analysis conducted with the reliable change index showed cognitive decline in the spatial 
reasoning domain compared to healthy controls. Although researchers did not find any group 
level interactions, outcomes showed an association between testosterone deprivation and 
spatial reasoning deficits. Shortcomings of the study were that it was not adequately powered 
therefore chance of errors were high.  
A further prospective 12 month investigation assessing a larger sample of 77 PC patients 
undergoing ADT (mean age = 69.3, SD=6.9) revealed that patients had worse spatial 
reasoning performance compared to age matched healthy controls. Moreover, patients had 
worse performance over time in domains of attention (immediate span) and working memory 
over time compared to controls although no group differences were found in these domains 
(Alibhai et al., 2010). Confines to the study were that the older ADT sample previously had 
more years of education and were in generally good health apart from PC (Alibhai et al., 
2010). This may constrain findings as the sample was not characteristic of the general PC 
older male population and hide any true group differences that would be apparent if the 
sample was from a normal distribution. Secondly, assessments of performance in some 
cognitive domains were measured with only one cognitive instrument which limits the 
robustness of findings by domains. Finally, a limitation of both studies above was that a 
healthy age matched sample was used rather than another PC group which was not 
administered any form of ADT. Another PC group may match more closely to ADT patients 
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as they are more likely to have comorbidities that reflect those of ADT patients. This thereby 
allows the isolation of ADT if all other factors are matched in both samples.  
 
Other assessments have found higher levels of complex processing are affected in ADT 
patients which could severely impact on daily functioning. One prospective study assessed 
the impact of ADT on cognition in 20 patients (mean age=62.05, SD=7.19) who had rising 
PSA levels without evidence of metastasis between baseline, three, nine and 12 month 
intervals (Cherrier et al., 2009). A group by time interaction revealed significant impairments 
in spatial reasoning and executive function domains in ADT patients at three months 
compared to baseline levels compared to age matched PC patients that were not administered 
ADT. However, cognitive performance measured between 9 and 12 months when treatment 
had ended was almost back to baseline levels. Nevertheless, some marginal discrepancies 
were evident in verbal ability, spatial ability and executive function domains at 9 and 12 
months. The study demonstrated that cognition deteriorated in ADT patients over the course 
of the ADT treatment period and marginal effects were present after cessation of therapy. 
However, a shortcoming was that patients were not followed up at longer post-treatment 
periods to assess if cognition returned to baseline levels. Researchers also recruited a small 
PC sample from a specialized oncology clinic which may be uncharacteristic of a normally 
distributed patient sample. Another larger investigation assessed 82 male patients with extra 
prostatic PC (mean age=73.3, SD=6.4) at baseline and six month follow up (Green et al., 
2002). A group by time analysis revealed that those patients administered LH-RH had 
significantly reduced executive functioning performance at six months compared to an age 
matched PC group administered cyproterone (anti-androgen steroid) (Green et al., 2002). 
Further, calculation using the reliable change index (RCI) showed the LH-RH group had 
declines on at least one cognitive task and seven participants in at least two cognitive tasks of 
26 
 
executive function (Green et al., 2002). A constraint of the study was that the close 
monitoring group had significantly higher baseline IQ scores compared to the LH-RH treated 
participants which led to biased differences. Therefore, lack of cognitive performance change 
may be due to higher baseline cognitive performance in the close monitoring group (Green et 
al., 2002). However one noteworthy aspect of both studies was that they included other PC 
groups that were administered other forms of treatment and matched ADT samples more 
closely compared to healthy controls. This suggests that the finding that executive function 
was affected in both studies was more robust since outcomes were discovered in a 
longitudinal study and groups were closely matched suggesting that ADT was the cause of 
these deficits. 
 
In contrast to the findings above, a study by Salminen et al. (2003) assessed cognition in 
LHRH administered PC patients compared to healthy controls between baseline, six and nine 
months (Salminen et al., 2003). Contrary to earlier studies, researchers found impairments in 
patients at baseline but improvements at six and twelve month follow-ups in domains of 
working memory, semantic memory and recognition memory (Salminen et al., 2003). No 
declines in any other cognitive domains or mood were found (Salminen et al., 2003). A 
constraint to the study was that assessments were not undertaken in controls at six and nine 
months (Salminen et al., 2003). Interpretations of the results were therefore restricted because 
the impact of practice effects could not be accounted for and patients could not be compared 
to normal distribution samples. This limits the interpretation of outcomes as normal ageing 
cognitive decline could not be separated from impairments due to the therapy. However, it 
does demonstrate that some cognitive deficits were present from baseline which warrants 
further investigation. 
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Outcomes from the studies reviewed above show mixed effects of ADT on cognition through 
cross sectional and longitudinal assessments. Furthermore, limitations of these studies such as 
participant attrition rates during longitudinal follow-up may have confounded outcomes. 
Nevertheless, a conducted systematic review and meta-analysis combining findings from 
previously conducted systematic reviews and meta-analyses assessing the effects of ADT on 
cognition has shown that ADT patients were most affected in domains of verbal fluency, 
verbal memory, spatial reasoning and executive functioning (Treanor et al., 2017). This lends 
support to an effect of ADT on spatial reasoning and higher level functions that are sub 
domains of executive function. Further research is therefore required to assess these domains 
in more depth with comprehensive neuropsychological batteries to limit shortcomings of past 
literature. This may also facilitate characterisation of cognition before patients begin ADT to 
allow researchers to assess cognition and develop strategies to prevent further cognitive 
decline during treatment. 
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1.4.2 Neural changes in ADT 
The above literature shows that testosterone does modulate cognition in some specific 
domains suggesting that specific brain regions are susceptible to the effects of testosterone 
depletion. Researchers examining neural changes in ADT patients have found mixed effects 
of the therapy in human cohorts. A study by Cherrier, Borghesani, Shelton, and Higano 
(2010) assessed 12 non-metastatic PC patients (mean age=65) treated with ADT for nine 
months (Cherrier et al., 2010). Functional magnetic resonance (fMRI) imaging was used to 
measure brain activation on a comprehensive battery of tasks that measured spatial reasoning 
ability at baseline and nine months (Cherrier et al., 2010). Findings showed decreased BOLD 
activation in the right parietal occipital region in ADT patients compared to 12 age matched 
healthy males, who had no such decreases at nine months compared to baseline (Cherrier et 
al., 2010). A shortcoming to the study was that task related BOLD performance differences 
were not subjectively or behaviourally assessed. Moreover, patients were highly educated 
which may not be true of the general population of PC patients. However, an attempt was 
made to match participants by age and education.  
A further fMRI study found that other cognitive domains were affected that required higher 
order processing. Researchers tested 15 non-metastatic PC patients undergoing ADT (mean 
age=69, SD=5.3) against 15 age matched non-metastatic PC patients who were not 
administered ADT (Chao et al., 2012). Researchers implemented an n-back working memory 
task and stop signal inhibition task to assess working memory and executive function (Chao 
et al., 2012). No performance differences were found at six months compared to baseline 
suggesting that both domains remained unaffected as a result of ADT (Chao et al., 2012). 
Nevertheless, a significant group by time interaction showed decreased BOLD activation on 
the stop signal task in the medial prefrontal cortex, right insula, and right inferior frontal 
gyrus at follow up (six months) vs. baseline (Chao et al., 2012). Resting state fMRI revealed 
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differences in resting state networks showing decreased connectivity in ADT patients 
between the right dorsolateral prefrontal cortex, insula and rostral anterior cingulate cortex 
when contrasted to the control group (Chao et al., 2012). The study therefore demonstrates 
differences in brain activity and task related BOLD activation of the ADT group compared to 
controls.  
In a second publication, Chao et al. (2013) used voxel based morphometry (VBM) to track 
altered brain and tissue composition in the same sample as in their 2012 study. Researchers 
also administered a verbal working memory n-back task. Participants were tested again as 
before in a prospective six month study (Chao et al., 2013). Decreased gray matter volume in 
the primary motor cortex, fronto polar cortex, and dorsolateral prefrontal cortex were found 
(Chao et al., 2013) in ADT patients compared to controls, despite there being no performance 
differences between groups. The above studies were valid due to ADT patients being closely 
matched to PC patients that were not undergoing ADT suggesting that ADT was a causal 
factor that affected PC patients specifically. This makes findings of executive function 
deficits more robust than those of spatial functioning (Cherrier et al., 2010). Nonetheless, the 
studies employed a less comprehensive battery of assessments to measure working memory 
and executive function (Chao et al., 2013; Chao et al., 2012). This may explain the lack of 
behavioural differences found compared to neural impairments that were not explained by 
functional task neural activity but resting state and structural assessments. Moreover, patients 
were on a restricted duration of ADT and a small sample size was investigated (Chao et al., 
2013; Chao et al., 2012). The impact of this is that the reliability and validity of the study 
may be compromised and chances of errors made were high as the study was not powered. 
On the other hand, Cherrier et al. (2010) had a small sample size but employed a 
comprehensive battery of assessments to assess spatial functioning which made outcomes 
more consistent across various aspects of spatial cognition. 
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Brain imaging literature of ADT patients suggests that ADT may be a causal factor that 
affects putative executive functioning and spatial reasoning areas of neural architecture. 
Whilst the studies showed that there were underlying associations between testosterone 
deprivation and cognition, they lacked the comprehensive assessment of cognition across 
domains. Nevertheless, the studies show that spatial reasoning and executive functioning 
networks may be affected in some way but require further investigation to assess if these 
adverse effects are present before ADT to later treatment periods. Both neuropsychological 
and neural literature show that spatial reasoning and executive functions were affected in 
patients undergoing ADT. Therefore, further assessments are required to assess these 
domains in more depth with comprehensive neuropsychological batteries and with some 
complementary techniques such as brain imaging to measure underlying cognitive constructs. 
This may facilitate in reflecting neural correlates of behavioural cognition but may also 
reveal further components that affect cognition which are not overtly visible through 
behavioural assessment alone in patients and ageing cohorts. Moreover, if these factors can 
be identified at baseline, then physicians may be able to create strategies to prevent further 
cognitive decline during therapy. This will allow patients to make informed decisions before 
ADT and to know if adverse effects occur that can be controlled. This could affect further 
treatment uptake and continuation. 
 
1.5 Effects of Normal Ageing on Cognitive Domains Affected 
The literature above shows deleterious effects of ADT in PC patients. However, these 
adverse effects may be age related and experienced as a normal function of ageing. 
Cognitive areas known to be affected by age related andropause include executive function, 
working memory and spatial reasoning (Janowsky, Oviatt, & Orwoll, 1994; Starkstein & 
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Kremer, 2001; Yogev-Seligmann, Hausdorff, & Giladi, 2008) which are closely linked to 
impairments found in PC patients undergoing ADT (Treanor et al., 2017). These domains 
are known to be involved in higher level multidimensional constructs involving short-term 
memory, longitudinal memory, problem solving, decision making, mental manipulation and 
language. Although literature exists maintaining their limited capacity in older samples, 
these aspects of cognition are important in preserving daily function and quality of life that 
warrants further investigation (Barrios et al., 2013; Vaughan & Giovanello, 2010; Williams 
& Kemper, 2010).  
Numerous explanations behind age related deficits have been hypothesised. However, some 
researchers suggest that age related inhibition failure may be the source of cognitive 
deficits. Inhibition refers to the failure to suppress irrelevant stimuli in order to maintain or 
manipulate relevant stimuli essential for cognition (Alichniewicz, Brunner, Klünemann, & 
Greenlee, 2013; May, Hasher, & Kane, 1999). However, the overarching inhibition 
hypothesis may be oversimplified in attempting to explain the myriad of factors that are 
known to affect cognition in elderly samples. A more complete view of inhibitory functions 
may include executive function which incorporates many facets of higher level cognitions 
that are known to deteriorate in ageing cohorts. One study assessing executive function 
employed a zoo map test which requires formation and planning and is an ecological 
planning subtask with two variants (Allain, Nicoleau, Pinon, Etcharry-Bouyx, Barré, et al., 
2005). The task was split into two parts and had a high demand component that required 
advanced planning. The second task was low demand in which participants were required 
to go to destinations from an externally made plan. Findings revealed a significant 
difference in the high demand formulation task in which older adults had problems in 
forward planning compared to young adults (Allain, Nicoleau, Pinon, Etcharry-Bouyx, 
Barré, et al., 2005). However, there were no significant differences in the second 
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component task (Allain, Nicoleau, Pinon, Etcharry-Bouyx, Barré, et al., 2005). This 
suggests that older adults had difficulty in planning and problem solving but were able to 
implement intricate pre-set plans.  
Another area commonly affected in ageing is verbal ability which has generally been sub-
categorised as a hybrid domain of executive function (Shao, Janse, Visser, & Meyer, 2014). 
Researchers assessing verbal ability administered a multilingual aphasia task to healthy 
older (mean age = 81) participants in one study (Schum & Sivan, 1997). A significant age 
related impairment was found in the sentence repetition sub test. A limitation to the study 
was that the sentence repetition test used high memory demands therefore besides testing 
verbal ability, it may also have assessed short-term and serial auditory information 
processing. This could be a sub domain of working memory rather than executive function 
and verbal ability. However, working memory may also be categorised under executive 
functioning (McCabe, Roediger, McDaniel, Balota, & Hambrick, 2010). A confine of the 
task implemented to measure verbal ability was that it lacked validity and that amalgams of 
domains were measured in the study. This limited the utility of the verbal ability test to 
assess the domain in question (Shao et al., 2014).    
While the studies above show behavioural impairments in participants with normal healthy 
ageing, they are descriptive. To gain an insight into the mechanisms, brain imaging has 
been used to investigate executive function in ageing populations. Regional brain 
investigations in the past have largely been conducted in the pre-frontal cortex (PFC) as 
these areas are known to be associated with high level cognitive operations (Yogev, 
Hausdorff, & Giladi, 2008). One study investigating inhibition in ageing reported 
activations in the ventrolateral and dorsolateral prefrontal cortex that were larger in area in 
older adults compared to younger adults when they completed a stroop task (Kumakura et 
al., 2005). This may be due to reductions in neural efficiency in older adults resulting in an 
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overcompensation on the task. However, it is more likely that older adults were unable to 
suppress irrelevant stimuli on the task resulting in surplus activation. This is evidenced by 
the increased number of interference effects in older adults on the task compared to young 
adults (Kumakura et al., 2005). This is supported in other studies of executive function 
assessing verbal ability that show greater activation in the right inferior frontal gyrus of 
older adults compared to younger adults (Persson et al., 2004). 
 
Spatial reasoning has been researched in healthy ageing populations due its role in daily 
living, orientation and could also influence social activities (Craik & Dirkx, 1992). 
However, previous literature does not point to an overwhelming age related decline in 
spatial cognition with healthy ageing (Klencklen, Després, & Dufour, 2012). Nevertheless, 
there is a general consensus that there are spatial processing, speed (motor), and neural 
functional differences in the processing of spatial stimuli as a function of age. Elderly 
cohorts have been found to specifically have self-reported trouble with tasks that involve 
mental rotation. One study found significantly reduced reaction time speed in older (mean 
age = 67.3) participants compared to younger (mean age = 21.2) participants (Band & Kok, 
2000). Researchers suggest there was a trade off in which older participants were less 
willing to sacrifice accuracy for speed. Nevertheless, a significant difference was found in 
which young adults had better accuracy compared to older adults (Band & Kok, 2000). 
Errors were assessed and found to be a product of hesitant decision making in older adults. 
This may explain the observed post error slowing in the elderly indicating that they were 
aware of errors made and therefore, sacrificed reaction time for accuracy but were less 
successful in doing so (Band & Kok, 2000). This was more apparent when degrees required 
to mentally rotate shapes were smaller rather than larger (Band & Kok, 2000). These 
outcomes are supported by mental rotation task experiments with variations in stimuli such 
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as faces, body parts and geometric shapes (Adduri & Marotta, 2009; De Beni, Pazzaglia, & 
Gardini, 2006; Saimpont, Pozzo, & Papaxanthis, 2009).   
Neural correlates of spatial ability and sub components such as mental imagery have been 
investigated in ageing adults. The parietal cortex and precuneous regions are areas that are 
regularly activated on spatial tasks in healthy samples (Burgess, 2008; Piefke, Onur, & 
Fink, 2012). Neural links of the mental rotation task have been explored in ageing samples 
showing recruitment of additional regions. One study showed activation of the bilateral 
premotor cortex, superior parietal lobe (bilateral), right insula, left thalamus, and bilateral 
cerebellum in both old (mean age = 70.9) and young (mean age = 30.4) participants (Van 
Impe et al., 2013) However, additional areas including the bilateral frontal poles and frontal 
operculum were also activated in older subjects during rotation activity but did not survive 
thresholds for multiple comparisons (Van Impe et al., 2013). Authors speculate these 
additional activation areas may have been recruited in older participants as compensation 
mechanisms. This is evidenced by non-significant behavioural differences in mental 
rotation task performance between groups with increasing task load (Van Impe et al., 
2013). This has been a consistent theory aforementioned in elderly participants to 
successfully compensate for and execute spatial transformations.   
 
The aforementioned studies show that participants of old age have reduced executive and 
spatial reasoning performance compared to younger samples. Furthermore, older adults 
may have neural functional changes as a function of increasing age. This may alter putative 
regional and neural cerebral mechanisms found in past research. Further research must be 
undertaken to establish and characterise neural maps in the elderly which account for these 
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changes during healthy ageing. This may thereby allow reliable neuroimaging comparisons 
to be made in geriatric clinical populations.  
 
1.5.1 Possible Causes of Cognitive Decline in Normal Ageing 
Volumetric Changes 
Examination of the aetiology behind executive and spatial function deficits in normal 
ageing samples have been conducted through post mortem and structural imaging 
investigations. This has generally shown reduced gray matter volumes in elderly adults 
compared to younger adults (Kearney, Harwood, Gladman, Lincoln, & Masud, 2013). 
Uniform whole brain changes have not been found but the PFC has been found to reduce in 
volume to a greater extent than other regions such as the occipital cortex (Mirelman et al., 
2012) with a 5 percent loss of gray matter per decade after the age of 20 (Schum & Sivan, 
1997). Furthermore, diffusion tensor imaging studies report loss of white matter integrity in 
anterior tissue matter as a function of increasing age (Shao et al., 2014).  
Cerebral perfusion changes 
Additionally, declines in blood perfusion of elderly participants have been found compared 
to younger participants in positron emission tomography studies (Persson et al., 2004). 
Several studies have shown smaller voxel area activations in old compared to younger 
adults. Nevertheless, when brain regions activated are corrected for multiple comparisons, 
these differences in area do not exist (Erixon-Lindroth et al., 2005; Monsell, 2003; Schipper 
et al., 2014; Smith et al., 2001). Moreover, the hemodynamic response function (hrf) of 
regions such as the prefrontal, parietal or striatal regions, have rarely been researched and 
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require characterisation due to their association with higher level cognition (Volkow et al., 
2000). 
Cerebral Biochemical changes 
In addition to changes in the PFC, other areas such as various neurotransmitter systems 
may undergo age associated changes. The dopamine system is shown as being an integral 
chemical pathway between fronto-parietal networks important for executive and spatial 
functioning. Declines in dopamine have been estimated at 8% per decade after the age of 40  
(Volkow et al., 2000) which has been associated with impairments on tasks of executive 
control, episodic memory and attentional control (Backman et al., 2000; Erixon-Lindroth et 
al., 2005; Kumakura et al., 2005; Volkow et al., 2000). This indicates that dopamine 
substitution in normal healthy participants could reduce the undesirable effects of cognitive 
ageing on executive functions. 
Environmental and Genetic Factors that affect Ageing 
Other research points to environmental and genetic factors that could impact on cognition 
in ageing subjects. Executive function has been assessed in ageing populations. One study 
evaluating male twin pairs demonstrated that executive function decline was due to genetic 
factors at follow-up after 10 years (Lessov-Schlaggar, Swan, Reed, Wolf, & Carmelli, 
2007). However, any declines at 18 years were determined to be due to environmental 
factors (Lessov-Schlaggar et al., 2007). This suggests genetic factors may underlie 
executive function impairments that were more evident at longitudinal follow-up rather 
than in the short-term. The study was advantageous because twin pairs were genetically 
matched and environmental variables were covaried into statistical models. 
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Mood Factors as a function of Ageing 
A complication in the assessment of cognition in healthy ageing is of comorbid 
psychosocial variances. Due to the advancement of medicine and scientific discoveries, the 
ageing population is growing. Past literature suggests a 1-5% prevalence of depressive 
disorder in adults 65 and over at any one time in the United States and internationally 
(Hasin, Goodwin, Stinson, & Grant, 2005). Presentation of depressive disorders different to 
those of younger cohorts. Sleep disorders, fatigue, loss of interest, hopelessness and 
loneliness are all common features among depressed older adults (Blazer, 2003). The 
aetiology of depression in late adulthood may be due to late life stressful events, 
cardiovascular changes, neurological changes, role changes, spousal bereavement, self-
negative evaluations, genetic risks etc. (Fiske, Wetherell, & Gatz, 2009). More importantly, 
slower cognitive information processing speed, spatial and executive function impairments 
are commonly found among adults with objective assessments (Butters et al., 2004). This is 
in line with findings previously aforementioned in slower reaction time speeds on spatial 
reasoning tasks and executive function impairments in healthy ageing adults. Some 
variance may therefore be explained by mood disorders.  
In conclusion, the majority of literature in ageing participants demonstrates that older 
cohorts often experience cognitive limitations. Healthy ageing samples have been shown to 
have deficits compared to young samples in executive functions (inhibition, verbal ability 
and working memory) that also seem to reflect affected fronto-parietal networks detected 
through neuroimaging techniques. Spatial reasoning has also been shown to decline in 
ageing healthy participants with correlating neuronal activity that has been suspected to act 
as compensatory mechanisms in areas including the dorsolateral prefrontal cortex, parietal 
regions and frontal poles. Causes of these declines have been hypothesised to be due to 
reductions of underlying gray and white matter volume, reductions in cerebral blood flow, 
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reductions in dopamine receptors, environmental factors and increases in prevalence of 
mood disorders as a function of ageing. Likewise, prostate cancer patients undergoing ADT 
were found to have deficits in executive function assessed through neuropsychological 
measures. Investigations of neural architecture showed decreases in prefrontal cerebral 
volume and reductions in fronto-parietal connectivity as assessed through resting state 
connectivity and morphometry methods. Spatial reasoning declines were also shown 
through neuropsychological assessments however, no in scanner behavioural performance 
differences were found. Nevertheless, neuroimaging has revealed decreases in activation 
and volume in parietal occipital, primary motor cortex and fronto-polar cortices which have 
been related to spatial ability functions. The aetiology of these declines in ADT patients 
requires careful consideration to separate cognitions perturbed due to deprivation of 
testosterone and those affected as a normal function of ageing. This may impact on 
treatment side effects and management of these effects during ADT. 
 
1.6 Limitations of current evidence base  
Brain imaging studies showed consistent adverse effects of ADT on cognition. However, the 
studies lacked power and findings may not be reliable or have missed significant effects due 
to the acceptance of the null hypothesis (type II error) as a result of small sample sizes. 
Previous behavioural research has generally used a limited set of two to three tests over a six 
to twelve month period, and many studies have not adjusted for practice effects. Whilst 
researchers have reported declines in verbal ability, verbal memory and spatial reasoning 
abilities of ADT patients to controls (Beer et al., 2006; Green et al., 2002; Jenkins et al., 
2005), other research has reported no such difference or improvements in cognitive ability 
(Alibhai et al., 2010; Almeida et al., 2001; Cherrier, Rose, & Higano, 2003; Salminen et al., 
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2003). Some studies have reported inferior processing speed (Green et al., 2002; Jenkins et 
al., 2005) but these findings have not been replicated in subsequent studies. Another study 
reported improvements in verbal fluency (Salminen et al., 2003) but a subsequent experiment 
reported a decline in verbal fluency scores of ADT patients (Jenkins et al., 2005). A difficulty 
in comparing publications is that there is a lack of congruity across the research in cognitive 
domains and measures employed. Moreover, numerous measures have been employed to 
measure psychosocial function in ADT patients. This is problematic when comparing 
findings between studies because sensitivities and precisions of assessments vary according 
to the population being assessed (Tombaugh & McIntyre, 1992). Another difficulty in 
comparing studies includes that cut off scores vary to categorise participants as being 
abnormal or normal per measure therefore these boundaries are ambiguous among multiple 
studies (Tombaugh & McIntyre, 1992). Furthermore, some studies have reported no 
correlations of psychosocial function with cognitive measures. Nevertheless, numerous 
aspects of psychosocial function were not addressed such as roles of patients, family cohesion 
after ADT, prostate specific QOL or return to work especially in younger ADT patients. This 
may allow the comprehensive assessment of psychosocial function on cognition that can be 
identified and rectified before or during therapy periods.  
In view of past literature, a longitudinal study was considered between patients and healthy 
controls to assess cognition before, during and after ADT. However, the data acquired in 
patients at follow-up, were not available for analysis during the time frame of the study. 
Therefore, the present study aimed to use a robust cognitive battery to assess cognitive 
function before PC patients underwent ADT. This was undertaken to resolve shortcomings of 
past research and to assess the nature of any deficits at baseline in the patient sample. 
Researchers may thereby be able to identify if any cognitive declines found at follow-up were 
carried over from baseline. The measures of the current project were selected through past 
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investigations indicating that verbal memory, verbal fluency, spatial reasoning and executive 
function were significantly affected in patients undergoing ADT. Moreover, brain imaging 
was undertaken to investigate cognition before ADT more thoroughly through neural 
examinations between groups. These differences were explored as past literature has shown 
that behavioural measures alone may not be sufficient to fully uncover the multitude of 
possible mechanisms by which cognition may be affected (Chao et al., 2012). Therefore, 
neuroimaging facilitates the neural correlates of neuropsychological outcomes. In this 
respect, brain imaging may be a more sensitive instrument to measure cognitive differences 
between groups. 
 
The initial part of this thesis reviews research regarding the role of ADT in affecting 
cognition and psychosocial function in men with PC. The second section presents the main 
studies, which examined cognitive change using behavioural and brain imaging measures in 
PC patients eligible to receive ADT. The purpose of this investigation was to determine the 
nature of brain changes that occur in PC patients before ADT, so that physicians can improve 
treatment decisions. Furthermore, knowledge of potential adverse effects of such therapy can 
help facilitate treatment choices and therapy continuation in patients.  
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1.7 Thesis aims and hypothesis  
Global Aim: To characterise the nature of cognition in prostate cancer patients before 
undergoing androgen deprivation therapy (ADT compared to healthy controls and to assess 
cognition in healthy controls over a longitudinal time frame of six months). 
 
The following sub aims will be used to address the global aim:- 
 
Aim 1: Use a comprehensive battery of measures to identify cognitive and psychosocial 
domains, affected due to prostate cancer diagnosis. 
 
This aim was addressed in chapter two in which PC patients were assessed in a cross-
sectional comparison before commencing ADT. Patients were assessed on a battery of 
comprehensive neuropsychological measures that evaluated cognition in domains of 
executive function and spatial reasoning compared to healthy ageing controls. Psychosocial 
function and testosterone were measured to assess their effect on cognition. Screening 
measures were put into place which measured intelligence and the presence of dementia in 
patients and controls that may confound outcomes. 
 
Aim 2: To characterise the neural basis of cognitive change in patients before receiving 
ADT. 
 
Chapter three addressed aim two in which patients were compared to healthy controls using 
brain imaging paradigms (fMRI), resting state functional connectivity (rfMRI) and arterial 
spin labelling (ASL). This allowed cerebral architecture to be measured in both groups that 
facilitated the understanding of neural mechanisms that underpinned neuropsychological 
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performance. Moreover, it allowed the identification of additional factors that could not be 
gauged through neuropsychological tests alone. Testosterone levels and psychosocial 
outcomes were added to all neuroimaging outcomes to assess its effect on brain imaging 
outcomes. 
 
Aim 3: Validate healthy controls do not have any underlying cognitive deficits and to 
characterise cognition in the sample to compare to PC patients. 
 
Aim three was investigated in chapter four. Healthy controls were assessed using 
neuropsychological assessments pertaining to executive function and spatial reasoning over 
six months. Neuroimaging fMRI, rfMRI and ASL were also measured at baseline and six 
months. This allowed the assessment of behavioural performance and underlying neural 
function in healthy controls alone when combined between time points to characterise 
cognition in ageing older samples. 
 
Aim 4: Map the time course of cognitive, neurological and psychosocial changes in healthy 
controls over a period of six months.  
 
Aim four was assessed in chapter four. Healthy participants were investigated using 
executive function and spatial reasoning neuropsychological paradigms at baseline and six 
months. Neuroimaging (fMRI, rfMRI and ASL) was undertaken at both time points. 
Psychosocial changes and testosterone level changes were analysed to assess their effect on 
performance differences between time points. This allowed the exploration of cognitive and 
neural reliability in controls and identification of factors that led to abnormal cognition and 
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underlying neural outcomes. Neuroimaging allowed the identification of additional factors 
not overtly apparent through behavioural measures alone. 
 
Global Hypothesis: 
a. No significant cognitive or neurological differences will be found between patients 
and controls before patients begin therapy in domains of executive function and 
spatial reasoning. 
 
b. No significant changes in cognitive or neurological function will be evident in healthy 
controls at baseline compared to six months follow-up in domains of executive 
function and spatial reasoning. 
The next chapters present data and analysis (behavioural and neural) of PC patients before 
undergoing ADT compared to healthy controls. This will help to characterise cognition in 
patients before they begin treatment. This may allow physicians to resolve side-effects before 
patients commence ADT to prevent any adverse effects during therapy. Moreover, this will 
inform patient treatment choices, uptake and continuance. Subsequent chapters characterised 
cognition using longitudinal behavioural and neuroimaging methodologies in the healthy 
controls that were assessed and compared to PC patients. This was to validate that the sample 
was representative of a normal ageing healthy cohort. 
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CHAPTER 2 
Study one: Comparison of cognitive function between pre-treatment prostate cancer patients 
and healthy age-matched controls. 
2.1 Introduction 
There is emerging evidence that treatment for PC is associated with cognitive decline. A 
recent systematic review of 28 reviews containing primary studies revealed impaired 
cognition in domains of verbal memory, executive functions and spatial reasoning ability in 
PC patients undergoing ADT (Treanor et al., 2017). These findings have also been supported 
by numerous findings from past research (Bussiere et al., 2005; Cherrier et al., 2009). These 
studies assume that adverse effects were due to ADT, however impaired cognition may 
already be present before treatment. Thus, there is a need to characterise cognition in PC 
patients before commencing anti-androgen therapy and to consider additional explanatory 
variables which might account for differences in men with PC. Furthermore, several previous 
studies employed healthy controls that had higher cognitive levels and higher education 
levels at baseline (Green et al., 2002; Green et al., 2004). This may bias outcomes as healthy 
controls had an advantage over patients thereby producing false differences between groups. 
In the next sections, data on relevant confounding variables is presented. 
 
Although with some mixed findings of the domains affected, numerous studies assessing 
cognition in prostate cancer (PC) patients before ADT have revealed comparable 
performance of patients to controls in the domains of executive function and spatial reasoning 
ability (Alibhai et al., 2010; Beer et al., 2006; Cherrier et al., 2009). However, other studies 
show that these domains may be affected prior to patients commencing treatment. One study 
assessing patients undergoing androgen deprivation therapy (ADT) found lower levels of 
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cognition before antiandrogen therapy compared to age and education matched healthy 
controls (Salminen et al., 2003). Patients had lower scores on the digit span, visuomotor digit 
symbol and word fluency task (Salminen et al., 2003). Interestingly, these tasks correspond to 
executive function and spatial reasoning domains, which were found to deteriorate in patients 
after commencing ADT compared to healthy controls and PC patients that were not receiving 
ADT (McGinty et al., 2014; Treanor et al., 2017). This could indicate that cognitive 
impairments were mediated by disease specific factors rather than to more specific effects 
such as age, intelligence, education or testosterone levels which were matched. Mixed 
findings of the domains affected and time period when patients were affected in previous 
research may be due to the methodological or non-comprehensive nature of batteries 
implemented in past assessments which the current study aimed to address. This allowed a 
detailed characterisation of cognition in patients before ADT that may be more valid to assess 
than during treatment. Identification of any side-effects or preventative strategies before 
therapy may allow physicians to avoid or prevent adverse effects worsening during therapy. 
This could permit patients to continue therapy with better treatment outcomes. 
 
There are a number of potential risk factors for cognitive decline in men with PC that might 
be independent of treatment per se. A possible relationship has been found between the 
apolipoprotein (APo) gene and PC (Lehrer, 1998). Research shows greater expressions of 
apolipoprotein epsilon in patients with PC of which apolipoprotein epsilon 4 (APoE4) is 
known to be associated with an increased risk for Alzheimer’s diseases and PC mortality 
rates (Grant, 2010). Males diagnosed with non-aggressive PC have been shown to carry 
copies of the genotype APoE3/APoE4 isoforms while patients diagnosed with aggressive PC 
have been shown to be carriers of APoE2/APoE4 isoforms (Ifere, Desmond, Demark-
Wahnefried, & Nagy, 2013). While APoE2 has been associated with a neuroprotective effect 
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on Alzheimer’s (Rebeck, Kindy, & LaDu, 2002) and APoE3 with neither an increase nor 
decreased risk on Alzheimer’s, when combined with E4, the risk for Alzheimer’s disease has 
been shown to escalate by 2-4 fold (Michaelson, 2014). Moreover, a higher prevalence (85%) 
of older males are diagnosed with non-aggressive low grade PC suggesting that these males 
could carry the APoE3/ApoE4 isoform (Ballentine Carter, 2012; Thompson et al., 2004). 
This puts PC males with the APoE4 isoforms at a higher risk for Alzheimer’s which could be 
influential in characterising any cognitive impairments of PC patients at the pre-treatment 
stage. 
 
Another important potential confounding variable to consider in the context of the diagnosis 
and treatment of cancer is mood. Cognitive changes found in patients before ADT could 
relate to anxiety and depression. The diagnosis of cancer is a stressful event for patients as 
evidenced by increased risk of cardiovascular deaths and suicides after PC diagnosis (Fang et 
al., 2010). Anxiety and depression in patients identified with PC have been explored in a 
meta-analysis and systematic review. The review found 27 journals with 4494 patients 
diagnosed with PC (Watts et al., 2014). The analysis revealed clinically diagnosed depression 
in 17.27% of patients and anxiety in 27.04% of patients before any treatments began (Watts 
et al., 2014). The article also found similar levels of anxiety and depression during and after 
treatment however, anxiety was more prevalent before treatment onset.  
Anxiety has been associated with cognitive deficits. A group of researchers assessing subjects 
with clinically diagnosed anxiety revealed that even normal ageing led to poor performance 
as assessed through an intelligence test (Wechsler Adult Intelligence Scale synonyms test) 
and spatial reasoning domain assessments that heavily depended on central executive 
functioning (Koh’s Block test, Card Rotations test, Visual Learning test and Analogies test) 
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(Wetherell, Gatz, & Pedersen, 2001). However, anxiety (State–Trait Personality Inventory 
(STPI)) assessments were taken at the participant’s homes where subjects were in familiar 
environment. This may confound outcomes by reducing validity and power. This is because 
assessments of anxiety in unfamiliar situations may have produced scores with higher 
variability because vulnerable subjects may experience more anxiety in novel situations 
before undergoing cognitive measures. This higher variability in anxiety scores and cognitive 
performance may facilitate the discovery of many more relationships if both assessments 
were conducted in novel settings. Nevertheless, the study did show that higher level 
executive functions requiring the central executive system, phonological loop and visuo-
spatial sketchpad (spatial reasoning) were affected by anxiety. 
The relationship between executive function and depression is well documented. For 
example, Alves et al. (2014) conducted a systematic review of 28 articles and showed that 
patients with depression had deficits in sub-components of executive function. These areas 
included planning, shifting, inhibition, working memory, integration of information, fluency 
and organisation (Alves et al., 2014). However, numerous measures were employed to assess 
executive functions by researchers in the studies included in the review, making it difficult to 
compare outcomes. Moreover, researchers did not control for disorder subtypes, level of 
severity, drug use or comorbidity which may lead to misinterpretation of findings (Alves et 
al., 2014). Another study assessing depression evaluated spatial reasoning in patients with 
melancholic subtype depression (Rogers et al., 2002). Results indicated motor slowing on the 
mental rotation task compared to non-melancholic participants (Rogers et al., 2002). 
Despite research showing associations between poor psychosocial function and cognitive 
impairments, the relationships are not well understood. Some research points to 
environmental factors affecting cancer patients after diagnosis. Multilevel modelling has 
found that family functioning surrounding cancer diagnosis is important. This is because 
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psychosocial function of the family can impact on the on the patient’s quality of life and 
mood (Edwards & Clarke, 2004). Moreover, researchers have illustrated that families able to 
openly communicate and express their feelings, have lower levels of depression and anxiety 
in both the patients and family members (Edwards & Clarke, 2004). Taken together, this 
suggests that clinicians and researchers could take a family focused approach to cancer 
diagnosis and illness. This in turn may improve the patient’s quality of life to help preserve 
cognitive function before and during treatment. 
Mood disorders may additionally lead to sleep deprivation and insomnia that lead to 
cognitive problems (Nutt, Wilson, & Paterson, 2008; Staner, 2003). Adverse effects of sleep 
deprivation have been extensively explored with findings generally showing that fatigue from 
total sleep deprivation can lead to neurocognitive slowing (Klumpers et al., 2015). This may 
in turn create abnormal brain patterns to compensate for cognitive slowing (Klumpers et al., 
2015). Furthermore, medications could create additional behavioural impairments. 
Experimenters investigating the effects of selective serotonin reuptake inhibitors in fifty 
patients with clinically diagnosed depression found a gradual decline in cognition over a 
period of eight weeks (Sayyah, Eslami, AlaiShehni, & Kouti, 2016). However, outcomes 
were limited to the mini-mental state exam which has been shown to measure many aspects 
of cognition to determine the presence of dementia. However, it is not known to thoroughly 
or comprehensively measure individual domains. Other medications that are anti-anxiolytic, 
such as benzodiazepines, may lead to cognitive impairments - affecting visuo-spatial ability, 
processing speed and verbal learning skills (Stewart, 2005). Moreover, a causal link between 
benzodiazepines and cognitive deterioration has been supported since cognition is known to 
return to normal when patients are removed from the therapy (Stewart, 2005). Therefore, 
identification of mood disorders were required so that the extent to which it impacts on 
cognition is accounted for in patients.  
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In summary, a number of factors affect cognition in patients diagnosed with PC, however, the 
majority of research employed samples of patients undergoing ADT and at least one study 
has shown that cognition may be affected before ADT. Moreover, some assessments 
implemented healthy control samples that were not matched compared to patients leading to 
naturally higher levels of baseline cognition in controls. This illustrates the need to identify 
whether cognitive impairments are present before the administration of ADT so that side-
effects during and after actual treatment periods can be evaluated. This may facilitate patients 
in making an informed decision on the type of treatment options available to them with their 
various adverse effects. 
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2.1.1 Aim 
The aim of this chapter was to characterise cognitive function in PC patients prior to 
commencing ADT and compare with healthy age-matched controls using a comprehensive 
battery of neuropsychological, testosterone and mood assessments. 
 
2.1.2 Hypothesis 
a. There will be no significant differences in pre-treatment PC patients and healthy age-
matched controls.  
b. There will be no significant differences between the scores of pre-treatment PC patients 
and healthy age-matched controls in areas of intellectual functioning, verbal memory, 
executive function and spatial reasoning 
c. There will be no significant differences between the testosterone levels of pre-treatment 
PC patients and healthy age-matched controls. 
d. There will be a significant difference in the levels of APoE4 carried by PC patients and 
healthy age matched controls. 
e. There will be no significant differences in anxiety and depression scores between pre-
treatment PC patients and healthy age-matched controls. 
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2.2 Material and Methods 
Design: A cross-sectional between subjects design was used to investigate cognitive 
performance in PC patients prior to commencing ADT compared with healthy age-matched 
controls. 
 2.2.1 Sample 
Control sample: 
Participants were included if they were (1) between the ages of 50-80; (2) able to speak and 
write English; (3) had high blood pressure if controlled; (4) diabetes if controlled. 
Participants were excluded if they were (1) unable to provide informed consent; (2) had a 
history of treatment for neurological impairments; (3) had a history of stroke; (4) had a 
history of epilepsy or neurodegenerative conditions; (5) had a serious past medical history 
(e.g. heart failure, aneurysm, congestive heart failure etc.); (6) had scores below 24 on the 
MMSE; (7) had a history of any illicit psychoactive drug use; (8) or failed to meet any MRI 
screening requirements (refer to Appendix 1). Participants expressing interest in the study 
were sent an email or telephoned to explain the nature of the study and of the time 
commitments required from them. If participants were still interested in participating then a 
date and time was set for them to come to the University of Birmingham.  
Patients:  
PC patients were included if they were (1) aged between 50 and 80; (2) had rising PSA 
levels; (3) diagnosed with PC; (4) prescribed ADT and; (5) were proficient in English. 
Patients were excluded if (1) they were unable to provide informed consent; (2) were already 
receiving ADT; (3) had metastatic cancer; (4) history of systemic cancer treatment; (5) any 
past treatment history affecting cognition; (6) neurodegenerative conditions; (7) dementia or 
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Alzheimer’s or scores below 24 on the mini mental state exam (MMSE); (8) failed to meet 
any magnetic resonance imaging (MRI) screening requirements. 
 
Table 2.1 Inclusion and Exclusion criteria 
Inclusion criteria 
PC patient group Community based control group 
-Proficient in spoken and written English 
-Diagnosis of PC and prescribed ADT 
-Aged between 50 - 80 
-Proficient in spoken and written English 
-Aged between 50 - 80 
-Similar age profile to PC patients 
Exclusion criteria 
PC patient group Community based control group 
-Unable to provide informed consent 
-Already started ADT  
-Receiving treatment for cognitive difficulties (inc    
dementia and Alzheimer’s treatment) 
-History of stroke, epilepsy or any neurodegenerative 
condition 
-Diagnosis of dementia or Alzheimer’s disease 
-Score below 24 on the mini-mental state exam 
(MMSE). 
-Any form of diabetes 
-Illicit psychoactive drug use 
-Failing to meet requirements in the fMRI screening 
sheet 
-Unable to provide informed consent 
-Receiving treatment for cognitive difficulties (inc 
dementia and Alzheimer’s treatment) 
-History of stroke, epilepsy or any 
neurodegenerative condition 
-Diagnosis of dementia or Alzheimer’s disease 
-Score below 24 on the mini-mental state exam 
(MMSE). 
-Any form of diabetes 
-Illicit psychoactive drug use 
-Failing to meet requirements in the fMRI screening 
sheet.  
Abbreviations: PC, prostate cancer; ADT, androgen deprivation therapy; fMRI, functional magnetic 
resonance imaging. 
 
2.2.2 Ethical approvals  
Controls: A protocol was developed and presented to the ethics and approval committee at 
University of Birmingham. The project was given a favourable decision by the ethics 
committee at the University of Birmingham to recruit and assess healthy controls 
behaviourally and through neuroimaging methods (Appendix 2: Reference number: ERN_11-
0429AP26; Science, Technology, Engineering and Mathematics Review Committee).  
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2.2.3 Recruitment 
Patients: were recruited through multidisciplinary meetings at University hospitals 
Birmingham Queen Elizabeth Hospital, England, UK. Research and development (R&D) 
ethical approval was gained through the integrated research application system (IRAS) form 
and submission to the NHS national research ethics service (NRES). Patients that were 
awaiting ADT were specifically recruited. This is because the treatment is commonly 
administered in cases where the cancer is localised thereby being less aggressive. These 
patients are more predisposed to having genotypes and genes (APoE4) that have been 
associated with non-aggressive cancers and can lead to Alzheimer’s disease especially when 
testosterone is deprived (Ifere et al., 2013).  
Healthy controls: were recruited from community based organisations which catered towards 
the needs of healthy elderly populations, including gym facilities, old age and elderly care 
homes, sports facilities (e.g. Birmingham bowls, golf establishments etc.) and religious 
organisations (churches, temples, mosques etc.) (Appendix 2: Reference number: ERN_11-
0429AP26; Science, Technology, Engineering and Mathematics Review Committee).  
  
2.2.4 Saliva Sample Collection 
Saliva samples were collected to measure testosterone levels through salivary concentration 
assays. Testosterone was selected in the unbound form and because it has been shown to 
correlate highly with serum saliva in males (Vining & McGinley, 1987). Saliva samples were 
obtained through a Salimetrics Enzyme Immunoassay kit. Participants were instructed not to 
eat anything within one hour of saliva collection and not to drink any alcohol 12 hours before 
collection as this could affect collection accuracy (Vining & McGinley, 1987). They were 
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also asked to drink water 10 minutes prior to collection so that any deposits affecting 
collection were eradicated in the mouth. Subsequently, subjects were asked to passively 
collect approximately 18 ml of saliva in a polypropylene vial without saliva stimulation. 
Once samples were collected, they were stored at -20oC to avoid bacterial contamination. 
Concentrations were assayed and measured in picograms per millilitre (pg/ml). Testosterone 
levels were acquired using a competitive assaying technique. This was undertaken by 
allowing testosterone in saliva samples to compete with testosterone amalgamated 
horseradish peroxidase to bind to antibody sites on a microtiter dish. Unbound components 
were washed away after an incubation period. Testosterone was measured by the reaction of 
horseradish peroxidase to tetramethylbenzidine which elicited a blue colour. A yellow colour 
was observed when the reaction had ceased. Testosterone enzyme conjugate was measured as 
being inversely proportional to the testosterone present in the sample (Chard, 1990). 
Testosterone concentrations were calculated by first subtracting raw pg/ml values from 
background values and then averaging any duplicates found. The non-specific binding wells 
were then subtracted from each reading. The percent bound value (Bo) was divided and 
multiplied by 100 to derive percentage bound value. These values were input into a PRISM 
(version 4.0) software to perform a nonlinear regression analysis using data reduction 
methods.  
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2.3 Outcome measures 
2.3.1 Neuropsychological measures 
Table 2.2 summarises key properties of the measures used in the thesis for cognitive 
assessment. A full rationale for the selection and scoring is provided in Appendix 3.  
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Table 2.2: Key Properties of Neuropsychological Measures 
Neuropsychological Measures key properties of the measures  
  
Mini Mini-Mental State Exam - II  
(MMSE-II) (Folstein, Folstein, & McHugh, 
1975). 
A quick test to assess multiple cognitive 
domains to detect surface level cognition to 
assess symptoms of Dementia. 
 
 
Wechsler Abbreviated Scale of Intelligence 
(WASI-II) (Wechsler, 2011). 
Rapid and thorough measure of IQ using a 
range of verbal comprehension and perceptual 
reasoning sub-tests 
  
Delis Kaplan Executive Function System  Comprehensive measure of executive function  
(D-KEFS) test (Delis, Kaplan, & Kramer, 
2001a). 
Subtests from the measure employed included: 
 
D-KEFS Trail making test  
D-KEFS verbal fluency test  
D-KEFS Design Fluency test  
D-KEFS Colour word interference test  
D-KEFS Tower test 
Wechsler Adult Intelligence scale (WAIS-IV) 
Working Memory Index (WMI) (Wechsler, 
2009). 
An assessment of working memory with tasks 
comprising:  
Digit span task: digits forward, backward and 
sequential  
Arithmetic: simple mental arithmetic 
Cambridge Neurological test Automated 
Battery (CANTAB) (Cambridge Cognition, 
2006). 
A spatial working subtest of the computerized 
battery was employed to assess spatial 
reasoning skills by assessing the ability to 
retain spatial information for later 
manipulation in working memory. 
 
  
Abbreviations: IQ, intelligence quotient  
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2.3.2 Psychosocial measures 
Table 2.3 summarises key properties of the measures used in the thesis for psychosocial 
assessment. A full rationale for the selection and scoring is provided in Appendix 3.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.3: Key Properties of Psychosocial measures 
 
 
Behaviour Rating Inventory of Executive 
Function – Adult version (BRIEF-A) 
(Gioia, Isquith, Guy, & Kenworthy, 2000).  
Meta-cognitive questionnaire that assess self-
report of constructs relating to executive 
function  components included inhibition, 
attentional shift, emotional control, self-
monitoring, initiation  of tasks, working 
memory, planning and organisation, task 
monitor and organisation of materials. 
  
Hospital Anxiety and Depression Scale 
(Zigmond & Snaith, 1983). 
Self-rating instrument used to detect any 
clinical or borderline levels of anxiety or 
depression 
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2.4 Procedure 
Patients were identified through a consultant at University hospitals Birmingham Queen 
Elizabeth Hospital, England, UK. Researchers from the University of Birmingham were 
present at the appointment and collected the relevant contact details (phone number and/or 
email address) required to contact interested patients at a later date. Patients were also given a 
research pack with participant information sheets with details of what the study involved 
(refer to Appendix 4). A researcher called the patient by phone call or by email if available to 
arrange a phone call appointment. The phone call was firstly to consent patients into the study 
if they were still interested after reading the information packs. Secondly, the call was to 
screen patients before study commencement on questions pertaining to the inclusion 
exclusion criteria in table 2.1 with a screening form (Appendix 5). Finally, a time was 
arranged for the patient to attend the University to take part in the study if successful at the 
initial screening stage. When participants arrived for the study, they were consented into the 
study by a trained researcher through written consent (Appendix 6). General practitioner (GP) 
details were also acquired from the participants in case the patient was to be referred for 
concerns of dementia. A similar procedure was undertaken with healthy controls that were 
recruited from various facilities including gym facilities, old age and elderly care homes, 
sports facilities and religious organisations. Information packs were either handed to 
participants or emailed. A phone call was made to interested participants to screen and 
consent them into the study. Participants were excluded if they did not meet the requirements 
of table 2.1. When participants arrived at the University, they gave written consent if 
interested and GP details were similarly acquired should they present with signs of dementia. 
Assessments commenced after screening and consent was obtained. An attempt was made to 
complete all assessments in one day and at the same time in each participant to control for 
confounding effects of tiredness and fatigue. However, participants who requested to 
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complete assessments over two to three days were assessed on separate days. 
Neuropsychological assessments were split into sessions in these cases. 
Exclusions were made if participants did not meet the inclusion criteria (table 2.1).  
Assessments were conducted in a small room with the examiner sitting opposite the 
participant at a table. Saliva samples were acquired from participants after 12pm to measure 
testosterone through assay and analysis. An attempt was made to collect saliva samples at the 
same time from all subjects. This was for consistency and to avoid variations in diurnal 
testosterone levels (Brambilla, Matsumoto, Araujo, & McKinlay, 2009). Duration of 
neuropsychological assessments were 2 hrs 45 minutes (Appendix 7). Fatigue and alertness 
confounds were controlled for by prohibiting any caffeine related beverages or foods during 
testing periods.  
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2.5 Statistical Analysis 
The main question was to assess if there were significant differences between PC patients 
prior to commencing ADT and healthy age-matched controls using neuropsychological and 
psychosocial measures. The primary outcome measures were scores obtained on a battery of 
executive function and spatial reasoning measures. A p value of either 0.05 or less (two-
tailed) was accepted as statistically significant. Firstly, independent samples t-tests (or Mann 
Whitney Whitney U tests were conducted where variance assumptions were violated) to 
assess the level of change that occurred in anxiety, depression and testosterone levels 
between healthy controls and patients. Subsequently, an independent samples t-test was 
conducted on the WASI-II FSIQ-4 subscale. Next, a MANOVA was employed to assess 
differences between groups on contrast scaled scores of the D-KEFS as dependent variables 
(TMT-A, VF, DF, CWI) and tower test scaled scores. The fixed factor again was group 
(healthy controls or patients). A similar MANOVA was conducted on the spatial working 
memory CANTAB task with number of between and double errors in the three conditions as 
dependent variables (4 boxes, 6 boxes and 8 boxes errors made). CANTAB strategy scores 
were compared in an independent samples t test. 
Further MANCOVAs were conducted where anxiety, depression and testosterone were added 
as covariates only if any group differences were found. However, testosterone level was 
added as a covariate to all models as it was relevant to the current investigation between 
patients and controls. The working memory Index from the Wechsler Adult Intelligence scale 
(WAIS) was added as a covariate in a separate MANCOVA so that it could be controlled for 
in the spatial working memory index CANTAB task. This was to control for working 
memory so that spatial reasoning performance of participants could be the assessed on the 
CANTAB. Testosterone was added to the model to assess the effects of testosterone on 
spatial reasoning performance whilst controlling for working memory. 
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The BRIEF-A assessment was modelled using similar MANOVAs where the dependent 
variables were all scaled scores on the self-report questionnaires (Inhibition, self-shift, self-
emotional control, self-organisation, ability to initiate, working memory, monitor, 
behavioural regulation index, metacognition and global executive function scores) and the 
grouping variable was patient and healthy controls (group) to model an interaction. 
Covariates (anxiety and depression) were added to the MANOVA in a MANCOVA if group 
differences were found to gauge if covariates covaried with any differences between cohorts. 
Testosterone was added to the model regardless of group change to assess if it contributed to 
any variance.  
The use of MANOVAs and MANCOVAs allowed the entry of many dependent variables in 
unison which benefited the management of family-wise error rates and reduced type 1 errors. 
Moreover, MANOVA analyses are known to be resilient to violations of homogeneity which 
is not the case with other statistical methods including ANOVAs etc. (O'Brien & Kaiser, 
1985). 
Significant findings from the conducted MANOVAs or MANCOVAs were followed up with 
ANOVAs and ANCOVAs with individual sub scale scores as dependent measures to ensure 
maximal sampling. Outliers were not deleted from any analysis due to small sample sizes. 
However, extreme outliers were checked for miss inputs by researchers. No outliers were 
deleted as a result. Due to the limitation of multiple testing issue and to reduce familywise 
error rate, post-hoc Bonferroni tests were undertaken if the main interaction was significant. 
This was to prevent chance findings from random sampling, to disentangle differences and to 
control for type I errors.  
Psychosocial covariates to be added were assessed first and revealed the anxiety and 
depression factors were correlated r = 0.54, p < 0.01 in healthy controls and patients r = 0.58, 
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p < 0.01. However, covariates were not excluded from MANCOVAs since the exclusion 
criteria for correlating variables has been found to be r > 0.80 (Vatcheva, Lee, McCormick, 
& Rahbar, 2016). A separate MANOVA was conducted to test for homogeneity of regression 
slopes where MANCOVAs were conducted and interactions were modelled between the 
fixed factor, which was group and covariates added to the model. If no significant differences 
were found then it was concluded that subsequent MANCOVAs did not violate the 
assumption of homogeneity of regression slopes.  
Caseness was assessed to explore if any mood variables related to behavioural outcome 
measures. Caseness refers to a clinical diagnosis of either anxiety or depression and is 
advantageous as it provides a quantification which can be used to clinically diagnose and 
understand the degree to which a disorder affects a patient (Westen, 2012). This allows 
caseness to be incorporated into categorical statistical analyses to measure relationships 
between variables which would otherwise not be possible. This method was used to 
investigate if caseness of anxiety and/or depression were associated with cognitive 
impairments compared to non-casness. Subscale sum scores > 8 were applied as a cut-off for 
caseness on the HADS scale that indicated borderline anxiety or depression and risk of 
developing clinical mood disorder. A regression was conducted with each outcome variable 
to assess if caseness had a relationship with any cognitive outcome measures. Caseness was 
coded as a dummy variable with categories coded as caseness and non-caseness of pure 
anxiety or depression. Then the dummy coding was applied where participants had a caseness 
score > 8 on both anxiety and depression and conducted a multiple regression of both 
caseness variables to determine their co-morbid effect on cognitive outcomes. 
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Table 2.4: Scaled Scores for patients and controls  
 
 Healthy Controls Patients    
Measure Baseline (n = 29) Baseline (n = 30) Difference 
 Mean SD Mean SD Mean SD 
MMSE 29.03 1.05 28.40 1.69 0.63 -0.64 
  
   
  
WASI-II       
Verbal Comprehension 124.83 16.16 115.40 19.86 9.43 -3.70 
Perceptual Reasoning 112.66 15.05 112.07 17.29 0.59 -2.25 
FSIQ-4 120.90 14.55 113.83 16.68 7.06 -2.14 
 
    
  
D-KEFS       
Visual Scanning 10.59 2.87 9.90 3.28 0.69 -0.41 
Number Sequencing 11.79 2.77 12.33 1.88 -0.54 0.89 
Letter Sequencing 11.55 3.13 12.47 1.61 -0.91 1.52 
Number Letter Sequencing 11.38 2.96 10.97 3.53 0.41 -0.57 
     
  
Verbal Fluency       
     
  
Letter Fluency 13.83 2.94 11.30 3.71 2.53 -0.77 
Category Fluency 12.72 2.96 11.17 3.43 1.56 -0.47 
Category Switching 12.59 2.93 11.73 2.66 0.85 0.27 
Switching Accuracy 12.38 2.72 12.00 2.48 0.38 0.24 
       
Design Fluency       
       
Filled Dots 12.52 2.75 11.10 2.64 1.42 0.10 
Empty Dots 11.48 3.27 11.77 2.70 -0.28 0.57 
Switching (Empty and Filled) 11.52 2.50 11.80 3.52 -0.28 -1.02 
     
  
Colour Word Interference Test       
     
  
Colour Naming 10.86 1.87 10.69 2.31 0.17 -0.44 
Word Reading 11.21 2.55 11.75 2.05 -0.54 0.51 
Inhibition 12.69 1.85 10.82 3.48 1.86 -1.63 
Inhibition Switching 12.55 1.76 11.34 2.27 1.21 -0.51 
     
  
Tower Test       
     
  
Number of Moves 149.90 82.78 119.53 34.17 30.36 48.61 
Total Time to complete (ms)  504.21 164.93 517.55 169.98 -13.34 -5.05 
Achievement Scores 11.41 2.85 12.07 2.79 -0.65 0.06 
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Healthy Controls 
 
Patients 
Measure Baseline (n = 29) Baseline (n = 30) Difference 
 Mean SD Mean SD Mean SD 
 
BRIEF-A 
    
  
     
  
Self-Report       
Inhibition 51.17 6.79 51.87 8.70 -0.69 -1.90 
Shift 52.17 9.75 52.83 10.39 -0.66 -0.64 
Emotional Control 50.03 9.48 50.33 9.53 -0.30 -0.05 
Monitor 49.38 8.02 50.83 10.86 -1.45 -2.83 
Initiate 50.28 7.10 52.60 11.17 -2.32 -4.07 
Working Memory 57.24 11.33 56.63 12.53 0.61 -1.20 
Plan/Organise 50.03 8.51 53.33 10.29 -3.30 -1.78 
Task Monitor 53.69 8.94 58.37 13.41 -4.68 -4.47 
Organisation of Materials 49.38 8.19 51.67 12.10 -2.29 -3.91 
BRI 51.24 7.83 51.33 10.81 -0.09 -2.98 
MI 51.86 7.00 55.97 13.42 -4.10 -6.41 
GEC 51.31 6.62 54.20 11.30 -2.89 -4.68 
     
  
CANTAB       
Between Errors       
4 boxes 1.34 2.78 1.07 1.82 0.28 0.96 
6 boxes 8.07 8.57 7.07 6.90 1.00 1.67 
8 boxes 19.93 11.08 20.00 12.27 -0.07 -1.19 
     
  
Double Errors       
4 boxes 0.00 0.00 0.00 0.00 0.00 0.00 
6 boxes 0.14 0.35 0.27 0.94 -0.13 -0.59 
8 boxes 0.28 0.80 0.60 1.25 -0.32 -0.45 
       
Strategy Score 33.10 7.56 32.60 5.44 0.50 2.12 
 
    
  
Testosterone (pg/ml) 83.43 26.40 257.92 152.22 -174.49 -125.82** 
 
HADS        
Anxiety 3.48 2.734 3.90 3.188 -0.42 -0.45 
Depression 1.76 1.596 2.30 2.744 -0.54 -1.15 
 
  
Abbreviations: SD, standard deviation; fsiq, full scale intelligence quotient; pg, picograms; ml, millilitre; ms, 
milliseconds; BRI, behavioural regulation index; MI metacognitive index; GEC, global executive composite; 
**p<0.01. 
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2.6 Results 
Twenty nine healthy controls (mean age = 67.45 + 6.96) and 30 patients (mean age = 66.47 + 
6.92) completed all neuropsychological and psychosocial assessments. No significant 
difference in age was found between patients and control (t(57) = 0.54, p > 0.05). Statistical 
analyses were conducted using SPSS 22.0 (IBM, 2013). Missing data was found in one 
healthy control participant on the D-KEFS colour word interference test. One patient’s data 
was missing from the Brief-A Informant questionnaire and another from the D-KEFS colour 
word interference test. The estimation maximization procedure was used to estimate and 
replace all missing data which has been demonstrated as being an effective strategy for 
managing omitted data (Rubin, Witkiewitz, Andre, & Reilly, 2007). 
2.6.1 Screening assessments 
All healthy controls assessed on the MMSE passed the criteria for participation (table 2.1).  
MMSE scores did not significantly differ between patients (mdn = 29) and controls (mdn = 
29) (U = 351.00, z = -1.33, p > 0.05). Levels of depression did not significantly differ 
between patients (mdn = 1) and controls (mdn = 1) (U = 425.00, z = -1.55, p > 0.05). Levels 
of anxiety did not significantly differ between patients and controls (table 2.2) (t (57) = -0.54, 
p > 0.05). However, testosterone levels did significantly differ between patients (mdn = 
212.585 pg/ml) and controls (mdn = 67.00 pg/ml) (U = 53.00, z = -5.79, p < 0.01). The 
assessment of the APoE4 gene was part of the hypothesis and rationale. However, data 
required to analyse this component were not available at the time of analysis due to the 
timeframe of the broader project. 
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Caseness of anxiety and depression showed that three healthy controls scored in the 
borderline zone for clinical anxiety. Patients’ caseness of anxiety showed that five 
participants had borderline levels of anxiety. No relationship between anxiety caseness and 
cognitive variables were found in controls. However, patients did have a significant 
relationship between anxiety and double errors made in the eight box condition on the 
CANTAB SWM task (F(1,28) = 14.41, p < 0.01 where R2 = 0.34 (β=1.92). This suggests 
that as caseness of anxiety increased in patients, number of double errors increased in the 
eight box condition. The patient group had two subjects presenting with caseness of 
depression. No significant relationship of depression casessness was found in controls or 
patients on any cognitive outcomes. Two patients had borderline caseness scores on both 
anxiety and depression. Both co-morbid mood factors did not have any relationship with 
cognitive outcomes.  
 
2.6.2 Intellectual functioning 
WASI-II 
An independent samples t-test showed no significant WASI-II FSIQ-4 score differences 
between controls and patients (t(57) = 0.74, p > 0.05). 
2.6.3 Executive functioning  
D-KEFS 
A MANOVA with all D-KEFS contrast scaled scores as dependent variables (table 2.2) 
showed no significant differences between groups (F(5,53) = 1.18, p > 0.05). Testosterone 
was added to the model with no significant effect (F(5,52) = 1.17, p > 0.05). Groups did not 
differ with the addition of testosterone (F(5,52) = 2.03, p > 0.05). 
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BRIEF-A 
The brief executive function assessment self-report questionnaire (BRIEF-A) was 
subsequently analysed with MANOVAs. Fixed factors were entered as patients and controls. 
Inhibition, shift, emotional control, self-organisation, ability to initiate, working memory, 
monitor, behavioural regulation index, metacognition and global executive function scaled 
scores were entered as dependent variables (table 2.2). No significant differences were 
evident across dependent variables between patients and controls (F(12,46) = 0.57, p > 0.05). 
Testosterone was added as a covariate to the model but did not predict performance 
independent of group (F(12,45) = 0.99, p > 0.05). Furthermore, group performance 
differences were not accounted for by testosterone (F(12,45) = 0.88, p > 0.05). 
Further exploratory analysis did not show any significant correlation between self-rated 
BRIEF-A questionnaire meta-cognitive Index scaled scores and D-KEFS contrast scaled 
scores. Correlations were not significant on the D-KEFS trail making test (r=-0.06, p=ns); 
verbal fluency test (r=0.05, p=ns), design fluency test (r=-0.10, p=ns), colour word 
interference test (r=0.08, p=ns) and tower test (r=-0.11, p=ns). This indicates that there were 
no correlations between meta-cognitive thought patterns and executive function. 
 
 
 
 
 
 
88 
 
2.6.4 Spatial reasoning 
Cantab 
No significant differences were found on the number of between errors made in the 4 box, 6 
box and 8 box conditions across groups on the CANTAB SWM task (F(3,55) = 0.18, p > 
0.05).  
Further analyses showed no significant differences between number of between errors made 
when testosterone (F(3,54) = 4.1, p > 0.05) was added to the model. No significant difference 
was found between groups when controlling for testosterone (F(3,54) = 1.11, p > 0.05).  
A MANCOVA was undertaken with the WAIS working memory index score added as a 
covariate to the number of between errors made. This allowed the isolation of the spatial 
reasoning portion of the SWM task whilst controlling for working memory. Findings showed 
a significant predictive relationship of the WAIS working memory index score on errors 
made on the SWM task (F(3,53) = 8.96, p < 0.01, η2 = 0.34). Specific ANCOVAs showed 
that the WAIS accounted for variance on the number of total between errors made (F(1,55) = 
24.16, p < 0.01, η2 = 0.31), errors made in the 4 box condition (F(1,55) = 12.24, p = 0.01, η2 = 
0.18), errors made in the six box condition (F(1,55) = 26.77, p < 0.01, η2 = 0.33) and errors 
made in the eight box condition (F(1,55) = 15.17, p < 0.01, η2 = 0.22) while controlling for 
group. No effect of testosterone was found when it was added to the model when also 
controlling for WAIS WMI (F(3,53) = 0.35, p > 0.05). No between groups differences were 
found while controlling for WAIS WMI scores and testosterone levels (F(3,53) = 0.48, p > 
0.05).  
No significant differences were found on the number of double errors made in the 4 box, 6 
box and 8 box conditions between groups on the CANTAB SWM task (F(2,56) = 0.92, p > 
0.05). Testosterone was added to the number of double errors which showed that it did 
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predict the number of errors made (F(2,55) = 10.46, p < 0.01, η2 = 0.28). Further ANCOVAs 
revealed testosterone had a significant effect on the number of errors made in the eight box 
condition (F(1,53) = 13.25, p < 0.01, η2 = 0.20) and total number of errors made (F(1,53) = 
17.58, p < 0.01, η2 = 0.25) independent of group. The MANCOVA showed no differences 
between groups while controlling for testosterone (F(2,55) = 1.39, p > 0.05). Finally, no 
difference in strategy score was found in an independent samples t-test (t (25) = 0.53, p > 
0.05). 
When testosterone and WAIS WMI were added to the number of double errors made a 
significant effect of testosterone was found (F(2,54) = 10.60, p < 0.01, η2 = 0.29) on average 
independent of group. Further analysis showed the effects of testosterone were significant on 
total double errors (F(1,55) = 20.25, p <0.01, η2 = 0.01) and number of errors in the eight box 
condition (F(1,55) = 17.68, p < 0.01, η2 = 0.24). However, WAIS WMI scores did not predict 
the number of double errors made (F(2,54) = 1.11, p > 0.05) whilst controlling for group. No 
change was found between groups while controlling for WAIS WMI and testosterone 
(F(2,54) = 1.63, p > 0.05).    
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2.7 Discussion 
No significant differences were found on the WASI FSIQ-4 and MMSE assessments 
indicating that intellectual functioning was similar between patients and controls which was 
in line with what was expected. Moreover, neuropsychological performance did not 
significantly differ between patients and controls on measures of the D-KEFS, BRIEF-A and 
CANTAB. This showed there were no differences in executive function and spatial 
reasoning, as was hypothesised. No significant psychosocial or mood differences were found, 
which was as projected. Testosterone levels did differ between groups which was not 
expected. 
 
In the current study neuropsychological outcomes on the D-KEFS assessment showed no 
significant differences with and without covariates, as was expected. Between groups 
analysis of the CANTAB spatial working memory outcomes showed no significant 
differences on the number of between errors or double errors made between patients and 
controls which is in line with the hypothesis. However, testosterone levels across both groups 
did significantly predict the average number of errors made. This was prevalent in the double 
errors condition when controlling for working memory performance and testosterone which 
was a purer measure of spatial reasoning performance. This was in contrast to what was 
expected. Spatial reasoning ability measures have been reported as being highly sensitive to 
testosterone. One study assessing this relationship administered just a single dose (0.5mg) of 
testosterone to females and showed improvements on a 3D mental rotation task compared to 
those administered a placebo (Aleman, Bronk, Kessels, Koppeschaar, & van Honk, 2004). 
However, the study was limited because researchers did not measure both levels of 
testosterone and oestrogens. Therefore, endogenous oestrogens may have increased through 
the aromatization process to establish an equilibrium (Crosnoe, Grober, Ohl, & Kim, 2013). 
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This could have biased findings and all effects found may have been due to increasing 
oestrogen levels. Despite this shortcoming, other studies have found similar effects when 
testosterone was administered to females with higher spatial task loads and over a 
longitudinal time frame (Li, 2014; Postma et al., 2000). 
 
Outcomes from the BRIEF-A measures showed no significant differences between groups. 
Low self-ratings of cognitive function were commonly found among participants (Pennequin, 
Sorel, & Mainguy, 2010). This may have had bearings on cognitive performance but in the 
present study, self meta-cognitive BRIEF-A scaled scores did not correlate with D-KEFS 
contrast scaled scores. This suggests that meta-cognitive perceptions of cognition did not 
have a bearing on cognitive performance. Nevertheless, this may not be the case for all 
executive function measures and clinically meaningful outcomes may have been missed. One 
study assessing participants on a number of neuropsychological measures, found significant 
correlations between the BRIEF-A self-reported cognitive impairments scale and executive 
functions (Rabin et al., 2006). Executive functions were assessed with the D-KEFS and 
Wechsler Memory Scale (WMS-III). Correlations were more pronounced in patients with 
mild cognitive impairment and those reporting cognitive complaints (Rabin et al., 2006). This 
suggests that self-reported cognitive impairments revealed clinically meaningful executive 
function deficits in patients compared to matched healthy controls. This may explain the lack 
of correlation found across groups between self-report measures and neuropsychological 
performance in the present study. This is because patients had cognition which matched to 
healthy controls that did not have any signs of MCI, thus there was no correlation between 
meta-cognition and executive function as illustrated by Rabin et al. (2006). 
 
92 
 
Anxiety and depression caseness revealed no relationship between neuropsychological 
performance and pure anxiety or depression caseness in healthy controls. However, caseness 
of anxiety did have a relationship between number of double errors made on the CANTAB 
eight box condition. Numerous researchers have shown an effect of anxiety on spatial 
reasoning (Shackman et al., 2006; Vytal, Cornwell, Letkiewicz, Arkin, & Grillon, 2013). This 
suggests that whereas testosterone may compensate for cognitive deficits, anxiety may lead to 
cognitive impairment even at baseline in patients that could not be compensated for by 
testosterone. However, this effect in patients was found on the more difficult items 
suggesting that easier spatial reasoning was intact despite caseness of anxiety. 
 
Despite similar cognitive performance between patients and controls, some subtle significant 
outcomes were noted that require further interpretation. One unexpected result was that 
testosterone levels were significantly higher in patients compared to controls. While past 
patient samples in other assessments did not have higher than control levels of testosterone, 
the higher levels found in the current sample may not be unusual and has been shown in 
numerous patient cohorts (Klap, Schmid, & Loughlin, 2015). This could be because androgen 
receptor signalling is required for malignant cell proliferation and PC progression (Heinlein 
& Chang, 2004). Moreover, high serum testosterone levels have been proposed as a risk 
factor for increasing prostate specific antigen levels (PSA) levels. Although, there is a link 
between higher testosterone levels and poor cancer outcome, it may have inadvertently 
benefitted the sample in the study undertaken. This is because testosterone has been shown as 
being neuroprotective to cognition (Beauchet, 2006; Bialek, Zaremba, Borowicz, & 
Czuczwar, 2004), which may facilitate neuropsychological performance in patients with 
neurodegenerative disease or cognitive deficits to that of normal levels (Kurth et al., 2014). 
Furthermore, primary studies support this link showing that testosterone replacement therapy 
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can mitigate some of the deleterious effects of Alzheimer’s disease. One study revealed 
improved verbal memory, spatial memory and constructional ability in Alzheimer’s disease 
patients administered DHT (Cherrier et al., 2005). Moreover, patients with higher 
testosterone levels were less likely to develop Alzheimer’s disease despite having gene 
expressions that increased Alzheimer’s disease risk (Moffat et al., 2004). The extent to which 
patients were affected by risk of Alzheimer’s was an aim of the study undertaken. 
Nevertheless, due to time constraints this information was not available in the current project. 
However, as part of future research, it may be proposed that APoE4 gene levels are measured 
in both groups to ascertain its effect on Alzheimer’s development in PC patients and of 
interactions with testosterone. The patient cohort had higher than control levels of 
testosterone which may have offset the risk of Alzheimer’s to allow for better cognition 
compared to past studies (Salminen et al., 2003). Thus, one possible mechanism for similar 
performance between patients and controls may be that the higher testosterone levels found in 
patients, facilitated compensation for cognitive deficits due to PC disease specific factors. 
This was evident as the sample assessed were not as severely affected on mood and cognitive 
measures as baseline patients assessed in past studies (Salminen et al., 2003; Salminen, 
Portin, Koskinen, Helenius, & Nurmi, 2004). However, during ADT the effects of this 
compensatory effect may be lost due to testosterone deprivation leading to cognitive decline 
during ADT. However, this requires careful consideration as it could affect ADT uptake, 
continuation and management of cognitive side-effects during therapy. 
 
There are a number of shortcomings to the current study that must be acknowledged. Firstly, 
sample size was small, which limits the ability to detect smaller group differences (see 
Appendix 8 for power calculation). Hence, a larger sample size is required in the future; this 
will overcome the limitation of small groups in between subjects designs, which are limited 
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by between subject variance and so although differences were not identified here they may 
still be present but small in magnitude. A further confound that could be rectified by larger 
samples size is of the multiple testing issue that arose due to the number comparisons made 
between variables. This may have increased family wise error rates leading to false 
discoveries. Bonferroni corrections were employed to control for chance findings, however 
the corrected adjustment method has been known to be extremely conservative and comes at 
the price of increasing false negatives. Therefore, while no significant differences were 
apparent in the study undertaken, they may be present, but were not identified due to false 
acceptance of the null hypothesis implying there were no differences between groups.  
The lack of relationship between mood and cognitive variables may reflect the nature of the 
measures used. Self-reported anxiety and depression questionnaires were employed to assess 
mood. However, informant questionnaires may have been beneficial on these measures to 
gauge another’s perspective. This may lead to more accurate psychosocial understanding of 
PC patients. This could also give an insight into the patient’s environmental factors such as 
family life which could affect psychosocial function. Therefore, informant questionnaires can 
add another dimension to the data which provides a network approach to psychosocial 
function from individuals related to or close to the patient (Edwards & Clarke, 2004). 
However, it was not the focus of the current study to assess informant reports. Formal 
assessment of mood may also allow better evaluation of a participant’s mood levels through 
qualitative methods and diagnosis by a clinician. This may allow physicians to gauge 
information that is not revealed through self-report forms alone due to bias (O'Brien et al., 
2001). Nevertheless, some researchers have shown that participants feel less embarrassment 
in reporting mood information on a questionnaire or computer than to a clinician (Kobak, 
Reynolds, & Greist, 1994). This implicates that both self-report and qualitative methods 
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should be administered to acquire a thorough understanding of psychosocial mood function in 
samples.  
Another limitation includes that assessments of psychosocial function from the participant’s 
perspective require a broader range of factors to be explored that were lacking in the current 
investigation. These are variables such as day to day functioning, quality of life, coping 
mechanisms or a specific questionnaire such as the prostate specific quality of life 
questionnaire (Stockler, Osoba, Corey, Goodwin, & Tannock, 1999). This may allow greater 
evaluation of patients’ level of psychosocial function while awaiting upcoming treatment and 
the effect on cognition may be assessed from a wider range of outcomes. Whilst cognitive 
assessments undergo rigorous reliability and validity checks, they may lack the ability to 
assess real world cognition. Further research should take into account physical functioning, 
cognitive performance inside and in the real world environment for a thorough understanding 
of everyday functioning and quality of life through ecological validity assessments (Spooner 
& Pachana, 2006). This could be achieved by administering a variety of alternative 
assessments or measured through qualitative means such as interviews. This may provide 
researchers with a greater depth of information that is ecologically accurate, allowing a better 
understanding of factors that may lead to cognitive changes in PC patients before, during and 
after therapy. 
 
In the current chapter, there were no behavioural differences between controls and patients 
however those data form an important baseline for longitudinal follow-up (refer to Chapter 4 
& 5). Furthermore, there is strong evidence in the ageing literature that preservation of 
behavioural performance may be observed and yet there are significant alterations in the 
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neural architecture engaged during performance of those tasks. In other words, it is possible 
that neural differences may exists in advance of overt evidence of behavioural changes. 
This is most evident in ageing populations. Some past studies have demonstrated normal 
spatial reasoning behavioural performance with altered brain activity to compensate for 
deficits. This is important because the study conducted showed an effect on spatial reasoning 
performance when testosterone was added as a covariate. Furthermore, spatial reasoning 
assessments are known to be sensitive to testosterone level fluctuations, therefore, 
deprivations of these levels may lead to spatial impairments or inabilities to compensate for 
deficits (Celec, Ostatníková, & Hodosy, 2015). One study assessed 25 older participants 
(mean age=70.9) and younger samples (mean age=22.4) on a mental rotation task under 
varying postural loads (sitting or standing balancing) (Van Impe et al., 2013). Brain imaging 
was undertaken with fMRI to identify neural associated mental rotation regions. Outcomes 
showed older participants had greater BOLD activation in frontal and parietal regions 
compared to the young cohort. Left lingual gyrus activation moreover modulated older 
participants’ success on the task. However, task performance and reaction times did not differ 
between groups even with increasing complexity of the task in the scanner or with increasing 
postural loads. Another study used positron emission tomography (PET) to assess 10 young 
subjects (mean age=21.2) and 10 older participants (mean age=67.4) (Reuter-Lorenz et al., 
2000). Researchers found no behavioural differences between groups but revealed mostly 
right lateralised activity in young participants while older participants showed activation in 
the anterior bilateral lobe. Additional frontal regions were active in older adults including 
bilateral dorsolateral prefrontal cortex.  
A further study also showed this effect in normal healthy participants. Researchers employed 
a task in which participants were asked to locate the midpoint of either symmetrical or 
asymmetrical shapes (Wilkinson & Halligan, 2004). Significant differences in activation were 
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found in the anterior cingulate gyrus suggesting it had a facilitatiory effect on symmetry. 
Nevertheless, the presence or absence of symmetry did not affect speed or accuracy 
performance. Therefore, activation of the anterior cingulate gyrus and its behavioural 
correlate was not shown. Other studies validate this effect of behavioural and neural pattern 
divergence in cognitive domains including episodic memory (Suzuki et al., 2002), conflict 
resolution (Paulus, Hozack, Frank, & Brown, 2002), lexical decision making (Peng et al., 
2003), guided movement (Handy, Grafton, Shroff, Ketay, & Gazzaniga, 2003) and spatial 
reasoning (Vingerhoets et al., 2001). Outcomes from previous studies suggest that cognitive 
compensation mechanisms are available in healthy ageing participants. This highlights the 
need for a control group in any further investigations when comparing controls to patients. 
This is because healthy ageing participants may have underlying neural networks that activate 
putative domain specific executive function and spatial reasoning regions that differ to young 
cohorts. Therefore, if activation in healthy ageing is not characterised when compared against 
older patients, any differences may be misconstrued as cognitive impairment in patients when 
in fact it is a normal function of ageing. 
 
Diverging brain activation to behavioural performance on spatial reasoning tasks have also 
been found in patients with neurodegenerative conditions that may allow compensation for 
cognitive impairments. Parkinson’s disease is characterised by deficits in motor control and 
planning due to cell death in the substantia nigra from dopamine deficiency (Marsden, 1982). 
This may lead to deficits on spatial reasoning tasks including the mental rotation task. A 
study which implemented the mental rotation task assessed 19 Parkinson’s patients to 
compare performance and brain activation on the most and least affected hand of patients 
(Helmich, de Lange, Bloem, & Toni, 2007). Participants were tasked with identifying 
handedness of hands presented to them in the medial or lateral planes at various degrees of 
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rotation whilst undergoing fMRI. Outcomes showed that reaction times increased as a 
function of hand degree rotation from zero suggesting that patients did use spatial reasoning 
to mentally rotate hand photos. However, patients did have increased reaction times to hands 
in the lateral condition which was accompanied with a significant increase in activation of the 
right extrastriate area and occipito-parietal cortex when they were required to rotate the 
affected hand corresponding to their own affected hand. Regions with higher activation have 
been linked to visual processing and seem to have been recruited to minimize behavioural 
weaknesses. Moreover, increased psychocophysicological interaction (PPI) connectivity was 
found in the contralateral premotor cortex of right handed most affected participants 
compared to controls. This suggests that compensatory cerebral activity in unaffected neural 
areas should attempt to minimize behavioural performance on tasks of spatial reasoning in 
patients known to be affected with neural impairments. Although much research has been 
conducted in Parkinson’s disease with motor tasks several studies support the theory of 
increasing activation in certain regions to support brain degeneration (Haslinger et al., 2001; 
Sabatini et al., 2000; Samuel et al., 1997). 
Discrepancies in behavioural performance and neuroimaging findings have also been found 
in ageing patient populations when compared to normal ageing participants. One study 
measured cognition through positron emission tomography (PET) in a visual recall and 
semantic memory task in older patients with Alzheimer’s Aβ deposition compared to age 
matched controls (Elman et al., 2014). Outcomes showed all groups had behavioural 
performance above chance levels and that there were no between group differences. All 
groups exhibited activation on the semantic recall and memory recall part of the task in the 
fronto-parietal network while deactivated areas were found in the default mode network. 
However, when only task correct items were compared between Alzheimer’s patients and 
elderly controls, patients had greater activation in right lateral, superior parietal and occipital 
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cortical regions. Moreover, patients had relatively less deactivation in task related default 
mode areas compared to ageing controls. Finally, task activation regions were attenuated in 
patients with greater Aβ deposition compared to patients with low levels of Aβ deposition 
(Elman et al., 2014). This suggests that hyper-activation was beneficial in patients with Aβ 
deposition which increased neural plasticity to serve as an over-compensatory mechanism to 
support cognitive processes. These findings have been supported by other research groups 
showing that neural plasticity is a factor that can suppress disease impairments that are 
unobservable such as dopamine deficiency in patients with Parkinson’s disease (Poletti, 
Emre, & Bonuccelli, 2011) and plaque build-up in Alzheimer’s disease (Sumowski, 
Chiaravalloti, & DeLuca, 2009). Taken together, this suggests that subjects with 
compromised cognition may be able to compensate for impairments through recruitment of 
underlying neural circuits. This may facilitate similar performance of patients to controls as 
demonstrated behaviourally in the current study and requires further investigation of 
underlying neurology. 
 
The underlying neural mechanisms in prostate cancer (PC) patients before or during ADT 
have rarely been examined. Studies conducted in healthy controls compared to ADT and non-
ADT PC patients at baseline, have found similar task performance (Chao et al., 2012; 
Cherrier et al., 2010). Furthermore, structural MRI generally showed intact gray and white 
matter volumes using voxel-based morphometry at baseline (Chao et al., 2013). However, 
one study demonstrated that despite the lack of behavioural cognitive difference found 
between patients and controls over a duration of six months, patients had significantly 
decreased connectivity between the medial prefrontal cortex and regions required for 
cognitive control during ADT (Chao et al., 2012). This shows that there were underlying 
neural alterations that did not manifest in behavioural tasks. In the context of the current 
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study, it is important to establish whether similar patterns of group difference exist at baseline 
so that we can interpret longitudinal changes carefully and appropriately. Furthermore, the 
presence of group differences at baseline might help us to identify which men are most at risk 
of later cognitive decline associated with ADT. Functional imaging offers an advantage in 
being able to identify different aspects of brain pathology that may be subtle and cannot be 
detected by behavioural assessment alone. These outcomes offer valid and novel insights into 
the nature of cognition of patients and controls. 
For the current study, this indicates that cognitive decline may not be detected through 
behavioural assessment alone in patients at the point of diagnosis. However, neuroimaging 
may highlight neural abnormalities in elderly PC patients. However, no neuroimaging studies 
have employed a comprehensive battery of cognitive assessments in PC patients before ADT, 
to evaluate executive function and spatial reasoning ability. These domains have been shown 
to decline in patients whilst undergoing ADT (Treanor et al., 2017). Therefore, the effects of 
neuroimaging deficits in patients before starting therapy must be investigated to mitigate any 
carry over effects to the actual therapy duration. This may help physicians devise a strategy 
or plan to restrain cognitive impairments during therapy. 
 
The research suggests that ageing participants or those with cognitive impairments could 
compensate for their deficits. The exploration of these underlying mechanisms allows the 
differentiation between neural changes that are related to the ageing process or those that are 
disease specific. This will be explored in the next chapter. Moreover, potential neural changes 
found in patients could be exacerbated during therapy leading to detrimental effects on 
cognition. Therefore, characterisation of neural function in patients at the early stages may 
prevent unwanted effects of the therapy through careful strategic planning and management.  
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CHAPTER 3 
Study 2: Neuroimaging comparison of neural function and underlying architecture between 
pre-treatment prostate cancer patients and healthy age-matched controls. 
3.0 Introduction 
Consistent with the behavioural literature relating to testosterone, cognition and aging, 
assessment of functional activation during paradigms that assess executive functions and 
spatial reasoning abilities is warranted, as these areas were shown to be affected in PC 
patients (McGinty et al., 2014; Treanor et al., 2017). Executive functions refers to a family of 
terms that encompass a wide number of cognitive sub domains such as inhibition, verbal 
ability, working memory, problem solving ability and mental plasticity (Alichniewicz et al., 
2013; Allain, Nicoleau, Pinon, Etcharry-Bouyx, Barre, et al., 2005; Baddeley & Della Sala, 
1996). These series of abilities are usually classified as a complex set of higher order skills 
that require top down processing to achieve goal oriented daily life activities such as 
independent function, ability to work and maintain social relations (Goel, Grafman, Tajik, 
Gana, & Danto, 1997; Grafman et al., 1996; Green, 1996).  
 
Two key cognitive domains (executive function and spatial reasoning) were studied in the 
current thesis, using a functional imaging framework, owing to data suggesting there may be 
poor performance in PC patients both before and while undergoing ADT (McGinty et al., 
2014; Salminen et al., 2003; Treanor et al., 2017). Inhibition, or inhibitory control, is an 
important aspect of executive function requiring higher order cognitive functioning to 
withhold an action, thought or response (Alichniewicz et al., 2013; May et al., 1999). It can 
also involve the self-control to interference (Diamond, 2013). Specific paradigms that employ 
inhibition include the stroop task (MacLeod, 1991), flanker task (Mullane, Corkum, Klein, & 
McLaughlin, 2009), anti-saccade task (Luna, 2009) and go/nogo task (Cragg & Nation, 
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2008). The task employed (stop signal task) has been found to assess motor response 
inhibition and shown to elicit brain activation in areas that have been associated with 
executive functions (Aron, 2007). Although spatial reasoning can also be measured in a 
variety of ways a prominent approach uses mental rotation of visually-presented objects 
(Potvin et al., 2013). Of note, the spatial reasoning task implemented (mental rotation task) 
incorporated a high spatial component but also required sub components of executive 
function such as short-term memory, working memory and mental flexibility (Pardo-Vazquez 
& Fernandez-Rey, 2012). The activation of areas associated with spatial ability from the task 
were important in the assessment of a spatial reasoning and executive function networks in 
patients. Furthermore, use of tasks with well-established patterns of activation in brain areas 
associated commonly with executive and spatial reasoning facilitates enabled the ability to 
not only investigate underlying neural architecture of behavioural responses in men with PC 
but also to assess  the integrity of these networks using methods comprising resting state 
functional connectivity and arterial spin labelling. This allowed inferences to be made 
regarding age-related changes compared to changes in brain activity present before therapy in 
patients. 
 
In this section the tasks employed in the current thesis are described. The stop signal task 
(SST) has a prevalent inhibition component to it that is considered a key component of 
executive function (Andrés, 2003; Aron, 2007; Stuphorn & Schall, 2006) and is suitable for 
assessments in a laboratory setting (Vince, 1948). The task employs the ability to supress 
inappropriate or no longer required responses (Verbruggen & Logan, 2009). Response 
inhibition impairments have been linked to disorders including attention deficit hyperactivity 
disorder (Nigg, 2001), obsessive compulsive disorder (Penades et al., 2007), and clinical 
disorders such as cancer (Chao et al., 2012). The paradigm typically involves a reaction time 
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response on go trials (no stop) and inhibition of responses to stop trials. The SST has been 
found to require intricate sensorimotor map representation, odd ball consideration, task 
switching, inhibition, and post error processing (Li, Huang, Constable, & Sinha, 2006). This 
is because the task requires retraction of an already initiated ‘go’ response thereby placing 
more emphasis on inhibition (Rubia et al., 2001). The task may transfer to everyday 
circumstances for example when an action that was on the edge of being implemented is 
suddenly changed in the evaluation of the condition. This requires quick motor inhibition in 
situations such as crossing a street or the decision whether to touch a hot object (Diamond, 
2013). 
 
The neural substrates of the SST have been explored in several studies, and provide strong 
evidence for the involvement of key brain regions in executing the task. For example, one 
study found that go trial presses elicited fMRI BOLD activation of the motor cortex, frontal 
and striatal cortex, whereas stopping (inhibitory trials) activated the right inferior frontal 
gyrus (rIFG) in 18 healthy subjects (mean age=29.2, SD=4.5) (Aron & Poldrack, 2006). 
Moreover, fast stop reaction times were shown to elicit greater activation. Another study 
showed similar regional activation in 14 healthy participants (mean age=29.4) (Chevrier, 
Noseworthy, & Schachar, 2007). Researchers found functional MRI BOLD activation in the 
right prefrontal and midline regions whereas inhibition activated the rIFG and basal ganglia. 
Furthermore, activation in the anterior cingulate was found during error detection. Further 
support of distinct regional involvement comes from a study demonstrating right fronto-
parietal activations in 22 healthy participants on inhibitory trials (mean age=23.5) (Zandbelt, 
Bloemendaal, Neggers, Kahn, & Vink, 2013).  These studies provide evidence that the SST 
elicits activation in consistent regions in healthy younger adults. Further brain regions have 
been implicated on the SST that have been associated with other behavioural aspects of the 
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SST. A study by Li et al. (2008) explored the behavioural correlates of post error slowing 
specifically in 40 slightly older healthy adults (age range=22-42). In this study behavioural 
adjustment was made during subsequent trials to adjust for errors made from previous trials 
and involves the slowing of reaction times. This reaction time latency allows better 
judgement on the task to increase accuracy and is behaviourally evident through increasing 
reaction times on inhibition trials (stop signal reaction time) and increasing go trial reaction 
times. However, it is a conflicted ability because the SST requires motor inhibition responses 
whilst also requiring slowing to increase accuracy. Researchers showed that neural correlates 
of this slowing effect were primarily in the right middle frontal gyrus and right inferior 
frontal gyrus which correlated with increasing stop signal reaction times and go reaction time 
as a function of error made (Li et al., 2008). Taken together the studies suggest a pattern of 
right prefrontal and parietal cortical activity during inhibition processing with midline regions 
being activated during go trials. Moreover, these areas correspond to typical areas associated 
with executive function (Takeuchi et al., 2013). 
 
Similar tasks such as the GO/NOGO task have been found to elicit neural activation of 
overlapping regions analogues to the SST in the medial, mesial, and parietal and inferior 
frontal cortices (Rubia et al., 2001). One study found that both response switching from the 
go/nogo task and inhibition from the SST elicited BOLD fMRI activations in similar regions 
including bilateral IFG and presupplementary gyrus (Kenner et al., 2010). However, other 
studies have found that the go/nogo task has been associated with lateralisation to the left 
hemisphere DLPFC areas specialising in motor planning and response selection (Rubia et al., 
2001). The SST has been correlated with right hemispheric laterization in the anterior 
cingulate cortex, inferior prefrontal, and parietal cortices which are known for specialisation 
of inhibition (Rubia et al., 2001). These areas  have predominantly been associated with 
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executive function, attention, and high working memory loads (Rubia et al., 2001). Lesion 
studies furthermore support right hemisphere dominance in which localised damage to the 
rIFG and MFG can lead to loss of inhibitory control (Drewe, 1975; Verfaellie & Heilman, 
1987). Differences in activation may reflect dissimilarities in inhibitory requirements. This is 
because the go/nogo task typically requires an alternative response to be made while the SST 
necessitates inhibition of a response that was on the verge of being made (Verbruggen & 
Logan, 2009). This suggests the SST may be more able to assess functions related to 
everyday tasks whereas the go/nogo task assess a utility required in unusual cases (Diamond, 
2013). This validates the SST as a suitable measure to assess inhibitory executive function, 
because it requires higher inhibitory loads when stop signals are presented compared to tasks 
such as the go/nogo task. Moreover, it activates cortical regions that have been implicated as 
being central to executive function such as the rIFG. The SST has not been found to be 
impaired by decreasing testosterone but literature does support that ageing participants have 
worse performance on the task compared to younger cohorts. 
 
The mental rotation (MRot) task has been found to assess spatial reasoning ability. The task 
has been considered as measuring spatial reasoning as it necessitates object manipulation, 
monitoring, and updating of information as the task progresses (Potvin et al., 2013). It 
requires the mental rotation of shapes using executive function control and spatial orientation 
(Potvin et al., 2013). The assessment of spatial reasoning is of importance in patients 
undergoing ADT since testosterone levels are exhausted (Green et al., 2002; Green et al., 
2004; Joly et al., 2006). Researchers have explored the effects of testosterone on cognition 
with findings leading to the conclusion that testosterone does affect cognition, and especially 
spatial reasoning. For example one study assessed the effects of normal endogenous serum 
testosterone levels and normal free testosterone levels on neuropsychological performance 
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(Moffat et al., 2002). Outcomes revealed a correlation between high visual memory, verbal 
memory, visuospatial function, and visuo motor scanning performance and high free 
testosterone levels. Higher mean free testosterone levels and longitudinal free testosterone 
levels were concomitantly associated with a decreased rate of visual memory decline (Moffat 
et al., 2002). Significantly impaired spatial reasoning performance was associated with visual 
memory decline in hypo-gonadal males (Moffat et al., 2002). The study therefore suggests a 
possible beneficial effect of free testosterone on cognition. A shortcoming was that 
participants classified as hypo-gonadal were on average eight years older than those 
participants with normal testosterone levels. Older participants have been known to have 
cognitive difficulties due to older age which may be a confounding factor (Lunenfield, 2003). 
Another study found that participants substituted with testosterone for six weeks had better 
spatial memory scores, and constructional ability scores compared to a placebo group 
(Cherrier et al., 2005).  The above behavioural literature illustrates that much research from 
the past has found associations between testosterone levels and impaired spatial reasoning 
ability (Barrett-Connor, Goodman-Gruen, & Patay, 1999; Fonda et al., 2005; Moffat et al., 
2002). The mental rotation (MRot) task has also been assessed in a longitudinal nine month 
neuroimaging (fMRI) study with ADT patients compared to matched healthy controls 
(Cherrier et al., 2010). Reductions in right parietal occipital lobes were apparent when ADT 
patients performed the MRot task compared to controls (Cherrier et al., 2010) leading to 
worse performance. This suggests ADT patients may suffer from spatial deficits during ADT 
treatment. Therefore, testosterone deprivation could lead to neuronal impairments which will 
be assessed in the current research. 
Past animal studies add support of brain region activation and have found neural correlates of 
the task in the bilateral occipital parietal lobes and supramarginal gyri, which are thought to 
be associated with spatial map generation to mentally code locations of targets (Andersen & 
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Buneo, 2002). This is apparent through electrophysiological research of the superior parietal 
cortex in primates (Snyder, Grieve, Brotchie, & Andersen, 1998); individual cells in these 
areas are known to be responsible for eye-centred coordinates modulated by primate head or 
body position (Snyder et al., 1998). Moreover, monkeys with spatial neglect in one part of 
space often have lesions in the parietal cortex that inhibits spatial reasoning ability (Karnath, 
Ferber, & Himmelbach, 2001). The motor cortex has also been found to be activated during 
mental spatial manipulation but its activation is much debated throughout neuroimaging 
literature. This is because task activated regions must dissociate between regions activated 
due to motor planning and those activated due to the motor demands of the task (e.g. button 
response pressing).  
 
Neural substrates associated with both SST and MRot have been speculated to be areas of 
abnormal activation in ADT patients due to ADT treatment. Functional MRI tasks can be 
used to measure underlying neural networks in PC patients before ADT in the presence of 
normal behavioural performance that would otherwise indicate normal brain function. This 
allows researchers to identify any affected brain regions before therapy that could accelerate 
adverse effects experienced by patients during treatment. This will allow physicians to 
implement strategies to manage the aetiology of side-effects to minimize cognitive 
impairments during therapy which could affect patient treatment uptake and continuation. 
Resting state connectivity 
Task-free functional connectivity is another tool with which to measure underlying neural 
changes that might occur in the absence of behavioural differences between groups. Resting 
state fMRI is measured by acquiring the BOLD signal at rest (Biswal, 2012). It can be used to 
measure correlations of neural patterns that occur between spatially separate regions (Biswal, 
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Van Kylen, & Hyde, 1997). Altered patterns of activity can thereby be identified that differ 
from standardised neural resting state networks (Damoiseaux et al., 2006; Fox & Raichle, 
2007). These networks are distinct regions known to be activated simultaneously and are 
thought to collaborate together to form functional connections at rest (Lowe, Dzemidzic, 
Lurito, Mathews, & Phillips, 2000). The connections are important to assess as they are 
thought to overlap with brain regions that are active during behavioural performance (van den 
Heuvel & Hulshoff Pol, 2010). The measure thereby provides an indirect evaluation of white 
matter tract integrity that allows for the sharing of information between regions (van den 
Heuvel & Hulshoff Pol, 2010). Moreover, testosterone decline is also known to affect white 
matter tracts in patients with multiple sclerosis whereas testosterone substitution could 
alleviate inflammation and deterioration of white matter tracts (Kurth et al., 2014). Therefore, 
investigation of resting state networks was warranted due to the effect of androgens on white 
matter architecture and applies to PC patients deprived of the hormone. 
 The default mode network (DMN) is known to be one of the networks that is thought have a 
high level of activity compared to other identified networks and overlaps with functional 
regions that are active during the performance of task based assessments (Raichle & Snyder, 
2007). Activity of the DMN was assessed in the current study as it has been associated with 
central processes including integration of emotional processing (Greicius, Krasnow, Reiss, & 
Menon, 2003); global monitoring (Gusnard, Raichle, & Raichle, 2001); divergent thinking 
(Heinonen et al., 2016) and mind drifting (Mason et al., 2007). These complex higher level 
process related to the DMN, indicate that it can provide a unique perspective in examining 
resting state connectivity that underpin behavioural cognitive concepts including executive 
function (Bullmore & Sporns, 2009; Garrity et al., 2007; Harrison, Yucel, Pujol, & Pantelis, 
2007). Moreover, the DMN can be assessed in relation to other regions which are known to 
be underpinned by executive functions that were explored in the present study (Beaty, 
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Benedek, Barry Kaufman, & Silvia, 2015). The DMN has also been shown to be sensitive to 
testosterone levels and deprivations in androgen have been associated with Alzheimer’s 
disease.  
In support of this, some researchers suggest that testosterone levels could modulate functional 
connectivity in the DMN. One study found that testosterone administration in females 
transferring to transgender males had increased functional connectivity in the frontal cortex, 
medial temporal lobe and cerebellum compared to males transferring to the female gender 
(Mueller, Wierckx, Jackson, & T’Sjoen, 2016). Another study assessed the influence of a 
single dose of testosterone in healthy females (Schutter, Peper, Koppeschaar, Kahn, & van 
Honk, 2005). The administration showed greater resting state EEG connectivity between the 
left prefrontal and right parietal cortex. This network has been commonly identified as a 
network with low connectivity and linked to depression in females. Moreover, it is a known 
network important to executive function and consists of DMN areas. Therefore, the role of 
androgens in increasing connectivity may be beneficial to executive function whereas 
deprivation of androgens could lead to impairment. The same has been shown in males with 
high endogenous testosterone levels suggesting testosterone is a core hormonal modulator of 
resting state connectivity in the DMN and related executive function regions (Miskovic & 
Schmidt, 2009). These studies are supported by fMRI assessments of subcortical and cortical 
resting state connectivity analysis (van Wingen, Mattern, Verkes, Buitelaar, & Fernandez, 
2010). 
This is corroborated in age comparison research in which elderly participants have been 
shown to have decreased patterns of connectivity compared to younger cohorts (Damoiseaux 
et al., 2008). This suggests that circulating androgens have an effect on resting state 
connectivity areas linked to executive functioning. Nevertheless, other literature shows 
connectivity impairments between emotional processing nodes such as the amygdala and 
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default mode network and inferior frontal gyri and anterior cingulate cortex (Westlye, 
Kaufmann, Alnæs, Hullstein, & Bjørnebekk, 2017). These areas have also been found to have 
reduced resting state connectivity as a function of steroid administration (Westlye et al., 
2017). Studies therefore infer that not only can resting state connectivity be modulated by 
testosterone levels but that declines in androgens are a natural part of ageing that can 
analogously affect resting state connectivity. This may affect inferences made on resting state 
network changes in patients that could be a function of normal ageing or due to disease 
specific or therapy factors. A control group was therefore warranted in the present 
exploration to characterise normal ageing resting state changes in relation to comparison to 
patients.   
 
Arterial spin labelling 
The BOLD signal is closely coupled to cerebral perfusion (Laurienti et al., 2003; Liu & 
Brown, 2007). Thus, changes in BOLD signal, whether induced by task-based paradigms or 
fluctuating at rest, may reflect fundamental alterations of underlying physiology rather than 
variation in functional architecture. Arterial spin labelling (ASL) is a relatively new 
technique that uses MRI to assess underlying cerebral blood flow changes that could occur in 
the absence of behavioural differences between groups. More specifically, measurement of 
functional MRI task-based or resting activation differences between or within groups may be 
affected by age-related changes or changes over time. This may be due to other relevant 
intermediary variables, such as cerebral perfusion, or blood flow (Chen, Rosas, & Salat, 
2011; Leoni, Oliveira, Pontes-Neto, Santos, & Leite, 2017) rather than functional brain 
changes per se. 
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The link between ageing and cerebral perfusion has been explored in recent studies. Leoni 
and colleagues measured cerebrovascular reactivity, which was explored through the 
assessment of changes in cerebral blood flow (CBF) in response to carbon dioxide (C02) 
inhalation, leading to widening of blood vessels (vasodilatory effect). Healthy ageing 
participants were tested and compared to young participants (Leoni et al., 2017). 
Investigators found significantly reduced CBF in older (46 + 9 mL/100g/min) compared to 
younger (57 + 8 mL/100g/min) adults using pulsed arterial spin labelling (PASL). Moreover, 
reduced cerebrovascular reactivity was observed in elderly participants compared to young 
participants in gray matter (Leoni et al., 2017). This indicates that there are age related CBF 
impairments even in healthy older participants. Regional CBF decreases were found in the 
gray matter superior, middle and inferior frontal gyri, precentral and postcentral gyri, superior 
temporal gyrus, anterior cingulate gyrus, insula, putamen and supramarginal gyrus. However, 
the study was cross-sectional and variability as factors including gas breathing was not 
controlled systematically. Furthermore, the hemodynamic response measured had greater 
variability between subjects, which limited findings as these variables could not be controlled 
between subjects. A better option may have been to conduct a longitudinal study so that 
variables could be compared across time thereby limiting sources inter-subject variance.  
 
Another more extensive study using PASL found reductions in CBF as a function of age in 
23-88 year old participants (Chen et al., 2011). Groups were split into healthy young adults 
(mean age 30 + 6.4), middle age adults (mean age 52.0 + 5.9) and older adults (mean age 
70.5 + 10.4). Cerebral perfusion values were 52.6 + 9.3, 52.0 + 10.7, and 42.7 + 8.8 
ml/100gtissue/min respectively. Whilst no significant differences were found between young 
and middle aged adults, significant differences were evident in young and middle aged adults 
compared to older adults (Chen et al., 2011). Regional differences between groups were 
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found in the superior frontal, superior parietal, orbito-frontal, inferior-middle temporal gyri, 
insular, precuneous, supramarginal, lateral occipital and cingulate regions. However, 
subcortical perfusion was unchanged as a function of age (Chen et al., 2011). The study was 
cross-sectional but had a large sample size making it more generalizable to healthy ageing 
populations. This shows that there are differences in perfusion between middle aged 
participants and older participants suggesting that reductions in perfusion is a normal function 
of ageing. Moreover, in relation to the current study, decreases in CBF may be a function of 
normal ageing in PC patients before therapy that could lead to changes in the BOLD signal. 
Previous research shows that CBF impairments could lead to BOLD signal drop offs (Ances 
et al., 2009). This is important to the current study since outcomes were heavily dependent on 
fMRI outcomes. Therefore, if the BOLD signal is solely interpreted then researchers may be 
led to outcomes showing that patients had functional/cognitive deficits in cerebral function as 
a result of impending treatment or due to the therapy itself. In other words, given that cerebral 
blood flow is known to diminish with age, this could lead to lower BOLD signal activation 
independently of clinically-relevant disease related factors (Liu et al., 2012). This highlighted 
the need for a control group in the present study so that normal perfusion levels could be 
characterised and compared to patients to assess if any changes were due to cognitive 
functioning or perfusion differences. Therefore, ASL was employed to validate that cohort 
samples did not have perfusion abnormalities that affected fMRI activation results by leading 
to BOLD signal fluctuations.  
 
In the context of the present study, and evidence that testosterone may influence brain 
connectivity at rest, it is important to establish whether testosterone levels influence CBF, 
particularly over longitudinal durations. Indeed, decline in testosterone levels associated with 
normal ageing may be one possible mechanism influencing changes in the CBF of normal 
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older samples. The association between cerebral perfusion and testosterone in ageing cohorts 
was explored in one study (Azad, Pitale, Barnes, & Friedman, 2003). Researchers assessed 
the effects of testosterone administration on cerebral perfusion using single photon emission 
tomography (SPECT) imaging. Seven hypogonadal subjects (age range=52-72) were 
administered with testosterone for three months. Results showed increased cerebral blood 
flow in the midbrain, anterior cingulate gyrus and superior frontal gyrus gray matter regions 
during treatment compared to baseline hypogonadal levels and was similar to that of controls. 
Moreover, testosterone administration led to better mood and quality of life (Azad et al., 
2003). The study was limited in sample size but outcomes show that not only can imaging 
methods be used to detect the effects of hormonal changes on cerebral perfusion, but that 
testosterone does impact on cerebral perfusion as a function of normal ageing. This has 
implications for interpretation of either group differences in BOLD activation (i.e. patients 
and controls) or longitudinal analysis within patients. To date, no research has been reported 
that assesses the impact of androgens on cerebral blood flow using ASL. Thus, in the current 
study, a measure of ASL was used to examine whether changes in BOLD during task-based 
or resting fMRI reflected changes in cognition per se or simply altered cerebral perfusion.  
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3.1.1 Aim 
The aim of this study was to characterise neural activation and functional connectivity in 
patients at baseline and controls. Moreover, the investigation aimed to assess whether 
cerebral perfusion accounted for any group differences.  
3.1.2 Hypothesis 
PC patients were not expected to have any changes in cerebral function or neural architecture 
before beginning androgen deprivation therapy. More specifically:  
a. There were expected to be no in-scanner behavioural differences between healthy 
controls and patients which included: 
 
i. No difference in stop signal performance or reaction times between 
controls and patients. 
ii. No behavioural differences between controls and patients on the MRot 
task. 
 
b.  Furthermore, no significant neural activation differences between controls and 
patients on the stop signal or MRot tasks were expected including: 
 
i. That the SST would activate putative task regions from past literature. 
These areas being the right inferior frontal gyrus, middle frontal gyrus, 
anterior cingulate cortex and inferior parietal regions in both groups. 
ii. That there would be bilateral parietal activation when participants 
engage in the MRot task. 
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c. There would be no resting state connectivity differences between controls and patients 
when regions of interest relevant to executive function were selected and correlated 
with the default mode network. 
 
d. No significant differences in cerebral perfusion were expected between controls and 
patients assessed through arterial spin labelling (ASL). 
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3.2 Methods  
3.2.1 Design 
A between subjects design was implemented to assess performance and neural activation in 
controls and patients on an event-related SST. MRot task performance and brain activation 
was measured with a block design interval model. Participants were scanned using functional 
magnetic resonance imaging (fMRI) before any cancer specific therapy commenced. 
3.2.2 Participants 
Participant details were as stated in chapter two. 
3.3 Brain Imaging Tasks 
SST (SS) task parameters 
Participants were presented with a white fixation cross for 500ms followed by a yellow hash 
(#) symbol in the centre of the screen. Hash symbol durations were separated into go trials 
(no flicker) and stop trials (short flicker, medium flicker, and long flicker) presentation 
timings (figure 3.1). The hash symbol was always yellow in colour and presented on a black 
background. All stimuli durations were kept equal (700ms) and a jittered blank screen 
duration (ISI) was presented subsequently after each stimuli to make trial occurrence 
unpredictable. An algorithm was used to create ISI durations which were contingent upon the 
timing of the jitter at the beginning of each trial. The ISI was presented for 3000ms initially 
and either increased if a correct inhibition was made in the previous trial, or decreased by 
50ms if a commission error was made in the previous trial where a button press is made on a 
stop trial. The ISI duration increased to a maximum of 3400ms and did not increase further 
even if correct inhibitions were made. The minimum ISI duration was 2600ms and did not 
decrease further even if further commission errors were made. Subjects were required to 
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respond on a keyboard to no flicker trials and to inhibit responses on stop trials. Go trials 
comprised 60 per cent of all trials and stop signals encompassed 40 per cent of trials [short 
flicker (15), medium flicker (5) and long flicker (20)].  Ordering of no flicker and flicker hash 
symbols were randomised (For durations of hash symbols see Figure 3.1). Apart from 
randomisation of stimuli each run was identical. The duration of each run was 5 minutes 14 
seconds and experiments were split into two runs each consisting of 100 trials with 200 trials 
in total. The task was made using E-prime 2.0 (Schneider, 2002) which collected behavioural 
data consisting of keyboard responses (correct, inhibited, incorrect and reaction time). 
 
SST outcome measures 
Performance on the SST can be modelled as an independent horse race model which 
describes the processes between the probability of responding p(respond|signal) and the 
probability of inhibiting p(inhibit|signal) on stop signal trials (Logan & Cowan, 1984). The 
p(respond|signal) depends on three factors including (1) the stop signal delay (SSD), (2) go 
reaction time (go RT), and (3) stop signal reaction time (SSRT). When the SSD increases, the 
p(respond|signal) increases. This is because the stop process starts later and finishes later in 
comparison to the go process which has already begun thereby forcing a response. As 
subsequent SSDs are presented the p(respond|signal) decreases and go RT increases. This is 
because of the increased probability that the stop process finishes before the go process 
(Verbruggen & Logan, 2009). Furthermore, SSRT increases for subsequent SSDs because the 
probability that the stop process finishes after the go process increases. 
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Stop signal reaction time calculation 
Stop signal reaction time (SSRT) was acquired with the most commonly used integration 
method. This method estimated the SSRT by subtracting the SSD from go RT distribution. 
The go RT distribution was acquired by rank ordering all go trial reaction times. The nth go 
RT was then selected and subtracted from the median SSD. This process was repeated for 
each participant and then averaged. For example in a session of 20 trials from which go RT 
can be measured, there are four stop trials (one correct stop and three incorrect stop). The 
probability of correctly stopping is 0.25, therefore, the probability of responding is 0.75. The 
stop signal is presented 350ms after the initial go onset of the go stimulus. Go RT are 300, 
320, 340, 380, 400, 410, 420, 460, 500, 520, 540, 550, 590, 600, 700, 750ms. 
n = number of go RTs (which can be measured) x probability of response on stop trials. 
n therefore = 16 x 0.75  = 12 
the 12th reaction time is 550ms. 
Therefore, the stop process finishing estimate is 550ms after the onset of the go stimulus. 
Subtraction of this from the SSD which is 350ms is 550-350 revealing an SSRT of 200ms 
(example from Eagle et al. (2008). 
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Figure 3.1: fMRI illustration of the SST. (A) No flicker timings in which participants must press the button on 
response pad. Arrows under hash symbol figures represent when participants must respond. (B) Stop trials were 
separated into short, medium, and long trials. In parts (A) and (B) of figure 2, blank screens labelled as ISI 
algorithm were varied in their duration and increased or decreased in duration depending on if the participant 
responded or inhibited correctly. Abbreviations: ms, milliseconds; ISI, interstimulus interval.       
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MRot task parameters 
The MRot task consisted of a 7.5 minute run with eight alternating 38 second blocks 
separated by 20 second rest periods. Blocks comprised of experimental and control 
conditions each repeated four times during the functional run. Eight shapes were presented 
per block. The task was adapted from Shepard and Metzler (1971) MRot task in which 3D 
shapes are displayed on a blank screen. In experimental blocks, one shape from each pair was 
rotated along its vertical axis at 60, 120, 180 or 300 degrees and contained identical shapes 
whilst the other half contained rotated mirrored shapes. Un-rotated identical or mirror shapes 
were presented in the control condition. Participants had to determine if shapes were identical 
or mirror images by pressing either their right index or middle finger respectively in both 
conditions. Slides were presented for 3750ms followed by a fixation point on a blank screen 
for 750ms. 
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Figure 3.2: Shows MRot task parameters and examples of presented shapes. A. Task rotated shape 
examples where subjects were required to make a response after mentally rotating shapes clockwise 
or anti-clockwise to judge if shapes were in the same orientation or mirror images of each other. B. 
same or mirror oriented shape pairs that require no rotation to distinguish if they were the same or 
different. Abbreviations: MRot, mental rotation task; ms, milliseconds. 
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3.4 Imaging acquisition 
All scans were acquired on a Philips 3.0T Achieve functional magnetic resonance imaging 
(fMRI) scanner with a 32 channel head coil receiver. 
3.4.1 Structural scans 
Sagittal T1 structural images were obtained using a 3.0 T scanner (Philips). Blood 
oxygenation level dependent (BOLD) signals were acquired with a gradient echo planar 
imaging (FEEPI) sequence in the sagittal plane (thickness of 1mm), repetition time (TR) = 
8.4s, echo time (TE) = 3.8ms, flip angle = 7.16°, field of view = 230 × 175 mm, matrix size = 
288 x 288. Voxel dimensions were 1mm x 1mm x 1mm isotropic. 184 dynamics (images) 
were acquired for SSTs with forty contiguous axial slices (3mm thickness) per image. These 
were acquired with TR = 2.5s, TE = 3.80s, flip angle = 90°, field of view (FOV) = 240 × 240, 
matric size = 68 x 68.  A tilted acquisition plane (30o to the rostral > caudal tilt) was used and 
adjusted individually to reduce signal dropout in frontal brain regions (orbitofrontal cortex) 
(Mennes et al., 2014). 
3.4.2 Functional Scan Imaging Acquisition Parameters 
Both SST and MRot functional scans were acquired with 3mm x 3mm x 3.5mm non-isotropic 
voxels. 184 dynamics (images) were acquired with 40 contiguous axial slices (3mm 
thickness) per image where the TR = 2.5s, TE = 3.80s, flip angle = 90°, field of view (FOV) 
= 240 × 240, matrix size = 68 x 68.  A tilted acquisition plane (30o to the rostral > caudal tilt) 
was employed and adjusted individually to reduce signal dropout in frontal brain regions 
(orbitofrontal cortex) (Mennes et al., 2014). 
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3.4.3 Functional Resting state connectivity 
Resting state scans were acquired with 30 contiguous axial slices (4mm thickness) using 
gradient echo planner imaging (FEEPI) with TR = 2.0s, TE = 3.5s, flip angle = 80°, field of 
view (FOV) = 80 × 80 matrix size. Voxel size were 3mm x 3mm x 4mm and 180 dynamics 
(images) were acquired. A tilted acquisition plane (30o to the rostral > caudal tilt) was used 
and adjusted individually to reduce signal dropout in frontal brain regions (orbitofrontal 
cortex) (Mennes et al., 2014). Scan duration was 6 minutes 13 seconds. 
3.4.4 Arterial Spin Labelling (ASL) 
Absolute cerebral blood flow was measured using pulsed arterial spin labelling (PASL) and 
was acquired with 15 axial slices (3.5mm thickness) at a distance of 3.5mm. A FAIR Double 
Acquisition back ground suppression (DABS) was used to acquire ASL data (Wesolowski, 
Gowland, & Francis, 2009) (TR =  8.0s, TE = 9.59s, flip angle = 90°, field of view (FOV) = 
240 × 240mm2 matrix size 68 x 66). Twenty-four dynamic images were acquired and voxel 
size were 3mm x 3mm x 7mm. A tilted acquisition plane (30o to the rostral > caudal tilt) was 
used and adjusted individually to reduce signal dropout in frontal brain regions (orbitofrontal 
cortex) (Mennes et al., 2014). The acquisition plane was also placed more toward the superior 
region of the brain so that maximum gray matter areas could be acquired in prefrontal and 
anterior regions. Scan duration was 6 minutes 66 seconds. Whole brain T1 sequences were 
acquired individually at 0.3, 0.6, 0.7, 1.1 and 1.3 seconds after bolus (endogenous water 
molecules in blood) were labelled (tagged by inversion). Control T1 sequences where no 
bolus was tagged were acquired eight seconds after tag images for later subtraction from T1 
tag inversions. A calibration image was finally acquired with the same dimensions as 
aforementioned for PASL with only 6 dynamics. The calibration scan duration was 56 
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seconds and was acquired for an estimation of absolute cerebral blood flow in 
ml/100gtissue/min, which was applied to control-tag subtraction images in later analysis. 
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3.5 Statistical Analysis 
3.5.1 FSL analysis 
3.5.2 Preprocessing 
Raw data files in ParRec from the Philips scanner were converted to Neuroinformatics 
Technology initiative (Niftii) format. Structural scans were reoriented using a reorient script 
in a Linux terminal. Structural T1s were skull stripped by employing a BET extraction tool in 
FSL 5.0.8 (Smith et al., 2004) BET brain extraction software (Smith, 2002). The point of 
interest on scans was corrected to determine the centre of the cortex for skull stripping. T1s 
were checked with FSL view to assess quality of skull extraction. Pre-processing steps 
included motion correction of images using FSL MCFLIRT. Regular slice timing correction 
was applied with a spatial smoothing full width by half maximum (FWHM) of 8mm. A high 
pass filter was applied to remove low frequency noise thereby allowing better signal to noise 
ratio (SNR). Functional images were co-registered to structural T1s and then co-registered 
images were registered to standard MNI standard space (Strother, 2006). Only voxels with 
significant (p < 0.05) functional activation were accepted as voxels with substantial signal 
change. 
3.5.3 First Level analysis 
Statistical analysis at the subject level on the SST was carried out at a single subject level 
first using the general linear model (GLM) in FSL. SST durations were separated into four 
conditions: go correct (gc), go incorrect (gin), stop correct (sc), and stop incorrect (sin) which 
were convolved with the GLM as regressors. The main contrast created to investigate 
inhibition compared to go activation was of go incorrect (gin) and stop correct (sc) trials 
compared to stop incorrect (sin) and go correct (gc) trials. As illustrated, gin and sc trials 
were paired together which was undertaken due to low trial power on gin trials. However, 
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this was further explored because although both trials types were related to inhibition, they 
used conceptually different mechanisms. This is because whereas, gin trials were associated 
with inhibition, they were errors made during go trials which may elicit activation in go 
related areas. Therefore, the pairing of trials may not be appropriate if this were the case since 
in the main contrast, the combination of gin and sc trials would not consist of solely 
inhibitory activation for comparison to go activation. Therefore, two exploratory contrasts of 
gin compared to gc trials and gc compared to gin trials were included to investigate if gin 
trials elicited inhibitory activation exclusively.  
Similarly, sin trials were paired with gc trials to increase the power of go trials. Contrasts of 
sin compared to sc and sc compared to sin trials were created to investigate if sin trials were 
associated with primarily go trial activation. This is because sin errors were made during stop 
trials that may elicit inhibitory activity and not activation associated with go trials. Moreover, 
sin responses have been associated with post-error slowing adjustments. This is a mechanism 
by which subjects may incorporate a longer latency period from the start of a trial 
presentation to the response made after an error is detected so that better performance is 
achieved on subsequent trials (Li et al., 2008). However, this mechanism has also been 
associated with right dorso-lateral prefrontal cortex activation related to inhibition (Li et al., 
2008). Therefore, it would not be appropriate to combine sin and gc trials in the main contrast 
if sin trials elicited inhibitory activity. The combination of contrasts also facilitated in 
balancing the main contrast so that it was not biased to the combined side with the majority 
of trials. 
The SST was additionally decomposed into trials of long correct (lc), long incorrect (lin), 
medium correct (mc), medium incorrect (min), short correct (sc) and short incorrect (sin) 
trials and run contrasts. The main contrast was long flicker correct trials compared to go 
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correct trials as this allowed comparison of maximum inhibition activation compared to 
response (go trial) activation.  
The MRot task was spilt into experimental (exp) and control (cont) task trial duration, which 
were convolved with the GLM. Experimental conditions were contrasted against the control 
condition. Contrasts were run with the general linear model in FSL and the canonical 
hemodynamic response function was used to model activation. Single subject analysis was 
performed with an uncorrected z-threshold (P < 0.05).  Analysis of single subjects was 
combined using a higher level analysis and mixed Flame effects stats were implemented to 
correct for multiple comparisons with a z-threshold of 2.3. A cluster significance threshold of 
P < 0.05 was used to locate any voxel clusters surviving multiple comparisons. 
First level analyses were entered into a group level analysis using FEAT’s higher level 
statistical modelling approach (Smith et al., 2004; Woolrich et al., 2009). Patients and 
controls were compared using an independent samples t-test. Anxiety, depression and 
testosterone levels were added as covariates by first demeaning raw scores and then entering 
them as covariates for each participant. Demeaning was undertaken by taking the group mean 
for the covariate and subtracting it from each raw covariate score. Covariates were assessed 
at the individual level and with an F-test to explore the variance contributed by all covariates 
on group activation contrast maps. Contrast masking was used to contain variance from 
covariates (anxiety, depression and testosterone) to contrast activated regions of specific 
contrasts only.  
Region of interest (ROI) analysis was done by masking specific regions taken from cluster 
activated areas above Z>2.3. Masks were binarised so that regions inside the mask were 
given a value of one and regions outside were given a value of zero using the fslmaths 
command. Featquery (http://www.FMRIb.ox.ac.uk/fsl/feat5/featquery.html) was used to analyse 
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ROIs in specific contrasts with output being mean percentage signal change over the 
functional run time course in the ROI. 
3.5.4 Resting State seed based functional connectivity 
Resting state analysis was undertaken by selecting predefined regions of interest cluster 
masks which were registered to pre-processed functional scans. Masks chosen were the 
default mode network (DMN) medial prefrontal cortex (mPFC) and right dorso-lateral 
prefrontal cortex (rDLPFC) as the seed region (Harvard-Oxford Cortical Structural Atlas). 
These areas were specifically chosen due to their putative involvement with executive 
functions (Koechlin & Summerfield, 2007; Seeley et al., 2007). All raw data went through 
preprocessing first where head motion in white matter and cerebrospinal fluid was filtered 
out. Region of interest of masks were then registered to each subject’s functional resting state 
run. The BOLD data was further filtered between 0.001 < f < 0.01.  
A dorsolateral prefrontal cortex (DLPFC) mask was generated using a 5mm ROI around the 
peak group average voxel in the whole DLPFC (38 18 32). Correlations were then gauged 
between the seed region (DLPFC) and DMN mPFC. These were output into a separate file. 
Regressors were generated by finding the time course of the seed region of interest. The seed 
region time course was inputted into the first level single subject GLM so that a connectivity 
map could be generated with the time course of the seed region and DMN mPFC. Positive 
and negative contrasts were used to assess positive/negative correlation activations from the 
seed region and mPFC to other regions in the default mode network. Single subject level 
analyses were then combined into a higher level group analysis to assess combined group 
activation. Two analyses were performed in which the DMN mPFC and DLPFC were 
analysed and another analysis in which the DMN mPFC and rIFG were analysed. The rIFG 
was chosen due to its putative role in executive function and especially in the SST during 
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fMRI (Hughes, Johnston, Fulham, Budd, & Michie, 2013). The rIFG was masked by 
selecting the voxel presenting greatest activation (MNI coordinates: 50 30 -2) (Harvard-
Oxford Cortical Structural Atlas) in the rIFG cluster area from the SST group activation map. 
A 5mm sphere was masked around these voxels for the resting state analysis. An independent 
sample t-test was conducted to assess the difference in resting state connectivity between 
patients and controls. 
3.5.5 Arterial spin Labelling  
Initial preprocessing steps were undertaken to establish there was normal cerebral perfusion 
estimates over time points that was obtained from a particular slice and voxel in each subject. 
This was accomplished by using a unique method where skull stripping was first undertaken 
of ASL data using the FSL BET extraction tool to create a mask of the brain (Smith et al., 
2004). The BET extracted data were subsequently segmented into multiple T1 images, which 
revealed tag-control subtracted images. Next, T1 tag-control T1 images were averaged over 
repeated acquisitions. A slice was then selected in a gray matter superior portion of the brain 
that encompassed the prefrontal cortex as normal perfusion in this region was required for 
further analysis. Voxel co-ordinates were subsequently selected in the nominated slice 
making sure it was in a part of the brain where there was gray matter to measure cerebral 
perfusion in the slice and voxel across time points. This allowed the selection of a slice to 
estimate perfusion in just one voxel and image. This calibration image was also selected to 
calculate absolute perfusion in mL/100g/min units. Average perfusion was estimated by 
fitting the data from the slice and voxel selected to the kinetic curve over five time points 
(0.3, 0.5, 0.7, 0.9 and 1.1 ms) (Chappell et al., 2010). This pattern of perfusion has been 
shown to be exponential at first and then decreases rapidly as bolus exits the cortex. The 
curve was calculated at each time point by subtracting the tag image from the control image 
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and then averaging the result which is fitted on a voxel by voxel basis using Chapell’s two 
compartmental model (Chappell et al., 2010). Further computations allowed gray, white and 
cerebrospinal fluid separation masks which were used to assess the kinetic curve over the five 
time points in each tissue type averaged over the whole brain. Moreover, a whole brain 
kinetic curve was explored and then just the top half of the brain perfusion was investigated. 
This procedure was undertaken in all subjects individually. If perfusion was severely 
abnormal due to motion effects or scanner software failure, then the scan of that subject was 
excluded from the analysis. The FSL package Bayesian inferencing toolkit (BASIL) 
(Chappell, Groves, Whitcher, & Woolrich, 2009) was used to analyse subject first level data 
where the tag and control images were subtracted to generate CBF images and registered to 
the BET extracted T1 structural image. The output revealed a CBF image tag-control 
averaged across the five inversion time durations. The CBF outputs were subsequently 
registered with the standard MNI template to standardise perfusion measures across subjects 
in gray matter only using the standardised brain.  
In order to assess group level averaged cerebral whole brain and regional perfusion, higher 
level group combinations were undertaken using the fslmerge, fslmaths and fslstats 
commands to calculate average perfusion across groups. Regions of interest (ROIs) masks 
were generated of the rIFG and right and left supramarginal gyri and these were then 
binarised and superimposed onto whole brain perfusion images. Fslstats was then used to 
extract perfusion values in these ROIs. Comparisons were made between groups and ROIs by 
extracting average CBF on an individual participant basis. Data were then entered into SPSS 
and a one-way between subjects ANOVA was used to make comparisons.    
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3.6 Procedure 
Participants were scanned at the Birmingham University Imaging Centre (BUIC) centre and 
screened before being scanned to confirm MRI safety protocols (Appendix 1). Participants 
were briefed about the nature of the study, their scan durations and the protocol that would be 
applied if any incidental findings were present. 
Participants were fully de-metalled and placed in the supine position into the scanner by a 
qualified radiographer or trained scan operator. Padding was placed to the side and 
underneath the head to limit head movement. An emergency buzzer was given to participants 
in case of distress, so that they could alert the scanner operator mid-scan if they wanted to 
stop for any reason. A computer screen image projected from a projector was reflected to 
participants through a mirror placed on the head coil.  Headphones were provided for 
communication to participants in the scanner room through the control room where either the 
radiographer or scan operator could communicate with the participant before individual scan 
runs. Ear plugs were provided for hearing protection.  
3.6.1 Functional runs 
Explanations of the SST and MRot tasks were administered before participants were scanned 
via a laptop computer. Participants completed 20 practice trial items from the SST and 15 
items of the MRot task, which were dissimilar to the actual tasks presented to minimize 
practice effects. Practice trials were presented on a laptop computer in the waiting room or a 
separate quiet area. Participants were instructed to press their index finger once as quickly as 
possible when they saw the hash symbol appear after a fixation cross on the SST. However, if 
the hash symbol flickered, they were instructed to inhibit their response. They were also told 
not to wait until after the hash symbol completely disappeared off the screen and the blank 
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screen appeared to make a response. This instruction was required to avoid prediction 
responses and inhibition or post-trial responding. 
Instructions for the MRot task included that participants should press their index finger as 
quickly as possible if shapes fit into each other after mentally rotating shape pairs. However, 
if shapes were a mirror image of each other and did not fit into each other then they should 
press their middle finger. Participants did the practice tasks on a desktop computer with 
screen and keyboard provided using E-prime 2.0 software, with analogous keyboard mapping 
to the scanner response pads. 
Participants were instructed to lie as still as possible during the resting state scan and ASL 
scan. Finally, before entering the scanner, participants were told the layout of the scanner and 
a NATA technologies (NATAtech, 2006) response pad was provided inside the scanner. The 
ergonomic response pad was placed under the right hand of the participant in the scanner 
where they were able to press two buttons (index and middle) out of four available. 
Instructions were repeated to participants before each functional and structural scan through 
headphones. Total scan duration was 90 minutes. 
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3.7 Results 
3.7.1 Behavioural Analysis 
3.7.1.1 Stop Signal Task (SST) 
In scanner behavioural performance was compared between healthy matched controls and 
patients with prostate cancer. Independent sample t-tests showed no significant differences 
between groups on overall go and stop signal accuracy (t(57) = -1.04, p > 0.05). No 
significant difference was found between groups on overall reaction time (t(57) = 1.49, p > 
0.05). Moreover, no significant between groups difference was found on stop trial inhibition 
accuracy (t(57) = -0.47, p > 0.05)  or stop signal reaction time (t(57) = 0.27, p > 0.05).  
A further independent samples t-test was conducted with group as the fixed factor and stop 
signal flicker trials (short, medium and long) performance as dependent variables. The 
independent samples t-tests showed no significant differences on inhibition accuracy in the 
short flicker condition (t(57) = -0.75, p > 0.05) medium flicker condition (t(57) = -1.47, p > 
0.05) or long flicker condition (t(57) = 0.06, p > 0.05) between patients and controls. 
Independent samples t-test of stop signal reaction time showed a significant difference 
between controls and patients in the short flicker condition (t(36) = 2.05, p = 0.05, r = 0.32) 
and medium flicker conditions (t(44) = 2.38, p = 0.05, r = 0.34) where patients had faster 
SSRTs compared to controls (Table 3.1). No significant SSRT between group differences 
were found in the long flicker (t(57) = 0.79, p > 0.05) condition. A MANCOVA showed no 
significant effects of anxiety (F(2,21) = 0.80, p > 0.05), depression (F(2,21) = 2.20, p > 0.05) 
or testosterone (F(2,21) = 0.34, p > 0.05) on stop signal flicker SSRT differences found 
between patients and controls. 
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Table 3.1 SST Descriptive Statistics  
 
 Healthy Controls 
(n=29) 
Patients  
(n=30)  
 
 Baseline  Baseline  
Trial type Mean SD Mean SD 
Go trials    
Accuracy (%) 78.64 11.92 81.5 8.99 
Reaction time (ms) 1317.34 311.55 1206.34 257.48 
 
Stop trials    
Accuracy (% 
inhibited) 
65.82 22.42 68.46 20.47 
SSRT (ms) 304.07 168.12 251.77 110.31 
 
Short flickers    
Accuracy (% 
inhibited) 
79.54 26.41 84.44 23.72 
SSRT (ms) 599.69 202.8 408.01 86.45* 
 
Medium flicker    
Accuracy 
(%inhibited) 
66.21 30.87 77 25.21 
SSRT (ms) 564.6 183.38 540.33 261.65* 
 
Long flickers    
Accuracy (% 
inhibited) 
54.66 21.39 54.33 20.82 
SSRT (ms) 615.95 147.57 557.62 114.6 
 
Abbreviations: ms, milliseconds; SD, standard deviation; SSRT,  
stop-signal reaction time; SST, stop signal task; *p<0.05. 
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3.7.1.2 Mental Rotation (MRot) task 
Independent samples t-tests were conducted and showed no significant difference in 
performance between patients and controls in the same oriented shape condition (t(57) = -
0.33, p > 0.05). However, a significant difference was found between groups on mirror shape 
tasks (t(57) = -2.19, p = 0.03, r = 0.28) where patients performed better than controls (Table 
3.2). No reaction time differences were found between groups in the same oriented shapes 
condition (t(44.16) = -1.93, p > 0.05) (equal variances were not assumed since Levene’s test 
indicated unequal variances, (F = 6.60, p = 0.01). Therefore, degrees of freedom were 
adjusted from 57 to 44.16) or mirror shapes (t(57) = -0.94, p > 0.05). Finally, no significant 
differences were found between groups on performance (t(57) = -1.86, p > 0.05) or reaction 
time measures (t(57) = -1.61, p > 0.05) when trials were combined across same and mirror 
shapes.  
 
Further ANOVAs were conducted to explore performance and reaction times on distinct 
shape orientations from zero. A one way ANOVA with group as the fixed factor and reaction 
times on the varying degrees of shape rotations (60, 120, 180 and 300 degrees) as four 
dependent variables was employed. The analysis showed no significant differences between 
groups in the 60 degree (F(1,57) = 1.34, p > 0.05), 120 degree (F(1,57) = 0.86, p > 0.05) and 
180 degree (F(1,57) = 0.005, p > 0.05) conditions. However, a significant reaction time 
difference was found in the 300 degree condition (F(1,57) = 6.70, p = 0.01, η2 = 0.11) where 
patients had slower reaction times compared to controls (Table 3.2 and figure 3.3). A similar 
ANOVA was performed with percentage correct in the varying degree conditions from zero 
as dependent variables.  The analysis showed no significant performance differences in the 60 
degree (F(1,57) = 2.50, p > 0.05), 120 degree (F(1,57) = 3.15, p > 0.05) or 180 degree 
(F(1,57) = 0.01, p > 0.05) conditions between groups. However, a significant difference was 
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found in the 300 degree condition (F(1,57) = 5.03, p = 0.03, η2 = 0.08) where patients 
performed better than controls (Table 3.2 and figure 3.4).  
Both mental rotation performance and reaction time in the 300 degree conditions were 
entered into a MANCOVA to assess if covariates mediated any of this difference. No effects 
of anxiety (F(2,53) = 1.89, p > 0.05), depression (F(2,53) = 0.43, p > 0.05) or testosterone 
(F(2,53) = 1.35, p > 0.05) were found to vary with differences in reaction time and 
performance. No significant reaction time or performance difference was found when 
controlling for all covariates (F(2,53) = 0.86, p > 0.05). 
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Table 3.2 MR task Descriptive Statistics 
 Healthy Controls 
(n=29)  
Patients  
(n=30) 
 
 Trial type      Baseline  Baseline  
 Mean SD Mean SD 
MR task performance           
           
Same orientation shapes           
        Accuracy (%)  60.78 24.14 62.71 20.60 
        Reaction Time (ms)  2086.34 349.76 2229.72 199.53 
           
Mirror orientation shapes           
    Accuracy (%)  46.55* 28.33 61.04 22.18* 
    Reaction Time (ms)  2138.55 287.86 2219.62 366.29 
           
Total same and mirror 
orientation shapes          
    Accuracy (%)  53.67 18.30 61.88 15.64 
     Reaction Time (ms)  2112.44 285.65 2224.67 249.80 
           
Divided degrees           
60 degrees           
    Accuracy (%)  61.21 27.42 71.25 21.06 
    RT (ms)  1979.39 350.19 2105.53 464.89 
120 degrees           
    Accuracy (%)  56.47 21.29 66.25 21.06 
    RT (ms)  2174.39 401.33 2261.48 316.01 
180 degrees           
    Accuracy (%)  47.84 18.92 48.33 18.49 
    RT (ms)  2177.86 386.81 2170.52 391.34 
300 degrees           
    Accuracy (%)  49.14 21.89 61.67 21.00* 
    RT (ms)  2118.13 405.16 2361.16 293.43** 
 
Abbreviations: MR, mental rotation task; ms, milliseconds; RT, reaction time; SD, standard 
deviation; *p<0.05, **p<0.01. 
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Figure 3.3: MRot task average reaction time between patients and controls. Abbreviations: cont, 
control condition; MRot, mental rotation task; ms, milliseconds. 
 
 
  
  
 
 
 
 
 
 
 
Figure 3.4: MRot task average percentage correct between patients and controls. Abbreviations: 
cont, control condition; MRot, mental rotation task; *p<0.05; **p<0.01.
*p<0.05 
**p<0.01 
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3.7.2 Whole brain cerebral blood flow (Arterial Spin Labelling analysis) 
Whole brain cerebral blood flow was explored first to validate that both groups did not have 
altered levels of cerebral perfusion. Whole brain CBF was classed as being abnormal if there 
were abnormalities such as hypo-perfusion (15-20 mL/100gtissue/min) or hyper perfusion in 
gray matter regions. These thresholds were implemented as they suggest there could be 
vascular abnormalities including arterial stenosis, occlusions or lesions etc. if such 
abnormalities are found (Pollock et al., 2009). 
 
Analysis of baseline ASL data was compromised due to errors detected in the raw data of 22 
cases (three patients, nineteen controls). Past research has shown that ASL is reliable over a 
longitudinal period and so in order to compare groups, data from follow up scans were used to 
estimate baseline perfusion. Researchers in one study assessed reliability in healthy older 
subjects (mean age = 75.5 + 5.3) that underwent resting state ASL (Jiang et al., 2010). 
Participants were scanned using pulsed arterial spin labelling at baseline, three, six and twelve 
months. Outcomes showed no significant differences in perfusion between time points. 
Moreover, reliability of perfusion measured through intra-class correlations were moderate to 
good. Moderate ICC values were attributed to slight variances and changes in slice 
positioning and coregistration. The study is supported by further studies showing that ASL 
was reliable over a longitudinal period (Parkes, Rashid, Chard, & Tofts, 2004). However, 
reliability of ASL measured between baseline and periods in excess of one year were not 
reliable (Parkes et al., 2004). This may be due to the changing morphology and age associated 
change in brain architecture of ageing adults. Taken together, the studies suggest that ASL is 
reliable over a period of one year and that only slight variations can be expected due to slice 
positioning. Thus, ASL acquired at six months is expected to be similar to baseline scans in 
the current study. With this in mind, healthy control baseline scans that were still intact were 
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combined with the remaining scans of participants from follow-ups at six months. Three 
participants’ scans were excluded from this analysis; two participants’ scans were excluded 
due to excessive motion which created distortion and made the image unusable. The third 
participant’s scan was not used due to withdrawal from the scanner during the ASL sequence. 
The final analysis was conducted with 26 control participants (mean age 67.69 + 6.90). Whole 
brain average perfusion with this sample was 48.61 + 51.88 ml/100gtissue/min. Group mean 
ASL perfusion subtraction analysis images are shown in Figures 3.5 and 3.6.  
The prostate cancer ADT sample consisted of 24 patients (mean age 67.21 + 6.35). Six patient 
scans were excluded due to scanner sequence failures and at the time of submission of this 
thesis, the follow up ASL data in these patients were not available for analysis in the manner 
in which corrupted baseline control data were incorporated. Whole brain average perfusion 
was 66.14 + 70.01 ml/100gtissue/min.  
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Figure 3.5: Healthy Controls (n=26) ASL Group Analysis. The colour bar represents least perfusion 
in black to red areas of the CBF map and greatest perfusion in yellow areas of the map. 
Abbreviations: g, grams; min, minute; mL, millilitres.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: PC patients ASL (n=24) Group Analysis. The colour bar represents least perfusion in 
black to red areas of the CBF map and greatest perfusion in yellow areas of the map. Abbreviations: 
g, grams; min, minute; mL, millilitres R, right.  
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Analysis showed that whole brain perfusion was in the normal range (above 15-20 
ml/100gtissue/min (Jann, Smith, Rios Piedra, Dapretto, & Wang, 2016; Pollock et al., 2009)). 
However, some areas did have hyper perfusion in both samples that was located in 
cerebrospinal fluid. This was normal and has been shown as being noise artefact (Duhamel, 
de Bazelaire, & Alsop, 2003). A one way independent Krushal Walis test was employed to 
compare group perfusion values. This test was used since it does not assume normality, is 
sensitive to outliers and can be used when samples are uneven. The analysis showed no 
significant whole brain CBF differences between the patient group (mean rank = 28) and 
controls (mean rank = 23.19) (χ2(1) = 1.36, p > 0.05). Thus, any differences between the 
group on functional MRI BOLD scans can be attributed to changes in neural function rather 
than perturbation of underlying perfusion.  
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3.7.3 Functional MRI analyses 
3.7.3.1 Inhibitory Control (SST) 
To determine whether brain function differed at baseline, task related activation was 
examined within each group (tables 3.3 and 3.4) and then a comparison between the groups 
was performed (Table 3.5). In healthy controls, activation during inhibitory control was 
apparent in putative inhibitory areas on the SST. These areas included the rIFG, rMFG and 
parietal regions. Left sided activation was also found in controls in the inferior frontal and 
middle frontal gyrus areas. The exploratory contrasts revealed activation in inhibitory areas 
on gin trials and go related areas on sin trials. 
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Table 3.3: SST group activation in healthy controls (n = 29) 
     Cluster  MNI Coordinates 
(Voxels) Z-MAX X Y Z Region  
Contrast       
Go incorrect and stop correct trials minus stop incorrect and go correct 
trials    
2027 4.29 -44 14 32 L.Middle Frontal Gyrus 
1582 3.87 44 -56 50 R.Angular Gyrus 
1001 3.93 -34 -78 46 L.Lateral Occipital Cortex 
724 3.36 44 26 16 R.Inferior Frontal Gyrus 
705 4.49 -44 52 -8 L.Frontal Pole 
210 3.5 54 30 -2 R.Inferior Frontal Gyrus 
191 3.17 28 6 48 R.Middle Frontal Gyrus 
 
Exploratory Contrasts 
 
Stop incorrect and go correct trials minus go incorrect and stop correct 
trials 
268 3.32 8 -68 2 R.Lingual Gyrus 
111 3.31 -8 -46 62 L.Postcentral Gyrus 
Go incorrect minus go correct trials 
375 3.48 62 -48 28 R.Angular Gyrus 
Go correct minus go incorrect trials 
701 4.09 -42 -16 16 L.Postcentral Gyrus 
Stop incorrect minus stop correct trials 
No Activation 
Stop correct minus stop incorrect trials 
191 4.54 26 42 36 R.Middle Frontal Gyrus 
 
Abbreviations: L, left; MNI, Montreal Neurological Institute; R, right; SST, stop signal task (Corrected for 
multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
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Activation regions in patients were localised to the right occipital cortex only. Further 
exploratory group analysis carried out in the patient sample with a more lenient Z threshold 
of 2.0 did show activation of the rMFG (MNI: 24 32 42, Z = 3.33, cluster size = 721 voxels) 
and rIFG (MNI: 42 58 -2, Z = 3.31, cluster size = 809 voxels). Exploratory contrasts showed 
activation in go related trials on sin trials. 
 
 Abbreviations: L, left; MNI, Montreal Neurological Institute; PC, prostate cancer; R, right; SST, stop 
signal task (Corrected for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
 
 
 
 
 
 Table 3.4: SST Contrast Group Activations PC patients (n = 30) 
 
        MNI Coordinates 
 
Cluster 
(Voxels) 
Z-MAX  X Y Z Region  
 
Contrast       
 
Go incorrect and stop correct trials minus stop incorrect and go correct trials    
 
633 3.94 48 -70 24 R.Lateral Occipital Cortex 
Stop incorrect and go correct trials minus go incorrect and stop correct trials 
 
1304 4.36 -66 -14 8 L.Superior Temporal Gyrus 
Exploratory contrasts 
 
Go incorrect minus go correct trials 
No Activation 
Go correct minus go incorrect trials 
No Activation 
Stop incorrect minus stop correct trials 
450 3.82 -64 -18 38 L.Postcentral Gyrus 
Stop correct minus stop incorrect trials 
No Activation 
155 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
1
M
e
an
 B
O
LD
 S
ig
n
al
 C
h
an
ge
 (
%
)
Groups
Patients Controls
ns.
A ROI analysis confirmed this ad hoc hypothesis (figure 3.7). A region of 210 voxels were 
masked in the contrast of go incorrect and stop correct minus stop incorrect and go correct 
where the rIFG (50 30 -2) was active in healthy controls. The mean BOLD signal was 
extracted from this region using featquery in controls and patients. An independent samples t 
test revealed no significant differences between the mean change in signal in the rIFG of 
healthy controls and patient BOLD levels (t(57) = -1.11, p > 0.05). This shows that there was 
BOLD signal change in patients at the group level in the rIFG, which is in line with healthy 
controls. 
 
 
 
 
 
 
 
 
Figure 3.7: Mean signal change on the SST in patients and controls in the rIFG. Abbreviations: ns, 
not significant. 
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An independent samples t-test was used to assess whole brain differences between groups 
which did not show any significant activation differences between controls and patients 
suggesting that the rIFG was involved in both groups on the main contrast (Table 3.5). 
Furthermore, no significant activation differences were found between groups on the 
exploratory contrasts. All covariates were added to whole brain difference analysis to assess 
their impact on activation between patients and controls. Anxiety and depression covariates 
did not have any impact on activation between patients and controls in any contrasts. The 
pattern of activation shows differences in the limbic lobe and occipital lobe between controls 
and patients. However, activation maps showed that only the right amygdala was affected by 
testosterone in the go incorrect and stop correct minus stop incorrect and go correct contrast 
(Table 3.5). To further explore this finding, a one way ANCOVA was conducted with group 
(patients and controls) as the fixed factor, anxiety, depression and testosterone as covariates 
and mean signal change (%) of both groups in the amygdala as the dependent variable. 
Testosterone levels of patients and controls had a significant effect on signal change 
differences (F(1,56) = 6.14, p = 0.02)  and accounted for 9% of variance in the model (η2 = 
0.09) in the amygdala. A significant difference was found in the amygdala while controlling 
for all covariates (F(1,56) = 4.65, p = 0.04, η2 = 0.07). Estimated marginal means moreover 
showed BOLD signal increases in controls (mean = 0.12, standard error = 0.08) and 
decreases in patients (mean = -0.15, standard error = 0.08) when adjusting for testosterone. A 
linear regression was used to assess the relationship between testosterone and the amygdala 
signal change in patients. A significant model was found when testosterone was added 
(F(1,25) = 4.59, p = 0.04, β=0.42) where the dependent variable was mean signal change in 
the amygdala and independent variable was testosterone levels of patients. Mean signal was 
found to increase by 0.009% for every unit change in testosterone where the intercept was 
0.08. 
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Table 3.5: SST Contrast Group Differences PC patients and Controls 
 Cluster         MNI Coordinates    
Contrast (Voxels) Z-MAX X Y Z Region   
         
Go incorrect and stop correct trials minus stop incorrect and go correct trials      
Comparison         
HC>PC 114 3.38 22 -4 -30 R.Parahippocampal Gyrus 
 82 3.17 28 -96 20 R.Occipital Pole  
        
 
Comparison         
PC>HC 83 3.04 20 -80 0 R.Occipital Fusiform Gyrus 
         
Covariate comparison 
      
 
PC>HC while controlling for    
testosterone 89 3.15 -30 -6 -20 L.Amygdala  
         
Stop incorrect and go correct trials minus go incorrect and stop correct trials   
Comparison         
HC>PC 83 1.35 3.04 20 -80 R.Occipital Fusiform Gyrus 
 
Abbreviations: HC, healthy controls; L, left; MNI, Montreal Neurological Institute; PC, prostate cancer; R, 
right; SST, stop signal task (Corrected for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
 
3.7.3.2  SST flicker activation 
Typical areas were activated in controls and patients when stop signal trials were separated 
into components (Table 3.6 and 3.7). Long correct trials were the most difficult trials as 
evidenced from Table 3.1 and had the lowest performance and longest reaction times in both 
groups.  
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Table 3.6: SST Flicker Contrast Group Activations PC patients. 
MNI Coordinates  
Cluster 
(Voxels) Z-MAX 
X Y Z Region 
  
        
Inhibition flicker contrasts  
        
Long correct trials minus go correct 
trials     
1693 4.43 -34 20 -4 L.Insular Cortex  
272 3.79 44 22 30 R.Middle Frontal Gyrus 
        
Medium correct trials minus go correct trials    
3241 5.07 58 -46 16 R.Angular Gyrus  
2550 4.37 44 18 -10 R.Frontal Orbital Cortex 
246 3.59 -38 -86 6 L.Lateral Occipital Cortex 
226 4.03 -42 32 24 L.Middle Frontal Gyrus 
208 3.35 44 -74 -6 R.Lateral Occipital Cortex 
204 3.29 48 -30 -14 R.Inferior Temporal Gyrus 
133 3.63 -2 48 32 L.Superior Frontal Gyrus 
        
Short correct trials minus go correct trials   
7110 4.84 56 -46 16 R.Angular Gyrus  
2574 3.71 2 -80 4 R.Intracalcarine Cortex 
1227 3.84 -58 -58 28 L.Angular Gyrus  
 
Abbreviations: L, left; MNI, Montreal Neurological Institute; PC, prostate cancer; R, right; SST, stop 
signal task (Corrected for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
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Table 3.7: SST Flicker Contrast Group Activations Controls (n = 29) 
  Cluster       MNI Coordinates 
(Voxels) Z-MAX X Y Z Region  
       
Inhibition flicker contrasts      
       
Long correct trials minus go correct trials  
8457 4.86 34 26 -8 R.Frontal Orbital Cortex 
8243 5.01 62 -46 30 R.Angular Gyrus 
3144 4.75 -66 -42 22 L.Supramarginal Gyrus 
367 3.84 -34 16 -4 L.Insular Cortex 
350 3.66 -44 32 20 L.Middle Frontal Gyrus 
314 3.67 -44 54 -6 L.Frontal Pole 
226 3.42 -58 -4 26 L.Precentral Gyrus 
108 3.91 -24 16 50 L.Superior Frontal Gyrus 
       
Medium correct trials minus go correct trials   
3539 4.33 32 -60 -16 
R.Temporal Occipital 
Fusiform Cortex 
1558 4 32 26 -10 R.Frontal Orbital Cortex 
1373 3.62 32 44 14 R.Frontal Pole 
960 4.32 -4 32 28 L.Paracingulate Gyrus 
753 4.2 -52 -72 -2 L.Lateral Occipital Cortex 
       
Short correct trials minus go correct trials   
1899 4.11 -18 -80 -12 L.Occipital Fusiform Gyrus 
1838 4.57 54 -36 32 R.Supramarginal Gyrus 
1478 4.3 58 12 8 R.Inferior Frontal Gyrus 
800 4.33 -48 -82 2 L.Lateral Occipital Cortex 
750 4.07 48 -62 -10 R.Lateral Occipital Cortex 
709 4.37 -58 -54 36 L.Angular Gyrus 
463 4.18 -4 32 28 L.Paracingulate Gyrus 
 
Abbreviations: L, left; MNI, Montreal Neurological Institute; R, right; SST, stop signal task 
(Corrected for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05) 
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Differences were found when independent samples t-tests were conducted (Table 3.8). The 
right supramarginal gyrus was more active in controls compared to patients on long correct 
trials. In contrast, the left inferior frontal gyrus showed greater activity in patients compared 
to controls.  
 
 
Table 3.8: SST Flicker Contrast Group differences PC patients and Controls   
        MNI Coordinates   
 
Cluster 
(Voxels) 
Z-MAX X Y Z Region 
  
         
Inhibition Flicker contrast      
     
Long correct trials minus go correct trials      
         
Comparison         
HC>PC 204 2.95 54 -32 30 R.Supramarginal Gyrus  
         
Comparison 
153 3.45 -56 20 -6 L.Inferior Frontal Gyrus 
PC>HC 
         
Medium correct trials minus go correct trials     
 
      
Comparison  ns.       
HC>PC         
         
Comparison  ns.      
PC>HC  
         
Short correct trials minus go correct trials      
         
Comparison  ns.       
HC>PC         
         
Comparison  ns.       
PC>HC       
Abbreviations: HC, healthy controls; L, left; MNI, Montreal Neurological Institute; ns, non-significant; PC, 
prostate cancer; R, right; SST, stop signal task (Corrected for multiple comparisons, Z >2.3; Cluster-wise 
threshold, p < 0.05) 
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Overlap images help to show differences in activation of patients and controls on the main 
contrast and activation areas on distinct flicker trials involved in inhibition. Differences in the 
left inferior frontal gyrus were found on the long correct minus go correct contrast (Table 
3.8). 
 
 
 
 
 
 
 
 
 
  
 
   
    (C)    (D) 
    
 
 
 
 
 
 
 
 
Figure 3.8: SST overlap images of patients and controls where red activation colour maps 
indicate activation of controls and purple shows activation maps of patients. (A) Main contrast 
(go incorrect and stop correct trials minus stop incorrect and go correct trials) overlap activation 
maps for controls and patients. (B) lc-gc contrast. (C) mc-gc contrast. (D) sc-gc contrast. 
(Corrected for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). Abbreviations: 
gc, go correct; lc, long correct; mc, medium correct; R, right; sc, short correct; SST, stop signal 
task. 
(A) 
(B) 
R 
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3.7.3.3 Spatial Reasoning (MRot task) 
Patients and controls displayed neural activation in putative MRot task regions located in the 
parietal and occipital lobes (Table 3.9). However, patients also displayed activation in 
bilateral prefrontal middle frontal gyrus regions on the exp-cont contrast. Despite these 
outcomes suggesting that there may be some difference between groups, when a whole brain 
independent samples t-test was conducted, no significant differences were found on the main 
contrast of exp-cont. 
 
Table 3.9: MRot tasks Contrast Group Activations Patients and Controls 
  
 
Group Level Patients 
  MNI Coordinates 
Contrast 
Cluster  
(Voxels) Z-MAX X Y Z Region 
exp-control 18160 5.22 20 -72 50 R.Lateral Occipital Cortex 
 529 5.32 -26 -8 44 L.Precentral Gyrus 
 521 4.12 -40 34 30 L.Middle Frontal Gyrus 
 467 3.71 30 2 56 R.Middle Frontal Gyrus 
 457 3.53 0 10 42 Cingulate Gyrus 
       
cont-exp 467 3.64 12 42 -6 R.Paracingulate Gyrus 
 414 4.24 -42 54 -8 L.Frontal Pole 
       
 Group Level Healthy Controls 
 MNI Coordinates  
Contrast 
Cluster 
(Voxels) Z-MAX X Y Z Region 
exp-control 30900 5.12 -14 -98 4 L.Occipital Pole 
 849 3.67 -34 -12 50 L.Precentral Gyrus 
 800 3.86 26 4 66 R.Superior Frontal Gyrus 
 626 3.73 12 18 42 R.Paracingulate Gyrus 
 564 3.57 32 24 6 R.Insular Cortex 
 
Abbreviations: L, left; MNI, Montreal Neurological Institute; MRot, mental rotation task; R, right (Corrected for 
multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05) 
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3.7.3.4 MRot task distinct rotation activation 
Patients exhibited activation in bilateral occipital, precentral regions and left prefrontal 
regions when MRot task activations were split into distinct rotation components. Healthy 
controls similarly elicited neural activations in bilateral occipital, bilateral precentral, left 
prefrontal regions and slightly more right sided frontal sided regions (Tables 3.10 and 3.11). 
No significant differences emerged between patients and controls in an independent samples 
t-test. 
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Table 3.10: MRot task distinct rotations Contrast Group Activations PC patients (n = 30) 
      Group Level PC patients 
        MNI Coordinates 
Contrast 
Cluster 
(Voxels) Z-MAX X Y Z Region 
60 degree-control 7208 4.05 2 -72 56 R.Precuneous Cortex 
 2224 3.75 -28 -12 48 L.Precentral Gyrus 
 402 3.48 0 8 46 Paracingulate Gyrus 
       
120 degree-control 4551 4.62 -24 -64 52 L.Lateral Occipital Cortex 
 1412 3.77 36 -78 12 R.Lateral Occipital Cortex 
 1124 4.06 -34 -84 0 L.Lateral Occipital Cortex 
 1016 4.22 28 -10 46 R.Precentral Gyrus 
 787 3.92 -26 -2 42 L.Middle Frontal Gyrus 
       
180 degree-control 11148 4.69 -22 -62 50 L.Lateral Occipital Cortex 
 550 3.6 -46 -4 32 L.Precentral Gyrus 
 438 4.07 -26 -8 48 L.Precentral Gyrus 
 436 3.58 4 28 28 R.Cingulate Gyrus 
       
300 degree-control 2113 4.5 -16 -70 56 L.Lateral Occipital Cortex 
 749 4.15 50 -32 36 R.Supramarginal Gyrus 
 
Abbreviations: L, left; MNI, Montreal Neurological Institute; MRot, mental rotation task; PC, prostate cancer; R, 
right (Corrected for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
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Table 3.11: MRot task distinct rotations Contrast Group Activations  
Healthy Controls (n = 29) 
      MNI Coordinates  
Contrast 
Cluster 
(Voxels) Z-MAX X Y Z Region 
60 degree-control 3016 4.43 -44 -90 -6 L.Lateral Occipital Cortex 
 947 3.79 54 -76 -16 R.Lateral Occipital Cortex 
 672 3.5 4 -56 52 R.Precuneous Cortex 
       
120 degree-control 3583 4.1 -22 -70 40 L.Lateral Occipital Cortex 
 1051 3.44 20 -78 24 R.Cuneal Cortex 
 896 3.79 -8 -106 -2 L.Occipital Pole 
       
180 degree-control 7843 4.72 -36 -44 40 L.Superior Parietal Lobule 
 3771 4.29 36 24 -6 R.Frontal Orbital Cortex 
 1099 3.75 44 -82 18 R.Lateral Occipital Cortex 
 685 4.3 -46 8 20 L.Inferior Frontal Gyrus 
 653 3.88 -30 -58 -12 L.Temporal Occipital Fusiform 
 454 3.53 -32 -4 50 L.Precentral Gyrus 
       
300 degrees-control 4738 4.43 24 -64 60 R.Lateral Occipital Cortex 
 4176 4.42 -46 -80 -4 L.Lateral Occipital Cortex 
 
Abbreviations: L, left; MNI, Montreal Neurological Institute; MRot, mental rotation task; R, right (Corrected 
for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
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Activation in controls and patients on the main trial and on the various degree shape rotations 
from zero was overlaid to visually inspect group concordance. Figure 3.9 shows that there are 
regions in both groups that do not overlap. For example, controls had more widespread left 
supramarginal gyrus activation in the main contrast (Figure 3.9A) and 180 degree-control 
overlap group activation map showed more bilateral anterior and cingulate activation (Figure 
3.8D). However, when examined using an independent samples t-test there were no 
statistically significant differences detected.  
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Figure 3.9: MRot task overlap images of patients and controls where red activation maps show group 
activation in healthy controls and purple activation indicate group activation of patients. (A) Main 
group contrast activation maps for patients and controls (B) 60 degree contrast. (C) 120 degree 
condition. (D) 180 degree condition. (E) 300 degree condition (Corrected for multiple comparisons, Z 
>2.3; Cluster-wise threshold, p < 0.05). Abbreviations: MRot, mental rotation task; R, right. 
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The analyses presented above suggests that there were generally no significant behavioural or 
neural differences between patients and controls on tasks of inhibition and spatial reasoning. 
However, underlying deficits in cognition may be more subtle and only detectable through 
advanced imaging methods such as resting state and regional arterial spin labelling analysis. 
This was explored subsequently to exclude the presence of any cerebral abnormalities in 
patients compared to controls at baseline. Any abnormalities could lead to group average 
BOLD signal drop offs which affect the interpretation of group differences analysis through 
bias. Moreover, any abnormalities found in patients could be exacerbated during further 
therapy from a clinical point of view. 
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3.8 Resting State Analysis 
Resting state analysis was conducted by first acquiring the default mode network seeded from 
the medial prefrontal cortex (mPFC) mask. The network consisted of the posterior cingulate 
cortex (PCC) medial prefrontal cortex and bilateral inferior parietal lobes. A mask generated 
of the right dorsolateral prefrontal cortex (rDLPFC) was used to measure connectivity by 
seeding it to the DMN mPFC regions. Both these regions and networks are known to be 
imperative to fronto-parietal executive functions (Niendam et al., 2012; Spreng, 2012). 
Analysis of baseline healthy control scans showed positive correlations between the right 
frontal pole, right angular gyrus, left middle frontal gyrus (Z = 3.74 to 7.92) and the DMN 
mPFC. Negative connectivity with the DMN mPFC was found in the left precentral gyrus and 
left fronto-orbital cortex (Z = -4.14 to -5.44) indicated by negative BOLD (figure 3.11A). At 
baseline PC patients exhibited activation in the right frontal pole, right supramarginal gyrus 
and left frontal pole (Z = 4.71 to 7.53) with the DMN. Negative BOLD was found in the left 
lingual gyrus (Z = -4.8) (figure 3.10A). 
Differences between groups were found in the right lingual gyrus where healthy controls had 
greater activation compared to patients (MNI: 6 -72 -12, Z = 4.18) with cluster size of 485 
voxels. An ANCOVA was used to assess the magnitude of difference in the right lingual 
gyrus and whether testosterone modulated this difference (MNI: 54 -58 24, 747 voxels, Z 
max=4.71). The analysis revealed a BOLD signal change difference in the lingual gyrus 
between controls (0.025 + 0.15) and patients (0.02 + 0.19) (F(1,56) = 4.01, p = 0.05, η2 = 
0.07) that significantly co-varied with testosterone (F(1,56) = 13.74, p < 0.01, η2 = 0.20). 
Therefore, testosterone differences alone facilitated 20% of variance in positive activation 
found. Estimated means confirmed this as signal change was higher in controls (mean=0.07, 
standard error = 0.03) and lower in patients (mean=-0.04, standard error = 0.03). 
170 
 
A small activation area in the rIFG was masked with the aim to investigate IFG connectivity 
with the DMN mPFC. The mask was selected and made from the activation acquired on the 
SST on the go incorrect and stop correct minus stop incorrect and go correct group activation 
contrast (MNI: 50 30 -2). A 5mm sphere was made around this co-ordinate and prepared for 
functional connectivity analysis. Healthy controls showed strong connectivity between the 
DMN and rIFG, right frontal orbital cortex and right paracingulate gyrus (Z = 4.31 to 6.1). 
Negative activation in healthy controls was found in the left precuneous cortex, left lateral 
occipital cortex, left superior frontal gyrus and left frontal pole (Z = -4.29 to -4.2) (figure 
3.11B). PC patients at baseline showed strong connectivity in the right frontal pole and right 
temporal pole (Z = 5.94 to 7.74). Negative BOLD was found in the left superior occipital 
fusiform cortex and right parahippocampal gyrus (Z = -3.63 to 4.98) of PC patients (figure 
3.10B).  
Differences between groups were found where healthy controls had significantly greater 
activation in the left middle temporal gyrus (MNI: -70 -52 10, Z = 4.09, cluster size = 5811 
voxels), left superior parietal lobule (MNI: -36 -58 66, Z = 3.8, cluster size = 730 voxels) and 
right insular cortex (MNI: 34 8 -4, Z = 3.74, cluster size = 660 voxels).  
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Figure 3.10: Resting state analysis masks of seed regions and regions of interest. (A) Masks showing 
the mPFC which was seeded to create a functional connectivity map of the default mode network. The 
strength of connectivity from the DLPFC was measured to the DMN. (B) The strength of connectivity 
was similarly measured from the rIFG to the DMN. Abbreviations: A, anterior; DLPFC, dorsolateral 
prefrontal cortex; IFG, inferior frontal gyrus; mPFC, medial prefrontal cortex; r, right.  
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Figure 3.11: Resting state analysis of patients and controls. (A) Patient and control resting state 
connectivity map with rDLPFC as region of interest to DMN. (B) Patient and control resting state 
connectivity map with rIFG as region of interest to DMN (Corrected for multiple comparisons, Z > 
+/-2.3; Cluster-wise threshold, p < 0.05). The colour bar represents negative BOLD in light blue to 
dark blue areas of brain maps and greater BOLD activation in red to yellow areas of brain maps. 
Abbreviations: DLPFC, dorsolateral prefrontal cortex; IFG, inferior frontal gyrus; mPFC, medial 
prefrontal cortex; r, right. 
   
 
 
 
 
(A) Healthy Controls  PC patients 
 DMN mPFC – DLPFC  DMN mPFC – DLPFC 
 
 
 
 
 
 
 
 
(B) PC patients   Healthy Controls 
DMN mPFC – rIFG  DMN mPFC - rIFG 
0 7.92 -4.14 0 7.53 -3.67 
R 
0 6.1 -4.29    -3.63 0 7.74 
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A post hoc analysis was conducted to explore if stop signal reaction times (SSRTs) correlated 
with resting state activity in the rIFG pars triangularis since this was where significant task-
based activation was found. Previous research has shown that resting state BOLD signal 
changes negatively correlate with SSRT (Lee & Hsieh, 2017). The rIFG was selected from the 
FSL atlas which was masked and binarised. The dependent variable was mean signal change 
in the rIFG pars triangularis with predictor as SSRT. There was a linear trend of increasing 
SSRT with increasing BOLD signal change (figure 3.12). The mean signal increased by less 
than 0.001% for every millisecond increase in SSRT (where the intercept was 0.05). 
Nevertheless, stop signal reaction time during the SST did not significantly predict BOLD 
signal change at rest in the rIFG in healthy controls (F(1,27) = 3.57, p > 0.05) (β=0.34).  
Stop signal reaction time likewise did not predict BOLD signal change in the rIFG of patients 
(F(1,28) = 0.09, p > 0.05) (β = -0.06). Mean signal decreased by less than 0.001% for every 
millisecond increase in SSRT (where the intercept was 0.15).  
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Figure 3.12: Regression of mean BOLD signal change in the rIFG correlated with stop signal 
reaction time (SSRT) from the SST. Abbreviations: IFG, inferior frontal gyrus; ms, milliseconds; r, 
right; SST, stop signal task. 
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3.9 Regional ASL perfusion 
Figure 3.13 shows CBF values in regions of interest of controls and patients. Regions were 
selected based on activation areas of the stop signal and MRot task. Regional ASL analysis 
was conducted subsequently to ensure that putative task regions were first active before 
conducting the analysis. Perfusion assessments were employed in these regions to assess the 
integrity of BOLD signal activation found in patients and controls. Hypoperfusion has been 
known to lead to reductions in the BOLD signal which may lead to reduction in SST 
activation. The rIFG pars triangularis and pars opercularis were both masked and combined so 
that a regional estimate of the rIFG could be gauged. Bilateral supramarginal gyri were also 
masked to measure CBF in these regions that were related to the MRot task. 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: (A) Healthy controls rIFG, right supramarginal and left supramarginal gyrus ASL 
group level perfusion maps. (B) PC patients Controls rIFG, right Supramarginal and left 
Supramarginal gyrus ASL Group Level perfusion maps. The colour bar represents least perfusion in 
black to red areas of the CBF map and greatest perfusion in yellow areas of the CBF map. 
Abbreviations: g, grams; min, minute; mL, millilitres.  
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When the rIFG was isolated in healthy controls, average perfusion was 40.66 + 13.45 
ml/100gtissue/min (range 0-108.07 ml/100gtissue/min). The right and left supramarginal gyri 
were masked and superimposed on the whole brain perfusion map. The left supramarginal 
gyrus was estimated as having average perfusion of 39.45 + 16.24 ml/100gtissue/min (range 
0-137 ml/100gtissue/min). The right supramarginal gyrus was estimated as having average 
CBF of 45.97 + 17.41 ml/100gtissue/min (range 0-119.57 ml/100gtissue/min). 
The rIFG was similarly masked in patients and average CBF was calculated as 53.14 + 
70.01 ml/100gtissue/min (Range = 0 – 1058.96 ml/100gtissue/min). The right and left 
supramarginal gyri were masked with left supramarginal gyrus estimated as having average 
perfusion of 57.41 + 21.05 ml/100gtissue/min (range 0-139.09 ml/100gtissue/min). The 
right supramarginal gyrus was estimated as have average CBF of 63.83 + 23.39 
ml/100gtissue/min (range 0-182.77 ml/100gtissue/min). 
 
Past studies have shown increased cerebral perfusion in subjects with high endogenous 
testosterone levels (Ghisleni et al., 2015). Exploratory ad hoc analyses were conducted to 
assess if associations occurred between testosterone levels and whole brain or regional CBF. 
This warrants investigation since patients had significantly higher testosterone levels 
compared to controls and testosterone appears to covary with amygdala activation at baseline. 
This could have led to hyperperfusion that was modulated by testosterone, which could in 
turn mask patient impairment by effectively compensating for any functional deficits. 
Individual groups were compared first using Pearson’s correlations. No significant 
correlations were found in controls between testosterone and average perfusion in the whole 
brain (r = 0.04, p > 0.05), rIFG (r = -0.10, p > 0.05), right supramarginal gyrus (r = 0.01, p > 
0.05) and left supramarginal gyrus (r = 0.009, p > 0.05). Patients also showed no significant 
correlation between testosterone and average perfusion in the whole brain (r = 0.05, p > 
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0.05), rIFG (r = 0.10, p > 0.05), right supramarginal gyrus (r = 0.13, p > 0.05) and left 
supramarginal gyrus (r = 0.05, p > 0.05). 
 
Both groups’ combined perfusion estimates were analysed across a spread of values to assess 
if testosterone correlated with any regional perfusion estimates. No significant Pearson’s 
level correlations were found between testosterone and average perfusion in the whole brain 
(r = 0.18, p > 0.05), rIFG (r = 0.19, p > 0.05), right supramarginal gyrus (r = 0.24, p > 0.05) 
and left supramarginal gyrus (r = 0.20, p > 0.05) across both groups. This indicates that no 
correlations were found between testosterone and whole brain or regional perfusion estimated 
averages in individual groups or across groups. 
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3.10 Discussion 
 
The current experiment sought to examine performance and activation of relevant functional 
imaging measures in men prior to the onset of treatment for prostate cancer relative to healthy 
control participants. The purpose of the study was to establish a framework for subsequent 
longitudinal imaging data in both groups, taking into account the possibility that men who 
had recently received a diagnosis of cancer may show different patterns of activation because 
of the potential impact of mood disturbance on neural function. A number of important 
findings are reported. These a summarised first and then discussed in light of some 
unexpected results.  
In line with expectations, overall performance of patients and controls on the tasks used 
inside the scanner did not differ. Reaction times on the SST and overall performance or 
reaction time on the MRot task were similar for patients and controls on the MRot task, as 
was expected. However, when mental rotation distinct rotations were divided, a difference 
was found on the reaction times between patients and controls in the 300 degree condition in 
which controls reacted quicker on the task. Nevertheless, patients had significantly better 
accuracy in judging mirror shapes compared to controls in the 300 degree condition. This was 
not in line with what was hypothesised but is consistent with differential engagement of a 
speed-accuracy trade off strategy. Reaction time and performance also increased as a function 
of shape orientation from zero showing that participants were attempting to mentally rotate 
shapes without assuming shape orientations. This was expected and in agreement with 
previous studies that have shown similar findings (Hertzog, Vernon, & Rypma, 1993; 
Lineweaver, Salmon, Bondi, & Corey-Bloom, 2005; Shepard & Metzler, 1971).  
The neuroimaging data also supported the hypothesis that groups would not differ at baseline. 
This was evident in the majority of regions with some exceptions showing dissimilarities as a 
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function of testosterone and without testosterone. Analysis of specific contrasts showed that 
activation on go incorrect trials was distinct compared to go correct trials. This suggests that 
while the underlying mechanisms of go incorrect and stop trials differed, their underlying 
activation was in line with inhibitory function providing support for the combination of go 
incorrect and stop correct trials in the main contrast. Moreover, stop incorrect trials elicited 
activation in go related areas supporting the combination of stop incorrect and go correct 
trials. However, activated voxel clusters were not apparent in both cohorts at the group level. 
This may have been due to the threshold set for multiple comparisons to avoid false positives 
and therefore some clusters were not apparent at this level. Nevertheless, further analyses 
showed no significant differences on the exploratory contrasts between groups which 
indicated that similar areas were active in both groups. Therefore, the combination of trials 
was warranted and benefitted the main contrast to increase the power of trials. The main 
contrast of the SST showed activation in regions in line with past research in healthy controls 
on the SST these being the rIFG, rMFG and inferior parietal regions (Aron, 2007; Aron, 
Fletcher, Bullmore, Sahakian, & Robbins, 2003; Li et al., 2006). Although activation was not 
apparent in putative SST regions of PC patients in a group first level analysis, subsequent 
signal change analysis confirmed that there was activity in task-associated regions. Further 
support was provided by the lack of significant group differences between patients and 
controls when their activation was compared directly in task associated regions on the SST. 
Of note, testosterone had an effect on the right amygdala which was a unique finding from 
the study on the SST main contrast of go incorrect and stop correct trials minus stop incorrect 
and go correct trials. Moreover, the left amygdala was active in the contrast when controlling 
for testosterone which was unexpected and will be discussed in more detail below.  
Differences on the SST were found in the left inferior frontal gyrus where patients had greater 
activation compared to controls on long correct trials only. This area may have been recruited 
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in patients on more difficult trials to compensate for executive function deficits. The left 
inferior frontal gyrus is a known mirror region area which can be recruited to facilitate 
executive function deficit (Kilner, Neal, Weiskopf, Friston, & Frith, 2009).  
 
Differences were also apparent in the right amygdala on the main contrast where testosterone 
covaried with some differences. Post hoc, exploratory analysis of mean BOLD signal 
difference whilst covarying testosterone showed that testosterone did covary with activation 
in patients in the amygdala and may have aided to offset inhibition deficits in patients. 
Although the amygdala is not critical to inhibitory control, evidence from previous research 
involving the amygdala raises the possibility that alterations of activity in this area may serve 
to assist patients that had inhibition deficits. This could explain the lack of performance 
impairment found in patients whilst having atypical brain activation (Dillon & Pizzagalli, 
2007). The amygdala is involved in fear conditioning and increased activation to stress 
responses. Researchers have found that the amygdala can modulate its responses to 
incorporate inhibition by briefly changing brain circuits involved in motor control (Sagaspe, 
Schwartz, & Vuilleumier, 2011; Stanton, Wirth, Waugh, & Schultheiss, 2009). The 
mechanism behind this change may be as a function of risk taking behaviour. One study 
implemented a typical SST, however, the risk taking component was hypothesised to be in 
the period where participants responded to go stimulus (Li, Chao, & Lee, 2009). It was 
supposed that long go trial responses reduced the risk of an incorrect inhibition since 
prolonged go latency allows better judgement on whether the stimulus presented is a go or 
stop trial. Therefore, shorter go trial reaction times were suspected to be associated with 
greater risk compared to longer reaction times. This was explored by separating contrasts of 
short go trial reaction times to long reaction times. Outcomes showed activation of the left 
inferior parietal lobes, posterior cingulate cortex, amygdala and prefrontal cortex during short 
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reaction time indicating greater risk taking behaviour. Amygdala activation was suspected to 
be a salient feature of risk taking and has been found in many previous studies (Nagai, 
Critchley, Featherstone, Trimble, & Dolan, 2004; Ohira et al., 2006). Risky decision making 
behaviour has also been correlated with testosterone and amygdala activation in animal 
studies of motor impulsivity and may explain the possible link between risk taking and 
amygdala activation (Batrinos, 2012; Cooper, Goings, Kim, & Wood, 2014; Goetz et al., 
2014). 
 
The amygdala has been known to have activation increases in response to high testosterone 
levels which in turn can increase emotional queues such as aggression, frustration etc. in 
males. One speculation may be that the nature of the SST increased these cues due to past 
failed inhibitions which allowed post-error corrections on subsequent trials. However, the 
exact level of testosterone required to elicit such emotional coupled psychological responses 
are not known which is a limit of this interpretation. Moreover, individual differences make it 
difficult to understand the interaction. This suggests that there could be some executive 
function component impairment in PC patients before treatment begins that was compensated 
for by higher testosterone levels. One possible neural mechanism may be better understood 
by a connective pathway between the amygdala and frontal connective network. A study 
assessing this connection measured resting state connectivity between healthy young and 
healthy older ageing adults (Cao et al., 2014). Older adults had a greater degree of connection 
between the right anterior cingulate cortex to the amygdala and superior temporal gyrus and 
IFG (Cao et al., 2014). This suggests that there may be a strong connective network between 
the amygdala and IFG that could be activated in response to inhibition activity and activation 
of the IFG. Moreover, due to a link between testosterone levels and risk taking behaviour, the 
network between the amygdala and IFG may be strengthened and activated to a greater 
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degree in the PC patients of the current study. Therefore, this connection between the 
amygdala in response to testosterone and IFG may be plausible during the SST given 
research showing connectivity between these networks at rest. 
Amygdala activation was moreover found in patients when controlling for testosterone during 
inhibition on the SST which was an unexpected finding. This suggests that other disease 
specific factors may have elicited this activation. One possible explanation may be through 
the APoE4 allele that is known to be more prevalent in PC patients (Ifere et al., 2013). 
Animal model research has shown hyper neuronal synaptic activity in the amygdala of aged 
mice that have expressions of the APoE4 gene (Klein, Acheson, Mace, Sullivan, & Moore, 
2014). Researchers speculate that the hyperactivity is likely due to reductions in the integrity 
of pyramidal cell neurons due to tau and beta amyloid formations. This makes neurons less 
likely to respond to gamma-aminobutyric acid (GABA) inhibitory signals resulting in over 
excitation (Nuriel et al., 2017). Thus, the above suggests that the APoE4 genotype has 
differential effects on parts of the brain where some areas display lower activity and others 
present with upregulated activity. This research warrants further investigation through single 
cell studies and human trials in relation to APoE4 (Hillman, 2014; Huneau, Benali, & 
Chabriat, 2015). 
Further differences were also found in patients compared to controls in the supramarginal 
gyrus. This area is well known to be involved on the SST due to its engagement of fronto-
parietal networks (Sharp et al., 2010).  
 
Activation during mental rotation in patients and controls occurred in regions including 
bilateral parietal lobes and occipital regions, and this is in line with past research (Potvin et 
al., 2013; Zacks, 2008). No significant differences between groups were found on the MRot 
task as was expected and no effect of anxiety or depression was apparent between groups to 
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account for any group difference activation as was expected. No significant differences were 
found in executive function and spatial reasoning areas in whole brain resting state analysis 
or regional resting state analysis between patients and controls which was as hypothesised. 
Importantly, careful analysis of arterial spin labelling data, which measures cerebral 
perfusion, through either whole brain or regional analyses found no differences between 
patients and controls as was predicted. 
 
The study demonstrates that older ageing PC patients and age matched healthy controls had 
similar neural activity that corresponded to behavioural performance before patients began 
any therapy. However some unforeseen outcomes were noted that require further 
clarification. An unexpected outcome was noted when task components were split on the 
MRot task and compared between groups. Differences were evident on the MRot task 
between groups on the 300 degree condition, where patients sacrificed speed for accuracy. 
This was reflected in better task performance by patients when judging whether shapes were 
mirror orientated compared to shapes orientated in the same plane. Further analysis showed 
no significant effects of anxiety, depression or testosterone on performance and reaction 
times in the MRot task. Past research has shown a correlation between greater testosterone 
levels and spatial reasoning ability and this may explain patient and control performance 
differences on mirror items (Lunenfield, 2003; Moffat et al., 2002).  Given that patients had 
significantly higher testosterone levels, this might have resulted in slower reaction times but 
better accuracy. This effect was not expected but may be a function of age and effects of 
higher than normal testosterone levels defined by the control group, which could lead to 
prolonged reaction times. A study in support of this supposition found that reaction times on 
an executive function task increased up to mid-range endogenous testosterone levels in 
ageing healthy participants (Muller et al., 2005). However, testosterone levels beyond this 
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point resulted in increases of reaction time durations in the highest level testosterone groups. 
This outcome is supported and has been found in numerous studies of healthy ageing samples 
(Barrett-Connor et al., 1999; Moffat & Hampson, 1996). Thus, even if other disease-specific 
factors that can influence activation levels – such as mood disturbance - were present in 
patients, their higher testosterone levels act to compensate and protect performance. The 
outcome of longer reaction times in patients may have inadvertently allowed better accuracy. 
This may be a function of the MRot task design incorporated in the current study which had 
longer duration of shape presentations. Nevertheless, this trade-off was required to gain 
performance in line with past research in both groups to significantly activate underlying 
neural networks associated with spatial reasoning and could not be avoided. 
 
The finding of better performance of patients in the mirror condition task is consistent with 
findings from past research. Previous literature has shown a correlation between greater 
testosterone levels and spatial reasoning ability which may explain patients’ and controls 
performance difference on mirror items (Lunenfield, 2003; Moffat et al., 2002). Although no 
direct effect of testosterone was found on performance in the mirror 300 degree condition, 
literature shows that testosterone is converted to other hormonal substrates that could affect 
cognition but were not measured in the current study performance. These factors may have 
contributed to better performance in the 300 degree condition of patients compared to 
controls. 
 
 
The underlying executive function networks of patients and controls were assessed to 
measure the strength of connectivity to SST specific regions and behavioural measures 
through resting state seed connectivity analysis. The exploration generally showed normal 
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patterns of fronto-parietal connectivity at rest. This was found when the dorsolateral 
prefrontal cortex and rIFG were used as seed connectivity regions with the default mode 
network medial prefrontal cortex in patients and controls. This supports the fronto-parietal 
network required for executive functions and is consistent with the idea that this network is 
especially engaged by the SST. One study found that spontaneous resting state activity was 
an effective indicator of inhibitory performance in middle aged and older aging participants 
(Lee & Hsieh, 2017). Researchers used resting state spontaneous brain activity measured by 
regional homogeneity and fractional amplitude of low-frequency fluctuations on blood 
oxygenation level dependent signals (Lee & Hsieh, 2017). Correlations showed that the 
bilateral inferior frontal gyri and default mode network negatively correlated with stop signal 
reaction time (Lee & Hsieh, 2017). This suggests that these regions were vital to inhibition 
functions. However, this is incongruent to what was found in the current study. Although 
non-significant, control SSRTs had a positive linear trending relationship with BOLD signal 
change whilst patients had a negative trending relationship. This could explain the lack of 
significant suprathreshold activity found at the group level in patients in the rIFG; it may be 
the case that there is a subtle functional deficit in the underlying resting state network, which 
in turn reduces task-related activation. This finding may suggest that there are very subtle 
functional changes in executive brain regions in men with prostate cancer prior to the onset of 
treatment. This has important implications for longitudinal research. Thus, an increased 
sample size would be helpful to confirm that this pattern is not simply a product of low power 
to detect activation in patient groups.  
 
Another explanation may be that the lack of difference between samples was due to a 
compensatory effect in patients that was facilitated by testosterone. Indeed, one study showed 
that participants transferring gender from females to males had increased functional 
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connectivity in the DMN and right postcentral gyrus when administered testosterone 
compared to controls that were not undergoing gender reassignment treatment (Burke et al., 
2018). Further support for the study comes from patients with Alzheimer’s disease where 
resting state connectivity in the medial prefrontal cortex which is part of the DMN in one 
study was attenuated (Mevel, Chételat, Eustache, & Desgranges, 2011). This may have been 
due to white matter disruptions from amyloid beta plaque formations that are known to alter 
the pathway of axons between connective resting state regions (Mevel et al., 2011). However, 
these plaques and formations may be reduced through testosterone therapy as demonstrated 
by one group of researchers assessing older males and could apply to the patients in the 
current study whereby deficits were avoided through higher testosterone levels (Gouras et al., 
2000).  
 
The research above suggests that there may be testosterone mechanisms by which resting 
state is compensated for in the patient sample of the study undertaken and suggests this may 
have allowed PC patients to have a cognitive reserve. This was evaluated through resting 
state examinations in the current assessment since commonly identified neural networks at 
rest often overlap with functional areas. Negatively activated networks can thereby provide 
an indirect assessment of integrity in specific regions when they are activated (Zhao et al., 
2016). Longitudinal investigations are required to assess the effects of deprivation of the 
testosterone reserve on resting state connectivity during and after ADT.  
 
Given the known age-related changes in brain perfusion, it was important to measure and, 
where necessary, control for perfusion deficits in participants. In addition, any perfusion 
deficit differences between groups could explain either resting or task-related BOLD group 
differences. Hence, arterial spin labelling imaging in patients and controls was collected, and 
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showed whole brain and local perfusion was in the normal range (Pollock et al., 2009). 
However a shortcoming to data collection was that a significant proportion of scans had to be 
discarded in controls at baseline. Based on evidence that ASL is reliable in the short term and 
changes are not seen over a 12 month period, (Parkes et al., 2004), data from six-month scans 
in the affected control participants, which were all in the normal range, were pooled with 
other control baseline ASL data. This analysis should be considered exploratory but supports 
the idea that there were no group differences. Further data are required to confirm this. This 
was, however, outside the scope of the current thesis.  
 
 
In conclusion, patients and controls had similar levels of function in the neural networks 
corresponding to executive function and spatial reasoning with some unforeseen exceptions 
(differences in RT and accuracy on the MRot task and small differences in brain activations). 
Variation in testosterone did account for some differences between groups. Those results that 
varied with testosterone showed that there were benefits to patients in having higher levels 
compared to controls that may have allowed for compensation of disease specific 
impairments. Nevertheless, other findings showed that higher levels were not beneficial and 
were posited to have impaired neural and cognitive function. Differences between patients 
and controls were suggested to be due to disease specific factors in patients that may be able 
to be recruited without testosterone manipulations. Another factor to consider was the 
efficacy of the control sample. This is explored in Chapter Four through a longitudinal study, 
which allowed an extensive investigation to confirm the control samples’ appropriateness as a 
comparison cohort as a group without any cognitive or underlying neural impairments. 
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CHAPTER 4 
Study 3: Neuropsychological performance and neuroimaging comparisons of neural function 
between baseline and follow-up. 
4.1 Introduction 
In the previous experimental chapters, data were presented on behavioural and imaging 
indices relevant to the measurement of change associated with depletion of testosterone in 
men with prostate cancer. The purpose of the current experiment was to conduct longitudinal 
assessment in participants to assess the integrity and reliability of cognitive performance 
across a period of six months. This was used to determine if any changes occurred in the 
healthy sample between baseline and follow-up and to determine if factors including 
testosterone contributed to any changes found. The within-subjects comparison allowed 
inferences to be made on the validity of the sample as being representative of healthy ageing 
controls over a longitudinal period that were compared to PC patients at baseline. Patients 
were not followed up because in the current timeframe of the study, insufficient numbers 
were available at follow-up for analysis. Nevertheless, it was important to confirm that the 
healthy sample did not show objective cognitive or brain function impairments over time. 
Previous assessments that compared ADT patients to healthy controls found differences 
between samples. As mentioned previously, however, the studies were limited because 
healthy controls were not matched for intelligence and education levels compared to patients 
(Green et al., 2002; Green et al., 2004). The current investigation thereby increased the 
robustness of outcomes found of patients in comparison to controls by assuring samples were 
matched and could be verified as participants without cognitive impairment (see chapters 2 & 
3). 
In the first part of the chapter, data are presented from participants who were evaluated 
through serial neuropsychological measures. Past research has determined that aging is 
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associated with executive function decline compared to young adults. One study assessing 
subjects on tasks of executive function updating, shifting and inhibition found a negative 
correlation between updating and ageing (Clarys, Bugaiska, Tapia, & Baudouin, 2009). 
Further investigations have shown similar patterns of executive function deficits in older 
ageing subjects (Alichniewicz et al., 2013; Mac Kay, 2016; May et al., 1999; Shao et al., 
2014).  Indeed, previous research indicates that executive functions deteriorate by -0.02 
standard deviations on average per year after the third decade of life (Salthouse, 2010). In the 
context of treatment for prostate cancer, it is possible that this decline is accelerated beyond 
age-expected limits.  
Spatial abilities that require the mental updating of spatial stimuli and mental manipulation 
are relevant to the current patient population and some studies suggest that these decline with 
age (Bo, Borza, & Seidler, 2009; Kumar & Priyadarshi, 2013; Schmiedek, Hildebrandt, 
Lovden, Lindenberger, & Wilhelm, 2009). However, a meta-analysis of 137 effect sizes 
found similar performance of normal aging participants to young subjects on tests of spatial 
ability including mental rotation and spatial perception (Techentin, Voyer, & Voyer, 2014). 
Nonetheless, speed of processing declined with age compared to accuracy alone (Techentin et 
al., 2014). This fits well with the notion of declining processing speed in elderly normal aging 
participants and was accompanied by large effect sizes (Park & Reuter-Lorenz, 2009). A 
shortcoming of the review however was that only cross sectional studies were included in the 
review, which limited the analysis of change over time that may have revealed further 
differences over time between groups.  
Although previous research suggests that there are age-related differences in cognition, many 
studies tend to compare behavioural performance in the cognitive domains of young to adult 
participants. This approach does not account for ageing per se, which requires repeated 
measurement of relevant domains in an older cohort.  Consequently, the present experiment 
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aimed to characterise an ageing healthy sample with a number of neuropsychological 
assessments while attempting to mitigate error confounds. Longitudinal change can be 
measured through statistical methods including omnibus tests or multivariate tests. However, 
these methods can hide or mask levels of cognitive decline due to the use of average 
performance. This may lead to under or over estimation of impairment (Jenkins et al., 2005). 
One effective method to measure significant statistical and clinical change while taking into 
account the scale of reliability between time points is the reliable change index (RCI) 
(Jacobson & Truax, 1991). The RCI is a technique to determine the proportion of participants 
that improve or decline in standardised performance score units over a longitudinal time 
frame and can account for practice effect (Zahra & Hedge, 2010). The RCI is particularly 
useful in small sample size studies that have less power but where the average is not 
representative of a normal distribution of scores (Zahra & Hedge, 2010; Zahra, Hedge, 
Pesola, & Burr, 2016). 
 
Similar to the absence of behavioural group differences at baseline, there may not be 
behavioural change over time on objective measures, however group differences in neural 
activity can be elicited over time. Thus, in addition to a comprehensive behavioural 
examination, the current chapter also investigated the possibility of underlying neurological 
changes that may occur in the absence of any cognitive behavioural differences. Several 
studies have explored cerebral neural mechanisms in older adults with outcomes showing that 
ageing was associated with underlying neural changes that were not overtly visible through 
neuropsychological assessments (Celec et al., 2015; Van Impe et al., 2013; Wilkinson & 
Halligan, 2004). These subtle differences may occur even in normal healthy ageing due to 
numerous gross differences in the cerebral structure of older adults compared to younger 
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adults with developing brain structures. These data are first reviewed before attention turns to 
potential functional compensation by brain regions when early structural changes occur.  
A range of different techniques that examine properties of brain tissues support the idea that 
there are age-related structural changes that might underpin a decline in brain functions with 
age. For example, post-mortem examination of brain tissues demonstrated that ageing is 
associated with reducing brain weight, reductions in brain volume, dilated ventricles 
(ventriculomegly) and enlargement of sulci (Skullerud, 1985).(Skullerud, 1985). Further, 
microscopic studies show loss of neuronal bodies in the neocortex, hippocampus and 
cerebellum (Ellis, 1920; Nairn, Bedi, Mayhew, & Campbell, 1989). These neurons have been 
found to shrink and often have structural abnormalities (Terman & Brunk, 1998). Sparser 
cerebral vasculature has also been demonstrated in older adults (Riddle, Sonntag, & 
Lichtenwalner, 2003) which has been associated with declines in synaptic density and loss of 
dendritic spines (Bertoni-Freddari et al., 2002; Morrison & Hof, 1997). Other post-mortem 
studies show accumulative mitochondrial damage, incapable DNA repair ability and failure 
of glia cells to remove neurons with impaired DNA in older participants (Brunk & Terman, 
2002; Rutten, Korr, Steinbusch, & Schmitz, 2003). Volumetric MRI studies have revealed 
that prefrontal cortices are most affected compared to other brain regions. Moreover, 
prefrontal cortex volume has been shown to have relatively strong, negative correlations with 
age (r= -0.56) in the majority of literature (Raz & Rodrigue, 2006; Raz, Williamson, 
Gunning-Dixon, Head, & Acker, 2000). Conversely the weakest correlation between age and 
brain volume occurs in the occipital cortical region with age  (Raz, Rodrigue, Kennedy, & 
Acker, 2007).  
Regional changes may give some insight into the nature of functional changes that occur with 
ageing. Longitudinal volumetric investigations conducted on the cerebral ventricles can give 
an indication of cerebral structure since white matter and nuclei tracts fall around them. This 
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indicates that measurement of these regions can provide an indirect summary measure of the 
entire central nervous system. Studies measuring ventricular size have generally found that 
they increase in size by an average of 2.9% per year (Raz et al., 2004). Five studies of older 
participants (mean age 70) revealed a yearly ventricular enlargement of 4.25% (Hu & Li, 
2012; Mueller et al., 1998; Resnick, Pham, Kraut, Zonderman, & Davatzikos, 2003; Sullivan, 
Pfefferbaum, Adalsteinsson, Swan, & Carmelli, 2002; Tang, Whitman, Lopez, & Baloh, 
2001) whereas younger subjects (below 40 years age) only exhibited a 0.43% increase in 
expansion (Cahn et al., 2002; DeLisi et al., 1997; Ho et al., 2003; Saijo et al., 2001). This 
suggests the rate of expansion accelerates with age.  
An important topic of research globally focuses on early structural changes in the medial 
temporal regions including the hippocampus, particularly given their putative roles in 
Alzheimer’s disease (AD). Hippocampal volume has been shown as a good predictor of AD 
in ageing samples (Laakso et al., 2000). Moreover, entorhinal volume may be a better 
prospective predictor for detecting transition from average ageing to AD (Gosche, Mortimer, 
Smith, Markesbery, & Snowdon, 2002). Within subjects longitudinal studies reveal that 
shrinkage of these regions among healthy adults is twice that of younger participants (Liu et 
al., 2003). Therefore, exploration of cognitive performance in healthy ageing samples is 
warranted to identify and exclude participants with dementia or Alzheimer’s like symptoms. 
Morphometric changes in global or regional brain structure could be due to numerous co-
morbid factors. These include disease such as diabetes and hypertension or environmental 
influences such as lifestyle. Chronic elevation of blood pressure in particular affects over 
55% of Americans and can alter the cognitive effects of ageing (den Heijer et al., 2005). Past 
literature has shown that subjects with medically controlled hypertension may be at less risk 
of cognitive decline compared to undiagnosed hypertensive subjects (Dufouil, Alperovitch, 
Ducros, & Tzourio, 2003). Research also points to abnormal white matter and reduced gray 
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matter volume in ageing subjects who are chronic hypertensives (Raz, Rodrigue, & Acker, 
2003; Raz, Rodrigue, Kennedy, et al., 2003). This has been known to lead to vascular 
diseases affecting regional cerebral blood flow which can cause white matter hyper intensities 
and gray matter changes (Raz et al., 2007). Thus, it is important to collect information of 
relevant medical conditions so that these can be factored in to analyses of group by time 
outcomes. 
 
Although the overall depiction indicates cognitive decline with ageing, vast individual 
differences exist. Many older subjects are able to outperform young participants on some 
cognitive tasks and others perform equally well compared to younger cohorts (Craik & 
Jennings, 1992). The reasons for this variability is of great interest. One hypothesis suggests 
that older adults are able to compensate for cognitive inabilities. Functional imaging studies 
provide a neural network view of cognition that changes with age. Aging has been shown to 
localise neuronal activity to specific regions rather than delocalise co-ordinated activity 
between brain regions in some cohorts (Andrews-Hanna et al., 2007). This suggests loss of 
global integrative function which has been associated poor regional co-ordination and worse 
cognitive performance (Andrews-Hanna et al., 2007). In contrast, some regional networks 
such as the prefrontal cortex have been shown to become less localised and connected with 
other regions as a function of ageing (Cabeza, 2002; Park & Reuter-Lorenz, 2009). However, 
younger participants have been found to utilise contained and distinct prefrontal regions to 
perform the same higher level executive tasks making the region function more proficiently 
in younger cohorts (Cabeza, 2002; Park & Reuter-Lorenz, 2009). However, researchers have 
also found that older adults with more delocalised activity outperform older adults whose 
activity is localised on higher level executive function tasks (Cabeza, 2002; Cabeza, 
Anderson, Locantore, & McIntosh, 2002). This suggests that regional associations in the 
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elderly may be a compensatory response to recruit additional brain areas during highly 
demanding cognitive activities in which the mechanism differs compared to younger adults. 
This may be because isolated regions may lose function with age that then begin to connect 
with other areas to increase cognitive efficiency.  
Another hypothesis proposed that the mirror neuron systems may allow compensation in 
ageing adults and presents itself as over activation in neural networks, particularly in 
prefrontal regions. Over activation in older participants has typically been found in mirror or 
opposite regions to where putative activation has been found in young adults in foregoing 
research (Reuter-Lorenz & Cappell, 2008). The interpretation of over activation has been 
much debated since its nature and neural correlates are ambiguous (Reuter-Lorenz & Lustig, 
2005). Many studies report over activation with age equivalent performance. This suggests 
that the surplus activity has an advantageous purpose as a compensatory mechanism without 
which poor performance would result (Reuter-Lorenz & Cappell, 2008). Moreover, the 
compensation hypothesis suggests that over activation should lead to higher performance 
among older adults even whilst being performance matched at a group level with those who 
are younger. Although significant correlations are lacking, positive performance correlations 
have been found supporting the compensatory hypothesis of age related over activations 
(Cabeza et al., 2004; Reuter-Lorenz & Lustig, 2005). Transcranial magnetic stimulation 
(TMS) studies have been applied in elderly participants in activation sites. One study found 
impaired performance in elderly participants when TMS was applied to one hemisphere in 
the prefrontal cortex on recognition memory tasks. This forced unilateral involvement on 
participants showing that bilateral activation may be required in seniors to successfully 
complete the task compared to younger cohorts (Rossi et al., 2004). Taken together, these 
data suggest that even though structural brain changes occur with ageing and these relate to a 
decline in cognitive performance, at the early stages of decline when performance differences 
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may not be evident on standard testing, regional functional brain compensation may occur. 
Accordingly functional MRI methodologies are relevant to the question of whether there are 
ADT-induced cognitive change in men with prostate cancer.  
The potential utility of fMRI measures must of course take into consideration the potential 
effect of normal testosterone decline on the brain in a healthy ageing cohort. Research 
suggests that these hormones have neuroprotective features in the brain and are able to cross 
the blood brain barrier (Pike, Carroll, Rosario, & Barron, 2009). Testosterone levels have 
been found to decline in healthy samples even in short time frames of six-months. One 
longitudinal six month assessment of healthy participants ranging from 30-90 years age found 
downward trends of testosterone over the period (Harman, Metter, Tobin, Pearson, & 
Blackman, 2001). Furthermore, numerous longitudinal investigations have demonstrated 
relationships between declining testosterone levels during ageing and cognitive impairments 
which has also been supported by neuronal and cerebral perfusion investigations (Moffat et 
al., 2002; Moffat et al., 2004). The study conducted therefore aimed to characterise neural 
function in healthy elderly ageing participants and to determine factors including testosterone 
that influenced cognition over a longitudinal duration. Moreover, the study sought to assess 
the reliability of activation across the six month period as this would then enable future 
assessment of the impact of testosterone depletion using ADT in PC.  
 
In light of the literature above in ageing healthy participants, cognitive performance and its 
neural correlates were characterised over a longitudinal study duration to assess reliability of 
behavioural performance between time points. Furthermore, the study design allowed the 
assessment of the underlying integrity of neural correlates of neuropsychological function. 
Due to the longitudinal nature of the study, variables such as mood and testosterone that may 
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have affected cognition over the time period could be factored into the analysis. This 
facilitated in identifying if the control sample in the assessment of PC patients at baseline 
were suitable as matched controls of normal ageing and in a longitudinal assessment of 
patients and controls. 
 
4.1.1 Aim 
The aim of this study was to characterise the cognition of the healthy control sample across a 
longitudinal duration using behavioural measures.  
Another aim was to assess the reliability and stability of the neural correlates of executive 
function and spatial reasoning domains over a period from baseline to six months in healthy 
ageing controls.  
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4.1.2 Behavioural Cognition Hypothesis 
The hypothesis for the study were as follows: 
Main hypotheses: 
a. Healthy elderly participants will not have any significant performance 
differences between baseline and follow-up on the Delis Kaplan Executive 
function test (D-KEFS) (Trail Making test, Verbal Fluency test, Colour Word 
interference and Tower test), self- report Behavioural Rating Inventory 
(BRIEF-A) and Cambridge Neuropsychological Test Automated Battery 
(CANTAB) spatial working memory (SWM) task. 
 
b. There will be no significant differences in levels of serum testosterone in 
healthy participants between baseline and follow-up.  
 
c. Change in testosterone will not contribute to any variance in 
neuropsychological performance change between time points. 
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4.1.2 Neuroimaging Hypotheses 
 
a. There will be no behavioural differences on the stop signal task (SST) or mental 
rotation (MR) tasks between baseline and six months. 
 
 
b. There will be no neural activation differences in healthy participants from baseline 
to six months on either the stop signal task or mental rotation task. 
 
c. There will be no significant correlation differences between baseline and six 
months on resting state seed functional connectivity analysis between seed regions 
and regions of interest.  
 
d. There will be no significant differences in cerebral blood flow in healthy subjects 
at baseline compared to six months assessed by arterial spin labelling (ASL). 
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4.2 Methods 
4.2.1 Design 
A longitudinal within subjects design was used to investigate cognitive performance at 
baseline and six months in healthy participants. Neural activation was assessed through MRI 
scans acquired to analyse neural differences in functional task related activation, and 
differences between time points on resting state connectivity and arterial spin labelling.  
4.2.2 Participants 
Twenty nine healthy male participants (mean age = 67.81 + 6.92) were initially recruited to 
participate in the study. Three participants were lost to follow-up due to loss of interest or 
other reasons (domestic, household circumstance changes etc.). Therefore, the final healthy 
elderly sample included 26 healthy participants assessed at baseline (mean age = 68.54 + 
6.10). Ethical approval was acquired from the University of Birmingham ethics committee 
for the assessment of neuropsychological measures. Healthy older ageing subjects were 
recruited from various organisational institutions which contained facilities catering towards 
the needs of healthy elderly populations. This included establishments such as gym facilities, 
elderly care homes, sports facilities (Birmingham bowls, golf establishments) and religious 
organisations (churches, temples, mosques etc.). Some participants were additionally 
recruited from the University of Birmingham elderly participant’s database.  
4.2.3 Inclusion and Exclusion criteria 
As described in chapter 2 section 2.2.1 table 2.1 - community based control group 
4.2.4 Ethical Approval 
As described in chapter 2 section 2.2.2 
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4.2.5 Saliva Sample Collection 
As described in chapter 2 section 2.2.3 
4.3 Behavioural Outcome Measures 
Participants were administered the D-KEFS, BRIEF-A self-report scale, WAIS-IV, 
CANTAB and HADS as described in chapter 2 section 2.3 at baseline and six month follow-
up. 
4.4 Brain Imaging in Scanner Task Measures 
The SST and MRot tasks were as described in chapter 3 section 3.3. 
4.5 Imaging Acquisitions 
Structural T1, T2 functional scans and resting state and arterial perfusion scans were acquired 
as described in chapter 3 section 3.4. 
4.6 Neuropsychological Outcomes Statistical Analysis 
The main purpose of the analysis was to assess cognitive change over time and if any change 
was accounted for by testosterone or psychosocial factors. A p value of either 0.05 or less 
was accepted as statistically significant (two-tailed). Paired samples t-tests were conducted to 
assess the level of psychosocial (anxiety and depression) change and testosterone level 
change that occurred from baseline to follow-up. Further multivariate techniques including 
within subjects MANOVAs and ANOVAs were employed to assess main effects and 
interactions between outcome measures and time. The repeated measures factor was time 
(baseline and six months) and primary outcome variables of each cognitive measure 
employed were the dependent variables in each analysis. Covariates were added to the 
models to assess their effect on change between time points (see Appendix 11 for more 
detail). One noteworthy influence was that the comparison of many variables by the analysis 
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methods implemented, may have led to issues with multiple testing due to the number of 
comparisons made between variables. A reliable change index was calculated to measure 
change between time points and chi-square test was employed to measure the proportions of 
the sample that had a change in performance between time points in relation to testosterone 
(Appendix 8). 
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Table 4.1: Scaled Scores for Neuropsychological baseline, six month follow-
up and change over time  
Measure   Baseline (n=26) 6-month (n=26) Difference 
    Mean SD  Mean SD  Mean SD 
D-KEFS  
 
Trail Making Test 
Visual Scanning  10.62 2.90  11.31 2.09  0.69 2.85 
Number Sequencing  11.85 2.62  12.81 1.79  0.96 2.52 
Letter Sequencing  11.81 3.01  12.04 1.95  0.23 3.24 
Number Letter Sequencing 11.46 2.89  12.15 2.31  0.69 3.43 
Verbal Fluency Test 
Letter Fluency   14.00 3.06  13.73 2.97  -0.27 1.64 
Category Fluency  13.04 2.88  13.46 2.69  0.42 2.23 
Category Switching  12.92 -2.74  12.23 3.60  -0.69 5.06  
Switching Accuracy  12.68 2.67  12.31 3.65  0.12 5.33 
Design Fluency 
Filled Dots   11.73 2.82  12.23 3.05  0.50 3.30 
Empty Dots   11.62 2.74  11.65 2.91  0.03 2.99 
Switching (Empty and Filled) 12.58 3.44  12.58 2.90  0.00 3.01 
Colour Word Interference Test 
Colour Naming   11.12 1.56  11.27 2.60  0.15 2.29 
Word Reading   11.35 2.68  11.81 2.04  0.46 2.40  
Inhibition   13.00 1.56  12.96 1.54  -0.04 1.54 
Inhibition Switching  12.92 1.38  13.23 1.11  0.31 1.38 
Tower Test 
Number of Moves  155.04 84.88  147.46 49.47  7.58 76.15 
Total Time to complete (ms)  494.88 166.61  505.96 164.13  49.15 205.33  
Achievement Scores  9.15 3.18  12.50 2.20  3.35 3.76 
Abbreviations: ms, milliseconds; SD, standard deviation.  
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Measure   Baseline (n=26) 6-month (n=26) Difference 
    Mean SD  Mean SD  Mean SD 
BRIEF-A 
Self-Report 
Inhibition   50.42 6.65  50.04 7.25  -0.38 5.49 
Shift    50.46 8.68  51.08 9.50  0.62 7.19 
Emotional Control  48.85 9.12  49.73 8.38  0.88 8.81 
Monitor   49.90 8.44  48.19 7.69  0.69 15.98 
Initiate    50.08 7.47  49.50 6.56  -0.58 6.87 
Working Memory  56.76 11.79  47.31 5.40  -9.46 10.08 
Plan/Organise   49.54 8.62  50.34 9.80  0.81 7.13 
Task Monitor   52.69 8.82  52.23 8.94  -0.46 7.06 
Organisation of Materials 49.96 8.12  50.23 7.80  0.27 6.38 
BRI    50.04 7.30  40.42 6.84  -9.62 5.61 
MI    51.50 7.22  55.42 9.03  3.92 7.19 
GEC    50.84 6.37  95.73 15.18  46.85 20.49 
CANTAB 
Between Errors 
4 boxes    0.58 1.33  0.72 1.46  0.14 1.04 
6 boxes    6.12 6.53  6.04 6.22  0.07 6.64 
8 boxes    17.85 9.41  18.32 13.00  0.47 10.75 
Double Errors 
4 boxes    0 0  0 0  0 0 
6 boxes    0.15 0.37  0.12 0.32  -0.03 0.45 
8 boxes    0.27 0.83  0.84 1.57  0.57 1.88 
Strategy Score   31.88 6.99  31.31 6.40  0.57 0.59 
HADS  
Anxiety   2.88 2.14  3.00 2.91  0.12 2.07 
Depression   1.50 1.39  2.00 1.94  0.50 1.70 
Abbreviations: BRI, behavioural regulation index; GEC, global executive composite; MI metacognitive index; 
SD, standard deviation. 
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4.7 Neuroimaging Statistical Analysis 
4.7.1 FSL analysis 
FSL analysis was as described in chapter 3 section 3.5.1 with healthy participants assessed at 
both baseline and six months on the SST and MRot task.  
Additionally, region of interest (ROI) analysis was undertaken. The ROI method allowed the 
assessment of small clusters of voxels in task related regions thereby reducing the amount of 
error due to multiple comparisons of voxels that could be prone to type-I errors and chance 
findings during whole brain analysis between baseline and follow-up (Logan, Geliazkova, & 
Rowe, 2008). Within subjects ANOVAs were employed to assess regional BOLD signal 
change between time points. Significant interactions were followed up with paired sample t-
tests that were corrected using the Bonferroni method. Likewise, paired sample t-tests were 
conducted in intact ASL scans to assess the stability of whole brain and regional perfusion 
between baseline and follow-up. While ROI analysis may reduce chances of errors, outcomes 
from the analysis should still be interpreted with caution due to issues of multiple testing 
since many factors were compared increasing the chances of type-I errors. This may lead to 
increases of chance findings where the null hypothesis was rejected for the alternate 
hypothesis to increase familywise errors. Consequently, signal change differences between 
time points may be susceptible to error. 
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4.7.2 SPM Analysis 
SPM analysis was undertaken to investigate intra-class correlations (ICC) in voxel regions of 
interest. The ICC method is an analysis technique used to measure test-retest reliability of the 
spatial distribution of BOLD fMRI voxel activation across separate sessions (Caceres et al., 
2009) (Appendix 12). MATLAB version 7.9.0.529 (R2009b) was used with SPM12 
(Welcome Department of Cognitive Neurology and collaborators, Institute of Neurology, 
London, UK (SPM)) to allow the conversion of raw data files to NIFTII format. Pre-
processing steps and group level analysis were implemented with SPM12 as detailed in 
Appendix 12. Contrasts made for both the MRot and SST were analogous to those generated 
using FSL (chapter 3 section 3.5.1). Maximally activated voxel regions were then masked 
and extracted using the SPM integrated Marsbar software (Matthew, Jean-Luc, Romain, & 
Jean-Baptiste, 2002) from the baseline group activation contrast maps and inputted into an 
ICC toolbox designed by Caceres et al. (2009) to measure activation consistency from 
baseline to follow-up (Appendix 12). 
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4.8 Procedure 
Behavioural 
Healthy participants underwent behavioural assessments as described in chapter 2 section 2.4. 
Subjects were administered identical behavioural assessments at baseline and six month 
follow-up. 
Neuroimaging 
Procedure was as described in chapter 3 section 3.6 and analogous at baseline and follow-up 
in healthy participants. Functional runs were administered as described in chapter 3 section 
3.6.1 in healthy participants at baseline and follow-up 
 
4.9 Behavioural Cognitive Performance results 
Twenty six participants completed all phases of the study from baseline to six months. Time 
between baseline assessment and six month follow-up ranged from 122 days to 223 (mean = 
77.46 + 17.37) days. Participants’ mean age at baseline was 68.54 + 6.10 ranging from 56 to 
80 years old. At six months participants’ mean age was 69.27 + 6.07 ranging from 56 to 81. 
Statistical analyses were undertaken with SPSS 22.0. Missing data was found for one 
participant at baseline and follow-up. The participant was excluded from the colour-word 
interference test due to colour blindness. To avoid the exclusion of the participant in 
statistical terms, an expectation maximization procedure was used to analyse missing values. 
This has been shown as an effective method for managing missing data (Rubin et al., 2007).  
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4.9.1 Screening assessments 
All healthy elderly participants included, passed the criteria for participation. Subjects scored 
an average 27 + 0.92 on the MMSE which was above the cut-off criteria of 24.  On average, 
participants had higher free testosterone levels at the six month follow-up (mean = 
91.63pg/ml, SE = 5.47) compared to baseline (mean = 82.84pg/ml, SE = 5.39). This 
difference was not significant (t(25) = -1.20, p > 0.05). Participants had marginally lower 
anxiety scores as measured by the HADs scale at baseline (M = 2.88, SE = 0.42) compared to 
six months (M = 3.00, SE = 0.57). This difference was not significant (t(25) = -2.85, p > 
0.05).  Furthermore, participants had marginally lower depression scores at baseline (mean = 
1.50, SE = 0.27) compared to follow-up (mean = 2.00, SE = 0.38). This was not a significant 
difference (t(25) = -1.50, p > 0.05). 
 
4.9.2 Intellectual Functioning 
All participants performed in the normal range for their particular age groups on subtests of 
the WASI-II as evidenced from the Full scale intelligence quotient 4 scores (FSIQ-4) (Mean 
= 123.62 + 12.33, range 88-141). Moreover, perceptual reasoning (mean = 115.23 + 13.23) 
and verbal comprehension index scores (127.12 + 15.18) were in the normal range.  Subtests 
encompassing FSIQ-4 included the block design task, matrix reasoning, vocabulary task and 
similarities task.  
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4.9.3 Executive functioning 
D-KEFS 
Overall, behavioural performance was equal between both time points within healthy 
participants. An omnibus MANOVA with all D-KEFS contrast scaled scores included, 
showed no significant differences in healthy controls between time points (F(5,46) = 0.85, p 
> 0.05). All one-way follow up ANOVAs showed non-significant interactions between each 
test and time variable. A MANCOVA was conducted to assess the influence of testosterone 
level with findings showing no significant effect of the hormone (F(5,45) = 2.01, p > 0.05). 
Furthermore, no significant difference in D-KEFS contrast scaled scores was found between 
time when controlling for testosterone (F(5,45) = 0.833, p > 0.05). 
BRIEF-A 
The brief executive function assessment (BRIEF-A) self-report scores were analysed with 
MANOVAs. The first conducted MANOVA assessed differences in healthy controls between 
baseline and six months. Inhibition, shift, emotional control, self-organisation, ability to 
initiate, working memory, monitor, behavioural regulation index, metacognition and global 
executive function scaled scores were entered as dependent variables. Fixed factors were 
entered as patients and controls. No significant differences were found across dependent 
variables between baseline and follow-up (F(6, 45) = 0.19, p > 0.05). Furthermore, 
testosterone did not predict scores on average between time points on the BRIEF-A (F(6, 44) 
= 1.50, p > 0.05). No differences were found between time points while controlling for 
testosterone level (F(6, 44) = 0.19, p > 0.05). 
Further exploratory analysis showed no significant correlations between the self-rated 
BRIEF-A questionnaire meta-cognitive Index scaled score and D-KEFS contrast scaled 
scores. Correlations were not significant on the D-KEFS trail making test (r = 0.27, p > 0.05), 
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verbal fluency test (r = 0.10, p > 0.05), design fluency test (r = -0.01, p > 0.05), colour word 
interference test (r = 0.17, p > 0.05) and tower test (r = -0.23, p > 0.05).  
 
4.9.4 Spatial reasoning 
CANTAB SWM between errors 
A MANOVA was conducted to assess spatial reasoning performance. Number of between 
errors made on the CANTAB SWM was the dependent variable and assessed between time 
points in a within subjects’ analysis. Findings showed no significant differences between the 
number of between errors made between time points on the CANTAB SWM task in the 4 
box, 6 box and 8 box conditions (F(3,47) = 0.07, p > 0.05). Further analyses showed no 
significant contribution of testosterone to performance on average errors made between 
baseline and follow up (F(3,46) = 0.30, p > 0.05). 
A MANCOVA was undertaken by adding the WAIS working memory index scores (WMI) 
as a covariate to the number of between errors made on the CANTAB SWM task. This 
allowed the isolation of the spatial reasoning domain of the SWM task while controlling for 
working memory. Findings showed a significant predictive effect of the WAIS working 
memory index scores on between errors made on the SWM task as was expected (F(2,46) = 
4.24, p < 0.01, η2 = 0.22). Specific ANCOVAs showed that the WAIS_WMI predicted scores 
in the 4 box condition (F(1,48) = 6.81, p = 0.01, η2 = 0.12) and 8 box condition (F(1,48) = 
5.26, p = 0.03, η2 = 0.10). Spatial reasoning scores did not significantly differ between time 
points while controlling for WAIS performance (F(2,46) = 0.08, p > 0.05). No effect of 
testosterone was found when it was concurrently added with WAIS WMI scores on average 
spatial reasoning scores between time points (F(3,45) = 0.71, p > 0.05). Moreover, no 
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significant difference was found between time points whilst controlling for WAIS WMI 
scores and testosterone levels (F(3,45) = 0.08, p > 0.05).  
 
CANTAB SWM double errors 
A subsequent MANOVA was conducted with double errors as the dependent variable to 
assess the number of errors made between time points by healthy subjects. This showed no 
significant differences on the number of double errors made in the 4, 6 and 8 box conditions 
between time points in healthy subjects (F(2,48) = 1.30, p > 0.05). When testosterone was 
added to the model, it had no effect on double errors made on average across baseline and 
follow-up (F(3,46) = 1.78, p > 0.05). Furthermore, testosterone did not covary with the 
number of double errors made between time (F(3,46) = 1.03, p > 0.05). 
A further MANCOVA was implemented with the WAIS scores as a covariate on the number 
of double errors made by healthy participants on the CANTAB SWM task. The analysis 
showed WAIS scores did not predict the number of double errors made independent of time 
(F(3,46) = 0.03, p > 0.05). Moreover, no predictive effect of the WAIS was found on double 
errors made between time points (F(3,46) = 0.95, p > 0.05) When testosterone was added 
with the WAIS to the number of double errors made, it had no predictive effect on number of 
errors made on average across baseline and six months (F(3,45) = 1.52, p > 0.05). No 
significant difference was found between time points while controlling for testosterone level 
and WAIS WMI scores (F(3,45) = 1.01, p > 0.05). No difference in strategy score was either 
found in a paired sample t-test (t(25) = 0.53, p > 0.05).
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4.9.5 Reliable Change index Outcomes 
Table 4.2 shows the proportion of reliable change that occurred between baseline and follow-
up. A paired sample t-test was conducted to assess if any difference in neuropsychological 
performance was evident between baseline and six months follow up in healthy participants. 
No significant difference was found (t(36) = 0.23, p > 0.05) suggesting that performance was 
similar between baseline (mean = 1.41 + 0.90) and at six months (mean = 1.35 + 1.09) (Table 
4.1).  
A chi-square test (3x3) was undertaken to assess the effect of the proportions of participants 
that had testosterone increases, decreases or same levels on cognitive improvement, decline 
or same performance over time (table 4.2). The independent variable was testosterone with 
three categorical levels these being reliable testosterone level increases, decreases or levels 
that stayed the same between baseline and six months. The outcome variables were the 
proportion of participants that either had cognitive performance RCI improvements, declines 
or stayed the same over baseline to six months (table 4.2).  
Results showed a significant relationship between testosterone level change across time and 
performance on the CANTAB eight box double errors condition between time points (X2 (2, 
N = 26) = 7.93, p = 0.02). More specifically, the relationship that predicted the most variance 
in the outcome showed that the proportion of participants with reliable testosterone declines 
across time also had reliably worse performance on the CANTAB eight box double errors 
condition (std. residual = 2.6). Another significant relationship was found between 
testosterone level change across time and the BRIEF-A self-report self-monitor scale (X2 (2, 
N = 26) = 12.67, p = 0.01). More specifically, the relationship that predicted the most 
variance in the outcome showed that the proportion of participants with reliable testosterone 
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increases across time had lower scores on the BRIEF-A self-reported self-monitor scale (std. 
residual = 3.3).
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Table 4.2: Change from baseline to six months with proportion improved and declined.  
Calculated using RCI method.   
    RCI Threshold 
Measure Mean Min Max Improved Declined 
 difference difference difference   N    %            N     % 
D-KEFS        
Trail making Test        
Visual Scanning 0.69 -6.00 7.00 1 3.85 2 7.69 
Number Sequencing 0.96 -3.00 9.00 0 0.00 1 3.85 
Letter Sequencing 0.23 -8.00 11.00 1 3.85 2 7.69 
Number Letter Sequencing 0.69 -10.00 10.00 1 3.85 2 7.69 
Total 
 
  3 2.88 7 6.73 
        
Verbal Fluency Test        
Letter Fluency -0.27 -4.00 3.00 2 7.69 1 3.85 
Category Fluency 0.42 -4.00 5.00 1 3.85 1 3.85 
Category Switching -0.62 -8.00 5.00 2 7.69 2 7.69 
Switching Accuracy -0.31 -7.00 7.00 2 7.69 2 7.69 
Total    7 6.73 6 5.77 
        
Design Fluency        
Filled Dots 0.50 -8.00 7.00 1 3.85 2 7.69 
Empty Dots 0.04 -4.00 8.00 2 7.69 0 0.00 
Switching (Empty and Filled) 0.00 -4.00 8.00 1 3.85 0 0.00 
Total    4 3.85 2 1.92 
        
Colour Word Interference Test        
Colour Naming 0.15 -9.00 2.00 0 0.00 2 7.69 
Word Reading 0.46 -3.00 11.00 0 0.00 1 3.85 
Inhibition -0.04 -4.00 2.00 3 11.54 0 0.00 
Inhibition Switching 0.31 -3.00 2.00 1 3.85 0 0.00 
Total    4 3.85 3 2.88 
        
Tower Test        
Number of Moves -7.58 -207.00 117.00 0 0.00 3 11.54 
Time to complete -0.08 -5.00 1.00 1 3.85 0 0.00 
Achievement Scores 0.73 -3.00 5.00 1 3.85 1 3.85 
Total 
 
  2 2.56 4 5.13 
Total D-KEFS change    13 2.78 16 3.42 
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    RCI Threshold 
Measure Mean Min Max Improved Declined 
 
difference difference difference   N    %            N     % 
BRIEF-A        
Self-Report        
Inhibition -0.38 -10.00 11.00 1 3.85 1 3.85 
Shift 0.62 -10.00 19.00 0 0.00 2 7.69 
Emotional Control 0.88 -18.00 15.00 2 7.69 0 0.00 
Monitor -0.96 -19.00 14.00 1 3.85 1 3.85** 
Initiate -0.58 -17.00 15.00 1 3.85 2 7.69 
Working Memory -2.19 -27.00 15.00 2 7.69 0 0.00 
Plan/Organise 0.81 -11.00 22.00 1 3.85 1 3.85 
Task Monitor -0.46 -14.00 11.00 1 3.85 0 0.00 
Organisation of Materials 0.27 -14.00 10.00 3 11.54 0 0.00 
BRI -0.23 -13.00 13.00 1 3.85 2 7.69 
MI -0.04 -12.00 21.00 1 3.85 1 3.85 
GEC 0.38 -9.00 17.00 2 7.69 1 3.85 
Total Self Report    16 5.13 11 3.53 
CANTAB        
Four boxes        
Between Errors 0.12 -2.00 3.00 3 11.54 1 3.85 
Double Errors -0.31 -14.00 15.00 2 7.69 1 3.85 
Total    5 9.62 2 3.85 
 
Six Boxes        
Between Errors 0.58 -19.00 21.00 3 11.54 4 15.38 
Double Errors -0.04 -1.00 1.00 3 11.54 2 7.69 
Total    6 11.54 6 11.54 
        
Eight Boxes        
Between Errors -0.04 -1.00 1.00 2 7.69 3 11.54 
Double Errors 0.58 -3.00 5.00 2 7.69 4 15.38* 
Total    4 7.69 7 13.46 
Strategy -0.58 -12.00 14.00 1 3.85 2 7.69 
 
Total CANTAB change    15 9.62 15 9.62 
 
Total reliable change all 
neuropsychological assessments    28 4.49 31 4.97 
        
Testosterone 8.79 -59.01 77.85 2 7.96 3 11.54 
 
Abbreviations: BRI, behavioural regulation index; GEC, global executive composite; MI metacognitive index; 
RCI, reliable change index; *p<0.05; **p<0.01. 
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4.10.1 Brain imaging results 
4.10.1 Behavioural in Scanner Task Analysis 
Tasks administered during fMRI were first behaviourally evaluated to assess longitudinal 
performance between time (baseline and six months).  
 
Inhibitory Control (SST) 
Table 4.3 shows SS task performance on go and stop trials between baseline and six month 
follow-up. Paired sample t-tests revealed a significant difference of inhibitory performance in 
which participants performed better at follow-up compared to baseline on stop trials (t(25) = -
2.51, p = 0.02). No significant differences were found on other measures of go accuracy, go 
reaction time and stop signal reaction time. This suggests there were some behavioural 
differences of participants from baseline to six months.  
 
A 2 x 3 ANOVA was performed where one variable was time with 2 factors and another 
variable was flicker trial accuracy. Flicker trials were separated into short, medium and long 
trials. Simple effects revealed a significant difference of time (F(1,25) = 7.16, p = 0.01, η2 = 
0.22). Furthermore, performance across flickers independent of time were significantly 
different (F(2,25) = 7.16, p < 0.01, η2 = 0.63). Nevertheless, a flicker by time interaction did 
not reveal any significant differences (F(2,24) = 0.407, p > 0.05). This shows that significant 
differences were found between short, medium and long flicker trials. Specifically, better 
performance was found on short flicker trials compared to medium flicker trials and worst on 
long flicker trials compared to both short and medium flicker trials. However, performance 
across time did not significantly differ across the distinct flicker trials. A similar ANOVA 
was undertaken for flicker stop signal reaction times (SSRT). No significant differences were 
found in this ANOVA measuring average flicker SSRTs between time points. However, a 
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significant difference was found in SSRTs across flicker trials independent of time (F(2,7) = 
11.03, p = 0.007, η2 = 0.76). No interaction between time and flicker duration was observed 
(F(2,16) = 1.36, p > 0.05) showing that whilst SSRT between flicker durations did differ, no 
difference was evident between time.  
 
 
Table 4.3 SST Descriptive Statistics 
Trial type Healthy subjects (n = 26) 
Baseline 
Healthy subjects (n = 26)  
 Six months  
 Mean SD Mean SD 
Go + stop trials     
Accuracy (%) 85.35 13.15 85.38 14.99 
Reaction time (ms) 712.83 178.30 714.09  154.25 
Stop trials     
Accuracy (% inhibited) 64.38 23.04 75.87 16.92 
SSRT (ms) 283.81 219.4 257.54 99.4 
Short flickers     
Accuracy (% inhibited) 77.56 26.89 89.62 12.09 
SSRT (ms) 470.5 122.97 446.85 90.67 
Medium flicker     
Accuracy (%inhibited) 65.38 31.53 80.77 21.89 
SSRT (ms) 524.36 164.89 456.84 44.83 
Long flickers     
Accuracy (% inhibited) 54.04 21.73 64.33 21.92 
SSRT (ms) 531.51 118.43 526.83 46.12 
 
Abbreviations: ms, milliseconds; SD, standard deviation; SSRT, stop-signal reaction time; SST, stop 
signal task. 
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Spatial Reasoning (MRot task) 
A paired sample t-test showed a significant performance difference between same and mirror 
orientation trials on average across baseline and six months (t(25)= -2.059, p = 0.05). 
However, reaction times did not significantly differ between time points on average in the 
same and mirror oriented shape conditions (Table 4.4).  
Further analysis of distinct rotations in a two way repeated measures ANOVA where time 
and rotation orientations were independent variables showed a significant simple effect of 
time independent of rotation orientations (F(1,25) = 4.24, p = 0.05, η2 = 0.15). A significant 
difference was also found on performance across varying degrees of rotation (F(3,75) = 7.87, 
p < 0.01, η2 = 0.24). More precisely, performance was better on average in the 60 degree 
condition compared to the other conditions between baseline and follow-up. Moreover, 
participants’ performance was worse in the 180 degree condition compared to all other 
conditions. Therefore, difficulty increased as a function of shape orientation up to 180 
degrees but did not decrease further on higher than 180 degree orientation shapes. No 
significant interaction was apparent (F(3,75) = 1.45, p > 0.05) suggesting that performance 
differences between time and variation in shape rotation from zero did not differ (figure 4.1). 
An analogues repeated measures ANOVA was conducted to gauge reaction time differences 
on rotated shape pairs. No significant effect of time was found (F(1,25) = 0.21, p > 0.05) 
suggesting that reaction times were similar at baseline and six months devoid of varying 
shape rotations. However, reaction times on average were significantly different depending 
on the rotated shape pair presented independent of time points (F(3,75) = 3.42, p = 0.02, η2 = 
0.12). This reflects findings from performance conducted above since slowest reaction times 
were evident on the 180 degree condition indicating the difficulty of this shape orientation 
(figure 4.2). No interaction effect was apparent (F(3,75) = 0.10, p > 0.05) indicating that the 
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mean difference between time points on varying shape orientations from zero, did not 
significantly differ. 
 
Table 4.4 MRot task descriptive statistics averages 
  
Trial type  
Healthy participants  
(n = 26) 
Healthy participants  
(n = 26) 
       Baseline  Six months  
 Mean SD Mean SD 
MRot task performance           
           
Same orientation shapes          
        Accuracy (%)  60.81 24.91 67.54 193.84 
        Reaction Time (ms)  2102.04 324.17 2175.27 368.31 
           
Mirror orientation shapes          
    Accuracy (%)  46.63 29.33 55.29 24.73 
    Reaction Time (ms)  2153.40 291.79 2160.11 393.27 
           
Total same and mirror 
orientation shapes         
    Accuracy (%)  53.72 18.56 61.41 15.66 
     Reaction Time (ms) 2127.72 285.27 2167.69 352.85 
           
Divided degrees           
60 degrees           
    Accuracy (%)  60.58 27.09 68.75 23.52 
    RT (ms)  2026.54 313.01 2039.74 488.75 
120 degrees           
    Accuracy (%)  55.29 20.97 66.83 22.34 
    RT (ms)  2167.22 423.85 2186.38 475.96 
180 degrees           
    Accuracy (%)  49.52 18.87 50.00 15.41 
    RT (ms)  2181.81 407.14 2229.25 445.54 
300 degrees           
    Accuracy (%)  49.52 23.04 60.10 23.46 
    RT (ms)  2135.30 379.47 2215.37 458.76 
 
Abbreviations: MRot, mental rotation task; ms, milliseconds; RT, reaction time; SD, standard deviation. 
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Figure 4.1: MRot task average reaction time at baseline and six months as a function of shape 
orientation from zero. Abbreviations: cont, control condition; MRot, mental rotation task; ms, 
milliseconds. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: MRot task average percentage correct at baseline and follow-up as a function of shape 
orientation from zero. Abbreviations: cont, control condition; MRot, mental rotation task.
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4.10.2 Whole brain cerebral blood flow (Arterial Spin Labelling analysis) 
Whole brain cerebral blood flow was explored between longitudinal time points initially to 
confirm that healthy elderly participants did not have altered levels of cerebral perfusion over 
time. This was assessed to exclude the presence of perfusion abnormalities that may affect 
further conducted fMRI BOLD activation outcomes. Eight Participants’ CBF scans were 
available from the baseline data (mean age 69.38 + 3.46) and the same participants’ scans 
were used for a longitudinal analysis at six months (mean age 70 + 3.39).  
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Figure 4.3: Whole brain ASL maps of healthy subjects at: (A) Baseline (n = 8) (B) Six Months (n = 
8). The colour bar represents least perfusion in black to red areas of CBF maps and greatest 
perfusion in yellow areas of CBF maps. Abbreviations: g, grams; min, minute; mL, millilitres, R, 
right. 
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The analysis of ASL at a whole brain level showed no significant differences between 
estimated baseline CBF (54.20 + 11.60 ml/100gtissue/min) (range 0-1021.30 
ml/100gtissue/min) and six month CBF (50.09 + 8.75 ml/100gtissue/min) (range 0-1112.05 
ml/100gtissue/min) in a paired sample t-test (t(7) = 1.28, p > 0.05). This showed that whole 
brain CBF was above the level considered abnormal and that CBF did not significantly differ 
between baseline and six months.  
 
4.11 Functional MRI analysis 
4.11.1 Inhibitory Control (SST) 
Tables 4.5 and 4.6 show activation whole brain maps elicited in the twenty-six healthy ageing 
participants while performing the SST at baseline and follow-up (figure 4.4). To explore the 
activation patterns associated with inhibitory control, a main contrast of inhibition was 
generated (go incorrect and stop correct trials compared to stop incorrect and go correct 
trials) and first assessed within each group. Other contrasts were also generated to assess 
activation on go trials that reflected motor responses (stop incorrect and go correct trials 
minus go incorrect and stop correct trials). Activation was found in putative SST areas at 
baseline in areas including the rIFG (pars triangularis and opercularis), rMFG and right 
inferior parietal lobe. Additional areas were also apparent including the left IFG and left 
MFG. Six month activation showed similar patterns of activity. At the group level, 
exploratory contrasts showed activation in inhibitory areas on go incorrect trials at baseline 
and six months and go associated activity on stop incorrect trials at six months. 
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A two sample paired t-test was performed on the main contrast of interest (go incorrect and 
stop correct compared to stop incorrect and go correct trials) to assess whole brain differences 
between time points. No significant whole brain activation differences were found between 
time baseline and follow-up. Furthermore, no significant activation differences were found 
between baseline and follow-up on the exploratory contrasts.
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Table 4.5: SST Contrast Activation areas Healthy participants  
 Baseline (n = 26).  
  
MNI Coordinates  
   
Cluster 
(Voxels) 
Z-MAX X Y Z Region   
Go incorrect and stop correct trials minus stop incorrect and go correct trials 
2027 4.29 -44 14 32 L.Middle Frontal/Inferior 
     Frontal Pars operularis 
1582 3.87 44 -56 50 R.Inferior Parietal Lobe 
1001 3.93 -34 -78 46 L.Lateral Occipital  
724 3.36 44 26 16 R.Inferior Frontal Gyrus 
     Pars Triangularis 
705 4.49 -44 52 -8 L.Frontal Pole  
449 3.47 26 -96 18 R.Lateral Occipital  
260 3.43 2 56 -14 Frontal Pole/Medial Frontal  
210 3.5 54 30 -2 R.Inferior Frontal Gyrus 
     Pars Triangularis 
191 3.17 28 6 48 R.Middle Frontal Gyrus 
151 3.41 -6 -74 46 L.Precuneus  
144 3.43 -28 -96 0 L.Occipital Pole  
131 3.14 -2 -42 32 Posterior Cingulate Gyrus 
123 3.68 -40 -16 -34 L.Temporal Fusiform  
104 2.97 16 10 -24 R.Frontal Orbital  
98 3.66 -38 -66 20 L.Lateral Occipital  
87 3.29 38 44 18 R.Frontal Pole  
 
Stop incorrect and go correct trials minus go incorrect and stop correct trials 
 
361 3.5 -54 -14 12 L. Secondary Somatosensory 
268 3.32 8 -68 2 R.lingual Gyrus  
111 3.31 -8 -46 62 L. GM Primary Motor 
 
Exploratory contrasts 
 
Go incorrect minus go correct trials 
248 3.68 60 46 30 R.Angular Gyrus  
Go correct minus go incorrect trials 
No Activation 
Stop incorrect minus stop correct trials 
No Activation 
Stop correct minus stop incorrect trials 
1894 4.79 44 -38 46 R.Supramarginal Gyrus  
982 4.42 24 34 40 R.Middle Frontal Gyrus  
Abbreviations: L, left; MNI, Montreal Neurological Institute; R, right; SST, stop signal task.  
(Corrected for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
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Table 4.6: SST Contrast Activation areas Healthy participants  
 six months (n = 26).  
  
MNI Coordinates   
Cluster 
(Voxels) 
Z-MAX X Y Z Region 
  
Go incorrect and stop correct trials minus stop incorrect and go correct trials 
 
3212 4.85 -34 -68 34 L.Lateral Occipital Superior 
1760 5.03 46 -66 32 R.Lateral Occipital Superior 
1522 4.57 -50 14 14 L.Inferior Frontal Gyrus 
538 4.58 4 -38 32 Posterior Cingulate Gyrus 
392 4.45 -58 -62 -14 L. Inferior Temporal Gyrus 
335 4.09 46 30 28 
R.Middle/Inferior Frontal 
Gyrus 
     Pars Triangularis 
308 4.29 16 16 -20 R.Fontal Orbital   
235 4.17 24 36 30 R.Frontal Pole  
226 3.84 -16 -54 10 L.Precuneus   
220 4.29 20 64 -4 R.Frontal Pole  
177 3.63 54 -62 12 R.Lateral Occipital Inferior 
75 4.11 16 42 -16 R.Frontal Pole  
66 3.92 -6 56 -10 L.Frontal Pole  
64 3.59 36 -26 42 R.Postcentral Gyrus  
52 3.69 18 32 -6 R.White Matter  
50 3.72 42 -80 -8 R.Lateral Occipital Inferior 
Stop incorrect and go correct trials minus go incorrect and stop correct trials 
26132 5.03 46 -66 32 R.Lateral Occipital Superior 
4008 4.29 20 64 -4 R.Frontal Pole  
1455 4.29 16 16 -20 R.Orbito-Frontal  
305 3.4 -28 6 -10 L.White Matter  
174 3.69 22 -12 -28 R.Parahippocampal Gyrus 
142 3.1 -12 52 30 L.Frontal Pole  
141 3.52 -10 -24 50 L.Precentral Gyrus 
111 3.42 -14 2 12 L.White Matter  
Exploratory contrasts 
Go incorrect minus go correct trials 
914 3.66 0 56 -14 R.Medial Frontal Cortex 
Go correct minus go incorrect trials 
No activation 
Stop incorrect minus stop correct trials 
174 3.69 -56 -28 34 L.Supramarginal Gyrus 
Stop correct minus stop incorrect trials 
384 5.49 -40 -74 42 L.Lateral Occipital Cortex 
  
Abbreviations: L, left; MNI, Montreal Neurological Institute; R, right; SST, stop signal task.  
(Corrected for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
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Figure 4.4: SST whole brain group activation. A. baseline group activation. B. Six month group 
activation. Abbreviations: R, right; SST, stop signal task. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
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4.11.1.2 Inhibition Stop signal flicker activation. 
Tables 4.7 and 4.8 show activation areas on the SST in healthy participants at baseline and 
follow-up. To explore the activation patterns associated with inhibitory control, durations 
from long correct, medium correct and short flicker trials were separated and compared in 
contrasts to overall go trials. These contrasts were assessed for activation at single time points 
(baseline and six months). left middle frontal gyrus, left supramarginal gyrus and left 
precentral gyrus regions were activation on long correct compared to go correct trials. Most 
putative inhibition regions on the medium correct compared to go correct trials activated 
were in the rIFG pars opercularis, left middle frontal gyrus, right middle frontal gyrus and left 
supramarginal gyrus. The short correct trials compared to go correct trials showed activation 
in the parietal cortex mostly consisting of areas including the right supramarginal gyrus and 
left lingual gyrus. 
 
Two sample paired t-tests were performed on all contrasts to assess whole brain differences 
between baseline and six months. No significant differences emerged between baseline and 
follow-up on the contrasts of long correct compared to go correct trials; medium correct trials 
compared to go correct trials and short correct trials compared to go correct trials. 
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Table 4.7: SST Flicker Contrast Activations in Healthy  
Participants at Baseline 
Baseline healthy participants (n = 26) 
 
Cluster 
 
MNI Coordinates 
   
(Voxels) Z-MAX   X    Y    Z Region 
 
Long correct trials minus go correct trials 
 
 
6748 4.71 54 12 2 R.Inferior Frontal Gyrus 
Pars Opercularis 
 
4282 4.58 62 -46 32 R.Supramarginal Gyrus 
 
3456 4.09 8 -80 10 R.Intracalcarine 
 
1576 4.81 -68 -40 20 L.Supramarginal Gyrus 
 
241 3.15 -50 30 18 L.Inferior Frontal Gyrus 
 
Pars Triangularis 
 
228 3.55 -40 54 0 L.Frontal Pole 
 
199 3.34 -32 18 -4 L.Insular 
 
186 3.53 -54 -6 26 L.Precentral Gyrus 
 
Premotor 
 
Medium correct trials minus go correct trials 
 
 
3539 4.33 32 -60 -16 R.Temporal Fusiform Gyrus 
 
2022 4.35 62 -34 20 R.Planum Temporal 
 
1558 4 32 26 -10 R.Frontal Orbital 
 
1373 3.62 32 44 14 R.Frontal Pole 
 
1005 4.16 -56 -32 10 L.Planum Temporal 
 
960 4.32 -4 32 28 Parascingulate Gyrus 
 
753 4.2 -52 -72 -2 L.Lateral Occipital  Inferior 
 
331 3.48 -44 46 16 L.Frontal Pole 
 
236 3.31 -34 14 -2 L.Insular 
 
142 3.01 54 -24 -12 R.Middle Temporal Gyrus 
 
Short correct trials minus go correct trials 
 
1899 4.11 -18 -80 -12 L.Occipital Fusiform Gyrus 
 
1838 4.57 54 -36 32 R.Supramarginal Gyrus 
 
1478 4.3 58 12 8 R.Inferior Frontal Gyrus 
 
800 4.33 -48 -82 2 L.Lateral Occipital Inferior 
 
750 4.07 48 -62 -10 R.Lateral Occipital Inferior 
 
709 4.37 -58 -54 36 L.Angular Gyrus 
 
463 4.18 -4 32 28 R.Parascingulate Gyrus 
 
Abbreviations: L, left; MNI, Montreal Neurological Institute; R, right; SST, stop signal task.  
(Corrected for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
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Table 4.8: SST Flicker Contrast Activations in Healthy  
Participants Six Month Follow-up 
 
Cluster 
 
MNI Coordinates 
 
(Voxels) Z-MAX      X     Y    Z Region 
Long correct trials minus go correct trials 
 
4879 5 60 -42 32 R.Supramarginal Gyrus 
4244 4.78 30 26 -10 R.Fronto-Orbital  
1569 4.36 -46 -56 42 L.Angular Gyrus 
1296 4.24 -38 10 -2 L.Insular  
1153 4.3 -60 -52 0 L.Middle Temporal 
Gyrus 
825 4.35 -6 32 18 Anterior Cingulate Gyrus 
767 3.77 0 -102 6 Occipital Pole 
399 4.09 -44 8 36 L.Middle Frontal Gyrus       
Medium correct trials minus go correct trials 
 
      
2394 4.28 -52 -60 24 L.Angular Gyrus 
2072 3.85 64 -40 6 R.Middle Temporal 
Gyrus 
1807 3.67 -12 54 28 L.Frontal Pole 
1218 4.45 48 -56 42 R.Angualar Gyrus 
1094 3.6 -26 4 34 L.White Matter 
847 3.92 0 32 20 Anterior Cingulate Gyrus 
666 3.46 -2 -86 -8 Lingual Gyrus Middle 
577 3.75 30 20 -22 R.Frontal Orbital  
552 3.92 -56 6 2 L.Precentral Gyrus       
Short correct trials minus go correct 
trials 
  
      
1551 4.56 52 -54 40 R.Angular Gyrus 
1358 4.35 50 -70 -14 R.Lateral Occipital  
Inferior 
806 4.32 -48 -58 44 R.Angular Gyrus 
791 4.54 30 28 -12 R.Frontal Orbital  
650 3.65 40 44 14 R.Frontal Pole 
549 3.95 40 24 40 R.Middle Frontal Gyrus 
421 3.5 -44 -70 -4 L.Lateral Occipital 
Inferior 
378 4.01 -44 8 36 L.Middle Frontal Gyrus 
 
Abbreviations: L, left; MNI, Montreal Neurological Institute; R, right; SST, stop signal task.  
(Corrected for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
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4.11.1.3 Region of interest analysis with main contrast and distinct flicker contrasts. 
Region of interest analyses was undertaken to assess regional consistency of mean BOLD 
signal change (%) between time points on the main inhibition contrast (table 4.9) and flicker 
contrasts (table 4.10). The rIFG, rMFG, left inferior temporal gyrus (LITG) and left middle 
frontal gyrus (LMFG) were masked using FSL atlas and the FSL maths command to binary 
masks (Harvard-Oxford Cortical Structural Atlas). A repeated measures ANOVA was 
conducted with time (baseline and six months) and percent signal change in regions on the 
main contrast and flicker contrasts separately. Testosterone was added as a covariate to assess 
its effect on signal change between time points in ROIs as it was the main factor of interest in 
the conducted study. The effect of testosterone was controlled for on all main effects. Its 
relation to interaction was reported only. 
 
Main Contrast (go incorrect and stop correct trials compared to stop incorrect and go 
correct trials). 
 
The ROI analysis on the inhibition contrast showed no significant main effect of averaged 
signal change across all ROIs between time points (F(1, 24) = 0.35, p > 0.05). A significant 
main effect was shown between the signal changes of ROIs regardless of time. Mauchly’s 
test of sphericity was violated (X2(2) = 9.32, p < 0.01), therefore, degrees of freedom were 
adjusted using Greenhouse Geisser estimates of sphericity (ε=0.75). This revealed a 
significant ANOVA (F(1.50, 36.00) = 7.07, p < 0.01, η2 = 0.38).  No significant effect was 
found on the interaction term of signal change in ROIs between time points (F(2, 48) = 0.89, 
p > 0.05). Variance in testosterone level change approached significance on the interaction 
term between baseline and six months (F(2, 48) = 2.63, p > 0.05) (Figure 4.5). 
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Figure 4.5: Mean signal change on main SST contrast (go incorrect and stop correct compared to 
stop incorrect and go incorrect). Abbreviations: IFG, inferior frontal gyrus; ITG, inferior temporal 
gyrus; L, left; MFG, middle frontal gyrus; r, right; SST, stop signal task. 
 
 
Flicker Signal Change 
Contrast long correct compared to go correct trials. 
 
No significant main effect of averaged signal change across all ROIs between time points was 
found (F(1, 24) = 0.20, p > 0.05). A main effect was shown between the signal changes of 
ROIs when controlling for time. Mauchly’s test of sphericity was violated (X2(5) = 36.56, p 
< 0.01), therefore, degrees of freedom were modified using Greenhouse Geisser estimates of 
sphericity (ε=0.51) (F(1,55, 37.10) = 6.65, p < 0.01, η2 = 0.22). No significant effect was 
found on the interaction term of signal change in ROIs between baseline and six months. 
Mauchly’s test of sphericity was violated (X2(5) = 30.64, p < 0.01), therefore, degrees of 
freedom were modified using Greenhouse Geisser estimates of sphericity (ε=0.57) (F(1.71, 
40.95) = 0.58, p > 0.05). Testosterone did not covary with signal change in ROIs between 
time points (F(1.71, 40.95) = 0.52, p > 0.05). 
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Contrast medium correct compared to go correct trials. 
 
No significant main effect of signal change averaged across all ROIs was found between time 
points (F(1, 24) = 0.10, p > 0.05). No main effect was shown of signal change between ROIs 
when controlling for time. Mauchly’s test of sphericity was violated (X2(5) = 45.45, p < 
0.01), therefore, degrees of freedom were modified using Greenhouse Geisser estimates of 
sphericity (ε=0.50) (F(1,49, 35.67) = 1.73, p > 0.05). No significant effect was found on the 
interaction term of signal change in ROIs between baseline and six months. Mauchly’s test of 
sphericity was violated (X2(5) = 33.51, p < 0.01), therefore, degrees of freedom were 
modified using Greenhouse Geisser estimates of sphericity (ε=0.56) (F(1.67, 39.98) = 1.16, p 
> 0.05). Change in testosterone between time did not covary with change in regional BOLD 
signal between time points (F(1.67, 39.98) = 0.25, p > 0.05). 
 
Contrast short correct compared to go correct trials.  
 
The ROI analysis showed no significant main effect of signal change averaged across all 
ROIs between time points (F(1, 24) = 0.03, p > 0.05). No main effect was found when signal 
change of ROIs were compared while controlling for time. Mauchly’s test of sphericity was 
violated (X2(5) = 35.19, p < 0.01), therefore, degrees of freedom were altered using 
Greenhouse Geisser estimates of sphericity (ε=0.52). This revealed a sign non-significant 
ANOVA (F(1.55, 37.25) = 2.24, p > 0.05).  No significant effect was found on the 
interaction term of signal change in ROIs between baseline and six months. Mauchly’s test of 
sphericity was violated (X2(5) = 28.99, p < 0.01), therefore, degrees of freedom were 
modified using Greenhouse Geisser estimates of sphericity (ε=0.57) (F(1.70, 40.98) = 0.16, p 
> 0.05). Difference in testosterone between baseline and six months did not covary with any 
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differences in the interaction between time points and mean regional signal change (F(1.70, 
40.98) = 0.41, p > 0.05). 
 
 
Table 4.9: ROI Signal Mean Signal Change Descriptives SST 
 Healthy subjects (n = 26) Healthy subjects (n = 26)  
  Baseline Six months 
 
Region Signal change (%) SD Signal change (%) SD 
Contrast go incorrect and stop correct compared to go incorrect and go correct trials 
rIFG 0.11 0.24 0.13 0.14 
rMFG 0.12 0.38 -0.05 0.23 
LITG -0.02 0.35 0.00 0.30 
LMFG -0.14 0.19 -0.08 0.20 
 
Abbreviations: IFG, inferior frontal gyrus; ITG, inferior temporal gyrus; L, left; MFG, middle frontal gyrus; R, 
right; ROI, region of interest; SD, standard deviation; SST, stop signal task (Corrected for multiple 
comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
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Table 4.10: Mean Signal Change Descriptive Stop Signal Flickers 
 Healthy subjects (n = 26) Healthy subjects (n = 26)  
 Baseline Six months  
Region Signal change (%) SD Signal change (%) SD 
 
Contrast long correct compared to go correct trials  
     
rIFG 0.08 0.18 0.10 0.20 
rMFG 0.01 0.42 0.12 0.45 
LITG 0.24 0.39 0.25 0.26 
LMFG 0.14 0.24 0.13 0.20 
     
Contrast medium correct compared to go correct trials 
     
rIFG 0.05 0.16 0.05 0.20 
rMFG 0.09 0.21 0.08 0.22 
LITG 0.14 0.38 0.14 0.30 
LMFG 0.00 0.34 0.13 0.44 
 
    
Contrast short correct compared to go correct trials 
     
rIFG 0.06 0.14 0.05 0.19 
rMFG 0.10 0.17 0.08 0.21 
LITG 0.15 0.24 0.14 0.27 
LMFG 0.04 0.31 0.08 0.45 
 
Abbreviations: IFG, inferior frontal gyrus; ITG, inferior temporal gyrus; L, left; MFG, middle frontal 
gyrus; R, right; SD, standard deviation. (Corrected for multiple comparisons, Z >2.3; Cluster-wise 
threshold, p < 0.05). 
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Overlapping of distinct flicker contrasts trials in figure 4.6 show areas contributing to 
activation on the separate flicker contrasts. This provides a better view that can be visually 
inspected. Activation seemed to be apparent in areas including the rIFG and RMFG. 
Furthermore, parietal areas were activated supporting a fronto-parietal network that is in line 
with an executive function network at baseline and follow-up. Additional areas of activity 
were present in the left IFG and left MFG. The lc-gc and mc-gc contrasts showed most 
activation.   
  
 
 
 
 
 
 
 
 
Figure 4.6: SST overlap images of healthy participants at baseline and six-month follow-up where 
red activation colour maps indicate activation of participant group activation at baseline and purple 
activation group maps at six months. (A) Group activation maps on the contrast lc-gc. (B) Group 
activation maps on the contrast mc-gc. (C) Group activation maps on the contrast sc-gc (Corrected 
for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). Abbreviations: lc, long correct; 
mc, medium correct; R, right; sc, short correct; SST, stop signal task.
R 
(A) (B) (C) 
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4.11.1.4 Inhibition Intra-class Correlation Analysis 
Intra-class correlation (ICC) analysis illustrates reliability across specific regions (Table 
4.11). This was calculated by comparing baseline group activation in SPM with a paired 
sample t-test to follow-up group activation (go incorrect and stop correct activation compared 
to stop incorrect and go correct activation). Median intra-voxel reliability showed the most 
reliability on the main contrast and subsequently less reliability across regions as task 
difficulty decreased. This indicates that reliably greater activation was required in putative 
stop signal areas as task difficulty increased.  
Table 4.11: Intra-class Correlations SST (uncorrected, p<0.001) 
                    ICCvmed Average 
ROI MNI coordinates t-max main contrast    (STE)  Flickers 
Contrast X  Y Z  gin+sc-sin+gc  lc-gc mc-gc sc-gc ICC(STE) 
R.Supra-  54 -34 35 7.25 0.57  0.32 0.01 0.07 0.13  
Marginal     (0.08)  (0.12) (0.10) (0.08) (0.09) 
Gyrus  
ACC   3 35 23 7.21 0.39  -0.01 0.11 0.18 0.09  
      (0.13)  (0.11) (0.09) (0.08) (0.06) 
R.IFG   54 14 -1 6.84 0.43  0.29 0.04 0.09 0.14  
Pars Opercularis     (0.10)  (0.09) (0.12) (0.06) (0.08) 
L.IFG   -45 11 20 6.83 0.43  0.15 -0.10 0.12 0.08  
Pars Opercularis    (0.15)  (0.07) (0.10) (0.15) (0.08) 
R.MFG   39 38 26 6.70 0.41  0.30 0.04 0.09 0.14  
      (0.09)  (0.09) (0.12) (0.07) (0.08) 
Average Contrasts ICC   0.45  0.21 0.02 0.11  
(STE)      (0.032)  (0.06) (0.03) (0.02) 
Abbreviations represent: ACC, Anterior Cingulate Gyrus; gin+sc-sin+gc, go incorrect and stop correct compared 
to stop incorrect and go correct; IFG, Inferior Frontal Gyrus; lc-gc, long correct trials compared to go correct 
trials; mc-gc, medium correct trials compared to go correct trials; MFG, Middle Frontal Gyrus; MNI, Montreal 
Neurological Institute; sc-gc, short correct trials compared to go correct trials; STE, standard error; SST, stop 
signal task. 
 
  
 
 
252 
 
4.11.2 Spatial Reasoning (MRot task) 
Tables 4.12 and 4.13 show activation regions of the MRot task at baseline and six months. 
Activation maps at baseline and follow-up are shown in figure 4.7. Activation was apparent in 
the parietal, precentral (premotor), precuneous, and occipital lobes at baseline and six months 
in healthy participants. A two samples paired t-test was run to assess any whole brain 
differences on the main contrast of rotations compared to control task (exp-cont) between 
baseline and six months. This revealed no significant activation differences between time 
points. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
253 
 
 
Table 4.12: MRot task Contrast Activations Separated by Healthy Participants  
assessed at Baseline (n = 26).  
Cluster 
 
MNI Coordinates 
(Voxels) Z-MAX X Y Z Region       
contrast exp-cont 
    
30900 5.12 -14 -98 4 L.Occipital pole 
849 3.67 -34 -12 50 L.Precentral Gyrus 
800 3.86 26 4 66 R.Superior Frontal Gyrus 
626 3.73 12 18 42 Paracingulate Gyrus 
564 3.57 32 24 6 R.Insular Cortex 
contrast cont-exp 
    
No activation 
    
Abbreviations: cont, control condition; exp, experiment condition; L, left; MRot, mental rotation task; MNI, 
Montreal Neurological Institute; R, right (Corrected for multiple comparisons, Z >2.3; Cluster-wise threshold, p 
< 0.05). 
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Table 4.13: MRot task Contrast Activations Separated by Healthy Participants 
assessed at six months (n = 26).  
  
MNI Coordinates 
Cluster 
(Voxels) 
 Z-MAX X Y Z Region 
 
contrast exp-cont 
    
19379 5.02 -18 -80 50 L.Lateral Occipital Cortex Superior 
295 3.39 56 -32 46 R.Supramarginal Gyrus 
212 3.49 60 -2 18 R.Precentral Gyrus 
181 3.21 -16 -24 4 L.Thalamus       
contrast cont-exp 
    
609 3.41 46 -58 32 R.angular Gyrus 
598 3.95 12 56 32 R.Frontal pole 
543 3.71 -52 -66 42 L.Lateral Occipital Superior 
Abbreviations: cont, control condition; exp, experiment condition; L, left; MRot, mental rotation task; MNI, 
Montreal Neurological Institute; R, right (Corrected for multiple comparisons, Z >2.3; Cluster-wise 
threshold, p < 0.05). 
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Figure 4.7: MRot task whole brain activation. (A) Baseline MRot activation. (B) six month MRot 
activation. Abbreviations: MRot, mental rotation task; R, right. 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
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4.11.2.1 Spatial reasoning distinct rotation activation 
Tables 4.14 and 4.15 shows activation during distinct rotation parts of the task when shape 
pairs were required to be rotated at baseline and follow-up. No significant whole brain 
differences were found between baseline and follow-up activations assessed with a two 
samples paired t-test.  
 
  
Table 4.14: MRot task Contrast Activations in healthy participants at baseline (n = 26) 
  
MNI Coordinates 
Cluster 
(Voxels) 
Z-MAX         X        Y         Z Region 
contrast 60 degree-control    
      
3016 4.43 -44 -90 -6 L.Occipital Cortex Inferior 
947 3.79 54 -76 -16 R.Occipital Cortex Inferior 
672 3.5 4 -56 52 R.Precuneus Cortex 
contrast 120 degree-control    
      
1454 3.53 -22 -70 40 L.Lateral Occipital Cortex Superior 
606 3.16 32 -84 30 R.Lateral Occipital Cortex Superior 
543 3.61 -44 -86 -6 L.Lateral Occipital Cortex Inferior 
contrast 180-control    
      
7843 4.72 -36 -44 40 L.Supramarginal Gyrus 
3771 4.29 36 24 -6 R.Frontal orbital Cortex 
1099 3.75 44 -82 18 R.Lateral Occipital Cortex Superior 
685 4.3 -46 8 20 L.Inferior Frontal Gyrus 
653 3.88 -30 -58 -12 
L.Temporal Occipital fusiform 
Cortex 
454 3.53 -32 -4 50 L.Precentral Gyrus premotor Cortex 
contrast 300-control    
      
4738 4.43 24 -64 60 R.Lateral Occipital Cortex Superior 
4176 4.42 -46 -80 -4 L.Later Occipital Cortex Inferior 
 
Abbreviations: L, left; MRot, mental rotation task; MNI, Montreal Neurological Institute; R, right (Corrected 
for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
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Table 4.15: MRot task Contrast Activations at six months in healthy participants  
(n = 26). 
  
MNI Coordinates 
Cluster 
(Voxels) 
Z-MAX X Y Z Region 
contrast 60 degree-control    
No activation 
    
      
contrast 120 degree-control 
   
No activation  
   
   
   
contrast 180-control    
15847 4.75 -24 -68 36 L.Lateral Occipital Superior 
3296 4.58 2 18 36 Anterior Cingulate Gyrus 
523 3.35 56 -32 46 R.Supramarginal Gyrus 
      
contrast 300-control    
9430 4.39 -20 -76 48 L.Lateral Occipital Superior 
2709 4.32 28 0 50 R.Precentral Gyrus 
575 3.66 60 -2 8 R.Central Opericular 
 
Abbreviations: L, left; MRot, mental rotation task; MNI, Montreal Neurological Institute; R, right  
(Corrected for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
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4.11.2.2 Region of interest analysis with main contrast and distinct rotation contrasts. 
Subsequently, ROI analysis was undertaken to assess regional consistency of mean BOLD 
signal change (%) between time points on the main contrast to compare mean signal change 
during rotation compared to the control condition in specific regions. Regions were extracted 
by first masking the regions of interest from putative MRot task regions. The left precentral 
gyrus, right superior frontal gyrus and right supramarginal gyrus were masked using FSL 
atlas and the FSL maths commands (Harvard-Oxford Cortical Structural Atlas). A repeated 
measures ANOVA was conducted with time (baseline and six months) and percent signal 
change in regions on the main exp-cont contrast (Table 4.16) and contrasts in the separated 
rotations (Table 4.17). Testosterone was added as a covariate to assess its effect on signal 
change between time points in ROIs. 
 
Contrast Exp-cont 
The ROI analysis on the exp-cont contrast showed no significant main effect of averaged 
signal change across all ROIs between time points (F(1, 24) = 0.63, p > 0.05). A main effect 
was found between the signal changes of ROIs regardless of time (F(2, 48) = 3.33, p = 0.05, 
η2 = 0.12). No significant effect was found on the interaction term of signal change in ROIs 
between time points (F(2, 48) = 2.19, p > 0.05). Testosterone change between time points did 
not account for any difference in this interaction (F(2, 48) = 0.21, p > 0.05).  
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Contrast 60-cont 
The ROI analysis showed a significant main effect of averaged signal change across all ROIs 
between time points (F(1, 24) = 8.56, p < 0.01, η2 = 0.25). A significant main effect was 
found between signal change in ROIs regardless of time. Mauchly’s test of sphericity was 
violated (X2(2) = 20.68, p < 0.01), therefore, degrees of freedom were adjusted using 
Greenhouse Geisser estimates of sphericity (ε=0.63) (F(1.27, 31.70) = 10.81, p < 0.01, η2 = 
0.30). A significant interaction was found of signal change in ROIs between time points. 
Mauchly’s test of sphericity was violated (X2(2) = 15.29, p < 0.01), therefore, degrees of 
freedom were adjusted using Greenhouse Geisser estimates of sphericity (ε=0.68) (F(1.36, 
33.99) = 14.70, p < 0.01, η2 = 0.37). A paired sample t-test showed a significant signal 
change difference in the left precentral gyrus between baseline and six months (t(25) = 4.70, 
p < 0.01) (Figure 4.8). Moreover, testosterone had a significant effect on the interaction term 
(F(1.46, 35.04) = 9.96, p < 0.01, η2 = 0.29) demonstrating that it accounted for a significant 
proportion of variance in signal change in the left precentral gyrus. 
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Figure 4.8: MRot mean signal change on 60-cont contrast showing a significant difference in the left 
precentral gyrus. Abbreviations: MRot, mental rotation task; ROIs, regions of interest. 
 
Contrast 120-cont 
No significant main effect of averaged signal change across all ROIs between time points was 
found (F(1, 24) = 1.25, p > 0.05). A main effect was shown between the signal changes of 
ROIs when controlling for time (F(2, 48) = 3.54, p = 0.04, η2 = 0.13). No significant effect 
was found on the interaction term of signal change in ROIs between baseline and six months. 
Mauchly’s test of sphericity was violated (X2(2) = 7.96, p = 0.02), therefore, degrees of 
freedom were modified using Greenhouse Geisser estimates of sphericity (ε=0.77) (F(1.54, 
37.14) = 0.89, p > 0.05). Change in testosterone did not covary with any differences between 
signal change between regions and time (F(1.54, 37.14) = 3.39, p > 0.05).  
 
Contrast 180-cont 
No significant main effect of averaged signal change across all ROIs between time points was 
found (F(1, 24) = 1.55, p > 0.05). No main effect was shown between the signal changes of 
ROIs when controlling for time. Mauchly’s test of sphericity was violated (X2(2) = 10.32, p 
< 0.01), therefore, degrees of freedom were modified using Greenhouse Geisser estimates of 
**p < 0.01 
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sphericity (ε=0.73) (F(1.47, 35.25) = 1.25, p > 0.05). No significant effect was found on the 
interaction term of signal change in ROIs between baseline and six months. Mauchly’s test of 
sphericity was violated (X2(2) = 13.53, p < 0.01), therefore, degrees of freedom were 
modified using Greenhouse Geisser estimates of sphericity (ε=0.69) (F(1.38, 33.23) = 1.11, p 
> 0.05).  
 
Contrast 300-cont 
No significant main effect of averaged signal change across all ROIs between time points was 
found (F(1, 24) = 0.01, p > 0.05). A significant main effect was shown between the signal 
changes of ROIs when controlling for time. Mauchly’s test of sphericity was violated (X2(2) 
= 9.32, p < 0.01), therefore, degrees of freedom were modified using Greenhouse Geisser 
estimates of sphericity (ε=0.76) (F(1.50, 36.00) = 6.66, p < 0.01, η2 = 0.22). No significant 
effect was found on the interaction term of signal change in ROIs between baseline and six 
months (F(2, 48) = 0.89, p > 0.05).  Testosterone was not shown to covary with change in 
signal between baseline and six months (F(2, 48) = 2.63, p > 0.05) 
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Table 4.16: Mean Signal Change Descriptives MRot task 
 Healthy subjects (n = 26) Healthy subjects (n = 26)  
 Baseline Six months  
Region Signal change (%) SD Signal change (%) SD 
Contrast Exp-Cont 
Left Precentral Gyrus 0.10 0.20 0.08 0.13 
Right Superior Frontal -0.11 0.18 -0.05 0.11 
Right Supramarginal 0.03 0.19 0.04 0.14 
 
Abbreviations: cont, control condition; exp, experiment condition; Montreal Neurological Institute; SD, 
standard deviation (Corrected for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
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Table 4.17: Mean Signal Change Descriptives Distinct MRot rotations  
 Healthy subjects (n = 26) Healthy subjects (n = 26)  
 Baseline Six months  
Region Signal change (%) SD Signal change (%) SD 
     
Contrast 60-cont     
     
Left Precentral Gyrus 0.10 0.20 -0.24 0.32 
Right Superior Frontal 0.12 0.21 0.03 0.24 
Right Superamarginal 0.09 0.17 0.06 0.31 
     
Contrast 120-cont     
     
Left Precentral Gyrus 0.08 0.20 0.13 0.15 
Right Superior Frontal 0.11 0.17 0.19 0.23 
Right Superamarginal 0.16 0.17 0.14 0.29 
     
Contrast 180-cont     
     
Left Precentral Gyrus 0.09 0.16 0.17 0.18 
Right Superior Frontal 0.08 0.16 0.14 0.18 
Right Superamarginal 0.13 0.26 0.15 0.17 
     
Contrast 300-cont     
     
Left Precentral Gyrus -0.02 0.23 0.01 0.22 
Right Superior Frontal 0.01 0.23 0.02 0.21 
Right Superamarginal 0.07 0.29 0.06 0.24 
 
Abbreviations: cont, control condition; Montreal Neurological Institute; SD, standard deviation. (Corrected for 
multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). 
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Overlap images assist in demonstrating activation visually in healthy participants at baseline 
and follow-up (figure 4.9). No activation was apparent in contrasts requiring least rotation at 
six months, however, activation was present at baseline (60-cont and 120-cont). The 180-cont 
contrast showed most activation in putative MRot areas including the bilateral supramarginal 
gyri, precentral gyri and parietal lobe areas. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: MRot overlap images of healthy participants at baseline and six-month follow-up where 
red activation colour maps indicate group activation at baseline and blue activation group maps 
show activation at six months. (A) Group activation maps on the contrast 60-cont. (B) Group 
activation maps on the contrast 120-cont. (C) Group activation maps on the contrast 180-cont. (D) 
Group activation maps on the contrast 180-cont. (Corrected for multiple comparisons, Z >2.3; 
Cluster-wise threshold, p < 0.05). Abbreviations: cont, control condition; MRot, mental rotation 
task; R, right.
R 
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4.11.2.3 Spatial reasoning Intra-class Correlation Analysis 
Intra-class correlation (ICC) analysis shows reliability across specific regions. Regions were 
selected from a one sample t-test of exp-cont contrast at p < 0.01 from baseline group 
activation in SPM. Intra-voxel reliability was found to be highest in the main contrast (exp-
cont).  
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Table 4.18: Intra-class Correlations MRot task  
        ICCv med  Average
         (STE)           ROI        
Contrasts MNI coordinates  exp- 120- 180- 300- 60- ICC        
ROI  X  Y Z t-max cont cont cont cont cont (STE) 
   
L.Precentral -45 -4 23 5.18 0.30 -0.08 0.10 0.22   -0.04 0.05  
       (0.14) (0.16) (0.11) (0.17) (0.18) (0.07) 
L.Precuneus -18 -76 -35 4.88 0.32 0.08 0.32 0.20 -0.02 0.15  
        (0.13) (0.09) (0.16) (0.10) (0.10) (0.07) 
L.Superior -24 -58 47 3.37 0.31 0.08 0.30 0.20 -0.02 0.14  
Parietal      (0.14) (0.09) (0.15) (0.11) (0.10) (0.07) 
 
L.Supra- -48 -55 26 4.08 0.31 0.05 0.17 0.03 0.15 0.10  
marginal      (0.12) (0.20) (0.11) (0.17) (0.29) (0.04) 
Gyrus 
 
R.IPL  45 -28 29 3.57 0.17 0.14 0.20 0.18 0.13 0.16  
        (0.13) (0.16) (0.17) (0.14) (0.12) (0.16) 
 
L.IFG Pars 
Triangularis -48 17 5 3.35 0.06 0.21 0.21 -0.02 0.05 0.11  
      (0.22) (0.25) (0.16) (0.16) (0.13) (0.06) 
Average Contrasts ICCv   0.25 0.08 0.22 0.14 0.04  
(STE)       (0.15) (0.03) (0.03) (0.04) (0.03) 
Abbreviations represent: cont, control condition; exp, experiment condition; ICCv med, intra-voxel median; IFG, 
Inferior Frontal Gyrus; IPL, Inferior Parietal Lobe; STE, standard error; MNI, Montreal Neurological Institute; 
ROI, region of interest. 
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4.12 Resting State Analysis 
Resting state analysis was conducted by first acquiring the default mode network seeded from 
the medial prefrontal cortex (mPFC) functional connectivity mask. The network consisted of 
the posterior cingulate cortex (PCC) medial prefrontal cortex and bilateral inferior parietal 
lobes at baseline and analogous regions were active at six months. The mask generated of the 
right dorsolateral prefrontal cortex (rDLPFC) (Harvard-Oxford Cortical Structural Atlas) was 
used to measure connectivity to the DMN mPFC at baseline and six months. Both these 
regions and networks are known to be imperative to fronto-parietal executive functions 
(Niendam et al., 2012; Spreng, 2012). Analysis of baseline scans showed positive correlations 
in the right hemisphere frontal pole, right supramarginal gyrus and left middle frontal gyrus 
(Z =3.48 to 7.43) with the DMN mPFC. Negative connectivity with the DMN mPFC was 
found in the right primary motor cortex and left frontal orbital cortex (Z = -3.78 to -5.26) 
indicated by negative BOLD. Six month follow-up illustrated connectivity of the right frontal 
pole, right supramarginal gyrus and left frontal pole (Z =2.3 to 7.19) with the DMN. The left 
inferior temporal gyrus was negatively correlated with the DMN (Z =-5.38).  
Further analysis was conducted to assess the integrity of resting state connectivity underlying 
executive functions associated with the SST. With this in mind, a small activation area in the 
rIFG was masked (Harvard-Oxford Cortical Structural Atlas) with the aim to investigate its 
connectivity with the DMN mPFC. The mask was selected and made from go incorrect and 
stop correct compared to stop incorrect and go correct group activation contrast (MNI: 50 30 -
2). A 5mm sphere was made around this point and prepared for functional connectivity 
analysis. Baseline analysis revealed connectivity of the rMFG gyrus, right angular gyrus, left 
precentral gyrus and precuneous cortex (Z = 2.47 to 7.25) with the DMN mPFC. Negative 
activation was found in the left occipital fusiform gyrus and left superior parietal lobe (Z = -
4.3 to -4.56). Six month follow-up analysis showed strong connectivity in the rIFG gyrus pars 
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Triangularis, paracingulate gyrus and left fronto-orbital cortex (Z = 4.42 to 7.18). Negative 
BOLD was found in the left postcentral gyrus (Z = -5.03). A paired sample t-test was used to 
find any whole brain resting connectivity differences however, no significant differences were 
found. 
4.13 Regional ASL Perfusion 
Region of interest CBF estimates were compared between baseline and six months 
longitudinally in the eight subjects’ intact data from baseline and six months (refer to mean 
age and standard deviations in section 4.10.2). Regional ASL analysis was conducted 
subsequently to ensure that putative task regions were active before conducting the analysis. 
Regions were selected based on activation areas of the SST and MRot task in healthy 
participants. Perfusion assessments were employed in these regions to assess the integrity of 
BOLD signal activation. Hypoperfusion has been known to lead to reductions in the BOLD 
signal which may lead to less task activation. The rIFG pars triangularis and pars opercularis 
were both masked and combined so that a regional estimate of the rIFG could be gauged 
(Harvard-Oxford Cortical Structural Atlas). Bilateral supramarginal gyri were also masked to 
measure CBF in these regions that were associated with the MRot task (Harvard-Oxford 
Cortical Structural Atlas). Baseline activation was analysed in chapter three showing that 
perfusion was above the range that suggests abnormal perfusion in the specified ROIs (section 
3.9). 
Estimated mean CBF at baseline in the rIFG was 40.43 + 10.80 ml/100gtissue/min (range 0-
381.44 ml/100gtissue/min) which did not significantly differ from six month estimates (37.86 
+ 10.11 ml/100gtissue/min) (range 0-354.53 ml/100gtissue/min) (t(7) = 0.57, p > 0.05). The 
right and left supramarginal gyri were also masked and superimposed on the whole brain 
perfusion map (Harvard-Oxford Cortical Structural Atlas). The left supramarginal gyrus was 
estimated as having a baseline mean perfusion of 37.08 + 11.90 ml/100gtissue/min (range 0-
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595.55 ml/100gtissue/min) that did not significantly differ from six month CBF (37.79 + 8.38 
ml/100gtissue/min) (range 0-492.30 ml/100gtissue/min) (t(7) = -0.13, p > 0.05). Baseline 
average CBF was estimated at 47.12 + 13.38 ml/100gtissue/min (range 0-840.78 
ml/100gtissue/min) in the right supramarginal gyrus which did not significantly differ to six 
month CBF estimates (45.69 + 14.26 ml/100gtissue/min) (range 0-515.77 ml/100gtissue/min) 
(t(7) = 0.29, p > 0.05). These estimates did not significantly change between time points and 
were above the range suggested as being abnormal (above 15-20 ml/100gtissue/min) (Jann et 
al., 2016; Pollock et al., 2009). Moreover, CBF values acquired in the sample of this study 
were in line and similar to those found in ageing adults of a comparable age and in similar 
regions (Leoni et al., 2017; Liu et al., 2012). 
Thus, normal CBF was apparent across time points in healthy ageing participants. Therefore 
abnormal perfusion was unlikely to have affected the BOLD signal activation; normal CBF 
should lead to unimpaired BOLD activation thereby allowing any longitudinal BOLD 
activation changes to be interpreted in light of changes in higher order function rather than 
underlying neurophysiology.  
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Figure 4.10: rIFG gyrus and right and left supramarginal gyri masked ASL perfusion of: (A) baseline 
(n = 8) (B) six months healthy participants (n = 8). The colour bar represents least perfusion in red 
areas of the CBF map and greatest perfusion in yellow areas of the map. Abbreviations: g, grams; 
min, minute; mL, millilitres; R, right. 
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4.14 Discussion 
The main aim of this study was to examine the stability of executive function and spatial 
reasoning performance in healthy older participants over a period from baseline to six months 
and to determine factors that may affect cognition over this time frame. Moreover, 
neuroimaging assessments were employed to investigate the neural underpinnings of 
executive function and spatial reasoning and to assess factors that may affect neural 
activation over the longitudinal period. Findings from the present study revealed little 
difference in testosterone levels between time in accordance with the hypothesis 
aforementioned and past research in healthy controls (Boxer, Kenny, Dowsett, & Taxel, 
2005; Lu, Masterman, Mulnard, & et al., 2006; Young, Baker, Liu, & Seeman, 1993). 
Healthy elderly participants were assessed with the MMSE and WASI-II which are known to 
be robust measures in detecting memory impairments and intellectual impairments among 
adults (Gontkovsky, 2016; O'Bryant et al., 2008). Findings showed all participants scored 
above the cut-off ranges on the assessments and were in the normal range according to 
specific age groups. This was in line with what was predicted and confirms that the sample of 
healthy controls were from the general population without intellectual difficulties or any 
apparent neurodegenerative conditions. 
Cognitive performance on the D-KEFS and CANTAB SWM tasks did not vary significantly 
in healthy participants between time points in accordance with the hypothesis. Furthermore, 
performance was consistent with analogous executive function and spatial reasoning ability 
tasks in elderly healthy controls (Albrecht, Masters, Ames, Foster, & The, 2016; Johnson, 
Storandt, Morris, & Galvin, 2009; Vanderploeg, Curtiss, & Belanger, 2005). Multivariate 
models employed to analyse distinct D-KEFS and CANTAB performance with group by time 
comparisons, revealed no significant differences from baseline to six months on any tasks. 
Moreover, these findings remained stable between time points while controlling for 
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testosterone. Outcomes from the BRIEF-A measures showed no significant differences 
between longitudinal time points. Low self-ratings of cognitive function have been reported 
in past research (Pennequin et al., 2010). This may have bearings on cognitive performance 
but the current study showed no significant correlation between dependent BRIEF-A 
measures and D-KEFS contrast scaled scores. This suggests that self-rated meta-cognition 
was accurate compared to participants’ neuropsychological performance which is consistent 
with past research (Rabin et al., 2006). The RCI change did show some relationship between 
proportion of testosterone change and proportion of cognitive change that are explored in 
more depth in subsequent paragraphs. Finally, psychosocial function also remained stable 
between time periods evidenced by HADS anxiety and depression scores in norm ranges 
(table 4.1). This is in line with the current hypothesis and previous research (Cella, Dymond, 
& Cooper, 2010; Hek et al., 2013; Wetherell et al., 2001). 
Neuroimaging outcomes showed no neural activation differences between baseline and 
follow-up on the SST. No significant activation differences were present on the contrast of 
interest on the MRot task (exp-cont). This is in line with what was predicted since healthy 
participants’ cerebral function were not expected to change over six months. Moreover, stop 
signal and MRot task activation were in putative inhibitory and spatial reasoning areas which 
was consistent with past research. This was also as hypothesised and further validates the 
sample of ageing participants had normal cerebral function. No significant differences were 
found in comparisons of resting state connectivity between the seed network and region of 
interests between time periods. Additionally, no significant CBF differences were found in 
elderly subjects between baseline and six months. This was as hypothesised and suggests 
cerebral perfusion and resting state connectivity did not change or deteriorate between time 
points. However, these outcomes should be interpreted with caution as comparisons between 
time were only assessed in eight participants. Psychosocial levels did not change in 
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participants between baseline and six months as expected and did not account for activation 
in fMRI task regions. Testosterone levels did not significantly differ between baseline and 
follow-up as anticipated. 
 
The above behavioural cognitive findings illustrate that no significant differences were found 
in healthy older ageing participants between time points. However, while group level 
statistical comparisons were made, they do not address the question of identifying the extent 
to which individual subjects can be expected to reliably improve or decline on 
neuropsychological measures over time. The current study used the reliable change index 
(RCI) to measure change in participants over a time so that assessment of longitudinal change 
could control for practice effects (Barr, 2002). The effectiveness of the RCI method was 
explored in one study (Frerichs & Tuokko, 2005). Researchers assessed six reliability 
methods and demonstrated that the RCI was regarded as the most useful clinical diagnostic 
utility to detect reliable change in healthy older participants (Frerichs & Tuokko, 2005). 
Furthermore, when coupled with a threshold of + 1.645 (90% CI) the RCI method gave a 
better indication of true change which addresses the potential influence of practice effects 
(Hensel, Angermeyer, & Riedel‐Heller, 2007). Previous research incorporating the RCI has 
commonly found stable or better performance amongst healthy subjects in longitudinal 
duration studies compared to patient populations (Alves et al., 2014; Lampe, Sitskoorn, & 
Heeren, 2004; Stordal et al., 2005; Taylor, Barker, Heavey, & McHale, 2015). However, 
these studies employed samples that primarily comprised of young healthy cohorts with 
stable performance across time. Research comparing aging participants to young samples 
have commonly found subtle but significant differences in performance using cross sectional 
and longitudinal methodologies (Adolfsdottir, Wollschlaeger, Wehling, & Lundervold, 2017; 
Cabral Soares et al., 2015). One study explored healthy aging in subjects between the ages of 
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18-80 over 2.5 years (Salthouse, 2010). Researchers found aging was associated with 
significant negative changes across domains of spatial reasoning, visualisation, perceptual 
speed and vocabulary (Salthouse, 2010). This may suggest that the current investigation was 
limited in its duration and that any significant changes detected through the RCI method may 
be apparent over periods longer than six months. Nevertheless, findings from the current 
study did show some unexpected change including a relationship between the proportion of 
testosterone change over time and BRIEF-A self-report monitor scale. The BRIEF-A self-
monitor scale measures the ability of a subject to be aware of a participant’s own behaviour 
on others. It thereby captures how the subjects own behaviour compares with expectations of 
standard behaviours (Gioia et al., 2000). Further interpretation of this effect may include that 
high testosterone levels lead to the reduced conscious ability to perceive social cues or 
corrective behavioural patterns. Researchers in one study gave 16 female participants either 
testosterone or a placebo in a within subjects design (van Honk & J.L.G. Schutter, 2007). 
Participants were administered tasks in which a morphed facial expression was presented to 
them. Subjects were instructed to consciously recognise and index facial expression as either 
expressing threat i.e. disgust, fear or anger or non-threat i.e. surprise, sad, happy. When 
participants were administered testosterone, they had a significant reduction in recognising 
faces expressing treat. Moreover, participants were less aware of faces expressing anger 
compared to any other expressions. This suggests that higher testosterone levels impaired the 
ability of participants to consciously detect socially corrective facial signals of anger. This 
may have further implications for predisposing individuals with higher testosterone to 
assertive dominance behaviour that could lead to reduced awareness of self and surrounding 
standardised behaviour patterns. This may be an aspect of executive function that is affected 
as a function of higher testosterone levels and may explain the relationship on the self-
monitor scale and testosterone relationship of the current undertaking. 
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Greater testosterone levels at follow-up in the conducted exploration were also associated 
with reliably better performance on the CANTAB spatial working memory eight box 
condition. This may be expected in light of studies showing that the domain of spatial 
reasoning is highly sensitive to testosterone manipulation (Moffat et al., 2002; Moffat et al., 
2004). The effect of testosterone may have been associated with the eight box condition as it 
required a higher level of spatial reasoning ability thus being higher in sensitivity to 
testosterone level. This suggests that the task is suitable in the assessment of patients 
undergoing ADT since their levels are depleted. Therefore, the CANTAB SWM can 
differentiate testosterone-depleted performance from normal ageing related performance in a 
longitudinal assessment. 
While neuropsychological findings generally revealed little difference between time points in 
line with the hypothesis, neuroimaging analyses revealed some interesting scanner task 
specific effects. Stop trial accuracy was significantly better at six months compared to 
baseline. This may reflect some practice effects in participants as they performed better at 
follow-up. However, this effect could also be due to environmental factors such as anxiety or 
stress during the participants’ first visit for the experiment to an MRI scanning facility. Self-
reported anxiety measurements were obtained but may not truly identify stress factors just 
prior to scanning. Thus, the second visit to the facility may have reduced anxiety levels to 
allow better performance on the task.  
Other outcomes of separate flicker behavioural outcomes showed no significant interactions. 
However, stop signal reaction time did change as a function of flicker trial difficulty which is 
analogous to past research (Li et al., 2006). Longer SSRT latency was found on long flicker 
trials since they required high levels of executive function and inhibition rather than 
prediction to correctly inhibit. This was demonstrated in pilot study two (appendix 4: study 2) 
and three in which long flicker duration induced long SSRTs and was aimed for. Medium 
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flicker trials induced long latency SSRTs however, they were of low power rendering the 
outcome prone to error. Short flicker trials had the quickest SSRTs and best trial accuracy. 
This is analogous to past research showing that shortening of the SSD should result in better 
inhibition performance (Li et al., 2006; Li et al., 2008; Verbruggen & Logan, 2009). Spatial 
reasoning performance in participants showed that they performed better when they had to 
judge shapes in the same orientation compared to mirror orientations. This is a common 
finding as mirror trials increase the difficulty of the trial (Shepard & Metzler, 1971; Wan, 
Chen, Wu, & Qian, 2011). Moreover, reaction time increased as a function of shape 
orientation from zero which is analogues to findings from past research (Hertzog et al., 1993; 
Lineweaver et al., 2005; Shepard & Metzler, 1971). This suggests the healthy sample was 
mentally rotating shapes and were not guessing responses. If they were estimating responses 
then reaction time may be equal for all trials. The 300 degree condition did not elicit worse 
performance or longer reactions time which may be due to rotation of shapes in the anti-
clockwise direction. This may have allowed participants to rotate shapes in the 300 degree 
condition quicker with better accuracy but may have required additional mental rotation 
related cerebral resources to change the direction of shape rotation.     
Neuroimaging revealed putative SST activation concentrated in the rIFG gyrus, middle 
frontal gyrus and bilateral parietal lobes supporting a fronto-parietal network of activity and 
consistent with previous research (Hughes et al., 2013; Zhang & Li, 2012). Exploratory 
analysis of specific contrasts showed that activation on go incorrect trials was distinct 
compared to go correct trials and in line with inhibitory function. Stop incorrect trials also 
exhibited activation in go correct related areas which provided support for the combination of 
trials in the main contrast. However, activated voxel clusters were not apparent at both time 
points at the group level. This may have been due to the threshold set for multiple 
comparisons to avoid false positives and therefore some clusters were not apparent at this 
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level. Nevertheless, further analyses showed no significant differences on the additional 
contrasts between time points which indicates that similar areas were active at baseline and 
follow-up in the controls. Therefore, the combination of trials was warranted and benefitted 
the main contrast to increase the power of trials. 
Region of interest analysis enabled the analysis of specific task associated regions activated 
at baseline and follow-up. This permitted the analysis of regional activation consistency 
without the restrictions imposed by whole brain analysis. The ROI analyses on contrasts of 
the stop signal task showed consistent activation in putative SST inhibitory areas including in 
the rIFG and rMFG. However, other regions including the LITG and LMFG were 
investigated as possible compensatory mechanism areas in older ageing samples as they were 
activated at either baseline or follow-up in whole brain activation maps. All regions had 
consistent BOLD signal change whether it was positive or negative BOLD between baseline 
and follow-up on the main inhibition contrast and across separate flicker trials. The main 
inhibition contrast was approaching significance in covarying with testosterone change 
between baseline and follow-up. This showed a linear trend indicating that as testosterone 
levels increased across time, differences between regional BOLD signals changed, although 
not significantly. Left hemispheric regions did not seem to contribute as a compensation 
mechanism as they had predominately negative signal change. However, when contrasts were 
split into flicker trials they did show some contribution. However, through averaging of the 
signal across all trials, they may have resulted in negative signal change. In addition, owing 
to the large number of analyses conducted to thoroughly explore the parameters of the task, 
this result should be interpreted cautiously and evaluated in independent samples.  
The MRot task heavily relied on the parietal regions and precentral premotor regions as seen 
from the contrast of exp-cont. Region of interest analysis showed consistent activation across 
baseline and follow-up in putative regions on the main contrast and when contrast ROI 
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analysis were separated for each distinct rotation contrast (i.e. 120-cont, 180-cont and 300-
cont contrasts). However, a significant interaction was found between regional signal change 
and time in the 60-cont contrast. More specifically, the left precentral gyrus had greatest 
change between time points. This covaried with change in testosterone indicating that as 
testosterone levels increased from baseline to follow-up, signal change in the left precentral 
gyrus decreased from baseline to six-months. Although testosterone change was associated 
with precentral gyrus change, it only accounted for 12% of variance. One explanation for 
signal change in the precentral gyrus (premotor cortex) between time points is that the MRot 
task has been found to elicit activation in the precentral gyrus that has been associated with 
mental imagery of self-hand movements during mental shape rotations (motor imagery) 
(Vingerhoets, de Lange, Vandemaele, Deblaere, & Achten, 2002). In the current study, motor 
imagery may have been a strategy implemented by participants in a novel task setting at 
baseline. However, at six months, participants may have recruited parietal brain regions due 
to practice effects or due to a different strategy employed that is compensated by testosterone. 
This may be more relevant to the 60-cont contrast as the rotation from zero on this sub 
component of the task required minimal rotation resulting in less precentral gyrus 
involvement at six months due to some practice effects. This is supported by BOLD signal 
change showing precentral gyrus involvement in the 120, 180 and 300 degree sub 
components of the task at six months (table 4.17). Thus the 60-cont sub component of the 
task may be more susceptible to testosterone change allowing differentiation of performance 
in PC patients undergoing ADT compared to performance as a result of normal ageing in 
especially the left precentral gyrus. 
Further findings showed reliable activation in regions identified from baseline at an intra-
voxel level in the main contrast (exp-cont). Reliability across conditions was slightly weaker 
but regional activation was highest when high degrees of shape rotation were required 
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indicating that these regions were consistently activated when difficulty increased to mentally 
rotate shapes (table 4.18). A limitation of the intra-class correlation method may be that there 
were activation differences when analyses were conducted in SPM compared to FSL. For 
example, the ACC was active in SPM baseline group analysis but was not active using the 
FSL analysis approach. This may be attributed to a higher sensitivity of SPM in the pre-
processing steps of pipeline analysis (Morgan, Dawant, Li, & Pickens, 2007). Nevertheless, 
SPM has also been associated with simple noise models and FSL which underestimates 
spatial smoothness (Eklund, Nichols, Andersson, & Knutsson, 2015). Further research should 
attempt to compare outcomes from both software’s analysis methods to isolate differences in 
analysis methods.  
Subtle underlying brain architecture was investigated using resting state analysis and ASL. 
Outcomes consistently showed activation in the fronto-parietal network when the right dorso-
lateral prefrontal cortex and rIFG gyrus were selected regions of interests. Moreover, 
negative deactivations were found in the opposite hemispheres to those that were activated 
such as the inferior parietal and superior parietal regions as was expected and has been 
related to stop signal performance in other studies (Lee & Hsieh, 2017). Arterial spin 
labelling was in the normal range and above the level classified as hypo-perfusion at baseline 
and six months (Pollock et al., 2009). Furthermore, no change was found in the healthy 
sample between time-points showing the suitability of the sample for longitudinal assessment 
during further investigations. A shortcoming to this analysis was of limited subjects assessed. 
This may limit the power of the analysis leading to increased type II errors where the null 
hypothesis was falsely retained. 
Limitations of the study conducted include that there was a probability that the null 
hypothesis was retained in favour of a significant difference (Faul, Erdfelder, Lang, & 
Buchner, 2007). This is because a small sample size was employed that could leading to type 
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II errors. However, the longitudinal nature of the study allowed the elimination of between 
subject variability which added power to findings reducing the chances of type II errors. A 
further shortcoming included that there was a high probability of type I errors in both the 
behavioural assessments and neuroimaging assessments. This was due to the number of 
analyses conducted between variables and between voxels in whole brain analyses, raising 
the issue of multiple comparisons that increase familywise error rates. Thus there was a 
chance that small findings were as a result of chance. Therefore, these small comparisons that 
were exploratory should be interpreted with caution. Future study methodologies should 
implement larger samples sizes to decrease the chance of type-I and type-II errors. Another 
shortcoming was that the investigation only had a follow-up duration of only six months. 
Previous research has found subtle yet significant cognitive deterioration in healthy older 
adults with longitudinal follow-ups of three years. Nevertheless, past studies have 
implemented a limited cognitive battery therefore in depth insights into cognition could not 
be gauged. Moreover, norms and averages of neuropsychological assessments are likely to 
change over very long periods. This could invalidate outcomes of studies with very long 
follow up periods. A final shortcoming was that spatial reasoning ability was 
neuropsychologically evaluated with a task comprising both a spatial condition and a working 
memory condition. The variability in working memory was controlled for to gauge purely 
spatial reasoning. However, the removal of working memory through statistical methods may 
not truly remove all components of the domain from spatial ability. Nevertheless, 
neuroimaging did show and support that spatial reasoning ability was intact in healthy 
participants across the longitudinal duration suggesting that neural underpinnings were 
reflective of behavioural performance that demonstrated that spatial reasoning did not decline 
over the six months period. 
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In conclusion, healthy participants assessed had normal and reliable executive function over a 
longitudinal time course that was supported by neural underpinnings indicating that the 
performance in the domain was intact in healthy ageing older participants. Spatial reasoning 
was also found to be stable over the time period with neuronal activation in putative regions 
confirming that cognitive function in the domain was reliable in the healthy sample. 
Testosterone did have an effect on reliable performance across time suggesting that it could 
either enhance or impair cognition at later time points. Nevertheless, the effects were subtle 
and did not indicate that the whole domain was affected but rather that sub components of the 
spatial domain were affected.  
The study confirms that the sample compared to patients were normal ageing healthy older 
ageing controls that did not confound the assessment of patients due to behavioural, 
biological or cerebral abnormalities. Moreover, it allows researchers to confirm that 
comparisons between patients and controls were robust. This may impact on patients 
informed choices of treatment, continuation of treatment and management of cognition in PC 
patients before therapy is administered. 
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CHAPTER 5 
 
5.1 General Discussion 
The current study sought to measure cognitive change associated with the reduction of 
testosterone levels (i.e. androgen deprivation therapy; ADT) used to treat men with prostate 
cancer (PC). It adopted an innovative approach combining clinically-relevant tasks to assess 
cognition and mood, together with sensitive functional neuroimaging measures. The thesis 
presented data from a cohort of men with prostate cancer prior to treatment onset and age-
matched controls, all assessed twice over a six month period. Longitudinal data in prostate 
cancer patients were not available for analysis, however, the thesis provides a comprehensive 
framework for ongoing research, as well as novel insights from available data.  
 
The treatment of PC has taken many forms including surgical methods (prostatectomy and 
orchiectomy), brachytherapy and cryotherapy that have been shown to be effective in 
reducing the risk of metastatic spread (Bill-Axelson et al., 2014; Gomella, 2009). However, 
these forms of treatment are associated with many side-effects such as erectile dysfunction, 
gynecomastia, mood impairment and impotence (Louda et al., 2012). Management of these 
adverse effects requires life-long treatment to recover from and may require additional 
testosterone replacement therapy. Androgen Deprivation therapy is a chemical castration 
method that has been shown to be as effective as other forms of treatment in preventing 
tumorigenesis and increasing survival rates (Heyns et al., 2003; Raina et al., 2007). 
Nevertheless, it has also been associated with side-effects similar to those of the previously 
mentioned surgical and radiation methods. However, an advantage of ADT is that these 
adverse effects can be reversed post ADT because testosterone levels endogenously return to 
baseline levels. Other treatments cannot offer this advantage due to complete prostate or 
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testes ablation and removal. Nonetheless, ADT has also been associated with deleterious 
effects on cognition and this has been reported to cause distress in patients (Sountoulides & 
Rountos, 2013). Although, many inconsistencies have been reported in the literature of the 
domains affected in patients during ADT, systematic reviews and meta-systematic reviews 
have found executive function and spatial reasoning abilities to be affected in ADT samples 
across multiple studies (McGinty et al., 2014; Treanor et al., 2017). However, as outlined in 
the current thesis, limitations of past assessments in the assessment of cognition in ADT 
samples meant that clear guidance for treating doctors and men with PC was not available. 
Therefore, the current investigation was employed to characterise cognition in PC patients 
undergoing ADT using an extensive battery of neuropsychological assessments and 
neuroimaging techniques at baseline compared to healthy controls. This was undertaken 
because past researchers have found that patients had cognitive impairments at baseline 
compared to healthy samples, therefore the pre-treatment period requires exploration 
(Salminen et al., 2003). The study undertaken was therefore conducted with the aim of 
providing physicians with the necessary information to facilitate the management of patients 
before they began ADT to prevent adverse effects from developing in the domains of 
executive function and spatial reasoning during therapy. This may allow patients to make 
informed choices on treatment uptake and continuation. 
A critical shortcoming of past research included that some studies did not incorporate 
matched control samples. This was evidenced, for example, in studies where controls had 
higher intelligence scores and higher levels of education compared to patients (Green et al., 
2002; Green et al., 2004). Therefore, any differences between groups were biased in favour of 
healthy controls, which would erroneously ascribe impairments to patients; this has 
implications for evidence-based practice. Specifically, men may elect to avoid what is a 
successful treatment for advanced PC due to concerns about the impact on their thinking 
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skills, even though the data currently supporting this outcome are not optimal. Thus, the 
present study therefore attempted to overcome several limitations by including assessment of 
potential confounds (for example, mood and testosterone levels) and matching groups. In 
addition, it aimed to characterise neural and cognitive function in the healthy control sample 
to validate that they did not have or develop any underlying cognitive deficits over a 
longitudinal period of six months. If any changes occurred in controls then it is important that 
these are accounted for in a longitudinal study of patients. Thus, in the current thesis, 
analyses and data collection focussed on identifying covariates including testosterone and 
mood factors that accounted for a significant proportion of variance on any differences. 
Moreover, it allowed inferences to be made on the usefulness of the sample compared to 
patients. The current PhD project was part of a broader study in which PC patients were 
compared over a longitudinal time period of 12 months before beginning ADT, during 
therapy and after therapy. Therefore, patient assessment was limited to investigating key 
background principles and development of neuroimaging paradigms rather than assessing 
patient outcomes owing to time constraints. 
 
The hypotheses of the study were largely supported. At baseline, testing of patients and 
controls using a comprehensive battery of executive function and spatial reasoning 
neuropsychological and neuroimaging methods was used to test the hypothesis that there 
would be no significant difference in cognition and neurological function between patients 
and controls’ before patients began therapy. This hypothesis was largely met with differences 
between patients and controls in testosterone levels and spatial function. The hypothesis was 
tested to determine if any cognitive impairments were present in PC patients before ADT 
treatment. If any deficits were found then this may provide physicians and therapists with the 
necessary information to develop a strategy to tackle any cognitive impairments which can 
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stem from the cancer diagnosis period to treatment period. Moreover, as testosterone has 
been shown to be a covarying factor between cognition and was higher in the patient sample, 
it may have been a contributing compensatory factor that resulted in null effects between 
patients and controls. Thus, ADT could exacerbate cognitive deficits in the treatment period 
due to its deprivation effect on androgens. Although a power analysis was conducted in the 
current undertaking, further mediating analyses are required to assess this relationship in 
larger sample sizes to account for null hypothesis testing effects.  
The second key analysis of the current thesis involved longitudinal change in measures used. 
The global hypothesis was that ageing healthy controls had stable cognition over a 
longitudinal period of six months with unchanging neural function over the time period. This 
was to validate that the sample was representative of ageing healthy male participants that 
had stable performance over six months. If the hypothesis was not met, then outcomes from 
when patients were compared to controls may be confounded. This is because controls’ 
performance and neural function was compared to patients to mitigate cognitive impairments 
that occur as a function of healthy ageing. The exploration confirmed that age matched 
healthy controls had no significant differences in cognitive performance in the domains of 
spatial reasoning and executive function between baseline and six months. Moreover, no 
underlying neural deficits were found that confounded neuropsychological and in scanner 
cognitive outcomes. This demonstrated that the control sample was matched compared to 
patients for age and intelligence without any underlying cognitive or neural impairments. 
Furthermore, it indicates that the control sample was a suitable comparator group to patients 
in the analyses that will arise in a future longitudinal comparison. 
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5.2 Implications for the study and treatment of prostate cancer with testosterone 
depletion 
At a simplistic level, it is perhaps unsurprising that patients’ and controls’ performance did 
not differ before therapy commenced, although a range of factors might have led to a 
different outcome. For example, the men with PC had recently had a life-altering diagnosis 
which may impact negatively on mood. There is a known association with mood and 
cognition, and so it was important to consider whether the patient cohort could have 
presented with cognitive deficits prior to treatment for reasons other than testosterone 
depletion. The current study, however, found that mood was similar between patients and 
healthy controls before therapy indicating that mood levels were in the normal range. In 
addition, the similarity in cognitive performance between groups reflects the relatively stable 
neuropsychological profile in both groups on initial testing. Nevertheless, this finding 
warrants further consideration, given that men with PC had slightly higher testosterone levels 
at baseline.  
Higher than normal testosterone levels could facilitate or support cognitive processes in the 
presence of cognitive impairment. This is of interest to the current study because an 
unexpected finding was that patients had significantly higher testosterone levels compared to 
controls at baseline assessment. Studies in patients with Alzheimer’s disease and multiple 
sclerosis (Cherrier et al., 2005; Gold et al., 2008) provide support for the notion that higher 
testosterone levels may offer a protective effect in the presence of early cognitive decline. 
Patients administered testosterone in these studies had better cognition despite having 
underlying neurological conditions. The study by Cherrier et al. (2005) showed that 
administration of testosterone increased peak testosterone levels in patients with Alzheimer’s 
disease and mild cognitive impairments. The increases corresponded with better performance 
in skills and domains including spatial memory, verbal memory and problem solving ability 
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compared to a patient cohort administered a placebo (Cherrier et al., 2005). This suggests that 
the increased testosterone was beneficial as a neuroprotective agent and may be a 
contributing factor that allowed patients to compensate for lower cognitive ability that may 
occur as a result of disease specific factors. Studies have also shown that low testosterone 
levels may be a vulnerability factor for major depressive disorder (McIntyre et al., 2006). 
Whereas administration of testosterone in patients resistant to serotonin reuptake inhibitors 
(SSRI) has been found to improve cognition in males suffering from major depression 
(McHenry, Carrier, Hull, & Kabbaj, 2014; Seidman & Rabkin, 1998; Seidman & Walsh, 
1999). Testosterone administration has been found to improve anxiety symptoms in males 
(Cooper & Ritchie, 2000; McHenry et al., 2014). Psychosocial factors are known to facilitate 
cognition and underlying neural activity (Baxter et al., 1989; Chen et al., 2014; Kalanthroff, 
Cohen, & Henik, 2013). This suggests that while testosterone is a contributing factor of 
adenocarcinoma growth, it may be protective to cognition which hides underlying and 
unnoticeable psychosocial impairments that affect cognition. No psychosocial impairments 
were found in patients at the group level or found to have a relationship with cognitive 
outcomes suggesting that higher testosterone levels may have compensated for any 
impairments. Nevertheless, caseness analysis showed that PC patients that had borderline 
anxiety disorder had impaired spatial reasoning function on the more difficult subtest of the 
CANTAB SWM. This could affect patient daily life and has implications for the strategies 
implemented by physicians and specialists to target cognition in the early stages to avoid 
cognitive impairments. These approaches should therefore be effective when testosterone is 
depressed in patients during therapy or when mood factors may be elevated, possibly due to 
impending treatment. 
Risks have been associated with testosterone administration in PC patients undergoing ADT 
including increases in PSA, development of cancer into metastatic growth and recurrence of 
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PC (Fowler & Whitmore, 1981; Huggins & Hodges, 2002). Physicians should therefore be 
aware of strategies or alternatives that could be implemented to tackle side effects especially 
those that involve biochemical administration methods. This is because previous human and 
animal assessments have been conducted with testosterone that is aromatizable to oestrogen. 
Therefore, oestrogen may partially have an effect of cognitive function rather than 
testosterone alone. Some studies suggest that androgen receptor production may be regulated 
by androgens (Lu, McKenna, Cologer-Clifford, Nau, & Simon, 1998) or oestrogens (McAbee 
& Doncarlos, 1999) in the central nervous system. Studies in which males are compared to 
females often show that men have better spatial reasoning compared to females which is 
attributed to the difference in testosterone. However, women have been found to outperform 
men in cognitive domains including short-term memory, verbal ability, perceptual speed and 
accuracy (Hampson, 2002). It is unknown whether these differences are due to gender 
differences or hormonal dissimilarities. One study assessed cognition in transgender subjects 
before undergoing oestrogen replacement therapy and after therapy (Miles, Green, & Hines, 
2006). Participants were concurrently administered cyproterone acetate to depress 
testosterone levels while undergoing oestrogen therapy. Outcomes showed no cognitive 
differences after hormone treatment in domains of spatial reasoning, verbal fluency, verbal 
memory, visual memory and working memory compared to baseline levels before treatment. 
This shows that while testosterone was depleted, oestrogen administration may have 
substituted for deficits normally caused by testosterone deprivation. Similarly, the effect of 
oestrogen therapy may be suitable in PC patients when testosterone is deprived to allow 
cognition to remain intact. Moreover, this may allow patients to retain cognitive function to 
those of levels before ADT administration.   
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5.3 The role of neuroimaging approaches in studying cognitive decline associated with 
testosterone 
Neuroimaging was employed in the study to assess the integrity of PC patient and healthy 
participant cerebral neuro-architecture through functional imaging methodologies. Neural 
correlates were investigated because past research has shown that underlying neurological 
structures may be affected despite participants having normal behavioural performance (Chao 
et al., 2013; Chao et al., 2012). To explore if this was the case, the present study utilised 
functional magnetic resonance imaging (fMRI) to assess brain activations and neural 
architecture differences with techniques including in scanner task activations and resting state 
fMRI seed connectivity. This allowed interrogation of differences in activation in underlying 
cerebral networks between groups pertaining to the domains of executive function and spatial 
reasoning. Cerebral perfusion was measured in the current study with a novel arterial spin 
labelling (ASL) technique. This allowed inferences to be made on underlying BOLD task and 
resting state activations through ASL at rest (Krainik et al., 2013; Wang et al., 2017). This is 
because the BOLD signal is an indirect measure of neuronal activity that is influenced by 
cerebral perfusion into cerebral tissue. In the context of studies of ageing or longitudinal 
studies, it is important to discount the effect of perfusion changes on BOLD differences over 
time. Although this is important for all such research, it is particularly relevant when the 
results of imaging studies have the potential to impact on clinical care. It would be erroneous 
to suggest that ADT is associated with cognitive changes through fMRI studies if the 
underlying basis for alterations in BOLD signals was instead differences in perfusion. Whilst 
changes in perfusion might not be favourable, the impact on clinical decision making is 
different given the suggestion that men treated for PC with ADT describe their experience of 
cognitive changes as distressing (Green et al., 2004). Therefore, the use of ASL here was able 
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to provide a unique perspective that supports accurate interpretation of BOLD task 
activations.  
Treatment of potential confounding factors in the analysis of functional imaging data extends 
to other variables, including clinical factors such as testosterone. In the current study, 
testosterone was covaried with all neural measures to assess its association in patients and 
controls. Outcomes in patients and controls showed a difference in activation on the stop 
signal task in which patients had more activation in the left inferior frontal gyrus. This may 
be speculated to have been recruited through mirror neural circuitry to assist in inhibition 
performance. A possible mechanism by which this compensation may have occurred could be 
from the contribution of additional androgens to pyramidal cell mirror neurons in the left IFG 
(Kilner et al., 2009). The IFG has a putative abundance of pyramidal neurons (Jacot-
Descombes et al., 2012) and has been shown to contain androgens in multiple layers of the 
gyrus (Kritzer, 2004). Dendritic density of these neurons has been linked to androgens 
because the hormone may facilitate dendritic spine formation by preventing ischemia and cell 
apoptosis (Yaffe, Grady, Pressman, & Cummings, 1998). This allows for a greater potential 
for the left IFG to mirror activity from the right IFG through facilitation of androgens in the 
patient sample of the current study. Testosterone was also shown to co-vary for activation in 
the amygdala on the stop signal task in PC patients. This suggests there may have been some 
effect of testosterone in facilitating compensatory activity in patients to produce inhibitory 
performance similar to that of controls. This shows the role of testosterone on executive 
function performance where the higher testosterone levels found in patients may have 
allowed them to produce similar performance to that of controls. Consequently, this finding 
has important implications; when testosterone is deprived during ADT, this compensatory 
recruitment may no longer be available and this may, in turn, lead to worse executive 
function performance as has been reported in past studies. Resting state and ASL analysis did 
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not uncover any facilitation of higher testosterone levels suggesting that BOLD activation 
during functional paradigms were valid and were not biased through testosterone 
modulations. Additionally, resting state executive function networks were not impaired in 
patients indicating that functional activation was not affected by underlying neural 
architecture impairment such as deteriorating white matter tracts that facilitate 
communication between cerebral regions.  
 
In addition to baseline comparisons, the analysis of neuroimaging data extended to healthy 
control networks longitudinally. Although there were some difficulties with the ASL 
analyses, this initial evidence suggests that there is stable neural activity and perfusion across 
time points. The lack of impact of testosterone, which showed no differences between time 
points, suggests that these paradigms will be sensitive to the effects of ADT. This is the first 
comprehensive study to examine domain-relevant neural activity in this manner and suggests 
that brain imaging differences between patients and controls will be useful in future research. 
The investigations conducted showed that testosterone could influence neural activity in 
patients before ADT to allow for normal cognition similar to that of healthy participants 
while PC disease specific factors are present. This could explain the range of deficits found in 
patients during therapy. Longitudinal assessment of healthy controls moreover supports this 
outcome by demonstrating that testosterone was unaffected and that this did not lead to any 
differences between time points. Reliability measures further support that there were no 
activation differences between time-points which were not influenced by testosterone. This 
implies that the control group was a healthy ageing cohort that was and will be useful in the 
comparison of patients cross-sectionally and longitudinally.  
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Although the above demonstrates intact cognition in patients and controls, further research is 
required to assess if androgens are converted to testosterone or oestrogen through the 
aromatization process after entering the blood brain barrier. The use of non-aromatizable 
testosterone may be a viable option to investigate this in future assessments as it is not 
converted to estrogen (Pospisilova et al., 2012). Additionally, although fMRI is a useful tool, 
it suffers from temporal limitations whereby slice acquisitions are acquired after the neuronal 
event. This is because acquisitions of images by fMRI rely on the neurovascular coupling 
whereby the HRF that occurs to deliver oxygen for glucose metabolism transpires after a 
delay of the neuronal event (Hillman, 2014). Thus, post processing is required after data 
collection to calibrate for this difference so that an estimate is gauged of the actual time of 
event (Hillman, 2014). This may hamper the accuracy of temporal associations between brain 
regions in relation to mediating variables. Therefore, other modalities such as 
electroencephalography (EEG) should be considered in conjunction with fMRI to help bridge 
this gap. This may provide for a better approach with sufficient spatial resolution through 
fMRI and superior temporal resolution from EEG to concurrently measure activation that 
corresponds to neuronal activity (Huneau et al., 2015). 
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5.4 Limitations of the current study 
The current thesis was conducted in the context of a larger longitudinal study, which was 
supported by the work presented here. Three key limitations arose during the course of the 
study: 1) lack of sufficient data at six-month follow up in men with PC, 2) sample size of the 
groups, and 3) corruption of some ASL data which limited planned analyses. In addition, 
multiple comparisons were made in the study that could limit outcomes from a behavioural 
and neuroimaging perspective which will first be addressed before moving on to discuss the 
limitations identified above. However, the current research and the imaging community 
incorporates control for this in software used for analysis. Moreover, only corrected threshold 
outcomes were reported in the current study. There is no accepted control for behavioural 
data. Bonferroni is considered too stringent, for example. Thus, whilst researchers in the 
present study were aware of these issues, findings were not stringently controlled for in this 
preliminary study. This was partly because the data required exploration so that any variables 
that might be relevant could be identified for future analyses when a fuller data set is 
available.  
As aforementioned a shortcoming of the study was that patients and controls were compared 
cross-sectionally. While this was advantageous in gaining data before ADT, it lacked the 
capacity to generate and make inferences of factors that caused cognitive decline before and 
during therapy. The cross-sectional methodology additionally confined the current study 
outcomes as sample sizes were small which limited power. Since participants were assessed 
at a single time point, power requirements were not met which may lead to type II errors 
where the null hypothesis is falsely accepted. Implications of this are that cognitive and 
neural deficits before therapy may be missed due to small sample size allowing only the 
largest effects to be detected whereas smaller effects may be missed (Tsang, Colley, & Lynd, 
2009). Caseness analysis was performed with mood measures to assess the relationship of 
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mood with cognition. However, no other variable could be compared such as testosterone due 
to the sample size. The comparison of healthy controls at longitudinal time points benefitted 
from the study design since between subjects variability was avoided due to within subject 
comparisons. However, calculation of the reliability change index (RCI) allowed 
measurement of proportions of participants that increased or decreased in performance over 
six months. This was advantageous as the RCI has been found to be sensitive when there are 
small sizes (Zahra et al., 2016). Moreover, the relationship between change in cognitive 
performance and change in testosterone could be assessed using statistical methodologies to 
provide links between factors that mediated this reliability over time in executive function 
and spatial reasoning.   
Another power constraint of the present investigation utilising neuroimaging was that only 
eight healthy controls’ arterial spin labelling (ASL) scans could be compared to patients. This 
increased chances of errors that may have biased findings. An attempt was made to include 
six month scans from missing controls’ which were combined with the eight baseline intact 
participants’ ASL data. This allowed a hypothetical healthy control group at baseline to be 
compared to PC patients. The basis of the concept came from past research showing that 
cerebral perfusion acquired with ASL was stable in healthy ageing older participants over a 
period of one year (Parkes et al., 2004). Moreover, only eight healthy controls’ data could be 
compared between time points. Therefore, findings should be interpreted with caution due to 
a lack of power in the paired sample analysis. 
A fundamental restriction of ASL is that the signal obtained from ASL is highly sensitive to 
noise and is dominated by thermal and physiological artefacts. Low SNR has been attributed 
to occur due to the relatively low ratio of blood (2%) to tissue ratio in the cerebral cortex and 
rapid decay rate of labelled bolus during transit time. This makes it difficult to employ ASL 
but can be improved by using background suppression techniques which implement multiple 
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inversion techniques to acquire a higher SNR (Ghariq, Chappell, Schmid, Teeuwisse, & van 
Osch, 2014). However, due to the above limitations of ASL, outcomes and reliability 
estimates from the currently conducted study may have been affected (Liu & Brown, 2007).  
 
5.5 Future Directions 
The optimal way in which to understand the cause of cognitive decline in ADT patients 
would be to recommend a longitudinal study. Patients should be assessed longitudinally 
before baseline close to the diagnosis phase to the time approaching therapy, during therapy 
and post ADT. This may allow researchers to observe changes present before therapy and 
their aetiology from the diagnosis phase to impending therapy, during therapy and after 
therapy. Physicians may thereby be able to make better judgements of whether ADT is the 
factor causing cognitive impairment or other co morbid factors (Caruana, Roman, 
Hernández-Sánchez, & Solli, 2015). Moreover, they can devise treatment methodologies to 
prevent adverse effects before therapy and during ADT to allow patients a better chance at 
continuing treatment. An analogous methodology was implemented by Cherrier et al. (2009) 
to reduce practice effects before baseline. However, researchers could utilise this 
methodology with a comprehensive battery of neuropsychological assessments and 
neuroimaging measures to identify factors affecting cognition before ADT commencement. 
Power of longitudinal assessments have been found to be higher due to within subject 
comparisons which allow smaller differences to be detected between time periods and groups 
(Caruana et al., 2015). Although the current study was designed to achieve this, it was not 
feasible in the timeframe of candidature to complete this. Ongoing data collection will 
provide an opportunity to expand and extend the current novel framework and provide 
evidence-based data for clinical decision making. A strength of the present study was that age 
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and intelligence of the healthy sample was controlled for which improved upon some past 
research (Green et al., 2002; Green et al., 2004). However, there are other factors that could 
be assessed in future research. These includes for example the exploration of genetic markers 
such as APoE4 and IGF that were collected in the present undertaking but not processed due 
to the time span of the project. These variables are important in the assessment of cognition 
in PC patients as they have been shown to be more preventative in this sample compared to 
normal ageing samples (Ballentine Carter, 2012). A shortcoming which was not listed but 
may benefit from future research is that while behavioural and neuroimaging approaches 
incorporated in the current assessment have their individual strengths, their complementary 
value in comparison to each other was not utilised. A combined and comparative analysis 
methodology is recommended during further research especially in longitudinal studies, as it 
could provide a more complete understanding of cognition and underlying pathways in 
relation to the aetiology of any deficits found.  
 
As outlined in the previous section, corruption of neuroimaging data impeded data analysis. 
In future, additional participants should be recruited to address and account for scanner data 
corruption or participant attrition rates during longitudinal follow-up. This was a shortcoming 
in the assessment of healthy controls in the current study with ASL which should be rectified 
by additional recruitment. A further limitation may be addressed by the inclusion of a 
comparison group of PC patients that are not undergoing ADT. This group may be more 
appropriate as it allows experimenters the ability to match groups more closely on factors 
including body fat index, physical functioning, medication regimes and genetic factors 
(Alibhai et al., 2010; Clay et al., 2007). This may elucidate the effect of solely ADT without 
the presence of confounding or comorbid factors.  
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Recent advances in MRI acquisition of perfusion include the simultaneous combined 
acquisition of PCASL and the BOLD signal. This is advantageous because unlike PASL 
alone, which was implemented in the study conducted, it has better SNR. A recent technique 
to combine both ASL and BOLD techniques used a pseudo continuous ASL (PCASL) 
sequence that could be implemented by future researchers to increase SNR (Fernandez-Seara, 
Rodgers, Englund, & Wehrli, 2016). A dual acquisition ASL sequence was employed with 
background suppression and 3D gradient and spin echo (GRASE) readout while BOLD was 
acquired with 2D multi slice echo planar imaging (EPI). This was carried out during a visual 
stimulation (motor) task in 10 healthy participants (mean age=23.3, SD=4.8). The dual 
acquisition (DA) sequence was compared to a PCASL dual echo EPI (DE-EPI) ASL 
acquisition sequence during the same task. A further experiment was implemented in five 
healthy participants to assess the potential of the DA sequence to measure maximum (M) 
mapping which is the maximum possible cerebral metabolic rate of oxygen (CMRO2). This 
was measured with a gas breathing challenge (hypercapnia and CO2 gas delivery) and 
acquired using DA. Results showed that the dual ASL and BOLD acquisition had a temporal 
SNR (tSNR) that was three time higher in the ASL sequence compared to the DE-EPI 
sequence. Furthermore, the BOLD tSNR obtained in the DA sequence was comparable to 
that of the BOLD signal obtained during the DE-EPI sequence but was slightly lower than the 
DE-EPI sequence. Nevertheless, this was not significant and was attributed to longer TRs 
during the DA sequence. The DA sequence M-mapping gas breathing acquisition during the 
motor task showed BOLD signal changes in bilateral motor cortices and gray to white matter 
contrasts analogous to past research (Fernandez-Seara et al., 2016). This suggests the DA 
sequence was better at detecting ASL and BOLD simultaneously allowing better calibrated 
images with higher tSNR compared to past techniques employing DE-EPI. Moreover, the DA 
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sequence allows better estimations of M-mapping during functional sequences due to better 
ASL tSNR acquired. One limitation was that long TRs during the DA sequence reduced the 
BOLD signal. Moreover, sample sizes were small but the study does validate that the DA 
sequence can improve tSNR in future assessments during functional MRI paradigms 
compared to techniques implemented in the past. 
The current study has important implications for care of men who choose to have ADT and 
require rehabilitation after diagnosis, before therapy and during therapy. Significant effort has 
been directed towards developing strategies that ameliorate the negative cognitive effects of 
ADT. Some approaches that have been implemented in past research include exercise, 
improving family cohesion and dietary care. Exercise has been shown to be effective in 
managing the cognitive effects of ADT and could improve patient quality of life. One study 
assessed quality of life and general health in 29 patients (mean age=69.5, SD=7.3) 
undergoing ADT that were assigned to an exercise regimen program for 12 weeks (Galvão, 
Taaffe, Spry, Joseph, & Newton, 2010). Patients reported better quality of life, decreased 
fatigue and had reductions in levels of C-reactive protein which is a marker for cancer and 
inflammation compared to 28 ADT patients that were not administered exercise therapy 
(mean age=70, SD=7.3). The brief period of exercise demonstrated its benefits on biological 
factors through a non-medicated medium. A limitation in view of the current study was that 
exercise therapy was commenced while participants were two months into ADT. This is 
promising as benefits of exercise were still evident, however, the effectiveness of exercise 
has not been explored before treatment. Nevertheless, a further group of researchers showed 
the effectiveness of a three month exercise program in ADT patients (mean age=69.6, 
SD=6.5) when the program was initiated earlier into ADT treatment (10 days) (Cormie et al., 
2015). Findings revealed that patients had lower levels of fat, less total cholesterol, higher 
muscular strength and reported better sexual function, less fatigue, better mental health and 
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decreased psychosocial distress compared to ADT patients that were not administered an 
exercise program (Cormie et al., 2015). This supports that exercise was beneficial in 
improving physical and mental aspects of life in patients during the initial period of 
treatment. Moreover, the exercise intervention was implemented at a period when adverse 
effects of ADT such as the initial flare effect is known to be fatal and can also be distressing 
and uncomfortable for patients (Sountoulides & Rountos, 2013). Next steps should be to 
assess exercise in PC patients before undergoing ADT in relation to cognition during therapy. 
This has not been explored but past research shows favourable effects of exercise in healthy 
ageing participants that could be applied to patients (Colcombe & Kramer, 2003; Erickson et 
al., 2011; Hamer & Chida, 2008).  
Another approach to tackle adverse effects before ADT may include working with the patient 
in the context of their family. Researchers have found that communication within the family 
of patients with cancer may affect patient recovery and treatment coping ability. Stressful 
events such as the diagnosis of cancer can trigger clinical levels of depression not only in 
patients but also in family relatives and partners. One study assessed the relatives (mean 
age=44.17, SD=18.87) of 48 patients (mean age=54.60, SD=15.87) diagnosed with 
colorectal, breast or prostate cancer (Edwards & Clarke, 2004). Patients and relatives were 
administered measures of anxiety, depression, illness concerns, physical functioning and 
family functioning. Outcomes showed that 12.8% of patients and relatives had clinical levels 
of depression. Moreover, 20.8% of relatives were shown to have risks of developing 
clinically diagnosable depression. Multi-level modelling revealed a relationship between 
communication within the family and psychosocial dysfunction, with unclear communication 
being associated with higher anxiety and depression levels. Furthermore, there was a 
significant interaction between patient with prostate cancer levels of anxiety and family 
communication. Intraclass correlations also found that 21 percent of variance from depression 
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and 15 percent of variance from anxiety came from family membership and support 
(Edwards & Clarke, 2004). This indicates that the capability of the family to act openly to 
express feelings directly correlated with lower levels of depression and anxiety. A limitation 
of the study was that it was cross sectional and did not measure whether family functioning 
affected depression and anxiety levels during and after the main treatment period. This is 
important because while many patients assessed in the study conducted did not have a clinical 
diagnosis of anxiety or depression at baseline, these factors may develop during treatment or 
after treatment especially in those patients with borderline mood disorders before impending 
therapy. Therefore, interventions to increase family cohesiveness could be implemented but 
require longitudinal follow-up to assess their efficacy during and after therapy in controlling 
mood impairments. 
In conclusion the current study conducted used neuropsychological and neuroimaging 
measures in the domains of executive function and spatial reasoning to assess PC patients 
before they underwent ADT. Findings showed mostly comparable levels of cognition and 
underlying neural architecture compared to healthy controls in these domains. However, 
some differences were evident in patients that may have been facilitated by higher 
testosterone levels to compensate for disease specific cognitive impairments and deficits in 
cerebral function even before ADT. This has implications on strategies that are devised and 
implemented by physicians to resolve side effects prior to therapy so that behavioural 
cognitive impairments are not intensified during ADT. Moreover, outcomes have 
consequences on patient therapy uptake and maintenance. The second part of this research 
assessed healthy controls longitudinally. Controls did not have any signs of cognitive or 
neural impairment in the domains of executive function and spatial reasoning across a 
longitudinal period. This demonstrated that the healthy control group was a valid comparison 
sample to patients. Furthermore, the study of healthy controls showed that the cohort had 
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reliable cognitive performance and activation across time points. This suggests that controls 
could be implemented in a longitudinal study in which patients are compared to controls. 
This forms the basis of future research to uncover and treat adverse effects associated with 
ADT in PC patients. 
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Appendices: 
Appendix 1: BUIC Screening form 
MRI SAFETY SCREENING QUESTIONNAIRE 
EVERYONE must fill out this form BEFORE entering the MRI suite. The 
MRI suite has a very powerful magnetic field that may be hazardous to 
those with metallic, electronic, magnetic or mechanical implants or 
devices. All information will be kept strictly confidential. 
Name:  Date of Birth:  
Email:  Tel No:  
 
Section A – To be completed by EVERYONE entering the MRI suite 
Please indicate if you have any of the following: YES NO If yes please explain 
Cardiac Pacemaker, pacing wires or defibrillator    
Aneurysm clip (metal clips put around blood vessels during surgery)    
Electrical Stimulator for nerves, bone or brain    
Ear or Eye implants (e.g. cochlear implants)    
Implanted insulin, drug or infusion pump    
Stent, catheter, coil or filter in any blood vessel    
Orthopaedic hardware (e.g. artificial joints, metal plates, 
screws) 
   
Any other type of prosthesis or implant    
Gun pellets, shrapnel, bullets or metal fragments    
Any surgery or an operation    
 
Section B – Complete ONLY if you are being scanned or intend to go inside the scanner room 
Please answer the following questions carefully YES NO Staff Notes 
Have you had an MRI scan before?    
Are you claustrophobic?    
Have you ever been a welder, machinist, grinder or worked 
with 
metal without eye protection? 
   
Do you suffer from any medical condition that may be 
relevant 
(e.g. epilepsy, diabetes, asthma)? 
   
Do you have any tattoos or body piercings (other than 
earrings)? 
   
Do you wear dentures, a dental plate or a brace (not 
fillings)? 
   
Do you have any transdermal skin patches (e.g. nicotine 
patch)? 
   
(Females only) Are you or could you be pregnant?    
Please state your weight (kg)   
Other information (e.g. spectacle prescription)  
 
Please tick the boxes before being scanned or going inside the scanner room 
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I confirm that the above information is accurate to the best of my knowledge. 
I will remove all metal including mobile phones, keys, watches, coins, credit cards, body piercings, 
jewellery, false teeth, hearing aids etc. before entering the scanner room. (Lockers available in waiting 
room.) 
I acknowledge that BUIC has taken reasonable precautions to screen for potential difficulties and is not 
liable for any event that might result from incorrect answers to the above. 
 
 
Signed: 
 
 
Date: 
 
 
Form verified by (*Authorised Personnel only*): 
Print 
Name: 
 
 
Signed: 
 
 
Date: 
 
Staff Note: This form is only valid for six months from date of initial screening                                                                                                             v4.0 July 2010 
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Patients assessment approval 
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From: Susan Cottam  
Subject: Application to use Programme of Work ERN_11-0429AP26  
Date: 05 December 2015 5:22:03 PM GMT  
To: Amanda Wood, Elizabeth Grunfeld Cc: Paras Joshee  
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Appendix 3 Neuropsychology measures 
Mini-Mental State Exam - II (MMSE-II) – Standard Version (Folstein et al., 1975). 
The test is known to purely assess multiple cognitive domains and thereby allows the detection of 
surface abnormalities in cognitive domains in a quick and easy manner. The 2nd edition was 
incorporated into the assessment which has been enhanced by past researchers to improve its clinical 
utility and standardization. The blue form version was employed since it was administered once only 
as a screening tool, therefore learning effects were minimised. The MMSE-II was implemented as a 
screening test in the current study to exclude participants with dementia or Alzheimer’s like 
symptoms.  One study assessing validity and reliability showed that the MMSE –standard version had 
high internal consistency, test-retest reliability, interrater reliability and good concurrent validity for 
detection of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) (Baek, Kim, Park, & 
Kim, 2016). However, researchers found decreased sensitivity of the test to detect MCI among a 
normal aging population (Baek et al., 2016). Nevertheless, it was sensitive in detecting Alzheimer’s in 
the normal aging population (Baek et al., 2016). Moreover, a number of studies among various 
samples and languages show satisfactory and respectable reliability and validity among aging 
populations (Awan et al., 2015; Boban et al., 2012; Keskinoglu et al., 2009). This was moreover 
found in the clinical differentiation of mild cognitive impairment, dementia or Alzheimer’s disease 
(Awan et al., 2015; Boban et al., 2012; Keskinoglu et al., 2009).  The cut-off score for the MMSE was 
kept at 24 and any participants scoring below this range were excluded from the study. The cut-off 
was selected based on the MMSE manual showing that scores of less than 24 were considered as 
abnormal and indicative of participants having dementia (Folstein, Folstein, & McHugh, 1975). 
Wechsler Abbreviated Scale of Intelligence (WASI-II) (Wechsler, 2011). 
Participants were assessed on the block design test; vocabulary test, matrix reasoning test and 
similarities sub-test. Each sub-test is unique and encompasses verbal comprehension and perceptual 
reasoning abilities to calculate a full-scale IQ score. The test was used to rapidly, efficiently and 
thoroughly measure IQ. Intelligence scores were obtained to screen and exclude participants with 
scores significantly below standardised norms as low scores. This is because low IQ scores indicate 
that performance on further measures may be compromised which could inflate sampling error. The 
WASI full scale intelligence quotient 4 (FSIQ-4) was the primary measure used in the current study 
and has a mean of 100 with SD of 15. Any participants with FSIQ-4 scores lower than 85 were 
excluded from further analyses as this indicated borderline of below average intelligence levels. 
Sub-tests 
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Block design test: Evaluated the combination of visual stimuli, fluid intelligence, organisation and 
visuo-motor speed. Different start points were provided for adults. Participants were given an initial 
model with examples provided by the examiner on the first two items. They were subsequently 
instructed to make the design themselves on further items. Each item had a time limit and participants 
were awarded bonus points for successful re-construction of designs the quicker they were made. The 
subtest was discontinued after two repeated failures. 
Vocabulary: Examined word definitions, word knowledge, crystalized intelligence and language 
development. Participants were asked to define a word presented to them. The manual outlined 
scoring criteria for the assessments ranging from 0 to 2 points per word definition. The test was 
discontinued after three repeated scores of 0. 
Matrix Reasoning: Assessed concepts of visual intelligence, fluid intelligence, spatial reasoning and 
spatial organisation. Subjects were required to choose one item from five which fit within a square 
matrix to complete a pattern. Each item received a score of 0 or 1. The test was discontinued after 
three consecutive errors. 
Similarities: Measured the ability of verbal theory formation, crystallised intelligence, abstract 
cognition and categorical thinking. Participants were asked to verbally describe a common feature 
between two words or concepts presented orally by the examiner. Participants were given points of 
either zero, one or two based on criteria in the WASI manual. The sub-test was discontinued after 
three consecutive scores of zero. 
Reverse rules and prompts: The test was employed to thoroughly assess intelligence. Moreover, the 
WASI has a set of reverse rules on each subtest. Reverse rule items were only administered if 
participants made an error on the first two items of each sub-test, in which case the examiner must 
administer items in reverse until two consecutive correct scores were obtained. Reverse items were 
generally easier than actual items on sub-tests and facilitated in reinforcing the criteria of the task. If 
two consecutive correct scores were not obtained in reverse, then the test was discontinued as this 
indicated that participants were not likely able to perform remaining items on the task. Prompts were 
given only on the vocabulary and similarities subtest on either zero or one point items and were 
indicated in the WASI manual sub-test sections. 
        
Reliability has been on the WASI-II with internal consistency coefficients per age group calculated 
through transformation of fishers-Z scores (Wechsler, 2011). Reliability coefficients obtained for 
adult samples between the ages of 55-84 were generally high and ranged from 0.87 - 0.94 for the 
block design task, 0.90 – 0.95 for the vocabulary task, 0.90-0.91 for the matrix reasoning task and 
0.90-0.93 for the similarities sub-test. Composites of these sub-tests show reliabilities ranging from 
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0.95-0.96 on the verbal comprehension index (VCI), 0.93-0.95 on the percentile rising index (PRI) 
composite score, 0.96-0.97 on the full scale IQ – 4 (FSIQ-4) and 0.94-0.95 on the full scale IQ – 2 
(FSIQ-2) composite score. Test retest reliability has been measured by testing a group of participants 
twice between 12 and 88 days. Outcomes reveal adequate test–retest reliability coefficients in adults 
between the ages of 55-90. Coefficients range from 0.83 – 0.96 across subtests and composite 
calculated scores. Inter-scorer agreements were also high and ranged between 0.98-0.99 and were 
calculated using intra-class correlation coefficients (Wechsler, 2011).  
Validity has been assessed through content scores (content validity) and construct validity (Wechsler, 
2011). Content validity was found to be strong when internal structures of the test were examined. 
Confirmatory factor analysis showed that subtests relating to PRI and VCI measured separate 
constructs of verbal comprehension and perceptual reasoning abilities. Confirmatory factor analysis 
also demonstrated that there were latent variables which highly correlated with g-factor intelligence or 
general intelligence. This is advantageous because the test shows validity in being able to measure 
intelligence. However, caution must be applied for interpretation of scores outside of the FSIQ. 
Intercorrelations of sub-test scores were generally modest and ranged between 0.40-0.70 in adult 
samples. This suggests that some aspects of cognition overlapped on sub-tests and that performance 
on one measure informed performance on other measures. Correlations with analogues intelligence 
measures (WISC-IV/WAIS-IV) have been found to be acceptable and in the range of 0.71-0.92.  
 
Delis Kaplan Executive Function System (D-KEFS) test (Delis et al., 2001a). 
The D-KEFS is a set of standardised assessments used to measure higher level cognitive functions 
referred to as executive functions. This draws on a myriad of cognitive skills such as attention, 
language, memory etc. to produce higher order levels of abstract thought and creativity. The D-KEFS 
is comprised of nine subtests which can be administered as either stand-alone assessments or as part 
of a whole assessment depending on the needs of the examiner or researcher. The test is known for 
measuring mild brain damage in especially frontal lobe areas. The test is able to empirically measure 
executive functions and fundamental skills required to achieve higher order abilities. This is because 
the scale of difficulty on each subtest is incremental and assesses basic cognitive abilities initially 
including for example language, attention, memory etc. and then moves onto items of higher 
difficulty, allowing the isolation of any deficits present on earlier task items. Furthermore, the test has 
high ceiling and floor benchmarks. This allows all relevant scores to be obtained regardless of an 
individual’s ability on each test. 
Characteristics of sub tests included 
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D-KEFS Trail making test: Consisted of a visual scanning task and four dot connection tasks. The 
primary task was a letter and number switching task. This allowed the assessment of flexibility of 
switching on a spatial motor task. The other sub components permitted examination of the 
components required to complete the primary task including visual scanning, number sequencing, 
letter sequencing and motor speed.  
D-KEFS verbal fluency test: Measured the ability to generate words from overlearned concepts in a 
phonemic manner whilst also requiring switching and set-shifting between category fluency elements.   
D-KEFS Design Fluency test: Assessed non-verbal ability and required that subjects draw as many 
different designs in 60 seconds as possible. The first condition was basic requiring simple design 
generation. Condition two required inhibition whilst also measuring design generation fluency. The 
final condition assessed fluency and shifting or switching ability which gauged visual attention, motor 
speed, perception and design construction skills. Executive functions recruited on the task included 
visual construction generation, creativity and inhibition.  
D-KEFS Colour word interference test: Evaluated inhibition of overlearned concepts of words read 
and colours named. Inhibition was necessary on condition three which was the primary test and 
required conflicting responses of naming discordant ink colours to the words that were written. 
Furthermore, if participants were successful, the last condition required switching between inhibition 
and flexibility on read words. The task was analogous to the design by stroop (Stroop, 1935) with the 
added element of cognitive flexibility on the final task.  
D-KEFS Tower test: Several executive functions including problem solving, spatial planning, rule 
learning, inhibition of impulsive responses, and rule maintenance were assessed from the task. Visual 
attention and visual-spatial skills were also measured on the task. 
Scoring of all tasks were standardised so that raw scores were converted to age group scaled scores 
that had a mean of 10 and standard deviation of three. Scores on some tasks were also combined and 
contrasted to reflect cognitive function on a particular domain. Primary contrast scaled scores were 
used in the current experiment providing global scores for typifying overall performance on a task 
domain. Moreover, the contrast scaled score was calculated as primary assessment score controlled 
for performance on basic performance. Scaled scores provided classification of contrast scores in age 
normative ranges.  
Validity of the D-KEFS has been cited in the D-KEFS manual (Delis, Kaplan, & Kramer, 2001b). 
Accuracy and error measurement intercorrelations of scaled scores have generally shown they are 
positive indicating that good performance on one variable is associated with good performance on the 
other variable. Correlations measured between primary scaled scores show low positive relationships 
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between tests. This suggests that the tests are related to each other but that they measure a unique 
aspect of executive function with only slight overlap.  
Reliability measurements of D-KEFS subtests indicate mid to good reliability estimates. The technical 
manual differentiates standard error of measurements expressed as standard deviation units and 
indicates the amount of measurement error observed in an individual’s test score (Delis et al., 2001b). 
An inverse relationship has been found between the reliability coefficient and standard error of 
measurement illustrating that as reliability increases, measurement error decreases. Test-retest 
reliabilities are grouped by all ages since sample sizes were small when assessed per age group. This 
creates high variability in coefficients. Test-retest coefficients by subtest are as follows: Coefficients 
for the trailing making test were shown to be in the range of 0.38 - 0.77 with the primary measure 
being the time to completion. Verbal fluency coefficients range from 0.36 - 0.80. Design fluency 
scores range from 0.32 - 0.58. Colour word interference coefficients range from 0.62 – 0.76. 
Coefficients for the tower test were 0.44. Overall coefficient values indicate mid to good reliability on 
sub-tests with higher reliability on initial assessments with less reliability on primary measures. 
Wechsler Adult Intelligence scale (WAIS-IV) (Wechsler, 2009). 
Subtests of the WAIS sub-tests selected were associated with working memory. 
Sub tests included: 
Digit span task: The task is composed of three assessments. One in which digits were said and 
immediately recalled by participants. The next task required the researcher to say digits which were 
then recalled backwards by subjects. The final task required participant to recall digits in sequential 
order from lowest to highest after researchers said them. This allowed isolation of simple memory 
recall and more complex working memory associated domain performance that required frontal brain 
regions. 
Arithmetic: Items on the test ranged from requiring simple mental arithmetic to more complex 
arithmetic that necessitated attention, memory and manipulation of already mentally held information. 
The WAIS has high internal consistency and when assessed over a twelve week time period, test 
retest reliability ranges from 0.70 to 0.90 in participants aged 60 – 80.  Inter scorer coefficients have 
been reported as being 0.90 which is considered very high, indicating that scorers generally agreed on 
scoring criteria.  
Content validity has been assessed through confirmatory factor analysis revealing moderate 
relationships between the digit span task and arithmetic task in measuring working memory 
constructs. Relationships of tasks to working memory were revealed as being slightly weaker in those 
aged 70-90 compared to those aged 16-69 in which higher correlation relationships were shown. 
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Intercorrelations of the WMI were 0.60 for the digit span and arithmetic tests suggesting that 
performance on one test informs performance on the other sub-test. Moreover, the working memory 
has been found to correlate with the nine sub-tests of the D-KEFS moderately (0.37-0.63). This is 
expected since executive function has been theorised to be part of the working memory system 
(Baddeley & Della Sala, 1996).  
The WAIS working memory index composite score has a resultant mean score of 100 with SD of 15 
 
Cambridge Neurological test Automated Battery (CANTAB) (Cambridge Cognition, 2006) 
The Spatial Working memory task (SWM) sub-test was employed to assess spatial reasoning skills by 
assessing the ability to retain spatial information for later manipulation in working memory. The task 
was also used to measure heuristic planning and strategy and has been known to be sensitive to 
measures of executive functions.  
The task requires a process of elimination strategy where participants were asked to find a blue token 
in a number of boxes and then place the token into an empty column on the right hand side of the 
screen. The token was never in a box that already contained a token. There were as many tokens to 
find as there were boxes on the screen which increased with trial successions. Location of tokens, 
number of boxes and colour of boxes were changed on each trial to avoid generalised search 
strategies. 
The version used to assess participants consisted of a practice phase of four three box sets and then six 
assessments of two each of four boxes, six boxes and eight boxes (3x3 boxes practice) + (2x4) + (2x6) 
+ (2x8). 
Outcomes from the task were number of errors made which could be divided into two sub outcome 
measures. 
Between errors: This was the number of times a box was revisited after a token was already found. 
Therefore, a lower number indicated less errors made. 
Double errors: These were the times categorised when participants revisited a box with a token 
already found and the time when a box was revisited that was empty during the same search to find a 
token. 
Total errors: this was the number of total combined errors made therefore lower scores indicated 
better performance. 
Another outcome measure implemented was strategy. Authors have recommended an efficient search 
strategy for completing the task (Owen, Downes, Sahakian, Polkey, & Robbins, 1990). Based on this 
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method the most proficient method has been suggested to start at a specific box then once a blue token 
has been found, to return to the starting box and continue with a new search from there. An estimate 
of strategy was acquired when the participant began a new search strategy with a different box. This 
was only however measured in the six and eight box condition (Cambridge Cognition, 2006).  
Validity of the CANTAB has been evidenced in studies of correlations between subtests of executive 
functioning and spatial reasoning (Kim, An, Kwon, & Shin, 2014; Torgersen, Flaatten, Engelsen, & 
Gramstad, 2012). Validity of the test has also been investigated in healthy participants showing 
moderate to high correlations with traditional cognitive assessments of WAIS, Controlled Oral Word 
Association Test, Animal Naming test, Trail Making Tests A and B, Stroop test and Green Story 
Recall test (Smith, Need, Cirulli, Chiba-Falek, & Attix, 2013). The CANTAB is advantageous due its 
ease in computerised administration and logging of outcome measures can be programmed through 
the software. This saves time and reduced experimenter errors. 
The resultant score on the number of errors made in the between errors condition and number of 
double errors made in the four, six and eight box conditions were converted to z-scores. The normal 
distribution falls between +1.96 and -1.96 SD of the mean.   
Psychosocial measures 
 
Behaviour Rating Inventory of Executive Function – Adult version (BRIEF-A) Self report 
(Gioia et al., 2000). 
The behaviour rating inventory is a meta-cognitive psychosocial questionnaire assessing clinical 
cognitive constructs relating to executive function. Executive function components assessed from the 
BRIEF-A included inhibition, attentional shift, emotional control, self-monitoring, initiation of tasks, 
working memory, planning and organisation, task monitor and organisation of materials. Cognitive 
domains were then grouped into sub-indexes comprising of the sub-tests aforementioned. The 
behavioural regulation index (BRI) was the first index acquired which represented the ability to 
regulate control of emotional responses. It was composed of inhibition, shift, emotional control and 
self-monitoring scale. The next index was the metacognitive index (MI) which represented problem 
solving ability, planning, organisation and working memory. Finally, a global executive composite 
(GEC) was acquired as a summary score measuring all scales. This is a summary score that 
represented all clinical scales. Furthermore, inconsistency scores and negativity scores have been 
implemented into the questionnaire to measure negative emotions associated with participants' meta-
cognition and inconsistency throughout the questionnaire. This was measured to assistant in assessing 
if the questionnaire was filled in, in haste or in a systematic pattern. Inconsistency and negativity 
scores can also be used as a means to measure validity of questionnaires. Outcome measures were raw 
scores that were converted to T-scores and have a mean of 50 and SD of 10. 
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Three measures of reliability have been made on the BRIEF-A. The BRIEF-A manual shows that 
internal consistency of the BRIEF-A is moderate to high with alpha coefficients of 0.80-0.94 (Gioia et 
al., 2000). The GEC index has been shown to have coefficients of between 0.93-0.96 in mixed 
clinical/healthy samples.  This reflects that items were measuring the same underlying construct of 
meta-cognitive executive function abilities. Test-retest reliability correlations of self-report measures 
were found to range between 0.82-0.94 on clinical scales and 0.93-0.96 on the GEC over an average 
of 4 weeks (Gioia et al., 2000).  
Content validity has been measured through agreement by experienced neuropsychologists on BRIEF-
A constructs. Average agreement across items ranged from 35%-98%. Low agreement was evidenced 
due to the removal of the task completion scale which was moved to another domain as it fit better 
statistically. Construct and discriminant validity has been assessed through correlations with other 
similar measures of meta-cognition and psychosocial function. Moderate correlations have were 
found with measures of anxiety and depression which may be explained by previous literature 
reporting depressive-executive dysfunction syndrome and anxiety induced executive function 
impairments. Exploratory factor analysis has been implemented by researchers to assess validity 
based on the internal structure of the BRIEF-A. A two factor model was revealed as being most 
suitable with each factor consisting meta-cognition and emotional control. Meta-cognition was 
comprised of sub domains of planning and organisation, initiation of tasks, working memory and task 
monitor. The second factor comprised of inhibition, shifting and self-monitoring. Factors were 
strongly correlated with each other. These variables remained constant in young and older adult 
cohorts (50-89 years) and in males and females (Gioia et al., 2000).  
Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983) 
The HADS is a self-rating instrument that was used to detect the presence of depression and anxiety 
present mentally or somatically (Zigmond & Snaith, 1983). It focuses on non-physical symptoms so 
that it can be used to diagnose depression in subjects with significant physical ill-health such as 
cancer or specific diseases. Validity has been assessed with large cohort samples using exploratory 
factor analysis. Researchers have shown that a two factor model best explains variance on the scale 
with factors being depression and anxiety accounting for 57% of variance. Moreover, high test-retest 
intra-class correlations have been reported with values of 0.944 (Michopoulos et al., 2008). Items on 
the HADS were scored from 0-3 with a maximum potential score of 21 on anxiety and depression 
measures. Cut-off scores were defined as being 0-7 = normal; 8-10 = borderline and 11-21 = 
abnormal on either anxiety or depression parts of the questionnaire. The range of scores obtained in 
the current sample was from 0-13 on the anxiety part of the questionnaire and 0-9 on the depression 
part of the questionnaire.
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Appendix 4: Participant Information Sheet 
Participant Information Sheet 
 
Study title: Modelling risk and resilience factors associated with cognitive changes following testosterone 
depletion in older men. 
 
We would like to invite you to take part in our research study. Before you decide we would like you to understand 
why the research is being done and what it would involve for you.  
 
One of our team will contact you at a later date to go through the information sheet with you and answer any 
questions you have. 
 
Thank you for taking the time to read the information sheet. The sheet is 9 pages long. Please make sure you have 
read all 9 pages.  
 
 
If you require any help with the information sheet please call  
 
 
Please read this information sheet carefully. 
 
 
What is an information sheet? 
 
The information sheet explains to you clearly and openly all the steps and procedures of the study. The information 
is to help you to decide whether or not you would like to take part in the research. 
 
 
What is this research study about? 
 
This study aims to understand whether undergoing androgen deprivation therapy affects cognition in patients with 
prostate cancer. We are interested in men who have prostate cancer compared to healthy participants who do not 
have such a condition and who are not undergoing androgen deprivation therapy. We wish to assess this from both 
a behavioural perspective, brain imaging perspective and from a quality of life perspective. 
 
Currently, we know very little about the cognitive effects of androgen deprivation therapy in prostate cancer 
patients. However, researchers who have looked at cognitive effects have found inconsistent findings which are 
contradictory and limited. Only three studies in the past have examined androgen deprivation therapy and cognitive 
side effects using brain imaging. This study will use a number of cognitive tests and brain imaging tests together in 
order to find a consistent pattern of findings between one time point and a follow up study of six and 18 months. 
This will in turn benefit future prostate cancer patients to retain as much cognitive functioning as possible and to 
have a higher quality of life.  
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Why have I been invited to take part? 
 
 You have been invited to take part because you are a healthy male who does not have prostate cancer or 
any other serious medical or neurological condition. 
 You are male and are between the ages of 50 - 80. 
 You have not received androgen deprivation therapy in the past. 
 You do not have any signs of epilepsy, history of stroke, or neurodegenerative conditions. 
 You speak and write English.  
 
A total of 100 men will take part in this study. Fifty will be patients just about to have androgen deprivation therapy 
and another 50 healthy men will not have had prostate cancer or are not undergoing androgen deprivation therapy.  
 
 
Can everyone take part in this study? 
 
If you are in one of the above groups, you can take part in this study.  
 
When the researcher telephones you, they will ensure that you are able to take part in the project. They will explain 
the study in more detail and you will be able to ask any questions.  
  
 
Do I have to take part in this study? 
 
No. Participation in this research project is voluntary. It is up to you to decide if you would like to take part in this 
study.  
 
If you do decide to take part in this study, we will ask you to sign a consent form.  
 
If you agree to take part in the study, but then change your mind, you can leave the study without giving any reason. 
You can withdraw yourself from the project at any time without any explanation. 
 
What will happen to me if I decide to take part? 
 
If you decide to take part, an appointment will be arranged at a time most convenient for you. Appointments will 
take place at the University of Birmingham.  
  
In your appointment at the University of Birmingham, a researcher will go through this information sheet with you 
again. You will have the opportunity to ask any questions you may have. If you decide to take part, you will be 
asked to sign a consent form.  
 
If you are happy with the procedure and have signed the consent form, you will be asked to complete a number of 
tasks in a screening phase. These should take no longer than 50 minutes. If you score below average on any of 
these tests, then a letter will be sent to your general practitioner (GP) and you may be excluded from the study. 
You will be given medical supervision from the GP and will not have to continue in the study. If you are eligible 
to continue further in the study then you will have a blood and saliva swab test. This will be taken in order to 
measure your testosterone levels and for detection of certain genetic strains. The genes include: Apolipoprotein 
E4 (ApoE4), catechol-O-methyltransferase (COMT), dopamine active transporter (DAT1), brain derived 
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neutrophic factor (BDNF), monoamine oxidase (MAO-A), ER-alpha (estrogen receptor-alpha), ER-beta, AR 
(androgen receptor), Aromatase gene (CYP19), GNB3 single-nucleotide polymorphism rs1047776. Information 
on yours or other individuals’ genetic information will not be revealed to you during or after the study has been 
completed. Blood samples will be processed at the University of Birmingham. Saliva samples will be transported to 
Coventry University within 7 days for processing. 
   
You will also be given a number of questionnaires about your general mood and quality of life.  If you have any 
problems completing the questionnaires, a researcher will be able to help you. On average the questionnaires should 
take one hour to complete.  
 
You will then be asked to complete a number of paper based thinking skill tasks (cognitive tasks) (2 hours 10 
minutes). Regular breaks between tasks will be taken to ensure you do not get tired. Altogether the appointment 
should last about 4.5 hours. If you become tired during the appointment, we will be happy for you to return on 
another day when it is convenient for you. You may be asked to complete tasks in a non-invasive brain imaging 
machine called a functional magnetic resonance imaging scanner. This will take approximately 1 hour. However, 
this is optional and a separate session and appointment time will be arranged for this. If you do decide to participate 
then you will be rewarded for your participation as detailed below.  
 
Your answers are entirely confidential and will not be disclosed to anyone outside the research team, but your GP 
may be forwarded your scores for your wellbeing and optimal treatment.  
 
At the end of each visit you will receive £30 for your participation  
 
Please see diagram 1 on the next page which shows the study procedure.  
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Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Will you access my medical records? 
 We will keep your contact details for 18 months and will contact you to invite you to take part in a 
follow-up study at 6 months and 18 months.  
 We will send you the group results once the study has finished. 
After the appointment 
At the end of the appointment any travel 
costs will be reimbursed. You will also 
receive a money reward for your 
participation. 
You complete a number of screening tasks 
(50 minutes).  
You complete a questionnaire on your 
general mood and quality of life (1 hr)  
You take part in a number of thinking 
tasks composed of neuropsychological 
tests (1hr 50mins) 
If you want to take part, you sign a 
consent form.  
Appointment arranged at the University of Birmingham after you contact researcher and 
are eligible for the study. You must give pre consent for researchers to contact you.  
Researcher goes through this information 
sheet with you again.  
At the appointment 
You may be asked to take part 
in a separate set of brain 
imaging tasks (1 hour). 
However this is optional and 
will be arranged at a separate 
time 
If you are eligible we will 
take a blood and saliva 
swab test.  
Blood samples will be 
processed at the 
University of Birmingham. 
Saliva samples will be 
transported to Coventry 
University for processing. 
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We would like to access your medical records in order to obtain information on your health status and previous 
medical history.  
 
We will access your medical records only if you provide additional consent to this. If you are happy for us to access 
your medical records, you will be asked to indicate this on the consent form. If you do not want us to access your 
medical records, you do not have to provide additional consent to this.  
 
You can take part in the rest of the study even if you do not want us to access your medical records.  
 
If you agree for the researchers to access your medical records, only the following researchers will have access to 
the identifiable data: 
 
Dr Amanda Wood (study supervisor), Dr Elizabeth Grunfeld (study supervisor) and research assistants suitably 
qualified.  
 
Other study investigators and staff will have access only to de-identified data files (that is, your name will not be 
associated with the medical data).  
 
 
What happens next? 
 
Once the study has been completed we will send you a summary of the group results.  
 
Will you contact me again? 
 
The researchers will keep your contact details and will contact you in the following 18 months to ask if you would 
like to take part in the follow-up studies. We will ask you to give further consent to participate in future studies. 
The follow up study will consist of the same tests which you took part in, in the first study. 
 
Agreeing to participate in this study does not mean you will have to take part in the follow up study. However, it 
does mean that we will contact you again and ask you if you would like to take part in the follow up study. 
 
 
Will I get rewarded for my time? 
 
You will receive £30 for your participation after each visit 
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MRI General Information sheet 
 
BIRMINGHAM UNIVERSITY 
 
IMAGING CENTRE 
 
 
www.buic.bham.ac.uk 
 
 
 
 
 
 
 
 
GENERAL MRI INFORMATION SHEET FOR RESEARCH PARTICIPANTS 
 
 
Dear Research Participant 
 
Thank you for volunteering to undergo a research magnetic resonance imaging (MRI) brain scan at 
the Birmingham University Imaging Centre (BUIC). 
 
Your participation at this research centre will help benefit understanding in the areas of knowledge 
about the central nervous system, in neuroscience and medicine. This information sheet broadly 
describes the MRI procedure, and answers some common questions. If you have any further 
questions, please do not hesitate to contact your researcher. 
 
You can find out more information about what we do from our web site www.buic.bham.ac.uk 
 
 
What is MRI?  
MRI is a relatively recently developed technique which combines the use of magnetic fields and radio-
waves to image the body. MRI does not use any ionizing radiation or X-rays and there are no known 
side-effects or cumulative risks. 
 
For your safety you will be asked to fill out an MRI Safety Screening Questionnaire, and to remove all 
metallic items before you enter the magnet room. FMRI (functional MRI) uses similar methods to 
conventional clinical MRI to obtain ‘functional brain images'. The technique relies on indirectly 
identifying small changes in blood flow/oxygenation in different parts of the brain. 
 
 
 
 
The MRI Scanner  
As you can see from the picture opposite, the scanner is 
a large cylinder which has a tube (bore) running through 
the middle, open at both ends. 
 
You will enter the scanner tube on a moveable bed, laid 
down on your back, head-first, with your lower legs 
remaining outside the magnet's bore. 
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Before You Arrive  
Individuals who are concerned about feeling claustrophobic during the scan may wish to discuss this with 
the researcher before their arrival. However, if you are nervous, please do not worry as we will do 
everything we can to ensure that you are comfortable and relaxed during the scan. You will hold a call 
button at all times which you can press to attract our attention and an intercom system will allow you talk 
to the scanner operator and the researcher. If you wish, a friend or relative is welcome to accompany 
you to the Centre. There is a reception area close to the scanner room for them to wait during the 
scanning procedure. 
 
When You Arrive at the Imaging Centre  
Prior to your scan you will be asked to fill out an MRI Safety Screening Questionnaire. This is necessary 
to ensure that it is safe for you to undergo an MRI scan. Certain participants cannot be scanned and 
should not enter the magnet area, for example people who have a heart pacemaker surgically implanted. 
 
You will be given a full explanation of the scan or study by the scanner operator/researcher and there 
will be an opportunity for you to ask any questions that you may have. When you are ready, and 
agreeable to participate, you will be asked to sign a form obtaining your ethical consent to undergo the 
research study. In this form you will see that you may withdraw from the study at any time without having 
to give a reason. Whether you choose to participate or not will not make any difference to any normal 
medical care you are currently receiving. 
 
Next you will be asked to remove all metallic objects from your person - before you enter the magnet 
room. Lockers are available for any valuables if required. 
 
Starting the Scanning Procedure  
Once you are positioned within the scanner, comfortable, and have no further questions, the researcher 
and scan operator will go into the adjoining room (where the control equipment is located) and speak to 
you from there via a 2-way headphone / microphone communication system. There is a large window 
between these rooms and a camera so that you can be monitored at all times. 
 
We will be able to see and talk to you whilst you are within the magnet throughout the entire study. You 
will be given a call button which you may hold throughout the scan. You may talk to us via the intercom 
system within the magnet and you may press the call button at any time to attract our attention. You may 
stop the scan, come out of the magnet or leave at any time without having to give any reason. 
 
During the Scan  
During the scanning you will hear various tapping and bleeping noises (some may be quite noisy, so 
earplugs will be supplied). This is the normal sound of the magnet taking pictures. Different types of scan 
sequences make different noises, so please don't be alarmed. You may also notice some mild vibration 
of the scanner bed. This too is normal. We will talk to you after each scanning sequence to make sure 
you are still comfortable, and you may talk to us at any time by pressing the call button in your hand. 
 
Please note that during the scanning period itself it is absolutely vital that you keep your head 
completely still. 
Some of the time, the scanner will be silent but please try to keep as still as possible during these periods 
as well. The length of the study will vary according to your particular study type, so please check with 
your researcher for exact times. 
 
 
Results of the Research  
Please note that this centre is not a clinical diagnostic department, but is wholly research orientated. 
Consequently, we are unable to give individual assessment or medical opinion on any clinical condition 
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you may be experiencing (which is the responsibility of your doctor). However, your participation is 
invaluable and will form part of the growing knowledge and future progress of understanding the brain. 
 
Your pictures will be analysed over several weeks/months, usually as part of a group of anonymous 
volunteer scans. Research papers are published by researchers at this centre in national and 
international academic journals of excellence, most of which are able to be purchased, or are sometimes 
freely available. More information can be found at our web site or from your researcher. 
 
 
Unexpected findings on your scan  
As you are aware, the images obtained of your brain are for specific research purposes only and are 
generally not suitable for diagnostic opinions. They do not form any part of your official medical records. 
However, although the pictures are not diagnostic scans, in the unlikely event that any unusual findings 
are noted incidentally by the scan operator, further advice will be sought and you will be contacted at a 
later date to discuss any follow-up. 
 
 
After the Scan  
Once you have collected your belongings and spoken to the researcher/scan operator, you may leave. 
There are no known after-effects from being scanned in an MRI scanner. 
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MRI Participation Information Sheet 
 
Birmingham University 
  
Imaging Centre 
       
  www.buic.bham.ac.uk   
       
    
  
           
 
PARTICIPANT INFORMATION SHEET 
 
Title of project: 
 
Part 1 
 
Introduction to the research and invitation to take part: 
You are being invited to take part in a research study. It is important that you understand why the research is 
being done and what it will involve before you decide whether or not to take part. Please read the following 
information carefully, and please discuss this with others if you wish. Feel free to ask us if there is anything that 
is not clear or if you would like more information. 
 
What is the purpose of the study? 
The study will be examining the relations between brain structure and brain function using magnetic resonance 
imaging. 
 
What kinds of stimuli will be presented? 
The stimuli will be visual images (pictures, words), sounds, tactile input or smells. Any stimuli that might 
potentially be distressing will be shown to you beforehand to enable you to judge if you feel distress. You will 
be able to withdraw from the study at any time (below). 
 
Do I have to take part? 
No. It is up to you whether or not to take part. If you do, you will be given this information sheet to keep and be 
asked to sign a consent form. You are still free to withdraw at any time and without giving a reason. 
Withdrawing from the study will not affect you in any way (e.g., your future medical treatment). 
 
What will happen to me if I take part? 
You will undergo an MRI scan and you may also be asked to carry out a task while in the scanner. As you carry 
out the task we will measure changes related to brain activity which will inform us about how brain areas 
operate while a task is being undertaken. The scanning session will last about 45 min, during which time you 
will be asked to lie still. 
 
What is magnetic resonance imaging? 
Magnetic resonance imaging involves changes the gradient of a magnetic field to produce shifts in the 
alignment of atoms in the body of the person being scanned. The changes in alignment can be used to measure 
the structure and function of the tissues. When the brain is scanned we can derive information about both brain 
structure and function. The procedure is non-invasive and carries no known harm outside of safety issues for 
operating in a high magnetic field (e.g., if you have a cardiac pacemaker). For this reason you will be asked 
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to go through a safety questionnaire with a scan operator prior to being allowed to proceed into the scanning 
environment. 
 
What are the possible benefits of taking part? 
By learning more about how the brain works, by using MRI, we will be able to develop better ways of diagnosing 
changes in brain function, and we will learn about how to improve brain function to optimize performance. 
 
What happens at the end of the research study? 
The results will be written for scientific publication. In addition we will report them in a newsletter that we will 
distribute to all participants and to hospitals. All data will be reported anonymously.  
Using your data in other research - we would ask you in the consent form if you are willing 
to share the data we collected from you with other researchers. If you agree we would upload 
your anonymized data on a server and make it available for research use. There are two 
levels of data sharing: sharing only with researchers associated with the University of 
Birmingham; or sharing it as an open access resource. In the latter case we would make the 
data available on the web as an open access resource. The latter adhere with current 
government and international policies on scientific data. You can choose to allow sharing 
your data in any or neither forms. In case of brain imaging data, you should be aware that there are software 
that can generate the skeleton shape of the face based on MR imaging data, hence by having access to your 
data one can potentially reconstruct your face. Furthermore, similar to fingerprint brain are individually unique, 
thus in the future technology may become available enabling to recognize an individual from the brain 
structure. If you are happy to share your data we would request you to fill up a short questionnaire about your 
general health and demographic. The data will never contain any personal details about you (name, address, 
etc.). 
 
 
What if there is a problem? 
It is possible that lying in the scanner might cause some back or neck pain, and it is possible to feel a burning 
sensation. If you experience any discomfort you can press the emergency buzzer and you will be brought out 
of the scanner immediately. Any complaint about the way the study has been conducted or any possible harm 
you may have suffered will be addressed. The detailed information on this is given in Part 2. 
 
Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. The details are included 
in Part 2. 
 
Contact Details -  BUIC Management: 
 
This completes Part 1 of the Information Sheet. If the 
information in Part 1 has interested you and you are 
considering participation, please continue to read the 
additional information in Part 2 before making any 
decision. 
V3 April 2015  
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Part 2 
What will happen if I do not want to carry on with the 
research study? 
You are free to withdraw from the study at any time, including following data collection, 
without giving a reason. If the data collected until the time of withdrawal could be used, 
you will specifically be asked to give your consent to having the data included in any 
analysis. However, note that if you have agreed to share your data with other researchers 
(with UoB or as open access), you can only withdraw it on the day it was collected. 
   
What if there is a problem? 
The University of Birmingham has an insurance policy in place which provides 
cover for claims arising from negligent harm. 
 
If you have any problems with the conduct of the study then you can contact 
various people: 
(i) phone the Research Governance Committee of the University of Birmingham, 
who have considered this project, on  who will arrange for your 
concerns to be investigated. 
(ii) Dr Amanda Wood, Ms Nina Salman or Ms Denise Clissett at the School of 
Psychology, University of Birmingham . 
 
Unexpected findings on your scan 
As you are aware, the images obtained of your brain are for specific research purposes 
only and are generally not suitable for diagnostic opinions. They do not form any part of 
your official medical records. However, although the pictures are not diagnostic scans, in 
the unlikely event that any unusual findings are noted incidentally by the scan operator, 
further advice will be sought and you will be contacted at a later date to discuss any follow-
up. 
 
Will my taking part in this study be kept confidential? 
Our procedures for handling, processing, storing and destroying your data are all compliant 
with the Data Protection Act 1998. All information that is collected about you during the 
course of the research will be kept strictly confidential. 
 
Who is organising and funding the research? 
The research is organised by the University of Birmingham. 
 
Who has reviewed the study? 
This study was given a favourable ethical opinion by the Research Ethics 
Committee, University of Birmingham. 
 
 
 
You will be given a copy of the information sheet and a signed consent 
form to keep. Thank you for considering taking part and taking the time 
to read this sheet. 
V3 April 2015 
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What are the possible disadvantages and advantages of taking part? 
 
There may be a chance that you may not feel well after your blood or saliva swab test. If so 
then you MUST immediately inform a nurse, doctor or staff personal on duty. 
 
There is a possibility in this study that the tasks we complete with you may show that you have 
one or more difficulties in different areas of cognition or behaviour (for example the screening 
phase of the test could suggest a neurodegenerative disease such as dementia).  
 
If difficulties are found, we will let your GP know and you may be able to get the help you 
need. This could be seen as an advantage of this study.  
 
You may find it difficult to come to terms with such results. This may be seen as a disadvantage 
of this study. 
 
You may also find the tasks tiring. We will make sure we take regular breaks. If you are 
unhappy and do not want to do the tasks, we will not continue the study. In this case you will 
not be given a cash reward but will be reimbursed for travelling costs. 
 
The information we get from this study may not benefit you directly. However, it will help to 
ensure that men who need to undergo androgen deprivation therapy in the future are able to 
preserve as much cognitive function as possible.  
 
It is important that you weigh up both the advantages and disadvantages of taking part in this 
study.  Please talk to a researcher if you have any questions or want to discuss this further.  
 
 
What will happen if you find that I have difficulties? 
 
If we do find that you have some difficulties with the screening tasks we will inform your GP 
in a letter. They may wish to discuss these results with you so that appropriate support can be 
identified for you. 
 
 
What will happen if I don’t want to carry on with the study? 
 
You can leave the study at any moment without giving a reason.  
 
Any information collected which can be used to identify you (such as name, address) will be 
destroyed.  Only information from you which has been made anonymous will be analysed. 
Anonymous means that no one will be able to identify you from that information.  
 
 
What will happen if I lose my mental capacity? 
 
 
Mental capacity means that you are unable to make informed decisions. Sometimes when 
people have mental health difficulties, their ability to make decisions can worsen during 
periods of ill health. This might affect your ability to provide us with informed consent. 
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If this happens, the researchers will withdraw you from the study and any data collected will 
be withdrawn from the study.  
 
 
 
What if I am already taking part in another study? 
 
If you are taking part in another study you can still choose to take part in this project. However, 
you need to make sure that taking part in multiple studies will not interfere negatively with 
your work/home life. Taking part in a study requires time and effort. If you are already taking 
part in another study and feel you do not have enough time to take part in this study, you don’t 
have to. 
 
What if there is a problem? 
 
If you have a concern about any part of this study, you should speak to the researchers who 
will do their best to answer your questions  
If you continue to have concerns then you can contact the ethics committee of X on Y. 
 
You can also contact the Patient Advice and Liason Service (“PALS”). The nearest office to 
our premises is PALS University Hospital Birmingham NHS Foundation Trust,  
The Birmingham and Solihull Mental Health NHS Trust PAL service offers 24 hour service, 7 
days per week. They can be contacted on FreePhone: , Phone:  
(24 hours, 7 days per week) 
They are located at  
PALS also has an online resource (http://www.pals.nhs.uk/) that offers details of their service 
as well as the location of other offices that might be more convenient to you.  
 
 
Will my taking part in this study be kept confidential? 
 
Any data collected from you will be kept strictly confidential.  
 
You will be assigned a unique code. Results from the questionnaires and tasks will be stored 
next to your code in a different place to where your contact details (name, address, telephone 
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number) and consent forms are stored. No information which can be used to identify you will 
leave the University of Birmingham premises.  
 
All hard copies of documents will be stored in locked filing cabinets in the lab of Dr Amanda 
Wood, which will be locked when the researchers involved in this study are not there. All other 
information will be stored on password-protected computers. Information which is stored on 
computers will have your name and contact details removed so that the information cannot be 
traced directly to you.  
 
Only researchers from this research team at the University of Birmingham will have access to 
your information. They will store your information after the study has ended and will contact 
you in up to 18 months to ask if you would like to participate in follow-up studies.  
 
You can ask to see the information stored about you if you wish to do so. If you believe the 
information stored is incorrect, the researchers will correct it.  
 
If you wish to leave the study, information which may be used to identify you will be destroyed. 
 
All verbal information you disclose will also be kept confidential.  
 
Confidentiality will only be broken if the researcher has serious concerns for your safety or if 
they have serious concern that you or others may be harmed.   
 
Will my doctor (GP) know that I am taking part in this study? 
 
Your family doctor will be informed that you are taking part in this study. They will be sent a 
brief letter saying that you are taking part in this study. Your doctor will also be sent a copy of 
your report if you have scored under average in the screening phase of the experiment. The 
report will say how you performed on the tasks.    
 
 
What will happen to the results of this study? 
 
Results from your participation will be analysed together with results from all of the other 
participants in this study. We may publish these results in scientific journals. Results that are 
published will typically be group results. We will not publish individual results with 
identifying information. This means it will be impossible for anyone to identify who 
participated in this study from the publications.  
 
We will also send you a clear summary of group results and the publications if you would like 
to receive these.  
 
 
Who is organising the research? 
 
The research is sponsored by the University of Birmingham. The following researchers are 
involved in this study: 
 
Dr Amanda Wood – Chief Investigator 
Dr Elizabeth Grunfeld – Co - Supervisor 
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Mr Paras Joshee – Doctoral Researcher 
 
Who has reviewed this study? 
 
All research in the NHS is looked at by an independent group of people called a Research 
Ethics Committee to protect your interests. This study has been reviewed and given favorable 
opinion by ....................... Research Ethics Committee. 
 
 
Who can I talk to about this study? 
 
You may want to talk about the project with: 
 your family 
 your friends  
 your doctor 
 the researchers (contact details listed below) 
 
Please feel free to contact Dr Elizabeth Grunfeld or Dr Amanda Wood if you have any 
questions: 
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Appendix 5: Phone Screening Form. 
fMRI study phone screening sheet 
Screening date:______________       Appointment:_______________ 
Screened by:________________       Arriving Via:________________  
Meeting @ where?___________ time?__________________________  
 
Name______________ ID: ____________               Phone number_____________ 
Sex_______________   Date of birth__________     Email_____________________ 
Handedness     R/L 
Sinistral family members Y/N   If YES, then who (are they blood relatives): 
 
OK to speak? Had chance to read participant information sheet?  
 
Medical details: Any current or past history of being diagnosed with the following: 
 
Diagnosis? Yes/No When? Where? How? What? Why? Who? 
Medication? 
Cancer 
 
YES / NO What cancer? Treatment? 
Any difficulties walking or 
climbing stairs? 
YES / NO  
Heart disease, incl angina YES / NO  
*Diabetes YES / NO  
Implanted insulin, drug or 
infusion pump 
YES / NO  
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Hypertension YES / NO  
*Head injury or concussion YES / NO  
*Stroke YES / NO  
*Meningitis / encephalitis YES / NO  
*Epilepsy / seizures YES / NO  
Asthma YES / NO  
Depression / anxiety / other 
psychiatric 
YES / NO  
Speech or language problems YES / NO  
Any implanted metal  YES / NO  
Stent, catheter, coil, filter in 
any blood vessels 
YES / NO  
Aneurysm clips (metal clip put 
around blood vessels) 
YES / NO  
Body piercing(s) YES / NO  
362 
 
Cardiac pacemaker or 
defibrillator 
YES / NO  
Cochlear, otologic, or ear 
implant 
YES / NO  
Hearing aid YES / NO  
Eye implants YES / NO  
Tattoos or permanent 
makeup 
YES / NO  
Artificial limb or prosthesis YES / NO  
Broken bones YES / NO How? Bump head? Hospital? What happened 
after? Painkillers? Dizzy? Insert any pins? 
 
 
 
 
Bone/joint pin, screw, nail, 
wire, plate 
YES / NO 
 
 
Surgical staples YES / NO  
Electrical stimulator for 
nerves, bone or brain 
YES / NO  
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Any implant held in place by a 
magnet (e.g., dental) 
YES / NO Permanently fixed? 
Coloured contact lenses YES / NO  
Welder, machinist, grinder or 
worked with metal without 
eye protection? 
YES / NO  
Any metal fragments (e.g., 
shrapnel), gun pellets, bullet 
YES / NO  
Any surgery or operation of 
any kind 
YES / NO Insert any pins? 
MRI before YES / NO At UoB? 
Claustrophobia YES / NO  
Transdermal skin patches 
(nicotine patch) 
YES / NO  
Smoker?   
Alcohol and other (illicit) drug history (if yes, then details of frequency, amount): 
 
Current medications (details of name, purpose): 
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Mention unexpected findings procedure…………………………………… 
Are you happy for us to contact your GP?     Y/N 
Once completed would you like to be emailed a lay summary? Y/N 
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Appendix 6: Consent Form 
 
 
    Consent form                          School of Psychology 
The University of Birmingham 
Edgbaston 
Birmingham B15 2TT 
United Kingdom 
 
Study name: The Effects of Androgen Deprivation Therapy on Cognition 
 
 
Participant identification number:  
 
 
Name of researcher spoken to: 
 Please write your 
inititals in the box 
 
1. I confirm that I have read and understand the information sheet 
dated....................  (version............) for the above study.  
 
 
 
2. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
 
 
 
3. I understand that my participation is voluntary and I am free to 
withdraw at any time without giving any reason, without my 
medical care or legal rights being affected. 
 
4. I agree to have a blood test.  
 
 
 
5. I agree to my GP being informed of my participation in the study  
 
 
 
6. I agree to be contacted at a later date up to six months from now.   
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7. I understand that I will be withdrawn from the study if my 
ability to provide consent changes. Data already collected from 
me will be kept.   
 
 
 
8. I agree to take part in the above study 
 
 
 
 
 
 
 
9. Consent to access medical records (please tick one of the boxes) 
 
I agree for the researchers to access my medical records. 
 
If you agree above, then please acknowledge the following by ticking 
the small box: 
 
I understand that relevant sections of my care record and data 
collected during the study may be looked at by responsible individuals 
from The University of Birmingham or from regulatory authorities, 
where it is relevant to my taking part in this research 
 
I acknowledge the above 
 
I do not agree for the researchers to access my medical records. 
 
 
 
 
 
Name of Participant                                                Date                                              
Signature 
 
 
 
 
 
Name of person taking consent                                      Date                                             Signature 
 
 
 
Please contact Dr Elizabeth Grunfeld or Dr Amanda Wood if you have any questions: 
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Appendix 7: Neuropsychological measures – duration breakdown 
Study measures 
Timing of 
measure 
 Measure Domain Time taken 
(mins) 
 
Screening Total – 45 
mins 
screening Mini Mental State Exam (MMSE) 
Wechsler Abbreviated Intelligence Scale II 
(WASI-II) 
fMRI screening 
Consent form. 
 
Cognitive impairment 
(dementia), premorbid 
intelligence, verbal 
intelligence. 
 
45 
Demographic information  
screening Age, marital status, ethnicity, occupation, living 
arrangements, education level 
 2 
Clinical information (gained beforehand in PC patients).  
From notes Diagnosis (inc date), tumour grade, treatments 
received (with dates), ADT treatment (inc start 
date/end date/frequency), co morbidities, family 
history (dementia, Alzheimer’s) 
 2 
Neuropsychological battery Total – 1 hr 
30 mins 
 Delis Kaplan Executive Function System 
(DKEFS) 
 
max duration allocated per DKEFS subtest: 
 
- Trail making task parts A & B (11 
mins) 
- Verbal fluency test (5 mins) 
- Design fluency test (5 mins) 
- Colour word interference test (6 
mins) 
- Tower of Hanoi test (19 mins) 
Executive 
function/working 
memory 
46 
 CANTAB spatial working memory task 
(SWM) 
Spatial reasoning 15 
 Behaviour Rating Inventory of Executive Function 
Adult Version (Brief A) 
Executive 
function/working 
memory 
20 
Psychosocial battery Total = 
10mins 
 Hospital anxiety and depression scale 
(HADS) 
 
 
Mood 10 
   Total Time = 
2 hrs 45 mins 
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Appendix 8: Power Analysis 
Power Analysis 
Power analysis was conducted using G*power software (Faul et al., 2007). Power required was 
calculated by main outcomes for each test. In the current study, MANOVAS were implemented based 
on main outcomes from each behavioural assessment. Number of participants required was based on 
effect size. The f2(v) effect sizes were implemented and used to calculate power. This f2(v) effect size 
is a measure of the difference between groups that is conveyed on a general dimensionless scale. The 
F2  has been categorised by Cohen (1988)  as being f2 > 0.02, f2 > 0.15 and f2 > 0.35 and signifies small 
medium and large effect sizes respectively.  
Effect sizes employed to calculate sample size were inputted as medium and large which for 
MANOVAS had been shown to be based on f2(V) equal to 0.15 and 0.35 respectively. These effect 
sizes were selected as they were practical. A 0.80 power β was employed which shows a 4:1 ratio 
trade-off between β (type 2 error) and alpha risk (type one error). The alpha error probability was 
0.05. This is the probability of making a type one error where a false positive is made and the null 
hypothesis is rejected. The, sample size calculated to avoid the above errors are presented in the table 
below: 
 
Effect 
size  
f2(V) 
Assessment Power 
Number  
of  
Groups 
Critical F 
Alpha  
error  
prob 
Outcomes 
Sample 
size  
required 
        
0.15 D-KEFS 0.80 2.00 2.32 0.05 5 92.00 
0.15 BRIEF-A 0.80 2.00 1.84 0.05 12 128.00 
0.15 
CANTAB 
SWM 0.80 2.00 2.03 0.05 8 110.00 
0.35 D-KEFS 0.80 2.00 2.46 0.05 5 44.00 
0.35 BRIEF-A 0.80 2.00 1.96 0.05 12 62.00 
0.35 
CANTAB 
SWM 0.80 2.00 2.03 0.05 8 52.00 
 
 
Main outcomes were entered per neuropsychological assessment and analysis conducted. The main 
outcomes for the D-KEFS assessment reflected the five primary contrast scaled scores on the trail 
making test, verbal fluency test, design fluency test and tower test. The BRIEF-A assessment had 
twelve main outcomes which were Inhibition, self-shift, self-emotional control, ability to initiate, 
working memory, monitor, planning and organisation, behavioural regulation index, organisation of 
materials, behavioural rating index, metacognition index and global executive function scores. The 
370 
 
CANTAB main outcomes reflected conditions in the between errors four box, six box, eight box and 
total errors. Double error conditions added were errors in the four box, six box, eight box and total 
errors.  
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Appendix 9: Imaging Methods 
Functional Magnetic Resonance Imaging Approaches. 
Functional magnetic resonance imaging (fMRI) was a key component in the current study. It 
was implemented because fMRI has significantly increased researchers’ ability to understand 
the localisation of brain activity. Due to the availability of fMRI scanners as well as the 
functional aspects of fMRI to measure cognition, research has grown in popularity. 
Furthermore, the non-invasiveness of MRI allows researchers to scan subjects a number of 
times and for longer durations thus increasing signal to noise ratio. 
The above techniques comes with a variety of ways to analyse data that each have positive 
and negative characteristics. This is because each tool can measure only partial but not all 
neural computations that occur during an imaging run. However, firstly to understand fMRI 
the causal relationship between the blood oxygen level dependent (BOLD) signal and neural 
activity must be examined. The BOLD signal does not correlate perfectly with action 
potentials but it measures a mix of continuous membrane and action potentials. Recent 
evidence suggests that the design of fMRI experiments may yield perfect causal relations 
between the BOLD signal and neural activity. However, this is not the case and the BOLD 
signal can only explain neural activation partially. While this is complicated to in 
understanding the BOLD signal, it offers the opportunity to understand neural information 
beyond action potentials and includes a variety of signals which are important in neural 
computations.  
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The BOLD signal 
Magnetic resonance imaging measures the effect of diploes in a magnetic field on 
electromagnetic radio frequency waves (Logothetis & Pfeuffer, 2004). Magnetic resonance 
(MR) signal arises from hydrogen nuclei in water (Haacke, Lai, Yablonskiy, & Lin, 1995). 
These nuclei are the only dipoles present in sufficient density to sustain any signal at high 
spatial resolutions (Haacke et al., 1995). The energy transition of these diploes between 
energy states leads to an MR signal. Transitions occur on the basis of nearby tissue or 
physiological activity. This is represented as MR image measurements. When human tissue is 
present in the longitudinal axis (B0) field of the MR scanner, hydrogen nuclei are in a low 
energy state referred to as the resting state (Logothetis & Wandell, 2004). The presence of a 
high tesla magnet (1.5T to 7T) causes nuclei to align either parallel or anti-parallel to the 
main magnetic field (van der Zwaag et al., 2009). Magnetic resonance measurement begins 
when the researcher introduces a radio frequency (rf) pulse into tissue. The pulse forces 
nuclei from their resting state equilibrium into a higher energy state. This excitation however 
is only effective at the larmor resonance frequency (Logothetis & Wandell, 2004). This 
frequency is proportional to the magnetic field strength and gyromagnetic constant of 
hydrogen nucleus. This is the ratio of its magnetic dipole moment, to its angular momentum 
measured in radian per second per tesla (rad⋅s−1⋅T−1). The RF pulse elicits the specific amount 
of energy required to transfer nuclei into a higher energy state and realign in the magnetic 
field. Magnetic field pulses and rf excitations can be applied in a variety of timing and 
amplitude parameters. Variations in these parameters allow investigation of other various 
properties of the brain including structure, perfusion imaging, diffusion weighted imaging 
and functional neural activity. Information of tissue in the surrounding area is evaluated from 
the rate at which hydrogen nuclei return to a low energy state.  
Exponential decay processes such as T1 and T2 describe the relaxation of nuclei back to a low 
energy state (Jarek, Flesher, & Shin, 1997). The T1 constant measures longitudinal relaxation 
in the direction of the main B0 magnetic field. The T2 constant measures transverse 
relaxation of the dipole in the x-y planes perpendicular to the B0 field. Transverse relaxation 
referred to as spin-spin interactions or spin dephasing allow transitions of energy to the local 
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field at neighbouring nuclei. These interactions cause exponential signal decay and are 
referred to as T2 (Michaeli et al., 2002). However, when decay occurs in tissue, transverse 
relaxation is additionally rapid due to field inhomogeneity’s and this is referred to as T2* 
(Chavhan, Babyn, Thomas, Shroff, & Haacke, 2009). Inhomogeneity’s depend on 
physiological states and blood supply which is dependent on neural activity for glucose 
metabolism. Therefore, T2* is an indirect measure of neural activity (Detre & Wang, 2002). 
BOLD Contrast 
The BOLD contrast mechanism is the mechanism relating neural activity to the T2* measure. 
The T2* parameter is dependent on neutral activity and changes in relative concentration of 
oxygenated and deoxygenated blood. Oxygenated haemoglobin (hb) is not paramagnetic 
however, deoxygenated haemoglobin (dhb) does have this property which influences the T2 
parameter. The T2 value increases quadratically with field strength and the effect of T2* 
increases exponentially in the presence of dhb (Ogawa, Lee, Kay, & Tank, 1990). 
Researchers found that contrast changes with variations in blood oxygen demand (Ogawa, 
Lee, Nayak, & Glynn, 1990). Contrast increases were therefore attributed to paramagnetic 
dhb from red blood cells (Ogawa, Lee, Nayak, et al., 1990). Increases in dhb may be 
proposed to decrease BOLD signal. However, enhancements in signal typical of fMRI 
experiments during neural activity have been proposed to be due to overcompensation of 
blood cerebral blood flow (cbf) for decreases in oxygen (Fox & Raichle, 1986). A 
shortcoming to this description is the disparity between supply and consumption remains 
unclear. This is because glucose consumption during neural activity matches demand but 
over supply of oxygen does not (Logothetis & Wandell, 2004). Few theories postulate that 
cerebral vasculature delivers fixed amounts of glucose to specific regions. Therefore, if more 
than one system requires aerobic or anaerobic processes that require glucose, then oxygen is 
likewise delivered in surplus (Magistretti & Pellerin, 1999). Further speculation suggests that 
inefficient delivery mechanisms create inefficient diffusion. Therefore, an oversupply is 
required to fulfil demand through passive diffusion at high flow rates (Buxton & Frank, 
1997). This glycolysis process is favourably upregulated over oxygenation during brain 
activation and the ratio of oxygen to glucose falls (Dienel, 2012). Therefore, excess oxygen 
delivery is termed as aerobic glycolysis whilst glycolysis during hypoxia is termed anaerobic 
glycolysis (Mergenthaler, Lindauer, Dienel, & Meisel, 2013). 
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These explanation can be tested by comparing theory with the time course of BOLD. The 
hemodynamic response function (HRF) is the amplitude and time course of the BOLD 
response to a brief stimulus (Logothetis & Wandell, 2004). Sensory and motor control 
responses are quick and can end in a few milliseconds. However, the BOLD response 
described through the HRF can occur up to a few seconds after stimulus response. This 
typically rises to a plateau of 6-9 seconds after stimulus onset and then returns to baseline 
with an undershoot sometimes in post stimulus intervals (Logothetis & Wandell, 2004). 
Predictions can be made from HRF responses to model into linear time invariant systems in 
which long duration responses are predicted from short duration events (Robson, Dorosz, & 
Gore, 1998). The neuro-metabolic connection between source and demand through cellular 
and neurovascular coupling as a function of the BOLD response have been investigated 
though deoxyglucose autoradigraphic techniques. This technique allows the ability to 
spatially gauge regional cerebral activation and glucose depletion in animals (Sokoloff, 
1977). Further research has also examined local blood flow and oxygen consumption in 
humans using radiotracer techniques such as positron emission tomography (PET) which 
measures the indirect effects of neural activity on cerebral blood volume. Although this 
coupling between regional blood flow and neural activity exists, the cellular mechanisms and 
sites dominating these processes remains inconclusive. 
Investigators have suggested that vascular density rather than number of neurons correlate 
highly with synapses (O'Kusky & Colonnier, 1982; Schuz & Palm, 1989). Researchers 
showed that cortical vascular networks can be divided into four layers which overlap with 
brodman layer cytoarchitecture. The first level has the lowest vascularization and consists of 
layers oriented parallel to neural fibers within the lower molecular layer. Layers have 
increasing amounts of vascularity from layers two to four with increasing numbers of 
perisynaptic elements rather than neuronal somata (Duvernoy, Delon, & Vannson, 1981). 
Subsequently, primary sensory areas are characterised by higher capillary density (Duvernoy 
et al., 1981). 
Cerebral metabolic rate (CMR) can be used to measure neural activity since glucose is 
metabolised through aerobic or anaerobic glycolysis to adenosine triphosphate (ATP) by 
neurons for energy (Mergenthaler et al., 2013). The function of specific neurons may reflect 
their shape, electrical activity and size (Mergenthaler et al., 2013). This raises questions of 
how cerebral flow is coupled to energy depletion by neurons and which specific cellular 
mechanisms govern these processes. Astrocytes, which are a specific type of glial cell have 
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the functional characteristics to make them ideal gateways between neutrophil and 
intraparenchymal capillaries. Furthermore, they are connected with neurons and brain 
vasculature. Researchers propose that for each synapse, two Na+ ions from an astrocyte 
uptake one glutamate molecule and one glucose molecule enters the same astrocyte. This 
glycolysis process of glucose thereby releases two ATP molecules and two lactate molecules 
which can be manipulated by neurons to produce 18 ATP molecules. This occurs in neuronal 
sites through oxidation with the introduction of phosphate molecules (phosphorylation) 
(Sibson et al., 1998). Nuclear magnetic resonance (NMR) spectroscopy studies reveal that the 
consumption of the excitatory neurotransmitter glutamate, is equivalent to the rate at which 
glutamate is changed to glutamine (Sibson et al., 1998). This conversion occurs in astrocytes 
and conversion energy is delivered through glycolysis (Schousboe, Scafidi, Bak, 
Waagepetersen, & McKenna, 2014). Astrocytes are further abundant in glucose transporters 
which are driven by Na+ gradients and therefore a tight coupling exists between Glucose and 
Na+ uptake. Studies illustrate that up to 80-90% of energy demands are from glutamatergic 
neurons in rodents (Sibson et al., 1998) and humans (Pan et al., 2000).  
Investigators have endeavoured to isolate neural events that trigger vascular cerebral blood 
flow and consume the most energy. Researchers assumptions are based on the number of 
vesicles released per synapse during action potentials and post-synapse receptor activation 
with vesicle release. The metabolic consequences of activating single receptors, ion 
fluctuations and neurotransmitter recycling are modelled to calculate energy expenditure 
(Logothetis & Wandell, 2004). Post-synaptic events have been attributed to consume the 
largest amount on energy through glutamate in humans (70%) (Harris, Jolivet, & Attwell, 
2012). Some conflict remains on dissociations found between neural signalling to initiate 
CBF verses energy consumption driving CBF. This is because neurochemicals such as 
gamma-aminobutyric acid (GABA) or glutamate have been known to control blood flow in 
areas such as the cerebellum in purkinje cells and interneurons (Caesar, Offenhauser, & 
Lauritzen, 2008). This is supported in a study demonstrating that GABA is required to elicit 
CBF in the cerebellum of rats (Thomsen, Offenhauser, & Lauritzen, 2004). Researchers 
tested their hypothesis through GABA blockade and increased Purkinje cell spiking activity. 
This led to an increase in energy consumption but did not change blood flow. Outcomes 
indicate that CBF changes required to support signals such as BOLD, are not due to neuron 
spiking activity, but that other neurochemicals could trigger increases in CBF (Thomsen et 
al., 2004). Findings propose that presynaptic activity and neuronal recovery initiate energy 
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production. This leads to the conclusion that CBF mechanisms are controlled by energy 
production prediction rather than those that measure depletion of energy. 
The estimation of neural signals from the BOLD response is complex. The coupling between 
neural activity and the vascular response (hemodynamic response) is essential in defining 
amplitude and spatial resolution of the BOLD signal. Hemodynamic response efficiency is 
likely to be low in regions of sparse vascularization. However, areas such as white matter 
may have low vascularization density with increases in neural activity and energy 
metabolism. This is because white matter requires energy to restore ionic gradients which are 
distributed by the spread of action potentials at the Ranvier nodes (Harris & Attwell, 2012). 
The BOLD response has rarely been reported in white matter despite known energy 
consumption. Moreover, if any activity is found, then researchers may disregard findings 
altogether. Other shortcomings of the hemodynamic efficiency theory could be from 
parenchymal vascularity. This is because these arteries have constriction points which 
regulate cortical arterial flow. These changes in arterial diameter could determine 
hemodynamic efficiency and whether a region exhibits BOLD signal (Duvernoy et al., 1981; 
Harrison, Harel, Panesar, & Mount, 2002; Reina-De La Torre, Rodriguez-Baeza, & 
Sahuquillo-Barris, 1998). Further experiments conducted through simultaneous recordings of 
intrinsic signal of parenchymal flow with electrodes reveal that regional activation flow in 
one area often leads to reduced flow to the adjacent cortex. This can enhance local spatial 
resolution favourably when in fact activation does not match the tissue region from which 
signal are generated (Harrison et al., 2002). Taken together, the issues above suggest that 
caution should be applied in the interpretation of the BOLD signal in localized brain regions. 
This is because no reliable quantitative relationship can be made between the HRF amplitude 
and neural activity. This may still be the case when the BOLD response is controlled for by 
manipulating local blood flow into surrounding tissue (Hyder, Renken, Kennan, & Rothman, 
2000; Kida, Kennan, Rothman, Behar, & Hyder, 2000).  
 
BOLD signal to Noise Ratio 
The signal to noise ratio (SNR) is a measure of the desired signal to the level of background 
noise. This is the comparison of the signal acquired from the image to the background noise 
from the image. A quantitative description of SNR is the mean signal intensity in a region of 
interest (ROI) and the standard deviation of signal intensity measured in a region from which 
378 
 
no tissue is obtained (i.e. outside the ROI when the ROI is not present). Multiple variables 
can be manipulated by researchers such as Tesla strength and slice thickness which can assist 
in increasing SNR of images as these parameters influence background noise. However, 
scanner hardware can affect SNR and a linear trend has been found with SNR and field 
strength (Redpath, 1998). This is due to the increases in bulk magnetization of protons with 
higher field strengths in the B0 field allowing magnetization over additional protons. This 
leads to increased spatial resolution as more protons emit signal relative to low field strengths 
(van der Kolk, Hendrikse, Zwanenburg, Visser, & Luijten, 2013). 
 
Other sources of noise during fMRI can stem from respiration, cardiac pulses, motion or from 
task performance. Therefore, these sources of noise must be captured to compare with noise 
from outside of the ROI. Since artefact detection during fMRI is over a duration, imaging 
noise in individual images may not be suitable. However, mean temporal SNR (tSNR) can 
determine SNR of an fMRI time series (Triantafyllou et al., 2005). Improvements in contrast 
to noise ratio (CNR) BOLD in relation to SNR have been found with higher scanner field 
strengths (Wald, 2012). Furthermore, no other parameters were found to affect BOLD CNR 
signal excluding tSNR. This is important since CNR is based on contrast image quality rather 
than raw signal. Time series SNR can be calculated as the signal divided by the noise in 
standard deviations of the time series. The CNR heavily relies on the tSNR because it is the 
proportion signal intensity change between the activated and non-activated state, divided by 
the noise standard deviation of the time series total (Wald, 2012). This is important because it 
provides a measure of the slightest activations that can be identified and determines the 
statistical significance of strong and weak activation in a population.  
In some ways CNR of a time series is preferred for structural MRI sequences as it allows the 
comparison of gray matter to white matter (Hyde, Biswal, & Jesmanowicz, 2001). This is 
because contrast refers to the properties to which the signal is sensitive. Therefore, areas with 
short T1 values will be brighter such as white matter and dark areas indicating long T1 
weighted values. In summary, SNR is used to assess quality of single images, tSNR is used to 
assess the quality of and fMRI time series. Contrast to noise ratio can be used to evaluate the 
statistical significance of experimentally elicited signal variabilities in gray and white matter. 
These signals are then captures by other MR coils into K-space and eventually into images. 
Images are transferred from a spatial number in K-space using fourier transformations This is 
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a mathematical concept used to separate the signal obtained, into the frequency components 
that initially made the signal (Twieg, 1983).  
 
 
BOLD Signal in Ageing 
The BOLD signal is acquired through an indirect measure of cerebral perfusion which is 
largely dependent on neurovascular components and glucose metabolism. Widespread 
research has shown that the vascular system undergoes numerous changes as a function of 
age (Farkas & Luiten, 2001). Changes during ageing can be silent or can lead to more serious 
vascular compromise such as cerebral ischaemia or stroke. Atherosclerotic changes and 
compromises encompass the most prevalent forms of change during ageing. Variations with 
increasing age as an independent risk factor (Knox, Yates, Chen, & Klara, 1980) include 
vessel wall thickening (Furuta, Ishii, Nishihara, & Horie, 1991), smooth muscle cell necrosis 
(Masawa et al., 1994) and basement membrane thickening (Nagasawa et al., 1979). These 
factors reduce flexibility, elasticity and compliancy of affected vessels including capillaries, 
arterioles and cerebral arteries (Kalaria, 1996). Changes in arterial structure with age can 
eventually occlude vessels leading to either compromised or redistributed of blood flow. This 
will affect the BOLD signal as the signal relies on perfusion through this architecture which 
if narrowed or blockaded, may lead to signal drops and decreased SNR (tSNR). Moreover, 
decreases in resting cerebral blood flow have been found in cortical and subcortical brain 
regions with advancing age (Krejza et al., 1999).  
Other sources of vascular change in ageing may a vascular reactivity component. This is a 
known reactivity of vasculature to chemical modulators such as upsurges in carbon dioxide 
concentrations resulting in arterial dilation (Tamaki, Nakai, Yokota, & Ogata, 1995). 
Decreased responsiveness has been found in animal models and in healthy ageing humans 
(Silvestrini et al., 2000; Tamaki et al., 1995). The BOLD signal in normal ageing has been 
measured using spatial and temporal features of the HRF. In theory if the HRF in young and 
old subjects is the same, then there should be no age related change in neural activation 
patterns. However, if there are changes in HRF between groups whilst subjects undergo a 
task, then any change in activation may be age-related and alterations in neurovascular 
coupling. One study found decreased SNR despite similar shape HRFs in old and young 
subjects on a simple motor task (D'Esposito, Zarahn, Aguirre, & Rypma, 1999). The decrease 
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was attributed to greater levels of noise on older participants which led to a decrease in the 
spatial degree of the BOLD signal. This suggests there are some neurovascular changes with 
age. Other studies have found similar reductions in the SNR and decreased activation patterns 
during behavioural imaging in ageing subjects (Hesselmann et al., 2001; Huettel, Singerman, 
& McCarthy, 2001; Taoka et al., 1998). 
Advantages and Disadvantages of fMRI 
Whilst advantages of fMRI are numerous and include that it is non-invasive; it does not 
require radioactive compounds; it can acquire high spatial scan resolution images and it can 
objectively measure brain activity (Glover, 2011). Some limitations are noteworthy. 
Resolution images acquired from fMRI are limited by SNR. Due to the nature of noise in 
fMRI images, pixel size is normally increased even in higher field magnets to accommodate 
for this factor. Nevertheless, higher tesla magnetic neuroimaging also suffers from noise from 
motion artefacts, field inhomogeneity and scanner drift noise that all exponentially increase 
with higher tesla scanners (Boubela, Kalcher, Nasel, & Moser, 2014). However, analysis 
methods do offer regression methods to control for noise factors. Spatial smoothing may also 
allow inferences to be made in adjacent voxels from other nearby voxel activations (Wang, 
Wang, Aguirre, & Detre, 2005). Nonetheless, the signal acquired after all these processes is 
relatively small and difficult to interpret without computational algorithms (Glover, 2011). 
Another shortcoming of fMRI includes that temporal resolution is restricted by the 
hemodynamic duration (Glover, 2011). This is because the BOLD HRF has an initial width 
of more than three seconds with the peak of this response occurring at five to six seconds 
after commencement of a neural event. The HRF is therefore slower than the underlying 
neural mechanism and temporal information is as a result, greatly skewed. Nevertheless, 
through paradigm jittering of event related stimuli, and various analysis methods, temporal 
interpretations can be attained in the range of 100ms (Ogawa et al., 2000). 
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Arterial Spin Labelling 
Until a direct and non-invasive method is created where adenosine 5 triphosphate (ATP) 
consumption and production can be measured, researchers must rely on correlates such as 
CBF as an indirect measure of neuronal activity. Many methods of measuring CBF use tracer 
kinetics which yield models that define the changing aspects of the tracer as it passes through 
arterial architecture and into cerebral microvasculature. An advantage of arterial spin 
labelling (ASL) is that it uses endogenous arterial bolus as a tracer and does not require 
invasive injection of tracers which could be harmful or uncomfortable. Moreover, it is safe to 
repeat and can be used to track changes over time. Absolute blood flow can be measured 
through ASL which can be conveyed as meaningful units. Furthermore, it can produce higher 
quality spatial and temporal resolutions than any other techniques (Borogovac & Asllani, 
2012).  
The theoretical framework of ASL involves the labelling of arterial water before reaching the 
imaged volume. Labelling denotes the inversion of magnetic spins in protons. After a time 
delay, the labelled spins exchange with cerebral tissue and a labelled image is acquired 
(Alsop & Detre, 1996). This image has arterial water (bolus) which is in an altered 
magnetisation from static tissue water. This can be modelled as static tissue = +1 and labelled 
water as -1 (inversion). Signals acquired from a voxel in a labelled image indicates a sum 
over the blood and tissue spins. A control image is also acquired in addition to the labelled 
image in which the arterial spins have not been labelled through inversion. The control image 
is then subtracted from the labelled image at each voxel and is measured relative to the 
amount of CBF delivered to that voxel. This can be shown as an equation: 
 
ASLsignal = (MC - ML) 
  MC 
Where MC is the control image and ML is the labelled image. Cerebral perfusion is calculated 
by applying a set of estimated physiological and MR factors on the ASL signal image. This is 
used to acquire voxelwise flow values in total physiological units. Several pairs of labelled 
and control images are acquired to ensure an average of multiple outputs have been acquired 
(Borogovac & Asllani, 2012). The two main types of ASL which exist are continuous arterial 
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spin labelling (CASL) and pulsed arterial spin labelling (PASL). Moreover, many software 
permutations have been designed within these categories. These variations methodologies 
allow greater background suppression of static tissue signal to improve SNR of the ASL 
signal (Garcia, Duhamel, & Alsop, 2005). Pulsed arterial spin labelling is used in the current 
investigation of patients and controls. This is because it is more easily implemented and 
requires only 10-15ms short intermittent pulses to invert spins in a specific region and 
referred to as the inversion slab (Golay, Hendrikse, & Lim, 2004). As aforementioned, a time 
delay is allowed until the bolus (inverted spins) reaches cerebral tissue where a T1 image is 
acquired as the labelled image. A control image is also acquired for perfusion subtraction in 
the analysis (Golay et al., 2004). The PASL method of ASL is widely used as it is 
straightforward compared to CASL and also requires shorter labelling pulses.  
In contrast, the CASL method uses long inversion durations which can lead to decreased 
signal. This is because of magnetization transfer (MT) effects which is when spin-spin cross 
relaxations occur in nearby protons. This can greatly reduce T2 signal acquired due to very 
fast dephasing which shortens T2 relaxation times (Wolff & Balaban, 1989). Therefore, an 
advantage of PASL is that it is less susceptible to magnetization transfer (MT) effects due to 
short inversion times which can in turn increase signal to noise ratio when labelled images 
are acquired (Wolff & Balaban, 1989). Nevertheless, PASL does have some drawbacks 
including low SNR, slice artefacts that limit brain coverage and sensitivity to bolus transit 
times. However, transit time confounds are worth noting and imperative to acquire ASL 
labelled images. This is because if arterial blood is labelled and a labelled image is acquired 
immediately following labelling, then CBF would be mis-estimated. Whereas if the image 
was acquired to late then voxels where bolus has left would be underestimated or 
overestimated. Therefore, blood destined for another voxel passes the intended voxel and 
reaches another voxel at washout. Hence, arterial transit time (ATT) which is the average 
time it takes for bolus to cross vasculature in the region of interest, and tissue transit time 
(TTT) which is the time required for the bolus to exchange with regional tissue, requires 
careful calibration. Nevertheless, a concession must be made between loss of signal due to 
relaxation processes and length of the delay transit (Alsop & Detre, 1996). This is important 
when whole brain imaging is required because transit times to specific regional destinations 
will have distinct transit times.  
For studies when labelled blood is assumed to be in microvasculature, careful ATT 
estimation must be employed as in the current study. However, if multiple ASL images are 
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acquired at multiple delays with inversion bolus, then an estimate can be estimated using a 
kinetic curve model which can be fitted to CBF measurements. This model describes cerebral 
perfusion and assumes that very little bolus will be present in microvasculature at first. The 
bolus increases exponentially in cerebral architecture which is followed by a venous tracer 
washout period where the curve exponentially declines (Buxton & Frank, 1997). However, 
ATT values are normally assumed to be homogenous throughout the brain and vary linearly 
with ascending slices (Borogovac & Asllani, 2012).  
Resting State Functional Connectivity 
Resting state fMRI (rsfMRI) is commonly used as a functional brain imaging method to 
evaluate spontaneous regional interactions when a subject is not performing a task (Biswal, 
2012; Buckner, Krienen, & Yeo, 2013). Any regional activations are measured using fMRI in 
which the BOLD signal is acquired at rest (Biswal, 2012). Resting state connectivity can be 
defined as temporal correlations of neural activity patterns between spatially distinct brain 
areas and neuronal groups (Biswal et al., 1997). More specifically, this refers to the level of 
co-activation of functional time sequences measured when a subject is resting (Lowe et al., 
2000). Examining these integrative networks provides insights about neuronal group activity. 
Moreover, it allows investigation of networks when they function normally and can be used 
to discover altered patterns in neurodegenerative disease (Bullmore & Sporns, 2009; 
Greicius, 2008). Researchers have located a number of networks which are commonly 
activated using rsfMRI where it is thought that co-activations in these regions denotes 
communication between brain regions (Biswal, Yetkin, Haughton, & Hyde, 1995; 
Damoiseaux et al., 2006; Greicius et al., 2003; Salvador, Suckling, Schwarzbauer, & 
Bullmore, 2005). The neuronal basis of resting state activity comes from the observation that 
brain regions co-operate with each other to form a functional linkage during rest. These 
regions are correlated even though they are anatomically separated to form a network (Biswal 
et al., 1995; Damoiseaux et al., 2006; Lowe et al., 2000; Salvador et al., 2005).  
 
Model dependent methods are commonly used to analyse functional resting state data. This is 
a simple way to examine functional connections. The technique involves the correlation time 
series in a particular region at rest against the time series of other regions which results in a 
functional connectivity map (fcMAP) (Biswal et al., 1997; Cordes et al., 2000). This defines 
the functional connections of the region of interest (Biswal et al., 1997; Cordes et al., 2000). 
The predefined region is called the seed region and can be selected in an a priori fashion from 
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a task-dependent activation map in a separate fMRI session. The seed forms the basis to 
measure connectivity with other identified regions. However, this approach is limited to 
functional connections from the seed region only, making it difficult to interpret connectivity 
on a whole brain scale (van den Heuvel & Hulshoff Pol, 2010). 
 
Many studies have shown the development of functionally connected sub-networks that are 
robustly detected during rest and are frequently denoted as resting state networks 
(Damoiseaux et al., 2006; Fox & Raichle, 2007). Whilst these regions are anatomically distal, 
they show high levels of functional connectivity when at rest (Beckmann, DeLuca, Devlin, & 
Smith, 2005). These networks include the default mode network (DMN) which is of interest 
in the current study consisting of the medial prefrontal cortex, inferior parietal lobe, 
precuneous and temporal regions (Buckner & Vincent, 2007; Fox & Raichle, 2007; Greicius 
et al., 2003; Raichle & Snyder, 2007). Most identified networks also seem to share and 
overlap with putative resting functional networks during task activation (van den Heuvel & 
Hulshoff Pol, 2010). The DMN has elevated level of neuronal activity which can sometimes 
be higher than functional activity in distinction to other resting state networks. This indicates 
that this network reveals the default state of neuronal activity and makes it a good network to 
measure seed connectivity from predefined regions (Raichle & Snyder, 2007). Activity and 
connectivity of the DMN have been associated with core process including integration of 
emotional processing (Greicius et al., 2003); global monitoring (Gusnard et al., 2001); 
divergent thinking (Heinonen et al., 2016) and mind drifting (Mason et al., 2007). These 
complex higher level process related to the DMN indicate that it can provide a unique 
perspective in examining resting state connectivity, in neurological disorders and underlying 
cognitive thinking concepts (Bullmore & Sporns, 2009; Garrity et al., 2007; Harrison et al., 
2007).  
 
However, the mechanisms behind functional connections are difficult to understand without 
considering structural connections between regions. This refers to white matter tracts that are 
bundles of lengthy axons that interconnect with large groups of spatially distal neurons. Due 
to these properties, they allow the transfer of vast functional data between spatially distinct 
brain areas (Damoiseaux & Greicius, 2009). Diffusion tensor imaging (DTI) research 
illustrates that regions with higher levels of structural integrity, have greater functional 
connectivity to the DMN and other resting state systems (Greicius, 2008; Hagmann et al., 
2008). Moreover, combined DTI and resting state data indicate that the integrity of the 
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cingulum tract is imperative to the interconnectivity of key regions involved in the DMN 
(Lawes et al., 2008; Schmahmann et al., 2007). Other white matter tracts have also been 
found to be interconnected to the DMN (van den Heuvel, Mandl, Kahn, & Hulshoff Pol, 
2009). This suggests that there is a more common relationship between the DMN and other 
resting state networks (van den Heuvel et al., 2009). Nevertheless, the exact nature of this 
relationship is largely unknown (Bullmore & Sporns, 2009). 
 
Advantages of resting state analysis include that resting state activity requires almost 20 
percent of the body’s energy expenditure and is used to facilitate ongoing neural signals at 
rest (Ames, 2000; Raichle & Mintun, 2006). Nevertheless, a majority of fMRI research is 
aimed towards functional task activations which require less than five percent of the bodies 
energy (Raichle & Mintun, 2006). Moreover, when participants complete a task, only 20% of 
total BOLD activity is task related which suggests that 80% is of signal is discarded as noise 
(Fox & Greicius, 2010; Fox & Raichle, 2007; Fox, Snyder, Vincent, & Raichle, 2007). 
However, BOLD modulations during resting state activity are comprised of most of the signal 
allowing a higher SNR (Daliri & Behroozi, 2013).  This implies that most knowledge of brain 
activations come from studies attempting to understand only small components of functional 
activity (Daliri & Behroozi, 2013). Another benefit of resting state connectivity is that it can 
be used in clinical settings where patients or participants are unable to perform a task. 
Therefore, resting state activity can be a good indicator of brain function in the absence of 
task related neural measures. Limitations of task related activity is that there task activity is 
contaminated with noise. This can be related to physiological interactions or motion. Since 
resting state activity does not require any parameter adjustments, there are fewer instances of 
noise which increases SNR.  
 
Confounds to resting state methods are that there is limited knowledge about neural 
interactions and their correlation to individual cognitive ability or skill. Therefore, task 
related functional activations must be used to characterise and inform the underlying brain 
regions at rest which inform inferences made of a structural network (Daliri & Behroozi, 
2013). Additionally, between group variability such as tiredness, anxiety etc. are difficult to 
control during resting state scans which can limit analysis outcomes (Behroozi, Daliri, & 
Boyaci, 2011). Another noteworthy finding revealed that cardiac pulses and respiratory 
BOLD signal changes have been known to resemble the DMN (Birn, Diamond, Smith, & 
Bandettini, 2006). Caution must therefore be taken to separate DMN activity from noise 
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through regression or to measure pulse and respiratory rate during resting state activity. 
Finally, there is no control on what subjects are thinking during resting state analysis, 
therefore it may not be clear if the subject is truly resting (Daliri & Behroozi, 2013). 
 
Ageing and Resting State Connectivity 
 
Ageing has been associated with cognitive decline. However, researchers also speculate that 
not only does ageing lead to specific regional declines, but that functional connectivity 
integration underlie age related impairments. One study exploring age related deficits in a 
group of healthy younger (mean age 22.8 + 2.3) and older (mean age 70.7 + 6) participants 
measured intrinsic functional connectivity of the DMN (Damoiseaux et al., 2008). All 
participants also underwent an extensive neuropsychological assessment containing attention, 
information and motor speed, working memory and executive function tasks. Outcomes 
showed decreased activity in older participants compared to the younger cohort. Additionally, 
correlations between tasks of executive function and the anterior DMN regions were 
weakened in the older group. Limitations to the study were that the sample size was small 
especially in the young group and does not allow researchers to infer when age related 
deficits occurred along an age continuum. Nevertheless, these findings are of importance in 
ageing because the DMN has highly correlated with Alzheimer’s disease due to amyloid-β 
deposition in DMN areas which can disturb DMN connectivity (Buckner, Andrews-Hanna, & 
Schacter, 2008). Many studies in general also suggest that ageing is associated with reduced 
resting state connectivity (Hafkemeijer, van der Grond, & Rombouts, 2012; Mevel et al., 
2011; Prvulovic, Bokde, Faltraco, & Hampel, 2011).  
 
Only one study has found improvements and declines with age and another study showed no 
age related declines in DMN resting state connectivity (Jones et al., 2011; Zuo et al., 2010). 
However, this may be because samples consisted of only middle age and older participants 
and suggests that age related decline may begin earlier than thought in middle age which 
resembles activity of the older group. However, this speculation remains inconclusive 
without a younger group for comparison concluding the study may be underpowered (Onoda, 
Ishihara, & Yamaguchi, 2012). Differences in study outcomes may stem from variations in 
model-free and model dependent methodologies and inconsistent analysis procedures 
between studies.  
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Many hypotheses have been made to determine the cause of reduced function connectivity 
with age. One of these theories is the loss of white matter integrity. Many studies support this 
notion showing that white matter integrity declines as a function of age. Weakening of white 
matter fibres has been correlated with decreased functional connectivity within specific brain 
networks in older populations (Chen, Chou, Song, & Madden, 2009; Davis, Kragel, Madden, 
& Cabeza, 2012; Teipel et al., 2010). White matter hyperintensities are also common in 
elderly participants (Soderlund, Nyberg, Adolfsson, Nilsson, & Launer, 2003). An 
investigation in subjects with severe white matter hyperintensities showed they also had 
decreased functional connectivity associated with the dorsolateral prefrontal cortex (Mayda, 
Westphal, Carter, & DeCarli, 2011). An increasing amount of research supports this 
disconnection theory in healthy ageing (O'Sullivan et al., 2001). One study found both 
increases and decreases in functional connectivity in patients with multiple sclerosis which is 
known to severely impair white matter tracts (Hawellek, Hipp, Lewis, Corbetta, & Engel, 
2011). This may facilitate or impede affected regions that have become less efficient over 
time.  
 
In conclusion, the mechanisms behind fMRI may allow comprehensive assessments of 
functional and structural integrity. However, caution must be taken when interpreting 
outcomes from ageing populations since numerous deductions can be made on the basis of 
under or over activations. Nevertheless, multi-model fMRI imaging approaches can help 
separate these factors to allow for a better understanding of brain activity in older 
populations. 
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Appendix 10: Pilot Study 
Background 
Measures employed in the present study were the stop signal (SS) task and mental rotation (MR) task. 
The SS paradigm has been employed because response inhibition is considered a key component of 
executive function (Andrés, 2003; Aron, 2007; Stuphorn & Schall, 2006) and is suitable for 
assessment in a laboratory setting (Vince, 1948). The task employs the ability to supress inappropriate 
or no longer required responses (Verbruggen & Logan, 2009). Response inhibition impairments have 
been linked to disorders including attention deficit hyperactivity disorder (Nigg, 2001), obsessive 
compulsive disorder (Penades et al., 2007), and clinical disorders such as cancer (Chao et al., 2012).  
The paradigm typically involves a reaction time response on go trials (no stop) and inhibition of 
responses to stop trials. Performance on the stop signal task can be modelled as an independent horse 
race model which describes the processes between the probability of responding p(respond|signal) and 
the probability of inhibiting p(inhibit|signal) on stop signal trials (Logan & Cowan, 1984). The 
p(respond|signal) depends on three factors including the stop signal delay (SSD), go reaction time (go 
RT), and stop signal reaction time (SSRT). When the SSD increases, the p(respond|signal) increases. 
This is because the stop process starts later and finishes later in comparison to the go process which 
has already begun thereby forcing a response. As subsequent SSDs are presented the p(respond|signal) 
decreases and go RT increases. This is because of the increased probability that the stop process 
finishes before the go process (Verbruggen & Logan, 2009). Furthermore, SSRT increases for 
subsequent SSDs because the probability that the stop process finishes after the go process increases. 
The calculation of SSRT using p(respond|signal) is aptly explained in a model by  
The SS task of the pilot studies below employed a fixed SSD design opposed to a performance 
adjusted SSD design. Both fixed and performance adjusted SSD tasks have been shown to activate the 
same brain regions in past studies. Previous investigations have found the inferior frontal gyrus (IFG), 
middle frontal gyrus (MFG), and anterior cingulate cortex (ACC) to be activated when inhibitory 
activity occurs through various paradigms (Ragozzino, 2007). Moreover, this is supported through 
findings of slower SSRT speed in participants with damage to the IFG and/or MFG (Aron et al., 
2003). This confirms IFG and MFG involvement in monitoring during SS go tasks whilst 
simultaneously preparing for inhibition if a stop signal occurs. (Kringelbach & Rolls, 2004). The ACC 
has been correlated with post error monitoring, outcome monitoring, and post error slowing (Li et al., 
2008). Research points to a neural network between the ACC and dorsolateral prefrontal cortex 
(DLPFC) (IFG/MFG) during subsequent task trials (Kerns et al., 2004).  
 
The SS task is preferred over other tasks such as the go/nogo task since it requires intricate 
sensorimotor map representation, odd ball consideration, task switching, inhibition, and post error 
processing (Li et al., 2006). Neural network maps associated with the  SS task and go/nogo task have 
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found activation of overlapping regions in the medial, mesial, and parietal and inferior frontal cortices 
(Rubia et al., 2001). The go/nogo task has been associated with lateralisation to the left hemisphere 
DLPFC areas specialising in motor planning and response selection (Rubia et al., 2001). The SS task 
has been correlated with right hemispheric laterization in the anterior cingulate cortex, inferior 
prefrontal, and parietal cortices which are known for specialising in inhibition (Rubia et al., 2001). 
These areas  are predominantly associated with executive function, attention, and high working 
memory load (Rubia et al., 2001). Lesion studies furthermore supports right hemisphere dominance in 
which localised damage to the right IFG and MFG can lead to loss of inhibitory control (Drewe, 1975; 
Verfaellie & Heilman, 1987). This validates the SS task as a suitable measure to assess inhibitory 
executive function, because it requires higher inhibitory loads when stop signals are presented 
compared to the go/nogo task. In one study, prostate cancer patients undergoing androgen deprivation 
therapy (ADT) were assessed on the SS task compared to control patients who were not receiving 
ADT (Chao et al., 2012). No difference in SS task performance was observed at six months compared 
to baseline between or within groups. However, decreased connectivity was observed between the 
medial prefrontal cortex and dorsolateral prefrontal cortex (DLPFC), right insula, right superior 
temporal gyrus, and ACC in ADT patients compared to the non-treatment group (Chao et al., 2012). 
As aforementioned, these cortical regions have been implicated as being central to executive function. 
Therefore, lowered testosterone levels from ADT may contribute to brain impairments during therapy 
compared to control participants. Limitations of the study were that of a small sample size and 
patients were only exposed to ADT for a short duration. In light of the above study, the  pilot study 
below uses brain imaging (fMRI) to assess neural correlates associated with the SS task, to find 
consistent activation in areas of the IFG/MFG (inhibition), and ACC (post error monitoring) so that 
the task can be implemented in a baseline to longitudinal study with ADT patients and healthy 
controls.  
 
The mental rotation (MR) task was implemented in the study below to assess spatial reasoning ability. 
The task is considered as assessing spatial reasoning due to the requirement of participants to spatially 
manipulate, monitor, and update information as the task progresses (Potvin et al., 2013). The task 
necessitates mental rotation of shapes using executive function control and spatial orientation (Potvin 
et al., 2013). Past animal studies have found brain activation of bilateral occipital parietal lobes and 
supramarginal gyri, thought to be associated with spatial map generation to mentally code locations of 
targets (Andersen & Buneo, 2002). This is apparent through  electrophysiological research of the 
superior parietal cortex in primates (Snyder et al., 1998). Individual cells in the area are known to be 
responsible for eye-centred coordinates modulated by primate head or body position (Snyder et al., 
1998). Conversely, monkeys with spatial neglect in one part of space often have lesions in the parietal 
cortex (Karnath et al., 2001). Motor cortex activation during mental spatial manipulation is much 
debated throughout neuroimaging literature. This is because task activated regions must dissociate 
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between regions activated due to motor planning or motor demands of the task (e.g. button response 
pressing).  
 
The assessment of spatial reasoning is of paramount importance in patients undergoing ADT since 
testosterone levels are exhausted (Green et al., 2002; Green et al., 2004; Joly et al., 2006). Researchers 
have explored the effects of testosterone on cognition with findings leading to the conclusion that 
testosterone does affect cognition, and especially spatial reasoning. For example one study assessed 
the effects of normal endogenous serum testosterone levels and normal free testosterone levels on 
neuropsychological performance (Moffat et al., 2002). Outcomes revealed a correlation between high 
visual memory, verbal memory, visuospatial function, and visuo motor scanning performance and 
high free testosterone levels. Higher mean free testosterone levels and longitudinal free testosterone 
levels were concomitantly associated with a decreased rate of visual memory decline (Moffat et al., 
2002). Significantly impaired spatial reasoning performance was associated with visual memory 
decline in hypo-gonadal males (Moffat et al., 2002). The study therefore suggests a possible beneficial 
effect of free testosterone on cognition. A shortcoming was that participants classified as hypo-
gonadal were on average eight years older than those participants with normal testosterone levels. 
Older participants have been known to have cognitive difficulties due to older age which may be a 
confounding factor (Lunenfield, 2003). Another study found that participants substituted with 
testosterone for six weeks had better spatial memory scores, and constructional ability scores 
compared to a placebo group (Cherrier et al., 2005).  The above behavioural literature illustrates that 
much research from the past has found associations between testosterone levels and impaired spatial 
reasoning ability (Barrett-Connor et al., 1999; Fonda et al., 2005; Moffat et al., 2002). The MR task 
has also been assessed in a longitudinal nine month neuroimaging (fMRI) study with ADT patients 
compared to matched healthy controls (Cherrier et al., 2010). Reductions in right parietal occipital 
lobes were apparent when ADT patients performed the MR task compared to controls (Cherrier et al., 
2010) leading to worse performance. This suggests ADT patients may suffer from spatial deficits 
during ADT treatment. Therefore, testosterone deprivation could lead to neuronal impairments which 
will be assessed in the current research. 
 
Neural substrates associated with both tasks aforementioned are speculated to be areas of activation in 
the present study of healthy participants, but less so in ADT patients due to ADT treatment. Previous 
imaging research has often assessed young samples with an increased difficulty in fMRI paradigms 
(Lineweaver et al., 2005; Potvin et al., 2013). These paradigms could lead to floor effects indicating 
high task difficulty in elderly patients and participants. To account for slower reaction times of senior 
participants (Lewis & Brown, 1994), longer duration stimulus presentation times and inter stimulus 
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intervals will be incorporated. The pilot study below aims to assess if the MR and SS tasks elicit brain 
activation in areas analogues to past research, so that tasks can be incorporated into a longitudinal 
study in ADT patients compared to healthy controls. 
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Pilot Study 
Pilot 1: Imaging task Development 
Pilot one was trialled in healthy controls to assess executive function performance on the stop signal 
(SS) task, and to assess if activated brain regions were consistent with past research. Stimuli and inter 
stimulus intervals (ISIs) were presented with extended durations relative to SS paradigms of previous 
literature. 
Higher levels of performance on go trials were expected compared to stop trials in which more 
commission errors were predicted. The inferior frontal gyrus (IFG), middle frontal gyrus (MFG), and 
anterior cingulate cortex (ACC) were hypothesised to be active on stop trials (successful inhibition) 
and ACC during commission errors. Activation of the motor cortex and cerebellum were speculated to 
be active during go trials 
The mental rotation (MR) task was trialled to assess spatial reasoning ability. Participants with hypo 
gonadal testosterone levels have been found to have lower levels of activation during MR 
performance.  
Participants were hypothesised to make more errors on shapes which have been rotated (experimental) 
compared to shapes which have not been rotated (control).  
This is because the number of correct responses are expected to decrease as the number of degrees 
needed to rotate shapes increase due to increased task difficulty. Conversely, reaction times are 
expected to increase as the number of degrees required to rotate shapes increase. This is because more 
time is required to compare shapes when they are rotated to a greater extent. Areas of precentral gyri, 
precuneous cortices, lateral occipital lobes, and supramarginal gyri are expected to be activated during 
experimental tasks. 
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Methods 
Design 
The SS task was assessed with a within subjects fMRI event-related design and the MR task was 
assessed with a within subjects fMRI block design. This was to ensure that tasks functioned correctly 
and to confirm that brain regions activated were in line with previous research. Participants were 
tested once only. 
Participants 
Three participants were recruited (females = 2: males = 1; Age: 22.4 + 4.2) for the SS task. Three 
participants were separately assessed on the MR task (females = 2: males = 1; Age: 27.2 + 3.1). 
Participants were recruited on the basis that they were healthy, had no previous medical conditions, 
and had normal to corrected vision. 
Brain imaging task 
Stop signal task. 
In the stop signal task, participants were presented with a white fixation cross (500ms) followed by a 
yellow hash (#) symbol in the centre of the screen. Hash symbol timings were separated into no 
flicker (350ms), short flicker (800ms), medium flicker (900ms), and long flicker (1000ms) durations. 
The hash symbol was always yellow in colour and presented on a black background.  After each 
presentation of a flicker or no flicker trial a blank screen was presented (inter stimulus interval) (ISI) 
which was randomly jittered between 2800ms, 3000ms, or 3200ms. The ISI started at the offset of an 
ending stimulus and ended at the onset of the white fixation point. The ISI was jittered to make the 
task more unpredictable so that the BOLD response did not habituate, and to avoid co-linearity in 
BOLD responses. This thereby increased the efficiency of the design. Go trials (no stop signals) 
consisted of no flicker trials in which the hash symbol did not flicker. Participants were instructed to 
press their right index finger onto a 2 x 2 NATA response pad on these trials. Stop signals (inhibition 
trials) consisted of flickering hash symbols which was composed of short, medium and long durations 
in which participants were instructed to refrain from responding. Participants were primed and 
provided with instructions before completing the task from the researcher. The task was split into two 
runs each containing 100 trials with 200 trials in total. Ordering of no flicker and flicker hash symbols 
were randomised (For durations of hash symbols see figure 1). No flicker signals comprised 60 per 
cent of these trials and stop signals made up 40 per cent of trials [short flicker (15), medium flicker 
(15) and long flicker (10)].  Apart from randomisation of stimuli, each run was identical. The duration 
of each run was 7 minutes 21 seconds 
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Figure 1: fMRI illustration of the stop signal task. (A) No flicker timings (go trials) in which participants must 
respond on a response pad. Arrows under hash symbols represent when participants must respond. (B) Stop 
trials were separated into short, medium, and long trials. In parts (A) and (B) of figure 1, blank screens labelled 
as ‘jitter’ were jittered around the temporal resolution of 3 seconds. Jittered durations varied between 2800ms, 
3000ms and 3200ms in a random order. Parts (A) and (B) were presented in random order. Abbreviations: ISI, 
interstimulus interval; ms, milliseconds.       
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Mental rotation task 
The MR task consisted of a 7.5 minute run with eight alternating 38 second blocks separated by 20 
second rest periods. Blocks comprised of experimental and control conditions each repeated four 
times during the functional run. Eight shapes were presented per block. The task was adapted from 
Shepard and Metzler (1971) MR task in which 3D shapes are displayed on a blank screen. In 
experimental blocks, one shape from each pair was rotated along its vertical axis at 60, 120, 180 or 
240 degrees and contained identical shapes whilst the other half contained rotated mirrored shapes. 
Un-rotated identical or mirror shapes were presented in the control condition. Participants had to 
determine if shapes were identical or mirror images by pressing either their right index or middle 
finger respectively in both conditions. Slides were presented for 3750ms followed by a fixation point 
on a blank screen for 750ms. 
Both SS and MR tasks were designed using E-prime 2.0 which triggered MR image acquisition and 
collected behavioural data consisting of responses and reaction times. 
 
Imaging Acquisition. 
 
Sagittal T1 structural images were obtained using a 3.0 T scanner (Philips). Blood oxygenation level 
dependent (BOLD) signals were acquired with a gradient echo planar imaging (FEEPI) sequence in 
the sagittal plane (thickness of 1mm), repetition time (TR) = 8.4s, echo time (TE) = 3.8ms, flip angle 
= 7.16°, field of view = 230 × 175 mm, matrix size = 288 x 288. Voxel dimensions were 1mm x 1mm 
x 1mm isotropic. 184 dynamics (images) were acquired for SS tasks with forty contiguous axial slices 
(3mm thickness) per image. These were acquired with TR = 2.5s, TE = 3.80s, flip angle = 90°, field 
of view (FOV) = 240 × 240, matric size = 68 x 68.  A tilted acquisition plane (30o to the rostral > 
caudal tilt) was used and adjusted individually to reduce signal dropout in frontal brain regions 
(orbitofrontal cortex). 
FSL analysis 
Rawdata in Par Rec from the Philips scanner was converted to Neuroinformatics Technology 
initiative (Niftii) format. Structural scans were reoriented using a reorient script in a Linux terminal. 
Structural T1s were then BET extracted using FSL 5.0.8 (Smith et al., 2004) BET brain extraction 
software (Smith, 2002). The point of interest on scans were corrected to determine the centre of the 
cortex for skull stripping. T1s were checked with FSL view to assess quality of skull extraction. Pre-
processing steps included motion correction of images using FSL MCFLIRT. Regular slice timing 
correction was applied with a spatial smoothing full width by half maximum (FWHM) of 8mm. A 
high pass filter was applied to remove low frequency noise thereby allowing better signal to noise 
ratio (SNR). Functional images were co-registered to structural T1s and then co-registered images 
406 
 
were registered to standard MNI space. For functional scans Dummy scans were discarded and only 
voxels with significant (p < 0.05) functional activation were accepted as voxels with substantial signal 
change. 
 
Statistical analysis at the subject level on the SS task was carried out at a single subject level first 
using the general linear model (GLM) in FSL. Stop signal task durations were separated into four 
conditions: go correct, go incorrect, stop correct, and stop incorrect which were convolved with the 
GLM. Trials associated with gin and sc runs were paired together due to low trial power on gin trials. 
Moreover, both trials required inhibition. The stop signal task was additionally decomposed into trials 
of long (correct/incorrect), medium (correct/incorrect) and short (correct/incorrect) and run as 
contrasts. Long flicker trials were compared against short flicker correct trials and medium flicker 
correct trials to determine which trials produced maximum inhibition activation. Long flicker correct 
trials were also run against go correct trials separately as this allowed comparison of maximum 
inhibition activation compared to response (go trial) activation.  
The mental rotation task was spilt into experimental and control task trial duration which were 
convolved with the GLM. Experimental conditions were contrasted against the control condition. 
Contrasts were run with the general linear model in FSL and the canonical hemodynamic response 
function was used to model activation.  For both tasks, first level analysis was performed with an 
uncorrected z-threshold with p < 0.05 for voxel activation.  Analysis of single subjects were combined 
using a higher level analysis and mixed Flame effects stats were implemented to correct for multiple 
comparisons with a z-threshold of 2.3 and 1.3. A cluster significance threshold of p < 0.05 was used 
to locate any voxel clusters surviving multiple comparisons.  
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Results  
Stop signal task 
First level analysis showed slight activation of IFG and MFG. However, group level analyses with 
mixed flame did not survive multiple comparison correction (cluster z-threshold 2.3). A lower cluster 
threshold was implemented but the chance of making type7 1 errors (false positives) using these 
methods were high, and did not confirm any reliable activation. Supplementary contrasts were run 
between short correct, medium correct, and long flicker correct response trials on stop signal runs. 
Activation of inhibition areas during long flicker runs were typically in the IFG, MFG and 
paracingulate gyrus. A contrast of long flicker correct minus go correct trials run at a minimum Z 
threshold corrected for multiple comparisons of 1.3 and showed most activation in the right MFG 
(MNI coordinates: x = 34; y = 18; z = 30; cluster size = 220 voxels; local maxima Z = 1.67; p < 0.05), 
right IFG (MNI coordinates: x = 58; y = 18; z = 22; cluster size = 140 voxels; local maxima Z = 1.53; 
p < 0.05), and paracingulate gyrus (MNI coordinates: x = -4; y = 30; z = 34; cluster size = 51 voxels; 
local maxima Z = 1.74; p < 0.05). This contrast was undertaken to clarify that inhibition was 
contained to primarily long flicker trials. Medium correct or short flicker trials did not activate any 
typical stop signal areas when contrasted with long flicker or go correct trials. Behavioural 
performance indicates lack of commission or omission errors. 
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Mental rotation task 
Activation was significant at an uncorrected threshold (P < 0.05) in bilateral supramarginal gyri, 
precentral gyri, supramarginal gyri, and lateral occipital cortices (MNI coordinates table 1). Activated 
areas were consistent with past research; however, no activation was present at Z = 2.0 or 2.3 
thresholds. Therefore, these findings were not considered to be reliable due to high probability of type 
1 errors. Behavioural performance showed a higher proportion of incorrect responses were made 
when discriminating between task pair shapes which had been rotated compared to control shapes 
which were unrotated. 
 
Table 1.  Regional brain activations for mental rotation task (uncorrected; p < 0.05) 
        MNI coordinates             Z 
Contrast  Side  Region   X  Y Z value 
Task - Control  L Supramarginal gyrus  -50  -38 50 3.03 
R Supramarginal gyrus  48 -34 50 3.34 
L Lateral occipital cortex  -26 -64 46 4.52 
R Lateral occipital cortex   32 -64 50 3.38 
R/L Juxtapositional lobule   -2   6 46 3.23 
L Precentral gyrus  -40  4 44 3.19 
R Precentral gyrus   40 -4 44 3.29  
L Superior frontal gyrus  -22  0 64 3.46 
Abbreviations: L, left; MNI, Montreal Neurological Institute; R, right. 
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Figure 2: Task condition compared to the control condition contrast. Axial and left hemisphere 
sagittal whole brain activation view (p < 0.05; uncorrected). Colour bars represent least (red) to 
most (yellow) activation on brain activation maps. Abbreviations: A, Anterior, P, posterior; R, right. 
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Discussion 
Stop signal (SS) task activation was not analogous to previous literature and to the present studies 
hypothesis (Menon, Adleman, White, Glover, & Reiss, 2001; Rubia et al., 2001). Motor cortex 
activation was not apparent in pilot study one but may be more widespread in succeeding trials if inter 
stimulus intervals (ISI) between go and stop signals were shorter in length. This could reduce reaction 
time responses leading to forced motor activation. A subsequent study was run with a third participant 
using short ISI jitter periods (1800ms, 2000ms, 2200ms) but no motor cortex activation was found. 
The cerebellum was activated in the aforementioned study and has been associated with motor 
control, fine motor movement, accuracy and timing (Van Mier & Petersen, 2002). Nevertheless, 
activation at low thresholds made the task unreliable thereby making the task invalid for further use. 
A weakness of pilot study one may be of low power issues due to fewer trials. Past research has 
incorporated a high proportion of total trials with high overall power. This allows for reliable 
activation at high thresholds (Bissett & Logan, 2011; Li et al., 2006; Li et al., 2008). With this in 
mind, increased trial numbers in further pilots could activate recognised SS task areas compared to 
pilot study one. 
 
Participants in pilot study one made every few commission errors which may have led to inactivity of 
the anterior cingulate cortex (ACC), or insula in conjunction with past research (Ramautar, Slagter, 
Kok, & Ridderinkhof, 2006). Researchers speculate ACC and insula activity may be due to error 
feedback processing (Ramautar et al., 2006). Error feedback allows response adjustments to be made 
on subsequent trials from faults made on previous trials (Ridderinkhof, Guido, & Gordon, 1999). The 
above pilot study did not account for this phenomenon due to low frequency of commission errors 
made. Furthermore, the majority of commission errors were made on long flicker correct trials which 
led to the most inhibition activity related to the IFG, MFG, and ACC when contrasted with other 
flicker durations. Inactive BOLD signal in areas hypothesised to be activate led to a further 
behavioural pilot study. The design of the SS task was altered so that participants were more likely to 
make commission errors. If behavioural performance is in line with past research then it may be 
plausible that the IFG and MFG are activated due to increased monitoring and unpredictability of 
subsequent trials on the task. This is referred to as the new SS task. Unpredictability of trial durations 
could engage participants in inhibition behaviour rather than prediction behaviour on subsequent 
trials. 
 
Activation on the mental rotation (MR) task was consistent with past research (Zacks, 2008) at an 
uncorrected threshold (p < 0.05). One shortcoming to this is that any activation could be due to noise 
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rather than actual signal. Participant feedback suggests a floor effect in which rotation task shapes 
were highly demanding to mentally manipulate. This likely disengaged participants from the task or 
led to increased errors. Interestingly, one participant achieved an 80% correct response rate which 
coincided with BOLD activation in regions typically associated with the MR task. This led to the 
speculation that a higher percentage of correct responses could indicate internal mental rotation, 
eliciting activation in brain regions typically associated in the MR task. In support of this assumption, 
MR task performance in literature of the past reports 94.6% accuracy in healthy controls compared to 
patients diagnosed with schizophrenia (76.7%) (Potvin et al., 2013). With this in mind, behavioural 
tasks in the second behavioural pilot aimed to replicate the above findings in healthy control 
participants. This should lead to brain activated regions consistent with previous MR tasks in a 
following fMRI study. 
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Pilot Study 2: Behavioural Study. 
 
The stop signal (SS) task and mental rotation (MR) task were piloted behaviourally with the 
contingent hypothesis being that if behavioural performance is consistent with past research, then it is 
plausible to suppose that brain areas activated are in typically task associated regions.  
 
The new SS task inter stimulus interval (ISI) durations were decreased. This was to make stimuli 
presentation less predictable. Long and short flicker trial frequency were increased whilst medium 
flicker trials were decreased. These is because the majority of task activations were found to be from 
long flicker trials compared to short flicker trials in pilot study one. Fixed SSD durations were altered 
in which the initial stop duration was varied between short, medium, and long flicker trials.   
 
Participants were hypothesised to make more commission errors on inhibition (stop) trials due to 
variable ISI periods and because initial stop trial durations were altered to make flicker presentation 
unpredictable. Errors were expected to increase due to inconsistency of stimuli presentation lengths, 
and higher frequency of long flicker trials. Instructions to participants clearly stated that go trials (no 
flicker) were reaction time tasks to decrease reaction times. 
 
Shapes in the MR task were altered so that fewer blocks were used per shape and no oblique 
projecting shapes were presented. Previous research has employed these methods allowing increased 
mental rotation efficiency.  
 
The altered version of the task is speculated to allow better mental rotational ability. Participants are 
expected to have significantly better performance on the new MR task compared to the task of pilot 
study one.  
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Study Design 
 
The new SS task was assessed with a within subjects design in which participants completed the old 
and new SS task in one session. There were two IVs (new or old stop signal task) with two levels. 
These were short flicker correct and long flicker correct trials. Old and new SS tasks were each run 
twice (figure 1) and in a counterbalanced order. 
The MR task similarly had two IVs of old or new tasks with two sub levels (rotated and un-rotated 
shapes). 
 
Participants 
Twenty-one participants (male = 12, females = 9; mean age: 20.2 + 3.01) were assessed on the new 
SS task. Two participants were excluded due to unforeseen circumstances and being performance 
outliers. The final analysis was conducted on 19 participants (mean age: 20 + 2.98). A separate cohort 
of 23 participants (male = 4, females = 19; mean age: 19.7 + 2.33) were assessed on an altered version 
of the MR task. The only inclusion criterion was that participants should be healthy, have corrected 
vision, and have no history of serious or major medical conditions.  
 
Procedure 
Subjects were assessed individually on an Acer aspire laptop in controlled conditions limiting 
interference from external environmental factors. Ethical consent was taken (Appendix 2 & 3) after 
which instructions for either the SS task or MR task were administered verbally. Practice trials of each 
task was administered and consisted of similar trials to the new versions of paradigms. Instructions 
were presented but only 10 stimuli from each task were undertaken to avoid practice effects. 
Instructions were repeated a maximum of twice if necessary. If further instruction was required then 
they were administered verbally only without stimuli practice to avoid practice effects. One group 
undertook a 45 minute session of both versions of the old and new SS tasks and another separate 
cohort undertook a 45 minute session of both the old and new versions of the MR task. 
Stop signal task 
Participants were presented with a white fixation cross for 500ms followed by a yellow hash (#) 
symbol in the centre of the screen. Hash symbol durations were separated into go trials (no flicker) 
and stop trials (short flicker, medium flicker, and long flicker) presentation timings (figure 3). The 
hash symbol was always yellow in colour and presented on a black background. All stimuli durations 
were kept equal (700ms) and a jittered blank screen duration (ISI) was presented subsequently after 
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each stimulus to make trial occurrence unpredictable. Jitters (0ms, 200ms or 400ms) occurred at the 
end of each ISI and before the fixation point. An algorithm was used to create ISI durations which 
were contingent upon the timing of the jitter at the beginning of each trial. This allowed trial length 
including hash trial jitters and ISIs to always be 2.5 seconds in length. Subjects were required to 
respond on a keyboard to no flicker trials and to inhibit responses on stop trials. Go trials comprised 
60 per cent of all trials and stop signals encompassed 40 per cent of trials [short flicker (15), medium 
flicker (5) and long flicker (20)].  Ordering of no flicker and flicker hash symbols were randomised 
(For durations of hash symbols see Figure 3). Apart from randomisation of stimuli each run was 
identical. The duration of each run was 5 minutes 14 seconds and experiments were split into two runs 
each consisting of 100 trials with 200 trials in total.  The task was made using E-prime 2.0 which 
collected behavioural data consisting of keyboard responses (correct, inhibited, incorrect and reaction 
time) and reaction times. 
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Figure 3: fMRI illustration of the Stop signal task. (A) No flicker timings (go trials) in which participants must 
respond. Arrows under hash symbol figures represent when participants should respond. (B) Stop trials were 
separated into short, medium, and long trials. In parts (A) and (B) of figure 1, blank screens labelled as ‘jitter’ 
were jittered around 0, 200 & 400ms. Blank screens labelled ‘algorithm (ISI)’ had durations which were 
contingent on jitter durations. These intervals varied between 1100ms, 1300ms and 900ms. Parts (A) and (B) 
were presented in a randomised order. Abbreviations: ISI, interstimulus interval; ms, milliseconds.       
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Mental rotation task 
The mental rotation task was as described in pilot study one. Complexity of shapes were reduced by 
decreasing the number of blocks per shape. Moreover, 3D blocks were altered to exclude blocks 
projecting in oblique directions (figure 4). 
 
 
Old task 
example 
 
 
 
 
 
 
 
New task 
example 
 
 
 
 
 
 
 
 
 
 
Figure 4: Shows change and modification of task from pilot study one to the new task of study three. 
The old task used many oblique angles which were removed from the new task of study two. 
Abbreviations: ms, milliseconds. 
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Findings 
Assumptions for a parametric test were met. These were that the data were interval level, independent 
of each other and normally distributed. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Percentage of mean correct responses and commission errors made by participants to short 
and long flicker stimuli in old and new stop signal tasks. 
 
Stop signal task 
Participants made significantly more commission errors on the old SS task compared to the new task 
(10.53 + 3.17), t(18) = 2.41, p = 0.03, r = 0.43).  
A two way ANOVA was conducted with one IV being task type (old or new). The other IV was the 
flicker trial (short flicker and long flicker) with the dependent variable being the number of 
commission errors made. Main effects revealed a significant difference in commission errors 
depending on the type of task this being old or new: F(1,18) =  8.71, p = 0.009, partial η2 = 0.33). The 
main effect of flicker trial (short or long) was also significant: F(1,18) = 126.97, p < 0.001, partial η2 
= 0.87). However, the interaction between task type and flicker trial was not significant: F(1,18) = 
0.215, p > 0.05).  
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Pairwise Bonferroni corrections between the old and new task revealed a non-significant but trending 
difference in mean number of commission errors made (old: 38.37 + 4.29) (new: 29.31 + 3.72) (p = 
0.09, confidence interval: 2.90 to 17.22). Significant differences were found in the mean number of 
commission errors made on short flicker trials (16.48 + 4.02) compared to long flicker trials (50.20 + 
3.83) (p < 0.01, confidence interval: -40.00 to -27.43). However, this finding could not explain 
differences in mean number of commission errors made between short and long flicker trials in the 
new task compared to the old task, illustrated by the non-significant interaction.  
Taken together, these results suggest that differences in the number of commission errors made 
between the old and new tasks were significant. This suggest that more commission errors were made 
in the old task compared to the new task and that more errors were made on long flicker trials 
compared to short flicker trials. However, no significant interaction emerged suggesting no difference 
in the number of commission errors made between old and new task short flicker trials and between 
old and new task long flicker trials.  
Mental rotation task 
A paired sample t-test showed significantly more mean correct responses in the new MR task (22.55 + 
4.81) opposed to the old MR task (16.40 + 4.02): t(19) = -5.37, p < 0.001. A further repeated 
measures one-way ANOVA revealed that the number of correct responses decreased as the number of 
degrees needed to mentally rotate shapes increased in the old MR task: F(3, 66) = 4.17, p < 0.01, 
partial η2 = 0.27. Posthoc Bonferroni pairwise comparisons indicated more correct responses in the 60 
degree condition (5.17 + 0.36) compared to the 240 degree condition (3.83 + 0.35) in the old MR task 
(p = 0.04, confidence interval: 0.05 - 2.64). A trend to sacrifice reaction time for accuracy was found 
as mental rotation required increased: F(3, 66) = 2.62, p = 0.06, partial η2 = 0.10.  
Analysis on the new MR task demonstrated decreased performance as the number of degrees required 
to rotate shapes increased: F(3, 66) = 6.70, p < 0.001, partial η2 = 0.23. Bonferroni correction 
revealed significantly better performance in the 60 degree condition (mean correct: 6.30 + 0.34) 
compared to the 180 degree condition (mean correct: 4.83 + 0.31) (p < 0.001). Again, a trend towards 
sacrificing reaction time for accuracy was found with increasing rotation required: F(3, 36) = 0.56, p 
> 0.05 ).  
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Figure 6: Mean percentage of correct responses (upper panel) and mean reaction time (lower panel) on the 
mental rotation test as a function of degree of orientation from vertical. Participants’ performance decreased 
and reaction time increased as the number of degrees needed to mentally rotate shapes increased. This was 
more evident in the old task compared to the altered MR task. Abbreviations: ms, milliseconds. 
 
 
 
 
420 
 
 
Discussion 
Significant differences were observed between the old SS task and new SS task and between flicker 
trials. However, this was in the opposite direction to the prediction of pilot study two. Fewer 
commission errors were made on the new task compared to the old task. Further analysis of short and 
long commission errors revealed the majority of errors were made on long flicker trials. This suggests 
the old SS task of pilot study one demanded more inhibitory ability compared to the new task. This is 
in contrast to what was predicted. 
 
Better performance was found in the new MR task in line with past research (Potvin et al., 2013) 
compared the old task. Moreover, performance decreased as a function of degree of orientation from 
vertical. This was more apparent on the old task compared to the new task leading to the assumption 
of better internal mental rotation ability with new task shapes. The new task will be implemented in 
further pilot assessments and is speculated to elicit brain activation consistent with past research. This 
is due to higher performance rates as a function of degree orientation from vertical, analogues to the 
performance of the participant in pilot study one. 
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Pilot study 3 
A longitudinal three month study was conducted to assess activation consistency of the MR task from 
pilot study two and a new SS task. Two SS tasks failed to activate brain regions consistent with past 
research in pilot studies one and two. As above-mentioned, this may be due to the lack of commission 
errors made. The subsequent pilot was undertaken to establish if areas previously associated with the 
SS paradigm were activated with further alteration to the SS task. Brain activity elicited from the MR 
task in pilot study two was also trialled to measure activation consistency over the three month period. 
  
 
Participants 
Four participants were recruited (females = 3, males = 1; Age = 28.2 + 2.3). Participants were neuro-
imaged with the SS task from baseline to three month follow-up period. All participants were assessed 
on the MR task at baseline and one participant (female; Age = 33) was assessed at the three month 
follow-up period. 
 
Brain imaging task 
Stop signal task 
Task presentation durations were similar to those of pilot study two in which stop signal delays (SSD) 
were fixed. However, the ISI was presented for 3000ms initially and either increased if a correct 
inhibition was made in the previous trial, or decreased by 50ms if a commission error was made in the 
previous trial. The ISI duration increased to a maximum of 3400ms and did not increase further even 
if correct inhibitions were made. The minimum ISI duration was 2600ms and did not decrease further 
even if further commission errors were made.  
Mental rotation task 
The MR task design was as described in pilot study two with the new task design from pilot two. 
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Figure 7: fMRI illustration of the Stop signal task. (A) No flicker timings in which participants must press the 
button on response pad. Arrows under hash symbol figures represent when participants must respond. (B) stop 
trials were separated into short, medium, and long trials. In parts (A) and (B) of figure 2, blank screens labelled as 
ISI algorithm were varied in their duration and increased or decreased in duration depending on if the participant 
responded or inhibited correctly.       
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Imaging Acquisition. 
fMRI scanning sequences were as described in pilot study one. 
FSL analysis 
Analysis was as described in pilot study one. 
SPM Analysis 
Rawdata par rec files produced by the Philips scanner were first extracted and converted into 
Neuroinformatics Technology initiative (Niftii) format for use in SPM5 (Welcome Department of 
Cognitive Neurology and collaborators, Institute of Neurology, London, UK (SPM5: 
http://www.fil.ion.ucl.ac.uk/spm) on Matlab version 7.9.0.529 (R2009b). Volumes were slice time 
corrected for the two SS task runs and one MR task run. Slice time correction was undertaken on 184 
slices acquired per run in both tasks. The repetition time (TR) was inputted as 2.5 seconds and the TA 
calculated as TR/(TR/number of slices). Slice order was entered in a regular up ascending order from 
slices 1 to 184. Volumes were then realigned and estimated. Images were realigned to the first image 
of each run, and then all images of each run were aligned to the first volume of the first run. 
Estimation was run with higher 5th degree spline interpolation. Image realignments were assessed for 
any motion in either the X, Y, or Z directions or in terms of pitch, roll, and yaw rotations. A pre-
established exclusion criteria was a correlation between movement parameters and task regressors 
greater than 0.5 or excessive movement. These standards have been associated with best practice 
based on previous fMRI studies (Whalley, Harris, & Lawrie, 2007). No subjects had to be excluded 
using the criteria. The anatomical image (T1) was first viewed to change the origin as the anterior 
commissure for each subject. This was undertaken to increase co-registration and normalisation 
accuracy. Images were subsequently co-registered to the mean reference epi image from the 
realignment procedure. The source image was the anatomical (MPRAGE) image which was revolved 
to be in alignment with the reference epi image. All functional images were realigned to the reference 
epi image with trilinear interpolation and then normalised to the standard SPM5 MNI EPI template. 
Normalization parameters were estimated using the mean image for each run, and applied to all 
volumes of that run. An 8mm3 full width by half maximum (FWHM) Gaussian kernel was used to 
spatially smooth normalised images. Smoothing involves the notion that nearby voxels with 
significant activation may have BOLD activation compared to those voxels distant from a specific 
voxel region. This allows amplification of true signals and increases signal to noise ratio.  
 
Statistical analysis at the subject level was carried out using the general linear model (GLM). Default 
settings were implemented from SPM5 with an SS task design matrix consisting of four conditions 
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including go correct, go incorrect, stop correct, and stop incorrect trials. The mental rotation task was 
composed of two conditions which were the task condition and control condition. Regressors were 
convolved with the traditional canonical hemodynamic response function model (hrf) to model data. 
A high pass filter of 100s cut-off was implemented to remove low frequency noise components such 
as drift. 
The main SS task contrast was of stop correct trials and go incorrect trials together verses go correct 
trials. This was the most efficient combination of inhibition trials against go trials. The contrast of 
interest in the MR task was the task condition against the control condition. A script was generated 
using SPM’s jobman to automate the entire preprocessing and statistical analysis processes.  
Reproducibility (intra class coefficient). 
Intra-subject reliability was calculated using intra-voxel reliability at specific regions of interest 
(Raemaekers et al., 2007). The reliability tool box used for this was designed by (Caceres, Hall, 
Zelaya, Williams, & Mehta, 2009) (http://www neuroimagingsciences.com/). The toolbox analysis 
measures the total amount of variance explained by intra voxel variations, thereby assessing the 
stability of spatial distribution of the BOLD signal in each subject in a selected region.  Consequently, 
this method can be used to assess between subject differences. The median and standard deviation 
were attained with a bootstrap method of 1000 resamples of subjects. Spatial smoothing can critically 
affect findings of intra-voxel ICC (Caceres et al., 2009). Therefore, rawdata was pre-processed using 
an 8mm smoothing kernel which has been demonstrated as being an optimal method in past research 
(Caceres et al., 2009). A one sample t-test was used to obtain the activation network of both baseline 
and follow-up sessions at a group level. Peak voxel region of interests (ROIs) were extracted and 
masked for further intra-voxel ICC analysis. The rIFG, right inferior parietal gyrus and ACC were 
extracted for analysis from SS task network activation. Regions with activation were significant at a 
cluster level FDR corrections (p < 0.05) and obtained with a voxel-wise extent threshold K = 20 voxel 
extent (Table 4 and 5).  The MR task showed significant activation in areas of the left and right 
supramarginal gyri, and superior parietal lobe which were extracted.  Masks were separately extracted 
using MarsBar toolbox (Brett, Anton, Valabregue, & Poline, 2002).  Reliability measures were 
implemented into Matlab toolbox with SPM5. 
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Behavioural findings 
Stop signal task 
 
Table 1.  Descriptive statistics for go and stop trials (pilot study three) 
 
Trial type   Baseline  Follow up   
 
Go        
    Accuracy (%)             76.11 + 1.92  75.00 + 2.83 
    Reaction time (ms)  602.61 + 29.21   618.75 + 30.36   
Stop 
    Commission errors (%)  32.08 + 2.92  27.92 + 5.42 
    Failed RT (ms)   525.24 + 6.22  523.19 + 66.05 
    Critical SSD (ms)  350   350   
    SSRT (ms)   267 + 314.67  338 + 331 
     
Abbreviations: ms, milliseconds; RT, reaction time; SD, standard deviation; SSD, stopsignal 
delay; SSRT, stop-signal reaction time 
 
Task performance 
Performance on go and stop trials are separately shown in table one. Baseline to follow-up session 
performance and reaction times were assessed with paired sample t-tests. However, no significant 
differences were found longitudinally.  Stop signal reaction time (SSRT) was acquired with the most 
commonly used integration method (Logan & Cowan, 1984). This method is estimates the SSRT by 
subtracting the SSD from go RT distribution. The go RT distribution can be acquired by rank ordering 
all go trial reaction times. The nth go RT is then selected and subtracted from the median SSD. This 
process is repeated for each participant and then averaged. For example in a session of 20 trials from 
which go RT can be measured, there are four stop trials (one correct stop and three incorrect stop). 
The probability of correctly stopping is 0.25, therefore, the probability of responding is 0.75. The stop 
signal is presented 350ms after the initial go onset of the go stimulus. Go RT are 300, 320, 340, 380, 
400, 410, 420, 460, 500, 520, 540, 550, 590, 600, 700, 750ms. 
n = number of go RTs (which can be measured) x probability of response on stop trials. 
n therefore = 16 x 0.75  = 12 
the 12th reaction time is 550ms. 
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Therefore, the stop process finishing estimate is 550ms after the onset of the go stimulus. Subtraction 
of this from the SSD which is 350ms is 550-350 revealing an SSRT of 200ms (example from Eagle et 
al. (2008) 
Table 2.  Descriptive statistics for go and stop trials between pilot study 
one and pilot study three. 
 
Trial type   pilot 1   pilot 3   
 
Go        
    Accuracy (%)             91.6 + 4.33  79.44 + 3.76*   
    Reaction time (ms)  1256.89 + 14.66  618.75 + 30.38**   
Stop 
   Commission errors (%)  18.10 + 6.85  30.33 + 5.51*   
    Commission errors RT (ms) 695.55 + 24.66  524.22 + 34.79 
    Critical SSD   900ms   350ms 
    SSRT (ms)   112 + 23.25  290.83 + 103.54*  
  
Pilot three means and SD were averaged between baseline and follow-up assessments. 
Abbreviations: ms, milliseconds; RT, reaction time; SD, standard deviation; SSD, 
stopsignal delay; SSRT, stop-signal reaction time; *p<0.05; **p<0.01. 
 
 
Table two shows SS task performance on go and stop trials between pilot studies one and three. An 
independent samples t-test revealed differences in go trial accuracy between study one and three. 
Findings show a higher percentage of accuracy in study one compared to study three: t(4) = 3.67, p = 
0.02. Reaction times in study three were also significantly quicker compared to study one: t(4) = 
32.77, p < 0.001. Commission error reaction times were significantly quicker in study one compared 
to study three t(4) = 6.96, p = 0.02. No significant differences emerged between the percentages of 
commission errors made in study one compared to study three. However, a trend was found in which 
more commission errors were made in study three in line with past research and the hypothesis of 
pilot three. An independent samples t-test was employed to assess SSRTs between pilot study one and 
three. This revealed significant increases in SSRT in pilot three compared to pilot one t(4) = 2.91, p = 
0.04.  
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Mental rotation task. 
 
Table 3.  Descriptive statistics. Pilot studies one and three 
 
Trial type  pilot 1    pilot 3 
MR task performance 
    Accuracy (%)            52.09 + 17.21   67.71 + 20.81   
    Reaction time (ms) 2457.44 + 64.45   1922.59 + 103.55**  
Divided degrees 
    60 degrees   
    Accuracy (%)  54.16 + 14.43   79.16 + 14.43 
    RT (ms)  2386.80 + 315.35   1783.30 + 267.67 
120 degrees    
    Accuracy (%)  37.50 + 0.00   58.33 + 14.43 
     RT (ms)  2382.07 + 119.07   1907.01 + 239.92 
180 degrees 
    Accuracy (%)  33.33 + 19.09   62.50 + 12.50 
    RT (ms)  2509.36 + 371.06   2223.07 + 313.02  
240 degrees 
    Accuracy (%)  62.50 + 25   62.50 + 33.07 
    RT (ms)  2596.06 + 79.46   1949.78 + 299.91 
Abbreviations: ms, milliseconds; RT, reaction time; SD, standard deviation; **p<0.01 
 
 
An independent samples t-test revealed no significant differences between the average MR percentage 
accuracy of pilot one compared to pilot three. However, faster reaction times were apparent in study 
three compared to study one: t(2) = 23.46, p = 0.002 in line with the hypothesis of pilot three. Further 
analyses were undertaken to evaluate differences between the percentages of correct responses and 
mean reaction time as a function of degree orientation from vertical. A Freidman’s ANOVA was 
employed since data were non parametric and were not normally distributed due to the small sample 
sizes. However, no significant differences were found in study one or study three using this analysis. 
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Functional fMRI findings 
Stop signal task 
The contrast of interest assessed was of inhibition trials minus go correct trials (go incorrect trials plus 
stop correct trials minus go correct trials). Go incorrect and stop correct trials were combined as they 
increased overall inhibition power. BOLD signal activation areas was predominantly found in the 
ACC and right IFG extending into the MFG in line with past literature (Chikazoe et al., 2009; Jahfari 
et al., 2012; Zandbelt et al., 2013). Activation survived correction for multiple comparisons and was 
consistent across participants when analysed individually, and amalgamated at a group level.  
 
Table 4.  Whole brain maximum voxel activations for stop signal task FDR corrected (p<0.05).
   
             MNI coordinates 
Contrast ROI    X  Y Z t-max        ICCv med
                (STE)  
L Insula   -33  14  -1 6.62    0.41 (0.33) 
L inferior parietal lobe  -48 -34 44 6.84    0.47 (0.39) 
Anterior cingulate cortex 6 11 53 7.54  0.63 (0.12) 
R cerebellum   30 -73 -55 6.54  0.55 (0.29) 
  R middle frontal gyrus  39 38 29 9.66  0.58 (0.18) 
  R postcentral gyrus  48 -34 53 7.89  0.43 (0.31) 
  R inferior frontal gyrus  48 20 -4 7.31  0.45 (0.31) 
  Superior frontal gyrus  6 11 53 7.54  0.45 (0.20)  
 
Abbreviations; ICCv med, intra-voxel reliability medians; L, left; MNI, Montreal neurological institute; R, right; 
ROI, region of interest; STE, standard error. Appendix one for ICCv reliability per subject and for each ROI. 
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Figure 7: Stop signal task brain regions of activation in the contrast of successful inhibitions and 
unsuccessful go trials compared to successful go trials. BOLD contrasts superimposed in T1 
structural image in axial sections from z = -10 to z = +58. Adjacent sections are 4mm apart. Colour 
bar represents voxel t-values. Colour bars represent t-values which correspond from least (red) to 
most (yellow) activation on brain activation maps.  
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Mental rotation task 
Areas of activation were compared by contrasting the task condition minus the control condition. 
Consistent neural activation was found in line with past research (Table 4). When baseline and follow 
up sessions were combined, activation was significant at an uncorrected threshold p < 0.001 (Table 
4). 
 
  
Table 5.  Whole brain peak activations for mental rotation task (p < 0.001) uncorrected. 
   Participant one intra-voxel reliability in region of interests. 
MNI coordinates 
Contrast ROI    X  Y Z  t-max              ICCv  
                       med 
Task - control L pyramis (cerebellum)  -12 -67 -40  13.52              0.52 
condition  
L cerebellar tonsil  -15 -58 -52  17.40              0.34 
R precuneous   -3 -58 65  12.97              0.40 
L supramarginal gyrus  -42 -52 29  14.33              0.87 
R inferior semi-lunar lobe 12 -73 -46  18.37              0.56 
R superior frontal gyrus  2 13 57  12.47              0.43 
R inferior frontal gyrus   30 35 -10  13.46              0.49 
Abbreviations; ICCv med, intra-voxel reliability medians; L, left; MNI, Montreal neurological institute; R, right; 
ROI, region of interest; STE, standard error. Appendix one for ICCv reliability per subject and for each ROI. 
 
The table shows median intra-voxel ICC for ROIs with peak voxel activation with most reliability 
found in posterior regions. Frontal regions were not expected to be active however, activation in these 
regions are consistent with past research (Potvin et al., 2013; Zacks, 2008). The range of ICCv values 
for both tasks between baseline and follow-up fall between 0.34 - 0.87. Established conventions 
classify values of ICC of less than 0.4 as poor, between 0.4 - 0.6 as fair and between 0.6 – 0.8 as good 
(Cicchetti & Sparrow, 1981). Furthermore, a review of brain activations amongst a variety of task 
condition found the majority of ICC values amongst studies to be fair (0.50). Moreover, the majority 
of studies reported median ICC values between 0.33 – 0.66 (Bennett & Miller, 2010). 
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Figure 8: Mental rotation task brain regions of activation in the contrast of the task condition 
compared to the control condition. BOLD contrasts superimposed in T1 structural image in axial 
sections from z = -8 to z = +76. Adjacent sections are 4mm apart. Colour bars represent t-values 
which correspond from least (red) to most (yellow) activation on brain activation maps. 
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Discussion 
Pilot study three aimed to first ascertain if activation was consistent with past research and secondly, 
to determine if activation was reliable over a longitudinal study interval. Both the SS task and MR 
task failed to activate neural networks that matched past research in pilot study one. However, pilot 
study three was successful in producing activation over a longitudinal period in line with earlier 
literature on the SS task (Aron, 2007; Aron & Poldrack, 2006; Chevrier et al., 2007; Li et al., 2006) 
and MR task (Lineweaver et al., 2005; Potvin et al., 2013; Zacks, 2008). One constraint of the pilots 
above was of low multiple comparison thresholds required to detect activation. This may be 
attributable to small sample sizes. However, both tasks did show reliable activation across a three 
month baseline to follow-up period despite low thresholds. Peak voxel activations were used to assess 
reliability, supporting that both activations and paradigms trialled were robust. Reliability of the 
longitudinal period leads to the conclusion that the tasks can be incorporated further with larger 
clinical and healthy sample sizes. The MR and SS task elicited activation in putative areas and will be 
incorporated in the future longitudinal clinical study. Both tasks showed activation of typically fronto-
parietal network regions characteristic of executive function tasks requiring higher order 
computations. More importantly, these networks are areas in which ADT patients have difficulty 
during and after treatment. 
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General Discussion and Plans for Future Research 
Pilot study one did not elicit regional brain activation on the SS task and MR task consistent with past 
research and of the studies hypothesis. Pilot study two was conducted with altered versions of both 
tasks to assess behavioural performance which if analogues to findings in past research, was 
speculated to activate brain regions comparable to the main studies hypothesis. An altered MR task 
with reduced difficulty was made and behaviourally tested with findings indicating fewer errors were 
made on the new task. This led to mental rotation related activity in brain regions analogues to past 
research in pilot three. The SS task was altered to contain a higher frequency of long flicker trials and 
short ISI jitter periods between go and stop signals. This was hypothesised to reduce trial 
predictability and increase commission error percentage. If commission errors significantly increased, 
then it was proposed that inhibitory brain regions were activated. Findings indicated that more 
commission errors were made on the old task compared to the new task in contrast to what was 
predicted. Pilot study three was conducted with variable ISI periods and fixed SSDs were altered in 
their duration. Participants made more commission errors in pilot study three and brain activation was 
analogous to earlier research. 
The new SS task generated a higher percentage of errors which could be due to long ISI durations. 
Long flicker trials reduced predictability of subsequent stop signal trials evidenced higher commission 
errors during these trials in pilot study two. Furthermore, most brain activation in pilot study one was 
contained to long flicker trials regardless of high commission errors. Participant feedback also 
informed that long flicker trials reduced predictability in the task forcing inhibitory behaviour. Pilot 
study two incorporated a higher frequency of long flicker trials but failed to increase the overall 
percentage of commission errors and therefore the SS task of study two was not incorporated. Pilot 
study three was altered with variable ISI periods that dynamically changed between trial presentations 
leading to high commission errors. Furthermore, variable ISIs were used because participant feedback 
from pilots one and two reported that long ISIs led to the task being challenging, and subsequent trials 
were unpredictable compared to pilot study two. This prevented habituation to the task. Instructions 
were also altered to emphasise the task was a reaction time experiment to reduce post error slowing. 
Delayed reactions in previous tasks allowed the accommodation and delay for the primary duration of 
a go period in a stop signal trial, thus slowing responses on go trials in conjunction to increase 
accuracy. Internal inhibitory reaction times increased verified by reduced SSRTs in pilot three 
compared to pilot one. This induced internal higher order executive function processing and inhibitory 
activity due to task unpredictability.  
Another consideration was that the SS task incorporated was chosen with fixed stop signal delays. 
The staircase procedure was piloted in one participant however it did not stimulate typical SST neural 
activation. This could be due to the time limitation set on the current paradigm. Whilst some studies 
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claim that performance adjusted delay (staircase procedural) SSDs produce more reliable activation in 
putative inhibitory areas (inferior frontal gyrus, rMFG inferior parietal gyri etc.) (Fauth-Buhler et al., 
2012). These studies incorporated multiple runs with a higher frequency of trials thereby increasing 
total task duration. This created sufficient power through trials alone to detect neuronal activation. 
Other experimental trials have also adopted this methodology with the SSD staircase procedure with 
task durations typically being between 19 – 40 minutes (Elton et al., 2014; Hu & Li, 2012; White et 
al., 2014). The current paradigm was restricted to small durations due to the number of scan runs 
required in the given time frame. This made scanning periods practical as subjects were elderly and 
some had added comorbidities. Elderly participants are known to have more movement artefacts 
during fMRI scans due to head movement especially in long duration scans (Power et al., 2014).  
Therefore, due to these concerns, the task had to be made practical in the given time frame and 
produce brain activation in typically found SST neural areas. Fixed SSDs were used since they have 
been found to elicit similar brain activations compared to staircase procedure SSTs (Fauth-Buhler et 
al., 2012). Moreover, fixed SSDs were successful in eliciting SST brain activations consistent with 
past research in a shorter duration task paradigm. 
 
Neural activity was consistent with past research in typical areas including the IFG, MFG, inferior 
parietal cortex (IPC) (angular and supramarginal gyri), ACC, and superior frontal gyrus (SFG) in pilot 
study three (Eagle et al., 2008; Li et al., 2006; van den Wildenberg et al., 2006; Zandbelt et al., 2013). 
The IFG and MFG have been associated with proactive control behaviour and inhibition (Braver, 
Barch, Gray, Molfese, & Snyder, 2001). Activation of the right IPC has been correlated with rule 
violation such as when a stop signal does not occur, thereby nullifying the stop rule which was 
expected (Zandbelt et al., 2013). Alternatively, IPC involvement could indicate unexpected inhibition 
during an expected go signal leading to activation when correctly inhibiting (Corbetta, Patel, & 
Shulman, 2008). From the above findings it may be proposed that the right IPC, IFG, and MFG are a 
neural network concerned with bottom up processes (updating expectations) rather than a top down 
processes such as expectation of a signal (Corbetta et al., 2008; Corbetta & Shulman, 2002). The ACC 
was involved in the task which may be active due to commission or omission errors according to past 
research (Aron & Poldrack, 2006). The SS tasks of the pilot above did not incorporate feedback which 
could increase ACC activity. However, feedback displays serve as a hindrance in task duration 
especially between TR excitations.  
 
The MR task was designed according to the Shepard and Metzler (1971) task. However, the paradigm 
failed to activate brain regions analogues to past literature in pilot one (Zacks, 2008). This could be 
because shapes were presented in 3D projected oblique angles requiring more time to process. 
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Nevertheless, stimuli presentation and block durations were similar to fMRI tasks previously reported 
(Butler et al., 2006; Potvin et al., 2013; Zacks, 2008). Furthermore, neural activity may not have been 
present due to loss of interest in the task because of high task difficulty. Difficulty of the task was 
verified by very poor performance rates inconsistent with past research (Potvin et al., 2013). 
However, one participant in pilot study one had close to 80 percent correct response rates and had 
activation in well-known MR associated regions. With this in mind a subsequent behavioural study 
with block shapes were assessed to decrease task difficulty. Performance increased in pilot two on the 
altered MR task compared to pilot one. It was therefore plausible to assume the altered version of the 
task activated putative MR task associated neural correlates. Pilot study three demonstrated that this 
assumption was met and brain regions activated were similar to those reported in previous studies 
(Lineweaver et al., 2005; Potvin et al., 2013). The behavioural performance in pilot study three 
demonstrated increased reaction time, and there was a decreasing trend in the number of correct 
responses as a function of shape orientation from vertical. However, reaction time decreased and the 
number of correct responses slightly increased when mentally rotating 240 degrees in the new MR 
task. This could be due to counter clockwise rotation in the altered MR task which was difficult to 
undertake in the old MR task of study one due to high task difficulty. Clockwise and counter 
clockwise rotation in study three could therefore elicit activation in MR associated regions which 
were not found to be activate in study one (Just, Carpenter, Maguire, Diwadkar, & McMains, 2001).  
Brain regions activated were subdivisions of the parietal lobes. These areas included the superior 
parietal lobes, lateral occipital lobes, and supramarginal gyri. Activation of the superior parietal lobe 
converges with neuropsychological data and has been known to be important in visuospatial image 
transformations (Ratcliff, 1979). The superior parietal cortex is associated with implementation of 
spatial maps which code the location of objects to be manipulated (Andersen & Buneo, 2002). This is 
most clearly seen in patients with hemi-spatial neglect with parietal cortex lesions in which space in 
the contralateral side to the lesion is disregarded (Karnath et al., 2001; Malhotra & Russell, 2015). 
Activation of motor regions in the precentral cortex is widely debated in literature during mental 
rotation of shapes (Potvin et al., 2013; Vingerhoets et al., 2001). However, it has been argued that 
motor region activity could reflect computation of motor recreations in relation to joint, or torque 
perspectives (Michelon, Vettel, & Zacks, 2006). This could assist in solving mental rotation problems 
through for example mentally rotating shapes and simulating hand movements (Zacks, 2008). 
Alternatively, motor activity during MR could simply be due to manual button presses (Zacks, 2008). 
Limitations of the current study and tasks to be incorporated in a longitudinal study of prostate cancer 
patients were that age of participants were not in parallel to prostate cancer patients. Elderly 
participants may have decreased executive functioning than younger subjects. Furthermore, 
activations in the tasks assessed were thresholded liberally for multiple comparisons at Z threshold < 
1.8, p < 0.05 and in SPM p < 0.001 (uncorrected threshold or corrected for multiple comparisons in 
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SS task only). The putative stringent level is normally Z threshold < 2.3 corrected for multiple 
comparisons. Thresholds at 2.3 or greater are implemented to discount type 1 errors in significant 
clusters thereby ruling out noise due to head motion, biological artefacts or scanner drift. Therefore 
the current pilot tasks have a higher probability of presenting activation with type 1 errors due to noise 
rather than true signal. Nevertheless, past research with high Z or t scores typically have greater 
sample sizes and are able to safely group findings. The current pilot study only assessed up to four 
participants per task. Therefore, activation areas rather than being conclusive are considered to be 
preliminary and trending in the direction of past research. A further shortcoming of the above pilot is 
of gender differences in the MR task (Parsons, 2004). The conducted MR pilot task used an 
opportunity sample with the majority being female participants. In the above pilot study, females 
tended to have more activation compared to males. This may be due to a larger female sample size or 
due to rotation abilities of female participants. Another explanation may be the ability of males to 
discriminate between two different objects without mental rotation. A study by Hooven, Chabris, 
Ellison, Kieveit, and Kosslyn (submitted for publication) assessed 123 male and female participants. 
Findings presented that males scored higher than females and males were better able to distinguish 
between same and different shapes without mental rotation, compared to female participants. Females 
reported a higher effort load to mentally rotating shapes and objects compared to males. This could 
account for higher fMRI activation in females compared to males in the pilot studies conducted 
above. However, no differences in fMRI activation areas were noted in the pilot above. Finally some 
journals report no sex differences in MR task performance and that context and instructions delivered 
to participants greatly affect their performance (Moè, 2009). Intra-voxel reliability in specific ROIs in 
pilot study three was stable and spatial distributions across voxels during the three month period was 
consistent in recognised areas for both tasks. Some between subject variability was present but 
reliability was consistent with fMRI studies of the past (Bennett & Miller, 2010). 
 
The current tasks are feasible in assessing executive function and spatial reasoning. The SS and MR 
task elicited activations with neural correlates in line with past research. Movement during scanning 
was at minimal levels although it is questionable if older patients require separate sessions to account 
for physical conditions affecting movement. These may be arthritis, osteoporosis or other health 
conditions requiring separate scanning sessions.   
 
In conclusion the results suggest both tasks in pilot study one did not elicit brain activations in areas 
parallel to past research. The MR task did achieve behavioural performance according to previous 
findings but the SS task did not. Pilot study three assessed the altered MR and SS task which elicited 
neural correlates associated with both tasks. Future research suggests tasks are feasible and can be 
437 
 
incorporated in longitudinal cognitive assessments of ADT patients with prostate cancer compared to 
matched healthy controls. 
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Appendix 11: Within subjects statistical analysis of healthy controls  
The main purpose of the within subjects analysis was to assess cognitive change over time and to 
assess if any change was accounted for by covariates (testosterone or psychosocial factors). Primary 
outcome measures were scores on a battery of executive function and spatial reasoning measures. A p 
value of either 0.05 or less was accepted as statistically significant (two-tailed). Paired samples t-tests 
were conducted to assess the level of psychosocial (anxiety and depression) change and testosterone 
level change that occurred from baseline to follow-up. A further t-test was conducted to assess change 
in testosterone levels between time points. A repeated measures multivariate analysis of variance was 
undertaken with contrast scaled scores on the D-KEFS as dependent variables (TMT-A, VF, DF, 
CWI). The Tower test scaled score was added as a scaled score dependent measure since contrast 
were not available for this measure. The repeated factor was time (baseline and six months). Contrast 
scaled scores allow assessment on primary measures whilst controlling for task performance on basic 
items. Scores were also scaled to provide normative age classification performance. A similar 
MANOVA was conducted on the spatial working memory CANTAB task with number of between 
and double errors in the three conditions as dependent variables (4 boxes, 6 boxes and 8 boxes errors 
made). CANTAB strategy scores were compared in a paired samples t test. 
Further MANOVAs were conducted with testosterone levels, HADS anxiety and depression at 
baseline and follow-up as covariates (MANCOVAs) with neuropsychological dependent variables. 
The working memory Index from the Wechsler Adult Intelligence scale (WAIS) was added as a 
covariate so that it could be adjusted for in the spatial working memory index CANTAB task. This 
was to exclusively gauge spatial reasoning performance of healthy participants on the CANTAB 
without the influence of working memory. 
The BRIEF-A assessment was modelled using similar MANOVAs where the dependent variables 
were all scaled scores on the self-report questionnaires (Inhibition, self-shift, self-emotional control, 
self-organisation, ability to initiate, working memory, monitor, behavioural regulation index, 
metacognition and global executive function scores). The grouping variables were questionnaire type 
(self) and time (baseline and follow-up), which were used to model an interaction. Covariates (anxiety 
and depression) were added to the MANOVA in a MANCOVA if differences were found between 
time points only. This was to gauge if covariates contributed to any variance in differences between 
time periods. Testosterone was added to the model regardless of group change to assess if it had any 
mediating effect as it was a key component of the current assessment of participants. 
The use of MANOVAs and MANCOVAs allows the entry of many dependent variables in unison 
which benefits the management of family-wise error rates and reduces type 1 errors. Moreover, 
MANOVA analyses are resilient to violations of homogeneity which is not the case with other 
statistical methods including ANOVAs etc. (O'Brien & Kaiser, 1985).  
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Psychosocial covariates to be added were assessed first and showed the anxiety and depression factors 
were correlated in healthy participants r = 0.41, p = 0.002. Although this relationship was found, the 
covariates were not correlated to the extent that they were excluded from the analysis. Past research 
has found that correlations of r = 0.50 or even 0.80 or above could cause multicollinearity issues 
(Vatcheva et al., 2016). A further MANOVA was conducted to test for homogeneity of regression 
slopes where interactions were modelled between the fixed factor, time and covariates. No significant 
differences were found, concluding that subsequent MANCOVAs conducted did not violate the 
assumption of homogeneity of regression slopes.  
Individual change was calculated for each neuropsychological measure per participant with the 
Reliable change index (RCI) according to the methodology of Jacobson and Truax (1991). This 
method allows the measurement of reliable performance changes across time (i.e. baseline and follow-
up) (Jacobson & Truax, 1991). Calculation of RCI in the current study first required that the test-retest 
reliability coefficient was computed for each measure (rxx). The standard error of each measure SEm 
was then calculated as (SD1 (√[1-rxx]) where SD1 was the standard deviation of group performance at 
baseline. Then the standard error of the difference (SEdiff) was calculated using SEm and the equation 
for this was SEdiff  = √[2(SEm)2] which represented the spread and distribution of change scores 
expected if no change occurred. A 90% confidence interval was set by multiplying the SEdiff by + 
1.645 (Kneebone, Andrew, Baker, & Knight, 1998). Practice effects were controlled for by 
subtracting the follow-up group mean scores by baseline group mean scores, then adding the result to 
the newly calculated SEdiff (Sawrie, Chelune, Naugle, & Luders, 1996). The equation for the 90% CI 
was therefore RCI = SEdiff x (+ 1.645) + practice effect. Finally, each subject’s follow-up score was 
subtracted from their baseline score (T2-T1) so that a difference score could be obtained. If the 
difference score fell outside of the RCI, then a significant and reliable change in cognitive 
performance was thought to have occurred in the subject.  
A chi-square test was conducted to assess the effects of the proportion of participants that increased or 
decreased in testosterone levels affected the proportion of participants that reliably improved or 
declined in performance on cognitive measures. Any relationship between proportions was considered 
significant by using the p < 0.05 alpha value (two-sided). The cross tabulation of any significant chi-
square was assessed to determine the cross-tabulation cells that had standardised residuals (std. 
residuals) above or below +/-1.96 as the alpha level of 0.05 which were then reported. 
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Appendix 12: FSL and SPM analysis 
FSL analysis 
Region of interest analysis allowed the assessment of small clusters of voxels in task related regions 
thereby reducing the amount of error due to multiple comparisons of voxels that could be prone to 
type-I errors and chance findings during whole brain analysis between baseline and follow-up. 
Therefore, the selection of a small number of voxels from a regional spatial distribution minimized 
the chance of errors due to chance findings (Logan et al., 2008). Moreover, temporal signal to noise 
ratio (tSNR) over the spatial distribution has been known to show true change that may not be visible 
during whole brain analysis (Logan et al., 2008). The quantification of the BOLD signal as a percent 
signal also allowed change across a time course to be calculated allowing comparisons to be made. 
Thus the analysis allowed assessment of task related regions without the requirement of stringent 
criteria to assess if voxels were activated and to assess their consistency in activation between time 
periods. While ROI analysis may reduce chances of errors, outcomes from the analysis should still be 
interpreted with caution due to issues of multiple testing since many factors were compared increasing 
the chances of type-I errors. This may lead to increases of chance findings where the null hypothesis 
was rejected for the alternate hypothesis to increase familywise errors. Consequently, signal change 
differences between time points may be susceptible to error. 
SPM Analysis 
SPM analysis was undertaken to investigate intra-class correlations (ICC) in voxel regions of interest. 
The ICC method is an analysis technique used to measure test-retest reliability of the spatial 
distribution of BOLD fMRI voxel activation across separate sessions (Caceres et al., 2009). It uses 
baseline fMRI activation in selected ROIs to predict consistency of intra-voxel activation in 
subsequent sessions in the same region. This allows the measurement of a within subjects analysis of 
repeatability of observations by calculating within subject error variance (Zandbelt et al., 2008). 
Reliable activations are those observations that have less than the agreed limit of within subject 
variance threshold (Bland & Altman, 1986). Correlations are specifically employed to measure the 
strength of reliability between sessions with high correlation indicating greater reliability 
(Raemaekers et al., 2007). Therefore, in the current study, ICCs were employed to measure the 
reliability of activation in the healthy ageing sample across baseline and follow-up. This allowed 
inferences to be made on the integrity of activation in specifically selected regions across a 
longitudinal period. Regional activated voxels were selected from putative SST and MRot task 
activation areas at baseline to predict activation at six months. These regions were selected through 
first level and group level analysis performed with SPM that generated task related contrasts. Regions 
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of interest (ROIs) for voxel ICC reliability were selected through maximal activation voxels in 
baseline group activation maps. These regions were masked and extracted through the SPM Marsbar 
software (Matthew et al., 2002). Masks were implemented into the ICC toolbox designed by (Caceres 
et al., 2009). 
Rawdata par rec files produced by the Philips scanner were first extracted and converted into 
Neuroinformatics Technology initiative (Niftii) format for use in SPM12 (Welcome Department of 
Cognitive Neurology and collaborators, Institute of Neurology, London, UK (SPM)) on Matlab 
version 7.9.0.529 (R2009b). The two SS task runs and one MRot task run were first slice time 
corrected (184 slices per run). The repetition time (TR) was inputted as 2.5 seconds and the TA 
calculated as TR/(TR/number of slices). Slice order was entered in a regular up ascending order from 
slices 1 to 184. Volumes were then realigned and estimated. Images were realigned to the first image 
of each run, and then all images of each run were aligned to the first volume of the first run. 
Estimation was run with higher 5th degree spline interpolation. Image realignments were evaluated for 
any motion in either the X, Y, or Z directions or in pitch, roll, and yaw rotations. A pre-established 
exclusion criteria was a correlation between movement parameters and task regressors greater than 
0.5. These standards have been associated with best practice based on previous fMRI studies 
(Whalley, Gountouna, et al., 2007). No subjects had to be excluded using the criteria. The anatomical 
image (T1) was first viewed to change the origin as the anterior commissure for each subject. This was 
employed to increase co-registration and normalisation accuracy. Images were subsequently co-
registered to the mean reference epi image from the realignment procedure. The source image was the 
anatomical (MPRAGE) image which was revolved to be in alignment with the reference epi image. 
All functional images were realigned to the reference epi image with trilinear interpolation and then 
normalised to the standard SPM12 MNI EPI template. Normalization parameters were estimated 
using the mean image for each run, and applied to all volumes of that run. A 8mm3 full width by half 
maximum (FWHM) Gaussian kernel was used to spatially smooth normalised images. 
Statistical analysis at the subject level was estimated using the general linear model (GLM). Default 
settings were implemented from SPM12 with an SS task design matrix consisting of four conditions 
including go correct, go incorrect, stop correct, and stop incorrect trials. The MRot task was 
composed of two conditions which were the task condition (exp) and control condition (cont). 
Regressors were convolved with the traditional canonical hemodynamic response function model (hrf) 
to model data. A high pass filter of 100s cut-off was implemented to remove low frequency noise 
components such as drift. 
The main SS task contrast was of go incorrect (gin) and stop correct (sc) trials together compared to 
stop incorrect (sin) and go correct (gc) trials. The contrast therefore was go incorrect and stop correct 
compared to stop incorrect and go correct (gin+sc-sin+gc). This was the most efficient combination of 
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inhibition trials against go trials. The contrast of interest in the MRot task was the task condition (exp) 
compared to the control condition (cont) (exp-cont). A script was generated using SPM’s jobman to 
automate the entire preprocessing and statistical analysis processes.  
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A. Rotation task 
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B. Mirror task 
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Figure 3.2: Shows MRot task parameters and examples of presented shapes. A. Task rotated shape 
examples where subjects were required to make a response after mentally rotating shapes clockwise 
or anti-clockwise to judge if shapes were in the same orientation or mirror images of each other. B. 
same or mirror oriented shape pairs that require no rotation to distinguish if they were the same or 
different. Abbreviations: MRot, mental rotation task; ms, milliseconds. 
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Figure 3.3: MRot task average reaction time between patients and controls. Abbreviations: cont, 
control condition; MRot, mental rotation task; ms, milliseconds. 
 
 
  
  
 
 
 
 
 
 
 
Figure 3.4: MRot task average percentage correct between patients and controls. Abbreviations: 
cont, control condition; MRot, mental rotation task; *p<0.05; **p<0.01.
*p<0.05 
**p<0.01 
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Figure 3.5: Healthy Controls (n=26) ASL Group Analysis. The colour bar represents least perfusion 
in black to red areas of the CBF map and greatest perfusion in yellow areas of the map. 
Abbreviations: g, grams; min, minute; mL, millilitres.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: PC patients ASL (n=24) Group Analysis. The colour bar represents least perfusion in 
black to red areas of the CBF map and greatest perfusion in yellow areas of the map. Abbreviations: 
g, grams; min, minute; mL, millilitres R, right.  
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Figure 3.10: Resting state analysis masks of seed regions and regions of interest. (A) Masks showing 
the mPFC which was seeded to create a functional connectivity map of the default mode network. The 
strength of connectivity from the DLPFC was measured to the DMN. (B) The strength of connectivity 
was similarly measured from the rIFG to the DMN. Abbreviations: A, anterior; DLPFC, dorsolateral 
prefrontal cortex; IFG, inferior frontal gyrus; mPFC, medial prefrontal cortex; r, right.  
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Figure 3.11: Resting state analysis of patients and controls. (A) Patient and control resting state 
connectivity map with rDLPFC as region of interest to DMN. (B) Patient and control resting state 
connectivity map with rIFG as region of interest to DMN (Corrected for multiple comparisons, Z > 
+/-2.3; Cluster-wise threshold, p < 0.05). The colour bar represents negative BOLD in light blue to 
dark blue areas of brain maps and greater BOLD activation in red to yellow areas of brain maps. 
Abbreviations: DLPFC, dorsolateral prefrontal cortex; IFG, inferior frontal gyrus; mPFC, medial 
prefrontal cortex; r, right. 
   
 
 
 
 
(A) Healthy Controls  PC patients 
 DMN mPFC – DLPFC  DMN mPFC – DLPFC 
 
 
 
 
 
 
 
 
(B) PC patients   Healthy Controls 
DMN mPFC – rIFG  DMN mPFC - rIFG 
0 7.92 -4.14 0 7.53 -3.67 
R 
0 6.1 -4.29    -3.63 0 7.74 
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3.9 Regional ASL perfusion 
Figure 3.13 shows CBF values in regions of interest of controls and patients. Regions were 
selected based on activation areas of the stop signal and MRot task. Regional ASL analysis 
was conducted subsequently to ensure that putative task regions were first active before 
conducting the analysis. Perfusion assessments were employed in these regions to assess the 
integrity of BOLD signal activation found in patients and controls. Hypoperfusion has been 
known to lead to reductions in the BOLD signal which may lead to reduction in SST 
activation. The rIFG pars triangularis and pars opercularis were both masked and combined so 
that a regional estimate of the rIFG could be gauged. Bilateral supramarginal gyri were also 
masked to measure CBF in these regions that were related to the MRot task. 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: (A) Healthy controls rIFG, right supramarginal and left supramarginal gyrus ASL 
group level perfusion maps. (B) PC patients Controls rIFG, right Supramarginal and left 
Supramarginal gyrus ASL Group Level perfusion maps. The colour bar represents least perfusion in 
black to red areas of the CBF map and greatest perfusion in yellow areas of the CBF map. 
Abbreviations: g, grams; min, minute; mL, millilitres.  
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Figure 4.3: Whole brain ASL maps of healthy subjects at: (A) Baseline (n = 8) (B) Six Months (n = 
8). The colour bar represents least perfusion in black to red areas of CBF maps and greatest 
perfusion in yellow areas of CBF maps. Abbreviations: g, grams; min, minute; mL, millilitres, R, 
right. 
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Figure 4.4: SST whole brain group activation. A. baseline group activation. B. Six month group 
activation. Abbreviations: R, right; SST, stop signal task. 
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Overlapping of distinct flicker contrasts trials in figure 4.6 show areas contributing to 
activation on the separate flicker contrasts. This provides a better view that can be visually 
inspected. Activation seemed to be apparent in areas including the rIFG and RMFG. 
Furthermore, parietal areas were activated supporting a fronto-parietal network that is in line 
with an executive function network at baseline and follow-up. Additional areas of activity 
were present in the left IFG and left MFG. The lc-gc and mc-gc contrasts showed most 
activation.   
  
 
 
 
 
 
 
 
 
Figure 4.6: SST overlap images of healthy participants at baseline and six-month follow-up where 
red activation colour maps indicate activation of participant group activation at baseline and purple 
activation group maps at six months. (A) Group activation maps on the contrast lc-gc. (B) Group 
activation maps on the contrast mc-gc. (C) Group activation maps on the contrast sc-gc (Corrected 
for multiple comparisons, Z >2.3; Cluster-wise threshold, p < 0.05). Abbreviations: lc, long correct; 
mc, medium correct; R, right; sc, short correct; SST, stop signal task.
R 
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Figure 4.7: MRot task whole brain activation. (A) Baseline MRot activation. (B) six month MRot 
activation. Abbreviations: MRot, mental rotation task; R, right. 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
260 
 
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
Left Precentral Gyrus Right Superior Frontal Right Superamarginal
M
ea
n 
Si
gn
al
 C
ha
ng
e 
(%
)
ROIs
Baseline Six months
ig t ramarginal 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: MRot mean signal change on 60-cont contrast showing a significant difference in the left 
precentral gyrus. Abbreviations: MRot, mental rotation task; ROIs, regions of interest. 
 
Contrast 120-cont 
No significant main effect of averaged signal change across all ROIs between time points was 
found (F(1, 24) = 1.25, p > 0.05). A main effect was shown between the signal changes of 
ROIs when controlling for time (F(2, 48) = 3.54, p = 0.04, η2 = 0.13). No significant effect 
was found on the interaction term of signal change in ROIs between baseline and six months. 
Mauchly’s test of sphericity was violated (X2(2) = 7.96, p = 0.02), therefore, degrees of 
freedom were modified using Greenhouse Geisser estimates of sphericity (ε=0.77) (F(1.54, 
37.14) = 0.89, p > 0.05). Change in testosterone did not covary with any differences between 
signal change between regions and time (F(1.54, 37.14) = 3.39, p > 0.05).  
 
Contrast 180-cont 
No significant main effect of averaged signal change across all ROIs between time points was 
found (F(1, 24) = 1.55, p > 0.05). No main effect was shown between the signal changes of 
ROIs when controlling for time. Mauchly’s test of sphericity was violated (X2(2) = 10.32, p 
< 0.01), therefore, degrees of freedom were modified using Greenhouse Geisser estimates of 
**p < 0.01 
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Overlap images assist in demonstrating activation visually in healthy participants at baseline 
and follow-up (figure 4.9). No activation was apparent in contrasts requiring least rotation at 
six months, however, activation was present at baseline (60-cont and 120-cont). The 180-cont 
contrast showed most activation in putative MRot areas including the bilateral supramarginal 
gyri, precentral gyri and parietal lobe areas. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: MRot overlap images of healthy participants at baseline and six-month follow-up where 
red activation colour maps indicate group activation at baseline and blue activation group maps 
show activation at six months. (A) Group activation maps on the contrast 60-cont. (B) Group 
activation maps on the contrast 120-cont. (C) Group activation maps on the contrast 180-cont. (D) 
Group activation maps on the contrast 180-cont. (Corrected for multiple comparisons, Z >2.3; 
Cluster-wise threshold, p < 0.05). Abbreviations: cont, control condition; MRot, mental rotation 
task; R, right.
R 
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Figure 4.10: rIFG gyrus and right and left supramarginal gyri masked ASL perfusion of: (A) baseline 
(n = 8) (B) six months healthy participants (n = 8). The colour bar represents least perfusion in red 
areas of the CBF map and greatest perfusion in yellow areas of the map. Abbreviations: g, grams; 
min, minute; mL, millilitres; R, right. 
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MRI General Information sheet 
BIRMINGHAM UNIVERSITY
IMAGING CENTRE
www.buic.bham.ac.uk
GENERAL MRI INFORMATION SHEET FOR RESEARCH PARTICIPANTS
Dear Research Participant
Thank you for volunteering to undergo a research magnetic resonance imaging (MRI) brain scan at 
the Birmingham University Imaging Centre (BUIC).
Your participation at this research centre will help benefit understanding in the areas of knowledge 
about the central nervous system, in neuroscience and medicine. This information sheet broadly 
describes the MRI procedure, and answers some common questions. If you have any further 
questions, please do not hesitate to contact your researcher.
You can find out more information about what we do from our web site www.buic.bham.ac.uk
What is MRI?
MRI is a relatively recently developed technique which combines the use of magnetic fields and radio-
waves to image the body. MRI does not use any ionizing radiation or X-rays and there are no known 
side-effects or cumulative risks.
For your safety you will be asked to fill out an MRI Safety Screening Questionnaire, and to remove all 
metallic items before you enter the magnet room. FMRI (functional MRI) uses similar methods to 
conventional clinical MRI to obtain ‘functional brain images'. The technique relies on indirectly 
identifying small changes in blood flow/oxygenation in different parts of the brain.
The MRI Scanner
As you can see from the picture opposite, the scanner is 
a large cylinder which has a tube (bore) running through 
the middle, open at both ends.
You will enter the scanner tube on a moveable bed, laid 
down on your back, head-first, with your lower legs 
remaining outside the magnet's bore.
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MRI Participation Information Sheet 
Birmingham University 
  
Imaging Centre 
       
  www.buic.bham.ac.uk   
       
    
  
           
 
PARTICIPANT INFORMATION SHEET
 
Title of project:
 
Part 1
 
Introduction to the research and invitation to take part:
You are being invited to take part in a research study. It is important that you understand why the research is 
being done and what it will involve before you decide whether or not to take part. Please read the following 
information carefully, and please discuss this with others if you wish. Feel free to ask us if there is anything that 
is not clear or if you would like more information. 
 
What is the purpose of the study?
The study will be examining the relations between brain structure and brain function using magnetic resonance 
imaging. 
 
What kinds of stimuli will be presented?
The stimuli will be visual images (pictures, words), sounds, tactile input or smells. Any stimuli that might 
potentially be distressing will be shown to you beforehand to enable you to judge if you feel distress. You will 
be able to withdraw from the study at any time (below). 
 
Do I have to take part?
No. It is up to you whether or not to take part. If you do, you will be given this information sheet to keep and be
asked to sign a consent form. You are still free to withdraw at any time and without giving a reason. 
Withdrawing from the study will not affect you in any way (e.g., your future medical treatment). 
 
What will happen to me if I take part?
You will undergo an MRI scan and you may also be asked to carry out a task while in the scanner. As you carry 
out the task we will measure changes related to brain activity which will inform us about how brain areas 
operate while a task is being undertaken. The scanning session will last about 45 min, during which time you 
will be asked to lie still. 
 
What is magnetic resonance imaging?
Magnetic resonance imaging involves changes the gradient of a magnetic field to produce shifts in the 
alignment of atoms in the body of the person being scanned. The changes in alignment can be used to measure 
the structure and function of the tissues. When the brain is scanned we can derive information about both brain 
structure and function. The procedure is non-invasive and carries no known harm outside of safety issues for 
operating in a high magnetic field (e.g., if you have a cardiac pacemaker). For this reason you will be asked 
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to go through a safety questionnaire with a scan operator prior to being allowed to proceed into the scanning 
environment. 
 
What are the possible benefits of taking part?
By learning more about how the brain works, by using MRI, we will be able to develop better ways of diagnosing 
changes in brain function, and we will learn about how to improve brain function to optimize performance. 
 
What happens at the end of the research study?
The results will be written for scientific publication. In addition we will report them in a newsletter that we will 
distribute to all participants and to hospitals. All data will be reported anonymously.  
Using your data in other research - we would ask you in the consent form if you are willing 
to share the data we collected from you with other researchers. If you agree we would upload 
your anonymized data on a server and make it available for research use. There are two 
levels of data sharing: sharing only with researchers associated with the University of 
Birmingham; or sharing it as an open access resource. In the latter case we would make the 
data available on the web as an open access resource. The latter adhere with current 
government and international policies on scientific data. You can choose to allow sharing 
your data in any or neither forms. In case of brain imaging data, you should be aware that there are software 
that can generate the skeleton shape of the face based on MR imaging data, hence by having access to your 
data one can potentially reconstruct your face. Furthermore, similar to fingerprint brain are individually unique, 
thus in the future technology may become available enabling to recognize an individual from the brain 
structure. If you are happy to share your data we would request you to fill up a short questionnaire about your 
general health and demographic. The data will never contain any personal details about you (name, address, 
etc.).
 
What if there is a problem?
It is possible that lying in the scanner might cause some back or neck pain, and it is possible to feel a burning
sensation. If you experience any discomfort you can press the emergency buzzer and you will be brought out 
of the scanner immediately. Any complaint about the way the study has been conducted or any possible harm 
you may have suffered will be addressed. The detailed information on this is given in Part 2. 
 
Will my taking part in the study be kept confidential?
Yes. All the information about your participation in this study will be kept confidential. The details are included 
in Part 2.
 
Contact Details -  BUIC Management:
 
This completes Part 1 of the Information Sheet. If the 
information in Part 1 has interested you and you are 
considering participation, please continue to read the 
additional information in Part 2 before making any 
decision. 
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Appendix 6: Consent Form 
 
 
    Consent form                          School of Psychology 
The University of Birmingham 
Edgbaston 
Birmingham B15 2TT 
United Kingdom 
 
Study name: The Effects of Androgen Deprivation Therapy on Cognition 
 
 
Participant identification number:  
 
 
Name of researcher spoken to: 
 Please write your 
inititals in the box 
 
1. I confirm that I have read and understand the information sheet 
dated....................  (version............) for the above study.  
 
 
 
2. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
 
 
 
3. I understand that my participation is voluntary and I am free to 
withdraw at any time without giving any reason, without my 
medical care or legal rights being affected. 
 
4. I agree to have a blood test.  
 
 
 
5. I agree to my GP being informed of my participation in the study  
 
 
 
6. I agree to be contacted at a later date up to six months from now.   
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Figure 1: fMRI illustration of the stop signal task. (A) No flicker timings (go trials) in which participants must 
respond on a response pad. Arrows under hash symbols represent when participants must respond. (B) Stop 
trials were separated into short, medium, and long trials. In parts (A) and (B) of figure 1, blank screens labelled 
as ‘jitter’ were jittered around the temporal resolution of 3 seconds. Jittered durations varied between 2800ms, 
3000ms and 3200ms in a random order. Parts (A) and (B) were presented in random order. Abbreviations: ISI, 
interstimulus interval; ms, milliseconds.       
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Figure 2: Task condition compared to the control condition contrast. Axial and left hemisphere 
sagittal whole brain activation view (p < 0.05; uncorrected). Colour bars represent least (red) to 
most (yellow) activation on brain activation maps. Abbreviations: A, Anterior, P, posterior; R, right. 
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Figure 3: fMRI illustration of the Stop signal task. (A) No flicker timings (go trials) in which participants must 
respond. Arrows under hash symbol figures represent when participants should respond. (B) Stop trials were 
separated into short, medium, and long trials. In parts (A) and (B) of figure 1, blank screens labelled as ‘jitter’ 
were jittered around 0, 200 & 400ms. Blank screens labelled ‘algorithm (ISI)’ had durations which were 
contingent on jitter durations. These intervals varied between 1100ms, 1300ms and 900ms. Parts (A) and (B) 
were presented in a randomised order. Abbreviations: ISI, interstimulus interval; ms, milliseconds.       
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Mental rotation task 
The mental rotation task was as described in pilot study one. Complexity of shapes were reduced by 
decreasing the number of blocks per shape. Moreover, 3D blocks were altered to exclude blocks 
projecting in oblique directions (figure 4). 
 
 
Old task 
example 
 
 
 
 
 
 
 
New task 
example 
 
 
 
 
 
 
 
 
 
 
Figure 4: Shows change and modification of task from pilot study one to the new task of study three. 
The old task used many oblique angles which were removed from the new task of study two. 
Abbreviations: ms, milliseconds. 
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Figure 7: fMRI illustration of the Stop signal task. (A) No flicker timings in which participants must press the 
button on response pad. Arrows under hash symbol figures represent when participants must respond. (B) stop 
trials were separated into short, medium, and long trials. In parts (A) and (B) of figure 2, blank screens labelled as 
ISI algorithm were varied in their duration and increased or decreased in duration depending on if the participant 
responded or inhibited correctly.       
